{"title": "PDF", "author": "PDF", "url": "https://seq.es/wp-content/uploads/2023/07/full.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "REVISTA ESPA\u00d1OLA DEREVISTA ESPA\u00d1OLA DEQuimioterapiaQuimioterapia\nISSN: 0214-3429\nVolumen 36\nN\u00famero 4\nAgosto 2023\nP\u00e1ginas: 334-443SPANISH JOURNAL\nOF CHEMOTHERAPYQuimioterapiaREVISTA ESPA\u00d1OLA DE\nRevista Espa\u00f1ola de Quimioterapia \ntiene un car\u00e1cter multidisciplinar \ny est\u00e1 dirigida a todos aquellos \nprofesionales involucrados en la \nepidemiolog\u00eda, diagn\u00f3stico, cl\u00ednica \ny tratamiento de las enfermedades \ninfecciosas\nFundada en 1988 por la Sociedad \nEspa\u00f1ola de Quimioterapia\nIndexada en\nScience Citation Index\nExpanded (SCI),\nIndex Medicus (MEDLINE), \nExcerpta Medica/EMBASE,\n\u00cdndice M\u00e9dico Espa\u00f1ol (IME), \n\u00cdndice Bibliogr\u00e1fico en Ciencias de \nla Salud (IBECS)\nSecretar\u00eda t\u00e9cnica \nDpto. de Microbiolog\u00eda\nFacultad de Medicina\nAvda. Complutense, s/n\n28040 Madrid\nrevista@seq.es\nDisponible en Internet:\nwww.seq.esPublicidad y Suscripciones\nSociedad Espa\u00f1ola de Quimioterapia\nDpto. de Microbiolog\u00eda\nFacultad de Medicina\nAvda. Complutense, s/n\n28040 Madrid\nAtenci\u00f3n al cliente\nTel\u00e9fono 91 394 15 12\nCorreo electr\u00f3nico\ninfo@seq.es\nConsulte nuestra p\u00e1gina web\nwww.seq.es\n\u00a9 Copyright 2023\nSociedad Espa\u00f1ola de\nQuimioterapia\nReservados todos los derechos.\nQueda rigurosamente prohibida,\nsin la autorizaci\u00f3n escrita del\neditor, la reproducci\u00f3n parcial\no total de esta publicaci\u00f3n\npor cualquier medio o\nprocedimiento, comprendidos la\nreprograf\u00eda y el tratamiento\ninform\u00e1tico, y la distribuci\u00f3n de\nejemplares mediante alquiler o\npr\u00e9stamo p\u00fablicos, bajo las\nsanciones establecidas por la leySociedad Espa\u00f1ola de Quimioterapia\nPublicaci\u00f3n que cumple los requisitos de\nsoporte v\u00e1lido\nISSN\n0214-3429\ne-ISSN \n1988-9518\nDep\u00f3sito Legal\nM-32320-2012\nMaquetaci\u00f3n\nVic+DreamStudio\nImpresi\u00f3n\nEspa\u00f1a\nEsta publicaci\u00f3n se imprime en papel no \u00e1cido. \nThis publication is printed in acid free paper.\nLOPD\nInformamos a los lectores que, seg\u00fan lo previsto \nen el Reglamento General de Protecci\u00f3n de Datos \n(RGPD) 2016/679 del Parlamento Europeo, sus \ndatos personales forman parte de la base de datos \nde la Sociedad Espa\u00f1ola de Quimioterapia (si es \nusted socio)\nSi desea realizar cualquier rectificaci\u00f3n o \ncancelaci\u00f3n de los mismos, deber\u00e1 enviar una \nsolicitud por e-mail a la Sociedad Espa\u00f1ola de \nQuimioterapia (info@seq.es)QuimioterapiaREVISTA ESPA\u00d1OLA DE\nDirector\nJ. Barber\u00e1n L\u00f3pez\nComit\u00e9 Editorial\nF. \u00c1lvarez Lerma (Barcelona) \nV. Asensi (Oviedo) \nE. Bouza (Madrid)\nR. Cant\u00f3n (Madrid)\nX. Guirao (Barcelona) \nJ. Gonz\u00e1lez del Castillo (Madrid)\nS. Grau (Barcelona)\nE. Maseda (Madrid)\nConsejo Editorial\nL. Aguilar (Madrid)\nJ. I. Al\u00f3s (Madrid)\nJ. R. Azanza (Pamplona)\nJ. Arag\u00f3n (Las Palmas de Gran Canaria) \nA. Artero (Valencia)\nG. Barbeito (Santiago de Compostela)\nJ. M. Barbero (Madrid)\nJ. Campos (Madrid)\nF.J. Candel (Madrid)\nE. Cant\u00f3n (Valencia)\nJ. A. Capdevila Morell\n(Barcelona)\nM. Casal (C\u00f3rdoba)\nJ. Castillo (Zaragoza) \nF. Cobo (Granada)\nJ. Cobo Reinoso (Madrid)\nN. Cobos (Madrid)\nJ. L. del Pozo (Navarra)\nR. De la C\u00e1mara (Madrid)\nC. De la Calle (Barcelona)\nM. Dominguez-Gil (Valladolid)\nJ. Eiros (Valladolid)\nP. Escribano (Madrid)\nA. Estella (C\u00e1diz)\nM. C. Fari\u00f1as \u00c1lvarez (Santander)J. Fort\u00fan (Madrid)\nJ. J. Gamazo (Vizcaya)\nE. Garc\u00eda S\u00e1nchez (Salamanca)\nI. Garc\u00eda Garc\u00eda (Salamanca)\nJ. E. Garc\u00eda S\u00e1nchez (Salamanca)\nE. Garc\u00eda V\u00e1zquez (Murcia)\nJ. G\u00f3mez G\u00f3mez (Murcia)\nM. L. G\u00f3mez-Lus (Madrid)\nJ. Gonz\u00e1lez del Castillo (Madrid)\nF. Gonz\u00e1lez Romo (Madrid)\nJ. J. Granizo (Madrid)\nJ.M. Guardiola (Barcelona)\nJ. Guinea (Madrid)\nJ. Guti\u00e9rrez (Granada)\nJ. B. Guti\u00e9rrez (C\u00f3rdoba)\nB. Isidoro (Madrid)\nP. Llinares (La Coru\u00f1a)\nJ. E. Losa Garcia (Madrid)\nJ. R. Maestre Vera (Madrid)\nL. Mart\u00ednez Mart\u00ednez (C\u00f3rdoba)\nR. Men\u00e9ndez (Valencia)\nP. Merino (Madrid))\nP. Mu\u00f1oz (Madrid)\nJ. L. Mu\u00f1oz Bellido (Salamanca)\nV. Navarro (Alicante)M. Ortega (Barcelona) \nJ. Oteo (Madrid)\nJ. A. Oteo (Logro\u00f1o)\nE. Palencia Herrej\u00f3n (Madrid) \nA. Pascual Hern\u00e1ndez (Sevilla)\nJ. Pasquau (Sevilla)\nJ. Pem\u00e1n (Valencia)\nJ. L P\u00e9rez-Arellano (Las Palmas)\nB. P\u00e9rez-Gorricho (Madrid)\nA. Ramos (Madrid)\nJ. Reina (Palma de Mallorca)\nM. A. Ripoll (\u00c1vila)\nI. Rodriguez-Avial (Madrid)\nM. Ruiz (Alicante)\nM. Sabri\u00e1 (Barcelona)\nB. S\u00e1nchez Artola (Madrid)\nM. Segovia (Murcia)\nR. Serrano (Madrid)\nD. Sevillano (Madrid)\nA. Su\u00e1rez (Madrid)\nA. Tenorio (Huelva)\nA. Torres (Murcia)\nC. Vallejo (Oviedo)\nJ. Vila (Barcelona)\nJ. Yuste (Madrid)J. Mensa (Barcelona) \nJ. M. Ramos (Alicante) \nJ. Reina (Palma de Mallorca)\nM. Salavert (Valencia)\nA. Soriano (Barcelona)\nA. Torres (Barcelona)\nC. Fari\u00f1as(Santander)Secretario de Redacci\u00f3n\nLuis Alou CerveraSumario\nEficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n  334 \nde 65 o m\u00e1s a\u00f1os de edad\nMar\u00eda Pilar Arrazola Mart\u00ednez, Jos\u00e9 Mar\u00eda Eiros Bouza, Pere Plans Rubi\u00f3, Joan Puig-Barber\u00e0,  \nJes\u00fas Ruiz Arag\u00f3n, \u00c1lvaro Torres Lana\nControl de la infecci\u00f3n en residencias de ancianos: Documento de reflexi\u00f3n  346 \nsobre la situaci\u00f3n en Espa\u00f1a\nEmilio Bouza, Jos\u00e9 Augusto Garc\u00eda Navarro, Sergio Alonso, Juan Carlos Duran Alonso, Carina \nEscobar, Benito J. Fontecha G\u00f3mez , Mar\u00eda Isabel Galv\u00e1 Borr\u00e1s, Am\u00f3s Jos\u00e9 Garc\u00eda Rojas, Francisco \nJavier G\u00f3mez Pav\u00f3n, Diego Gracia, Jos\u00e9 Guti\u00e9rrez Rodr\u00edguez, Martha Kestler, Fernando Mart\u00ednez \nCuervo, Francisco Javier Mart\u00edn S\u00e1nchez, Carlos Melero, Rosario Men\u00e9ndez Villanueva, Patricia \nMu\u00f1oz,  Esteban Palomo, Juan Manuel P\u00e9rez-Castej\u00f3n Garrote, Jos\u00e9 Antonio Serra Rexach, \nSebasti\u00e1n Jos\u00e9 Santaeugenia, Francisco Jos\u00e9 Tarazona Santabalbina, Mar\u00eda Teresa Vid\u00e1n Astiz\nReducci\u00f3n del riesgo de progresi\u00f3n en receptores de trasplantes infectados  380 \npor SARS-CoV-2 tratados con anticuerpos monoclonales\nFrancisco Javier Candel, Miguel Salavert, David Lorite Mingot, Marta Manzano Crespo,  \nPaula P\u00e9rez Portero, Rafael Cuervo Pinto\nInfluencia de factores epidemiol\u00f3gicos y cl\u00ednicos en la reactogenicidad a la  392 \nvacuna Comirnaty\u00ae en trabajadores sanitarios de un hospital universitario espa\u00f1ol \n(estudio COVIVAC)\nCarlos Risco-Risco, Diego Mart\u00ednez-Urbistondo, Rafael Su\u00e1rez Del Villar, Luis Ayerbe Garc\u00eda-\nMonz\u00f3n, Alberto P\u00e9rez-Rubio, Jos\u00e9 Barber\u00e1n-L\u00f3pez, David Andaluz-Ojeda, Paula Villares \nFern\u00e1ndez\nManejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en  400 \ndos hospitales comarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n  \nfalleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempo\nDavid S\u00e1nchez Fabra, Tina Herrero Jord\u00e1n, Alicia Alda Lozano, Victoria Duro Su\u00e1rez, Nuria Saura \nBlasco, Isabel Torres Courchoud\nCapacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los  408 \npacientes atendidos por infecci\u00f3n en urgencias\nAgust\u00edn Juli\u00e1n-Jim\u00e9nez, Rafael Rubio-D\u00edaz, Juan Gonz\u00e1lez Del Castillo, Eric Jorge Garc\u00eda-\nLamberechts, Itziar Huarte Sanz, Carmen Navarro Bustos, Francisco Javier Candel, Pedro \u00c1ngel De \nSantos, Ra\u00fal Alonso Avil\u00e9s En Nombre Del Grupo Infurg-Semes\nElevada tasa de resistencia a macr\u00f3lidos y fluoroquinolonas en 416 \nMycoplasma genitalium  en el \u00e1rea sur de Tenerife\nCristian Mateo Le\u00f3n, Diego Garc\u00eda Mart\u00ednez De Artola, Berta Pino-CalmOriginales\nOriginal BreveQuimioterapiaREVISTA ESPA\u00d1OLA DE\nRevisi\u00f3nVolumen 36\nN\u00famero 4\nAgosto 2023Sumario\nNocardiosis pulmonar despu\u00e9s de infecci\u00f3n por COVID-19: caso cl\u00ednico y revisi\u00f3n 421 \nde la literatura \nJos\u00e9 Ortiz, Francisco Jover, Victoria Ortiz De La Tabla, Elisabet Delgado\nAbsceso corneal f\u00fangico producido por Exophiala  dermatitidis 425\nSaray Mormeneo Bayo, Alba Bell\u00e9s Bell\u00e9s, Iv\u00e1n Prats S\u00e1nchez, Eric L\u00f3pez Gonz\u00e1lez, Jes\u00fas \nAramburu Arnuelos, Albert Bernet S\u00e1nchez, Merc\u00e8 Garc\u00eda Gonz\u00e1lez\nConcordancia entre el GeneXpert y el Life Real Detection Kit en el diagn\u00f3stico de  427 \nlas infecciones respiratorias agudas\nCelia Garc\u00eda-Rivera, Isabel Escribano, Esperanza Merino, Juan Carlos Rodriguez\nEnfermedad de Kikuchi-Fujimoto: una rara linfadenopat\u00eda y su relaci\u00f3n plausible  429 \ncon las vacunas del virus del papiloma humano\nAdri\u00e1n Rodr\u00edguez-Ferreras, Ivan Maray, Covadonga Coya-Fern\u00e1ndez, Manuela Mar\u00eda Octavio-\nBocigas, Manuel Felic\u00edsimo Fern\u00e1ndez-Del R\u00edo, Susana Casares-L\u00f3pez, Jes\u00fas Ruiz-Salazar\nBacteriemia por Solobacterium  moorei  en paciente con sinusitis 432\nIzaskun Alejo-Cancho, Ana Gual-De-Torrella, Raquel Vielba Postigo, I\u00f1igo Perez Abraguin,  \nLaura Redondo Farias, Mar\u00eda Jos\u00e9 Lopez De Goikoetxea\nUso de ceftarolina en infecciones complejas del sistema nervioso central 434\nAlicia Alonso \u00c1lvarez, Efr\u00e9n S\u00e1nchez Vidal, Luc\u00eda Ramos Merino, Dolores Sousa Regueiro,  \nJoaqu\u00edn Serrano Areba, Enrique M\u00edguez Rey, Pedro Llinares Mod\u00e9jar\nAjuste posol\u00f3gico de linezolid por interacci\u00f3n con rifampicina en  436 \nendocarditis infecciosa\nAaron Pupl\u00e0 Bartoll, M\u00aa Dolores Bell\u00e9s Medall, Ignacio P\u00e9rez Catal\u00e1n, Celia Roig Mart\u00ed,  \nJulia Bodega Azuara, Mayte Gil Candel, Vicent Esteve L\u00f3pez, Ra\u00fal Ferrando Piqueres\nDos casos de Prevotella  oris causando infecciones pleuropulmonares graves 439\nDomingo Fern\u00e1ndez Vecilla, Mary Paz Roche Matheus, Gotzon Iglesias Hidalgo,  \nEst\u00edbaliz Ugalde Z\u00e1rraga, Miren Josebe Unzaga Bara\u00f1ano, Jos\u00e9 Luis D\u00edaz De Tuesta Del Arco\nDiagn\u00f3stico v\u00edrico alternativo en las sospechas de viruela del mono 442\nJordi Reina, Elisa Gonz\u00e1lez De HerreroQuimioterapiaREVISTA ESPA\u00d1OLA DE\nVolumen 36\nN\u00famero 4\nAgosto 2023\nCartas al DirectorContents\nQuimioterapiaREVISTA ESPA\u00d1OLA DE\nEfficacy, effectiveness and safety of the adjuvanted influenza vaccine in the  334 \npopulation aged 65 or over\nMar\u00eda Pilar Arrazola Mart\u00ednez, Jos\u00e9 Mar\u00eda Eiros Bouza, Pere Plans Rubi\u00f3, Joan Puig-Barber\u00e0,  \nJes\u00fas Ruiz Arag\u00f3n, \u00c1lvaro Torres Lana\nInfection control in long term care institutions for the elderly:  346 \nA reflection document on the situation in Spain\nEmilio Bouza, Jos\u00e9 Augusto Garc\u00eda Navarro, Sergio Alonso, Juan Carlos Duran Alonso, Carina \nEscobar, Benito J. Fontecha G\u00f3mez , Mar\u00eda Isabel Galv\u00e1 Borr\u00e1s, Am\u00f3s Jos\u00e9 Garc\u00eda Rojas, Francisco \nJavier G\u00f3mez Pav\u00f3n, Diego Gracia, Jos\u00e9 Guti\u00e9rrez Rodr\u00edguez, Martha Kestler, Fernando Mart\u00ednez \nCuervo, Francisco Javier Mart\u00edn S\u00e1nchez, Carlos Melero, Rosario Men\u00e9ndez Villanueva, Patricia \nMu\u00f1oz,  Esteban Palomo, Juan Manuel P\u00e9rez-Castej\u00f3n Garrote, Jos\u00e9 Antonio Serra Rexach, \nSebasti\u00e1n Jos\u00e9 Santaeugenia, Francisco Jos\u00e9 Tarazona Santabalbina, Mar\u00eda Teresa Vid\u00e1n Astiz\nReduction in the risk of progression of solid organ transplant recipients infected  380 \nby SARS-CoV-2 treated with monoclonal antibodies\nFrancisco Javier Candel, Miguel Salavert, David Lorite Mingot, Marta Manzano Crespo,  \nPaula P\u00e9rez Portero, Rafael Cuervo Pinto\nInfluence of epidemiological and clinical factors in the reactogenicity to  392 \nComirnaty\u00ae vaccine in health care workers of a Spanish university teaching  \nhospital (COVIVAC study)\nCarlos Risco-Risco, Diego Mart\u00ednez-Urbistondo, Rafael Su\u00e1rez del Villar, Luis Ayerbe Garc\u00eda-\nMonz\u00f3n, Alberto P\u00e9rez-Rubio, Jos\u00e9 Barber\u00e1n-L\u00f3pez, David Andaluz-Ojeda, Paula Villares \nFern\u00e1ndez\nManagement of COVID-19 pandemic in hospital at home in two regional  400 \nSpanish hospitals. what it meant, who we cared for, who died and how assistance  \nhas evolved over time\nDavid S\u00e1nchez Fabra, Tina Herrero Jord\u00e1n, Alicia Alda Lozano, Victoria Duro Su\u00e1rez, Nuria Saura \nBlasco, Isabel Torres Courchoud\nAbility of qSOFA1-lactate to predict 30-day mortality in patients seen 408 \n for infection in the Emergency Department\nAgust\u00edn Juli\u00e1n-Jim\u00e9nez, Rafael Rubio-D\u00edaz, Juan Gonz\u00e1lez del Castillo, Eric Jorge Garc\u00eda-\nLamberechts, Itziar Huarte Sanz, Carmen Navarro Bustos, Francisco Javier Candel,  \nPedro \u00c1ngel de Santos, Ra\u00fal Alonso Avil\u00e9s en nombre del grupo INFURG-SEMES\nHigh macrolides and fluoroquinolones resistance rate in 416 \nMycoplasma  genitalium  in southern Tenerife\nCristian Mateo Le\u00f3n, Diego Garc\u00eda Mart\u00ednez de Artola, Berta Pino-CalmReview\nOriginalsVolume 36\nNumber 4\nAugust 2023\nBrief ReportContents\nQuimioterapiaREVISTA ESPA\u00d1OLA DE\nPulmonary nocardiosis after covid-19 infection: case report and literature review 421\nJos\u00e9 Ortiz, Francisco Jover, Victoria Ortiz de la Tabla, Elisabet Delgado\nFungal corneal abscess caused by Exophiala  dermatitidis 425\nSaray Mormeneo Bayo, Alba Bell\u00e9s Bell\u00e9s, Iv\u00e1n Prats S\u00e1nchez, Eric L\u00f3pez Gonz\u00e1lez,  \nJes\u00fas Aramburu Arnuelos, Albert Bernet S\u00e1nchez, Merc\u00e8 Garc\u00eda Gonz\u00e1lez\nConcordance between GeneXpert and Life Real Detection Kit in the diagnosis of  427 \nacute respiratory infections\nCelia Garc\u00eda-Rivera, Isabel Escribano, Esperanza Merino, Juan Carlos Rodriguez\nKikuchi-Fujimoto Disease: a rare type of lymphadenopathy and its plausible  429 \nrelationship with human papillomavirus vaccines\nAdri\u00e1n Rodr\u00edguez-Ferreras, Ivan Maray, Covadonga Coya-Fern\u00e1ndez, Manuela Mar\u00eda Octavio-\nBocigas, Manuel Felic\u00edsimo Fern\u00e1ndez-del R\u00edo, Susana Casares-L\u00f3pez, Jes\u00fas Ruiz-Salazar\nSolobacterium  moorei  bacteriemia in a patient with sinusitis 432\nIzaskun Alejo-Cancho, Ana Gual-de-Torrella, Raquel Vielba Postigo, I\u00f1igo Perez Abraguin,  \nLaura Redondo Farias, Mar\u00eda Jos\u00e9 Lopez de Goikoetxea\nUse of ceftaroline in complex central nervous system infections 434\nAlicia Alonso \u00c1lvarez, Efr\u00e9n S\u00e1nchez Vidal, Luc\u00eda Ramos Merino, Dolores Sousa Regueiro,  \nJoaqu\u00edn Serrano Areba, Enrique M\u00edguez Rey, Pedro Llinares Mod\u00e9jar\nDose adjustment of linezolid due to interacction with rifampicin in  436 \ninfective endocarditis\nAaron Pupl\u00e0 Bartoll, M\u00aa Dolores Bell\u00e9s Medall, Ignacio P\u00e9rez Catal\u00e1n, Celia Roig Mart\u00ed,  \nJulia Bodega Azuara, Mayte Gil Candel, Vicent Esteve L\u00f3pez, Ra\u00fal Ferrando Piqueres\nTwo cases of Prevotella  oris causing serious pleuropulmonary infection s 439\nDomingo Fern\u00e1ndez Vecilla, Mary Paz Roche Matheus, Gotzon Iglesias Hidalgo,  \nEst\u00edbaliz Ugalde Z\u00e1rraga, Miren Josebe Unzaga Bara\u00f1ano, Jos\u00e9 Luis D\u00edaz de Tuesta del Arco\nAlternative viral diagnosis in suspected monkeypox   442\nJordi Reina, Elisa Gonz\u00e1lez de HerreroVolume 36\nNumber 4\nAugust 2023\nLetters to the \neditorISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/145.2022\nRev Esp Quimioter 2023;36(4): 334-345334Efficacy, effectiveness and safety of the \nadjuvanted influenza vaccine in the population \naged 65 or over\nABSTRACT\nMost of the complications and deaths related to seasonal \nflu occur in the elderly population ( \u226565 years) with comorbid -\nities, and the influenza vaccine is the most effective way to \nprevent them. Immunization is less effective in older adults \ndue to immunosenescence. MF59-adjuvanted vaccines, de -\nsigned to improve the magnitude, persistence and amplitude \nof the immune response in elderly people, have been used in \nclinical practice since 1997 in their trivalent formulation and, \nsince 2020, in their tetravalent formulation. Data from various \nstudies show that these vaccines are not only safe for all age \ngroups, with a reactogenicity profile similar to that of the con -\nventional vaccine, but also that they are especially effective in \nboosting the immune response in the population aged 65 or \nover by increasing antibody titers after vaccination and sig -\nnificantly reducing the risk of hospital admission. Adjuvanted \nvaccines have been shown to provide cross-protection against \nheterologous strains and to be as effective as the high-dose \nvaccine in the population aged 65 or over. In this review, the \nscientific evidence on the efficacy and effectiveness of the \nMF59-adjuvanted vaccine in real clinical practice in people \n\u226565 years of age is analyzed through a narrative and descrip -\ntive review of the literature with data from clinical trials, ob -\nservational studies and systematic reviews or meta-analysis.\nKeywords: Influenza Vaccine; Adjuvanted Vaccine; MF59\nINTRODUCCI\u00d3N\nLa gripe estacional es una infecci\u00f3n v\u00edrica aguda que al -\ngunos a\u00f1os puede alcanzar incidencias del 5-10% [1]. El riesgo \nde complicaciones, hospitalizaciones y fallecimientos por gri -Eficacia, efectividad y seguridad de la vacuna \nantigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s \na\u00f1os de edad\n1Hospital Universitario 12 de Octubre, Madrid, Espa\u00f1a\n2Hospital Universitario R\u00edo Hortega, Facultad de Medicina, Valladolid, Espa\u00f1a\n3Agencia de Salud P\u00fablica de Catalu\u00f1a, Espa\u00f1a\n4\u00c1rea de Investigaci\u00f3n en Vacunas (AIV). Fundaci\u00f3n para el Fomento de la Investigaci\u00f3n Sanitaria y Biom\u00e9dica de la \nComunidad Valenciana (FISABIO), Valencia, Espa\u00f1a\n5Hospital de la L\u00ednea de la Concepci\u00f3n, C\u00e1diz, Espa\u00f1a\n6Direcci\u00f3n General de Salud P\u00fablica. Servicio Canario de la Salud, Santa Cruz de Tenerife, Espa\u00f1a \n7Medicina Preventiva y Salud P\u00fablica. Universidad La Laguna, Santa Cruz de Tenerife, Espa\u00f1aMar\u00eda Pilar Arrazola Mart\u00ednez1\nJos\u00e9 Mar\u00eda Eiros Bouza2\nPere Plans Rubi\u00f33\nJoan Puig-Barber\u00e04\nJes\u00fas Ruiz Arag\u00f3n5\n\u00c1lvaro Torres Lana6,7Review\nArticle history\nReceived: 22 December 2022; Revision Requested: 27 January 2023; Revision Received: 27 February 2023; Accepted: 22 \nFebruary 2023; Published: 20 April 2023\nRESUMEN\nLa mayor\u00eda de las complicaciones y fallecimientos rela -\ncionados con la gripe estacional ocurren en poblaci\u00f3n de 65 \na\u00f1os o m\u00e1s y con enfermedades de base, y la vacuna frente \na la gripe es la forma m\u00e1s efectiva de prevenirlas. La inmu -\nnizaci\u00f3n es menos eficaz en los adultos mayores debido a la \ninmunosenescencia. Las vacunas adyuvadas con MF59, dise\u00f1a -\ndas para mejorar la magnitud, persistencia y amplitud de la \nrespuesta inmunitaria en personas de 65 a\u00f1os o m\u00e1s, se vie -\nnen utilizando en la pr\u00e1ctica cl\u00ednica desde 1997 en su formu -\nlaci\u00f3n trivalente y, desde 2020, en formulaci\u00f3n tetravalente. \nLos datos de diversos estudios muestran que estas vacunas son \nseguras para todos los grupos de edad, con un perfil de reacto -\ngenicidad similar al de la vacuna convencional, y que resultan \nespecialmente efectivas para potenciar la respuesta inmunita -\nria en la poblaci\u00f3n de 65 a\u00f1os o m\u00e1s, al aumentar los t\u00edtulos \nde anticuerpos tras la vacunaci\u00f3n y reducir significativamente \nel riesgo de ingreso hospitalario. Las vacunas adyuvadas han \ndemostrado otorgar protecci\u00f3n cruzada frente a cepas hete -\nr\u00f3logas y ser igual de efectivas que la vacuna de alta dosis en \npoblaci\u00f3n de 65 a\u00f1os o m\u00e1s. En esta revisi\u00f3n se analiza la evi -\ndencia cient\u00edfica sobre la eficacia y la efectividad de la vacuna \nadyuvada con MF59 en la pr\u00e1ctica cl\u00ednica real en personas \u226565 \na\u00f1os mediante una revisi\u00f3n narrativa y descriptiva de los datos \npublicados en ensayos cl\u00ednicos, estudios observacionales y revi -\nsiones sistem\u00e1ticas o metaan\u00e1lisis.\nPalabras clave: Vacuna antigripal; Vacuna adyuvada; MF59\nCorrespondencia:\nDra. Mar\u00eda Pilar Arrazola Mart\u00ednez\nServicio de Medicina Preventiva. Hospital Universitario 12 de Octubre \nAv. de C\u00f3rdoba, s/n, 28041 Madrid, Espa\u00f1a\nE-mail: mpilararrazola@gmail.comEficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-345335El objetivo de este trabajo es analizar la evidencia cien -\nt\u00edfica sobre la eficacia y la efectividad de la vacuna adyuva -\nda con MF59 en la pr\u00e1ctica cl\u00ednica real en poblaci\u00f3n \u226565 a\u00f1os \nmediante una revisi\u00f3n narrativa [14] de los datos publicados \nprocedentes de ensayos cl\u00ednicos, estudios observacionales y re -\nvisiones sistem\u00e1ticas o metaan\u00e1lisis.\nMETODOLOG\u00cdA\nPara elaborar este art\u00edculo, se realiz\u00f3 una b\u00fasqueda bi -\nbliogr\u00e1fica no sistem\u00e1tica en septiembre de 2022 en las bases \nde datos electr\u00f3nicas Medline (PubMed) y Embase empleando \nlos siguientes descriptores: vacuna adyuvada, gripe, vacuna \nantigripal, MF59 y estudios publicados desde enero de 2014 \nhasta septiembre de 2022 que incluyeran a poblaci\u00f3n de 65 \na\u00f1os o m\u00e1s. Tras revisar el contenido de las publicaciones, se \nseleccionaron aquellas que, a criterio de los autores, fueron \nm\u00e1s relevantes por presentar datos sobre la vacuna adyuvada \ncon MF59 en la pr\u00e1ctica cl\u00ednica real en poblaci\u00f3n de 65 a\u00f1os o \nm\u00e1s. Se revisaron un total de 19 estudios, incluyendo ensayos \ncl\u00ednicos, estudios observacionales y revisiones sistem\u00e1ticas/me -\ntaan\u00e1lisis (Tabla 1). \nEFICACIA, INMUNOGENICIDAD Y SEGURIDAD DE \nLAS VACUNAS ANTIGRIPALES ADYUVADAS \nEnsayos cl\u00ednicos. A continuaci\u00f3n, resumimos los princi -\npales resultados de eficacia, inmunogenicidad y seguridad de \nlas vacunas adyuvadas frente la gripe en adultos \u226565 a\u00f1os \nprocedentes de 5 ensayos cl\u00ednicos de fase 3 [15\u201319] (Tabla 2).\nEn el ensayo cl\u00ednico con asignaci\u00f3n aleatoria (ECA) llevado \na cabo por  Frey et al. [15] (2014) se evaluaron en la tempo -\nrada de gripe 2010-2011 la inmunogenicidad, la seguridad y \nla eficacia de la vacuna trivalente adyuvada con MF59 (aTIV) \nen comparaci\u00f3n con la vacuna trivalente sin adyuvar (TIV) en \nsujetos con o sin comorbilidad. La eficacia, la reactogenicidad y \nlos eventos adversos (EA) graves se evaluaron hasta el d\u00eda 366 \ntras administrar la vacuna. La vacuna aTIV indujo respuestas \nsignificativamente m\u00e1s elevadas de anticuerpos (por inhibici\u00f3n \nde la aglutinaci\u00f3n) (p<0,001) que las obtenidas por la vacuna pe es mayor en personas de 65 o m\u00e1s a\u00f1os, ni\u00f1os menores de \n5 a\u00f1os, mujeres embarazadas y pacientes con comorbilidades \n[1]. Las epidemias de gripe anuales causan 290.000- 650.000 \nmuertes en el mundo y 3-5 millones de casos de enfermedad \ngrave [1]. La infecci\u00f3n por gripe duplica la mortalidad en los \npacientes coinfectados por el virus SARS-CoV-2 [2]. \nEn los pa\u00edses industrializados, la mayor\u00eda de las muertes \nrelacionadas con la gripe ocurren en poblaci\u00f3n de 65 a\u00f1os o \nm\u00e1s [1]. Se ha descrito una mortalidad de alrededor del 12% \nen mayores hospitalizados por gripe [3,4]. Adem\u00e1s, la gripe dis -\nminuye de forma notable la calidad de vida relacionada con la \nsalud (CVRS), con una p\u00e9rdida de autonom\u00eda que puede provo -\ncar gran discapacidad en hasta un 14,6% de las personas de 65 \na\u00f1os o m\u00e1s [3]. \nLa vacuna frente a la gripe es la forma m\u00e1s efectiva de \nprevenir la gripe y sus complicaciones [1]. Sin embargo, la in -\nmunizaci\u00f3n es menos eficaz en las personas de 65 o m\u00e1s a\u00f1os \ndebido a la inmunosenescencia [3\u20135]. Esto hace que los mayo -\nres muestren una respuesta menos intensa y efectiva a la va -\ncuna en comparaci\u00f3n con la poblaci\u00f3n adulta m\u00e1s joven [6,7]. \nCon objeto de mejorar la respuesta a la vacuna antigripal en \nlos mayores se han propuesto diversas estrategias, tales como \nel uso de adyuvantes (por su efecto inmunoestimulador), v\u00edas \nde administraci\u00f3n alternativas, o vacunas atenuadas en lugar \nde inactivadas [8]. \nLas vacunas adyuvadas con MF59, dise\u00f1adas para mejorar \nla magnitud, persistencia y amplitud de la respuesta inmuni -\ntaria en poblaci\u00f3n de 65 a\u00f1os o m\u00e1s, se vienen utilizando en \nla pr\u00e1ctica cl\u00ednica desde 1997 en su formulaci\u00f3n trivalente y, \ndesde 2020, tambi\u00e9n en formulaci\u00f3n tetravalente [9\u201311]. Nue -\nve estudios de evidencia con datos de pr\u00e1ctica cl\u00ednica ( real-\nworld evidence ) publicados en 2020-2021, que analizaron va -\nrias temporadas consecutivas de gripe e incluyeron 53 millones \nde participantes, han demostrado que la vacuna con MF59 es \nm\u00e1s efectiva que las vacunas convencionales e igual de efecti -\nva que la de alta dosis en poblaci\u00f3n de 65 a\u00f1os o m\u00e1s  [12,13]. \nEsto complementa la evidencia de 12 estudios de efectividad, \nidentificados en una reciente revisi\u00f3n, que compararon la va -\ncuna con MF59 frente a las vacunas convencionales no adyu -\nvadas y que incluyeron 14 millones de participantes [12,13].\nTipo de estudio N\u00famero de estudios incluidos N\u00famero de estudios con aTIV N\u00famero de estudios con aQIV*\nEnsayos cl\u00ednicos [15\u201319] 5 3 2\nEstudios observacionales [20\u201331] 12 12 -\nRevisiones sistem\u00e1ticas/metaan\u00e1lisis [13,33,34] 3 3 -Tabla 1  N\u00famero de estudios incluidos en la revisi\u00f3n en funci\u00f3n del dise\u00f1o\naQIV: vacuna antigripal tetravalente adyuvada y de dosis est\u00e1ndar; aTIV: vacuna antigripal trivalente adyuvada y de dosis est\u00e1ndar\n*Debido a la comercializaci\u00f3n en 2020 de la primera vacuna aQIV, todav\u00eda no se dispone de datos en vida real para esta, por lo que la mayor\u00eda de datos \nde efectividad de las vacunas adyuvadas proceden de estudios realizados con la vacuna aTIV. Sin embargo, debido a la formulaci\u00f3n, composici\u00f3n en parte \ncoincidente y proceso de fabricaci\u00f3n similar entre ambos tipos de vacuna, la evidencia de la efectividad de la vacuna aTIV resulta tambi\u00e9n pertinente para \nla vacuna aQIV.Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-345336Autor (a\u00f1o)\n[referencia]Dise\u00f1o n Temporada de gripe Resultados principales\nFrey (2014) [15] Fase 3, prospectivo, \naleatorizado, controlado \ncon placebo y enmascarado \npara el observadoraTIV: 3.541\nTIV: 3.5412010-11  -aTIV: respuestas significativamente m\u00e1s elevadas vs. TIV frente a todas las \ncepas hom\u00f3logas y heter\u00f3logas, incluso en caso de comorbilidad \n -No se estableci\u00f3 la superioridad seg\u00fan los criterios predefinidos\n -Aunque la reactividad fue mayor en el grupo de aTIV, las reacciones \nfueron leves/moderadas y transitorias\nEssink (2020) [16] Fase 3, multic\u00e9ntrico, \naleatorizado, doble \nenmascaramiento, \nde grupos paralelos y \ncontroladoaQIV: 889\naTIV-1: 445\naTIV-2: 4442017-18  -aQIV: respuesta similar a aTIV frente a cepas de gripe hom\u00f3logas \n -El beneficio inmunol\u00f3gico de aQIV tambi\u00e9n se demostr\u00f3 en los subgrupos \nde 65\u201374, 75\u201384 y \u226585 a\u00f1os y en aquellos sujetos con alto riesgo de \ncomorbilidad\n -aQIV y aTIV fueron inmunog\u00e9nicas y bien toleradas\nBeran (2021) [18] Fase 3, multic\u00e9ntrico, \naleatorizado, estratificado, \ndoble enmascaramiento y \ncontroladoaQIV: 3.381\nComparador: 3.3802016-17  -aQIV: EV 19,8% frente a todas las cepas y 49,9% frente a compatibles \nantig\u00e9nicamente \n -No se cumpli\u00f3 el criterio preespecificado para mostrar la eficacia de aQIV \n -85% de los aislamientos caracterizados no coincidieron con la cepa \nvacunal \n -aQIV: mayor protecci\u00f3n contra la gripe cl\u00ednicamente relevante durante \nlas temporadas dominadas por el subtipo A(H3N2), antig\u00e9nicamente \ndivergentes\n -Eficacia mayor en los casos asociados a fiebre m\u00e1s alta (enfermedad \ncl\u00ednicamente m\u00e1s significativa)\n -EA local m\u00e1s com\u00fan: dolor en el sitio de inyecci\u00f3n (16,3% aQIV y 11,2 % \ncomparador)\nCowling (2020) [17] Fase 3, aleatorizado, \ncontrolado, de comparaci\u00f3n \ndirectaQIV: 200\naTIV: 200\nHD-TIV: 200\nQIVr: 2002017-18  -aTIV: mejor respuesta humoral y celular vs. QIV, especialmente para las \ncepas de tipo A \n -Efectos para las cepas de tipo B menos claros: elevados para la cepa B/\nlinaje-Victoria, especialmente con QIV\n -EA leves y transitorios\n -Algunas reacciones locales agudas fueron m\u00e1s frecuentes con aTIV o con \nHD-TIV vs. QIV\n -A medio plazo, menos EA como hinchaz\u00f3n, dolor o sensibilidad con aTIV \nvs. SQIV\nSchmader (2021) \n[19]Prospectivo, aleatorizado, \nenmascaramiento simpleaTIV: 378\nHD-TIV: 3792017-18\n2018-19 -Seguridad y calidad de vida de aTIV vs. HD-TIV\n -La proporci\u00f3n de pacientes que notificaron dolor moderado o intenso \nen el lugar de inyecci\u00f3n que limitara o impidiera la actividad con aTIV \nno fue inferior vs. HD-TIV (3,2% vs. 5,8 %; diferencia \u22122,7 %; IC 95%: \n\u22125,8-0,4)\n -Cambios en las puntuaciones de CVRS: no fueron cl\u00ednicamente \nsignificativos y no difirieron entre los grupos\n -Los resultados de seguridad indican que ambas vacunas pueden usarse en \ncampa\u00f1as de vacunaci\u00f3n preventivas en adultos mayoresTabla 2  Ensayos cl\u00ednicos aleatorizados con la vacuna antigripal adyuvada en adultos de 65 a\u00f1os o m\u00e1s\naQIV: vacuna antigripal tetravalente adyuvada y de dosis est\u00e1ndar, aTIV: vacuna antigripal trivalente adyuvada y de dosis est\u00e1ndar, EA: efecto adverso, HD-QIV: vacuna \nantigripal tetravalente de alta dosis, HD-TIV: vacuna antigripal trivalente de alta dosis, n: tama\u00f1o muestral, QIVr: vacuna tetravalente de hemaglutinina recombinante, \nTIV: vacuna antigripal trivalente sin adyuvar y de dosis est\u00e1ndar.Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-345337Estudio (a\u00f1o)\n[referencia]Dise\u00f1o n Temporada de gripe Resultados principales\nIzurieta (2019) [21] Retrospectivo de cohortes \nque compara 5 vacunas>13x1062017-18  -Comparaci\u00f3n en EE.UU. de 5 vacunas (QIVc, QIVe, TIV, aTIV y HD-TIV) en la \nprevenci\u00f3n de hospitalizaciones\n -Eficacia de QIVc: \u2248 10-11% mayor que QIVe en evitar hospitalizaciones, \nvisitas hospitalarias y consultas \n -Mayor EVr en reducci\u00f3n de visitas hospitalarias y n\u00famero de \nhospitalizaciones relacionadas con la gripe con QIVc y HD-TIV \nIzurieta (2020) [20] Retrospectivo de cohortes \nque compara 6 vacunas>12,7x1062018-19  -Comparaci\u00f3n en EE.UU. de 6 vacunas (QIVc, QIVr, QIVe, TIV, aTIV y HD-TIV)\n -aTIV y HD-TIV fueron algo m\u00e1s efectivas que QIVe \n -Las vacunas QIV no mostraron diferencias significativas de eficacia entre \nlas producidas en cultivo celular y las basadas en huevo\n -Las vacunas adyuvadas y la a HD-TIV a base de huevo fueron ligeramente \nm\u00e1s eficaces que las vacunas QIV basadas en huevo\nIzurieta (2021) [22] Retrospectivo de cohortes \nque compara 5 vacunas>12,7x1062019-20  -Comparaci\u00f3n en EE.UU. de 5 vacunas (HD-TIV, aTIV, QIVe, QIVc y QIVr)\n -En la prevenci\u00f3n de visitas hospitalarias, QIVr (EVr 13,3%: 7,4-18,9%), aTIV \n(8,2%: 4,2-12,0%) y HD-TIV (6,8%: 3,3-10,1%) fueron significativamente \nm\u00e1s eficaces que QIVc\n -La vacuna recombinante fue moderadamente m\u00e1s eficaz que el resto, \nmientras que HD-TIV y aTIV fueron m\u00e1s efectivas que QIVe. \nVan Aalst (2020) [23] Retrospectivo de cohortes HD-TIV: >1,9x106\naTIV: 223.7932016-17\n2017-18 -Comparaci\u00f3n de HD-TIV vs. aTIV en EE.UU.\n -HD-TIV se asoci\u00f3 a menos visitas hospitalarias por causa respiratoria que \naTIV \nMcConeghy (2021) \n[24]Por conglomerados \n(clusters)aTIV: 24.926\nTIV: 25.0862016-17  -Comparaci\u00f3n en residencias de ancianos del n\u00famero de hospitalizaciones \n(poblaci\u00f3n vacunada con aTIV vs. TIV) en EE.UU.\n -aTIV: m\u00e1s eficaz que TIV en prevenir hospitalizaciones por cualquier causa \ny por neumon\u00eda o gripe \n -Ambas mostraron una tasa de hospitalizaci\u00f3n respiratoria similar en una \ntemporada de baja efectividad vacunal \nPelton (2020) [25] Retrospectivo de cohortes aTIV: 234.313\nHD-TIV: \n1.269.855\nQIV: 212.287\nTIV: 106.4912017-18  -Comparaci\u00f3n de aTIV, HD-TIV, QIV y TIV. \n -aTIV: EVr significativamente mayor en reducci\u00f3n de hospitalizaciones/\nvisitas a urgencias relacionadas con la gripe vs. QIV y TIV, y similar a HD-\nTIV \n -aTIV se asoci\u00f3 a una EVr significativamente mayor que TIV en evitar \nhospitalizaciones/visitas a urgencias por causa respiratoria\nPelton (2021) [26] Retrospectivo de cohortes aTIV: 561.315\nHD-TIV: \n1.672.7792018-19  -aTIV vs. HD-TIV en la prevenci\u00f3n de hospitalizaciones y visitas a urgencias \nrelacionadas con la gripe \n -Hospitalizaciones/visitas a urgencias relacionadas con la gripe similares \nentre ambas vacunas\n -aTIV: ligeramente m\u00e1s efectiva para prevenir las consultas relacionadas \ncon la gripe y cualquier evento cardiorrespiratorio vs. HD-TIV\nLevin (2021) [27] Retrospectivo de cohortes aTIV: 798.987\nHD-TIV: \n1.655.9792019-20  -aTIV vs. HD-TIV en prevenci\u00f3n de hospitalizaciones y visitas a urgencias \npor eventos cardiorrespiratorios relacionados con la gripe \n -aTIV: eficacia similar a HD-TIV en la prevenci\u00f3n de hospitalizaciones/\nvisitas a urgencias relacionadas con la gripe, hospitalizaciones totales \ny hospitalizaciones/visitas a urgencias por causa cardiorrespiratoria \nrelacionadas con la gripeTabla 3  Estudios observacionales con la vacuna antigripal adyuvada en adultos \u226565 a\u00f1osEficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-345338vocaba una respuesta inmunitaria no inferior en comparaci\u00f3n \ncon aTIV-1 y aTIV-2; as\u00ed como examinar la superioridad de aQIV \nfrente a la cepa B, adem\u00e1s de analizar la reactogenicidad y se -\nguridad. Los t\u00edtulos de anticuerpos se determinaron antes de la \nvacunaci\u00f3n y a los 21 d\u00edas de la misma para cepas hom\u00f3logas. \nLa vacuna aQIV cumpli\u00f3 con los criterios de no inferioridad \nfrente a aTIV en cuanto a diferencia en la media geom\u00e9trica \nde los t\u00edtulos de anticuerpos (MGT) y tasa de seroconversi\u00f3n. \nTambi\u00e9n cumpli\u00f3 con los criterios de superioridad para la cepa \nB. Todas las vacunas fueron inmunog\u00e9nicas y bien toleradas. \nEn el ECA de  Cowling et al.  [17] (2020), adultos de 65-\n82 a\u00f1os fueron asignados a recibir una vacuna tetravalente de \ndosis est\u00e1ndar (QIV), una vacuna aTIV, una vacuna trivalente TIV frente a todas las cepas hom\u00f3logas y heter\u00f3logas del virus \nde la gripe, incluso en sujetos con mayor riesgo de complica -\nciones por presentar comorbilidad, aunque no se estableci\u00f3 la \nsuperioridad seg\u00fan los criterios predefinidos. Respecto la segu -\nridad, la reactogenicidad fue mayor en el grupo de aTIV; pero \nlas reacciones fueron leves o moderadas y de corta duraci\u00f3n.\nEssink et al. [16] (2020) realizaron un ECA con doble en -\nmascaramiento y multic\u00e9ntrico en el que los pacientes fueron \nasignados 2:1:1 a recibir una vacuna tetravalente adyuvada \ncon MF59 (aQIV), una vacuna aTIV-1, correspondiente a la va -\ncuna autorizada para el hemisferio norte en la temporada de \ngripe 2017-2018, u otra vacuna aTIV-2 con la cepa B alternati -\nva. El estudio tuvo por objetivos evaluar si la vacuna aQIV pro -Estudio (a\u00f1o)\n[referencia]Dise\u00f1o n Temporada de gripe Resultados principales\nBoikos (2021) [28] Retrospectivo de cohortes 2017-2018\naTIV: 524.223 \nQIV: 917.609\nHD-TIV: \n3.377.860\n2018-2019\naTIV: 1.031.145\nQIV: 915.380\nHD-TIV: 3.809.6012017-18\n2018-19 -Comparaci\u00f3n de aTIV, QIV y HD-TIV en cuanto a prevenci\u00f3n de eventos y \ncomplicaciones relacionadas con la gripe en EE.UU.\n -aTIV: mayor reducci\u00f3n de eventos m\u00e9dicos relacionados con la gripe vs. \nQIV y HD-TIV para ambas temporadas \n -En poblaci\u00f3n anciana de alto riesgo con comorbilidades de base, EVr de \naTIV superior a QIV y similar a HD-TIV\nBoikos (2021) [29] Retrospectivo de cohortes \n(parte de Boikos et al., \n2021a)2017-2018\naTIV: 168.125 \nQIV: 360.379\nHD-TIV: 1.226.916\n2018-2019\naTIV: 328.227\nQIV: 351.260\nHD-TIV: \n1.375.5252017-18\n2018-19 -Comparaci\u00f3n de aTIV, QIV y HD-TIV en cuanto a evitar consultas \nrelacionadas con la gripe en EE.UU.\n -En comparaci\u00f3n con QIV, la efectividad de aTIV fue un 7,1% (IC 95%: 3,3-\n10,8) y un 20,4% (16,2-24,4) mayor para prevenir consultas relacionadas \ncon la gripe en las temporadas 2017-2018 y 2018-2019, respectivamente \n -Eficacia similar a HD-TIV en ambas temporadas\nImran (2022) [30] Retrospectivo de cohortes aTIV: 936.508\nQIV: 651.034\nHD-TIV: 1.813.8192019-20  -Comparaci\u00f3n de aTIV, QIV y HD-TIV en cuanto a prevenci\u00f3n de eventos y \ncomplicaciones relacionadas con la gripe en EE.UU.\n -aTIV: mejor EVr frente eventos hospitalarios y ambulatorios vs. QIV y HD-\nTIV\n -Resultados consistentes en todos los subgrupos de edad y en ambas \ntemporadas \nLapi (2022) [31] Retrospectivo de casos y \ncontroles anidadosaTIV: 5.610\nTIV/QIV: 41.5942002-03 a 2018-19\n(18 temporadas) -Eficacia relativa de aTIV frente a TIV/QIV en la reducci\u00f3n de \nhospitalizaciones por cualquier causa\n -En comparaci\u00f3n con la TIV/QIV, aTIV se asoci\u00f3 con una reducci\u00f3n del 12% \nde las probabilidades de hospitalizaci\u00f3n por cualquier causa\n -Los resultados para la temporada 2018-19 son consistentes para la vacuna \naTIV pero no para la aQIV. \naQIV: vacuna antigripal tetravalente adyuvada y de dosis est\u00e1ndar; aTIV: vacuna antigripal trivalente adyuvada y de dosis est\u00e1ndar, c: tecnolog\u00eda celular, e: basada en \nhuevo, CVRS: calidad de vida relacionada con la salud, EVr: efectividad vacunal relativa, HD-TIV: vacuna antigripal trivalente de alta dosis, n: tama\u00f1o muestral, QIV: va -\ncuna antigripal tetravalente sin adyuvar y de dosis est\u00e1ndar, QIVr: vacuna tetravalente de hemaglutinina recombinante, TIV: vacuna antigripal trivalente sin adyuvar y de \ndosis est\u00e1ndar.Tabla 3  Estudios observacionales con la vacuna antigripal adyuvada en adultos \u226565 a\u00f1os (cont.)Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-345339de alta dosis (HD-TIV) o una vacuna tetravalente de hemaglu -\ntinina recombinante (QIVr) autorizadas para la temporada de \ngripe 2017-2018. Se analizaron los sueros de 200 receptores \nde cada vacuna, antes y 30 d\u00edas despu\u00e9s de la vacunaci\u00f3n, para \ndetectar anticuerpos frente a las cepas vacunales producidas \nen huevo (mediante inhibici\u00f3n de la aglutinaci\u00f3n, HAI) y frente \nal virus A/Hong Kong/4801/2014(H3N2) de cultivo celular (me -\ndiante microneutralizaci\u00f3n, MN). Se evaluaron las respuestas \nde linfocitos T CD4+ y CD8+ espec\u00edficos de gripe en 20 par -\nticipantes por grupo. Los aumentos medios ( mean fold rises , \nMFR) en los t\u00edtulos de HAI para A(H1N1)pdm09 y A(H3N2), y \nde MN para A(H3N2) fueron significativamente superiores con \nlas vacunas mejoradas frente a las de dosis est\u00e1ndar (p<0,05). \nDe igual modo, en los receptores de la vacuna QIVr el t\u00edtulo \nfrente a A(H3N2) fue 2,57 veces mayor que con la vacuna de \ndosis est\u00e1ndar; la magnitud de esta diferencia fue significati -\nvamente mayor que las diferencias de 1,43 y 1,33 observadas \nen los receptores de vacuna de alta dosis y vacuna adyuvada \ncon MF59, en comparaci\u00f3n con los que recibieron una vacuna \nde dosis est\u00e1ndar. Los autores concluyeron que los sujetos que \nrecibieron vacunas mejoradas (aTIV, HD-TIV o QIVr) mostraron \nuna mejor respuesta inmunitaria (humoral y celular) respecto a \nlos que recibieron la de dosis est\u00e1ndar.\nEl ECA de  Beran et al. [18] (2021), con doble enmascara -\nmiento, fue realizado en 12 pa\u00edses en las temporadas 2016-\n17 en el hemisferio norte, y en la 2017 en el hemisferio sur. \nLos participantes, estratificados en funci\u00f3n de la edad (65-74 \ny \u226575 a\u00f1os) y del riesgo de complicaciones de la gripe, se asig -\nnaron al azar 1:1 a recibir aQIV o una vacuna no antigripal. Se \ntrata del \u00fanico ensayo cl\u00ednico con resultados de casos de gripe \nconfirmados por laboratorio. El resultado principal seg\u00fan pro -\ntocolo fue la eficacia absoluta de la vacuna en prevenir casos \nde gripe, confirmada por RT-PCR, frente a cualquier cepa de \ngripe en pacientes con s\u00edntomas de gripe y fiebre \u2265 37,2\u00baC. Se \nregistraron un 3,6% de casos de gripe confirmados en el grupo \nde aQIV y un 4,5% en el comparador, la mayor\u00eda causados por \nel subtipo A(H3N2). Un 85% de los aislamientos caracterizados \nno coincidieron con la cepa vacunal. Aun as\u00ed, la vacuna aQIV \nmostr\u00f3 una eficacia seg\u00fan protocolo del 19,8% (IC 95% -5,3 a \n38,9) frente a todas las cepas y del 49,9% (-24,0 a 79,8) fren -\nte a cepas compatibles antig\u00e9nicamente. Cabe destacar que \nla eficacia frente a casos de gripe con pruebas de laboratorio \npositivas en sujetos con fiebre \u2265 38,0\u00baC fue del 51,1% (28,2 a \n66,7). La reacci\u00f3n m\u00e1s com\u00fan a la vacuna adyuvada fue el do -\nlor en el sitio de inyecci\u00f3n. La eficacia de la vacuna adyuvada \nfue mayor en los casos de fiebre m\u00e1s alta, que corresponden a \nenfermedad m\u00e1s relevante.\nPor \u00faltimo, en el ECA con enmascaramiento simple de \nSchmader et al. [19] (2021) se compararon la seguridad, la \nreactogenicidad y las variaciones en la CVRS tras la vacuna -\nci\u00f3n con aTIV frente a HD-TIV en las temporadas 2017-2018 y \n2018-2019. La proporci\u00f3n de pacientes que notificaron dolor \nmoderado o intenso en el lugar de inyecci\u00f3n con aTIV fue simi -\nlar respecto a HD-TIV (3,2% frente al 5,8%; diferencia -2,7%; \nIC 95%: -5,8 \u2013 0,4%). No se observaron EA de inter\u00e9s cl\u00ednico. \nNing\u00fan participante precis\u00f3 atenci\u00f3n m\u00e9dica por una reacci\u00f3n a la vacuna y no se asoci\u00f3 ning\u00fan EA grave a la vacunaci\u00f3n. \nLos cambios en las puntuaciones de CVRS no fueron cl\u00ednica -\nmente significativos y no difirieron entre los grupos de edad \ncon ambas vacunas.\nEstudios observacionales. Resumimos seguidamente \nla evidencia de 12 estudios observacionales [20\u201331] sobre la \nefectividad de la vacuna antigripal adyuvada en la pr\u00e1ctica cl\u00ed -\nnica (Tabla 3).\nIzurieta et al. llevaron a cabo 3 grandes estudios indepen -\ndientes, de cohortes y retrospectivos, en pacientes \u226565 a\u00f1os \nde la base de datos Medicare en EE.UU. [20\u201322]. En el primero \nde ellos [21], realizado en la temporada 2017-18 en m\u00e1s de 13 \nmillones de sujetos que recibieron distintas vacunas frente a \nla gripe (QIVe basada en huevo, QIVc en cultivo celular; HD-\nTIV en huevo, aTIV o TIV), la efectividad vacunal relativa (EVr) \nde las vacunas de cultivo celular en relaci\u00f3n con la QIVe fue \ndel 10% (IC 95%: 7\u201313%). La vacuna aTIV demostr\u00f3 ser lige -\nramente m\u00e1s efectiva que las vacunas TIV (EVr 3,6%; IC 95%: \n0,7\u20136,4%; p \u22640,05) y QIV (EVr 3,9%; IC 95%: 1,4\u20136,3%; p \u22640,05) \nbasadas en huevo sin adyuvar en la prevenci\u00f3n de hospitali -\nzaciones relacionadas con la gripe, pero fue menos efectiva \nque la vacuna QIVc (EVr 7,5%; IC 95%: 4,1\u201310,7%; p \u22640,05) y la \nHD-TIV (EVr 5,3%; IC 95%: 3,3\u20137,3%; p \u22640,05). El segundo es -\ntudio [20], realizado en la temporada 2018-19, investig\u00f3 en 12 \nmillones de personas la EVr en la prevenci\u00f3n de consultas hos -\npitalarias asociadas a la gripe. La efectividad fue algo superior \npara la vacuna basada en huevo adyuvada (EVr 7,7%; IC 95%: \n3,9\u201311,4%; p \u22640,05) y la vacuna de alta dosis (EVr 4,9%; 1,7\u2013\n8,1%; p\u22640,05) respecto a la QIV. En el tercero de estos estudios \n[22], en la temporada 2019-20, se estim\u00f3 la EVr de las vacunas \nHD-TIV, aTIV, QIVe, QIVc y la vacuna tetravalente recombinante \n(QIVr) en 12,7 millones de sujetos. Se observ\u00f3 una superioridad \nsignificativa en la EVr de QIVr (13,3%: 7,4\u201318,9%), aTIV (8,2%: \n4,2\u201312,0%) y HD-TIV (6,8%: 3,3\u201310,1%) respecto a la vacuna \nQIVe en la prevenci\u00f3n de visitas hospitalarias, mientras que QI -\nVc no fue significativamente m\u00e1s efectiva que QIVe (EVr 2,8%: \n-2,8\u20138,2%). En la temporada 2019-20 la circulaci\u00f3n del virus \nde la gripe A(H3N2) fue escasa, por lo que los resultados deben \ninterpretarse teniendo en cuenta esta circunstancia.\nUn estudio de cohortes retrospectivo, llevado a cabo por \nVan Aalst et al. [23] (2020) en las temporadas de gripe 2016-\n2017 y 2017-2018, compar\u00f3 la efectividad vacunal en casi 2 \nmillones de personas \u226565 a\u00f1os que recibieron la vacuna HD-\nTIV frente a la aTIV. La EVr agrupada para ambas temporadas \nde HD-TIV frente a aTIV, en cuanto a hospitalizaciones rela -\ncionadas con problemas respiratorios, fue del 12% (IC 95%: \n3,3\u201320%); 13% (-6,4\u201332%) para la temporada 2016-2017 y \n12% (2,1\u201321%) para la 2017-2018. \nEn un estudio observacional, McConeghy et al. [24] (2021) \nasignaron al azar 823 residencias de ancianos de estancia pro -\nlongada para que ofrecieran a sus residentes (n=50.012) aTIV \no TIV en la temporada 2016-2017. Se evalu\u00f3 la efectividad \nde aTIV frente a TIV en evitar hospitalizaciones. Las tasas de \nhospitalizaci\u00f3n por neumon\u00eda o gripe y por cualquier causa \nfueron menores con aTIV que con TIV (HR ajustado 0,80 [IC Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-345340cionadas con la gripe en ambas temporadas (un 7,1% [IC 95%: \n3,3\u201310,8%] y un 20,4% [IC 95%: 16,2\u201324,4%]). En la primera \ntemporada, la efectividad de aTIV fue estad\u00edsticamente supe -\nrior en los pacientes con diabetes; en la segunda, tambi\u00e9n fue \nsignificativamente superior en los pacientes con enfermedad \npulmonar obstructiva cr\u00f3nica (EPOC), asma, infarto de miocar -\ndio, enfermedad cerebrovascular, enfermedad renal y c\u00e1ncer. \nSe observ\u00f3 una efectividad similar de aTIV respecto HD-TIV en \nambas temporadas de gripe.\nEn 2022, Imran et al. [30] estudiaron de forma retrospec -\ntiva la efectividad de aTIV, QIV y HD-TIV (temporada 2019-\n2020) en 3.553.040 sujetos \u2265 65 a\u00f1os. La EVr total de aTIV fue \ndel 27,5% (IC 95%: 24,4\u201330,5%) frente a QIV y del 13,9% (IC \n95%: 10,7\u201317,0%) frente a HD-TIV. La efectividad de la vacu -\nna aTIV fue superior tanto en pacientes hospitalizados como \nambulatorios. Los valores de EVr para pacientes hospitalizados \n(ingresos con cualquier diagn\u00f3stico) y consultas relacionadas \ncon la gripe en pacientes ambulatorios fueron significativos \nen la comparaci\u00f3n entre aTIV y QIV. La EVr de aTIV frente a \nHD-TIV en pacientes hospitalizados no fue estad\u00edsticamente \nsignificativa cuando la gripe fue el diagn\u00f3stico principal de in -\ngreso, aunque s\u00ed lo fue cuando la gripe se notific\u00f3 en cualquier \nposici\u00f3n de los diagn\u00f3sticos asociados al ingreso. Los hallazgos \nse mantuvieron en los subgrupos de edad (65-74; 75-84 y \u226585 \na\u00f1os). La vacuna aTIV se asoci\u00f3 significativamente a menos \nconsultas relacionadas con la gripe que las otras dos vacunas.\nEn el estudio recientemente publicado de Lapi et al. [31] \n(2022) se ha analizado la EVr de las vacunas aTIV frente a las \nno adyuvadas (TIV y QIV) en la prevenci\u00f3n de hospitalizaciones \npor cualquier causa en 18 temporadas de gripe en atenci\u00f3n \nprimaria. Este estudio realiz\u00f3 un an\u00e1lisis de casos y controles \nanidados empleando la base de datos Health Search e inclu -\ny\u00f3 una cohorte de 58.252 pacientes vacunados con aTIV, TIV o \nQIV. Durante las 18 temporadas de gripe estudiadas, se iden -\ntificaron 2.504 casos de hospitalizaci\u00f3n por cualquier causa y \nla vacuna aTIV se asoci\u00f3 a una reducci\u00f3n relativa en la proba -\nbilidad de ingreso por cualquier causa [12% (OR 0,88; IC 95%: \n0,80-0,97; p<0,05)] en comparaci\u00f3n con las vacunas no adyu -\nvadas. \nRevisiones sistem\u00e1ticas y metaan\u00e1lisis. Tres revisiones \nsistem\u00e1ticas/metaan\u00e1lisis [13,33,34] recientes han estudiado la \nefectividad de la vacuna adyuvada con MF59 en pacientes ma -\nyores en la pr\u00e1ctica cl\u00ednica real (Tabla 4).\nLa primera de ellas fue publicada por Coleman et al. [33] \nen 2021 y su objetivo fue determinar la efectividad de la vacu -\nna aTIV/aQIV en personas \u226565 a\u00f1os, comparado con la ausen -\ncia de vacunaci\u00f3n o la vacunaci\u00f3n con vacunas est\u00e1ndar o de \nalta dosis basadas en huevo. Este metaan\u00e1lisis encontr\u00f3 que \naTIV redujo el n\u00famero de consultas debido a gripe confirmada, \ncon estimaciones agrupadas del 40,7% (IC 95%: 21,9\u201354,9) y \ndel 58,5% (IC 95%: 40,7\u201370,9) para visitas ambulatorias no ur -\ngentes y para pacientes hospitalizados. La estimaci\u00f3n agrupa -\nda de EVr fue del 51,3% (39,1\u201361,1; I 2=0%; p=0,42) en cuanto \na hospitalizaciones relacionadas con gripe o neumon\u00eda. Las es -\ntimaciones agrupadas de la EVr de aTIV en evitar consultas re -95%: 0,66\u20130,98; p=0,03] y 0,94 [0,89\u20130,99; p=0,02]). La tasa \nde hospitalizaci\u00f3n por cualquier causa respiratoria fue similar \nen ambos grupos de vacunados, en una temporada donde la \nefectividad vacunal se consider\u00f3 baja [32].\nDurante la temporada 2017-2018, Pelton et al. [25] (2020) \nevaluaron la efectividad de la vacuna aTIV respecto a otras \nvacunas antigripales (HD-TIV, QIV, TIV) en prevenir eventos \ncardiorrespiratorios relacionados con la gripe en m\u00e1s de 1,82 \nmillones de personas. La vacuna aTIV fue m\u00e1s efectiva en re -\nducir las consultas relacionadas con la gripe y otras hospitali -\nzaciones/visitas a urgencias por causa respiratoria en compa -\nraci\u00f3n con el resto de vacunas. En cuanto a hospitalizaciones/\nvisitas a urgencias relacionadas con la gripe, aTIV mostr\u00f3 una \nEVr significativamente mayor que QIV y TIV (aTIV vs. QIV 8,6% \n[IC 95%: 1,2\u201315,6%]; aTIV vs. TIV 11,2% [2,3\u201319,4%]), y fue \nsimilar a HD-TIV. Tambi\u00e9n se asoci\u00f3 con una EVr significati -\nvamente mayor que TIV en cuanto a hospitalizaciones/visitas \na urgencias por causa respiratoria (aTIV vs. HD-TIV 2,4% [IC \n95%: 0,7\u20134%]; aTIV vs. QIV 4% [1,9\u20136,2%]; aTIV vs. TIV 7,2% \n[4,6\u20139,7%]). Se demostr\u00f3 un beneficio significativo de aTIV \nen los eventos relacionados con la gripe o respiratorios en \ncomparaci\u00f3n con el resto de vacunas. En la temporada 2018-\n2019, este mismo autor public\u00f3 (2021) la efectividad vacunal \nde aTIV en comparaci\u00f3n con las mismas vacunas en prevenir \neventos cardiorrespiratorios y relacionados con la gripe [26]. \nEn este caso, la vacuna aTIV fue m\u00e1s efectiva en reducir las \nconsultas relacionadas con gripe que la HD-TIV (6,6%; IC 95%: \n2,7\u201310,3%; p<0,001). Adem\u00e1s, aTIV fue similar a HD-TIV (EVr \n2,0%; IC 95%: -3,7\u20137,3%) en prevenir hospitalizaciones/visitas \na urgencias relacionadas con la gripe, pero m\u00e1s efectiva en re -\nducir las hospitalizaciones/visitas a urgencias por enfermedad \ncardiorrespiratoria (EVr 2,6%; IC 95%: 1,9\u20133,2%; p<0,0001). \nOtro estudio retrospectivo, llevado a cabo por Levin et al. \n[27], compar\u00f3 la efectividad vacunal de aTIV con la de HD-TIV \nen la prevenci\u00f3n de hospitalizaciones/visitas a urgencias rela -\ncionadas con la gripe y enfermedades cardiorrespiratorias. La \nEVr de aTIV fue similar a la de HD-TIV en evitar hospitaliza -\nciones/visitas a urgencias relacionadas con la gripe (3,1%; IC \n95%: -2,8\u20138,6%), hospitalizaciones totales (-0,7%; IC 95%: \n-1,6\u20130,3%) y cualquier hospitalizaci\u00f3n/visita a urgencias re -\nlacionada con enfermedad cardiorrespiratoria (0,9%; IC 95%: \n0,01\u20131,7%). \nBoikos et al. publicaron en 2021 dos estudios retrospec -\ntivos correspondientes a las temporadas 2017-2018 y 2018-\n2019 [28,29]. En el primero de ellos [28] se compar\u00f3, en m\u00e1s \nde 10 millones de estadounidenses \u226565 a\u00f1os, la efectividad de \naTIV, QIV y HD-TIV en t\u00e9rminos de prevenci\u00f3n de consultas re -\nlacionadas con la gripe. En 2017-2018, la EVr de aTIV frente \na QIV fue de 18,2% (IC 95%: 15,8\u201320,5%) y de 7,7% frente \na HD-TIV (IC 95%: 2,3\u201312,8%). En 2018-2019, la EVr de aTIV \nfrente a QIV fue de 27,8% (IC 95%: 25,7\u201329,9) y de 6,9% frente \na HD-TIV (IC 95%: 3,1\u201310,6%). El segundo  [29], realizado en \nlas mismas temporadas, compar\u00f3 la efectividad de aTIV, QIV y \nHD-TIV en evitar consultas relacionadas con la gripe en m\u00e1s \nde 3,8 millones de pacientes con al menos una comorbilidad. \nRespecto a QIV, aTIV fue m\u00e1s efectiva en evitar consultas rela -Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-345341Autor (a\u00f1o)\n[referencia]Dise\u00f1o N\u00ba estudios Temporada de gripe Metodolog\u00eda Resultados principales\nColeman (2021) \n[33]Revisi\u00f3n sistem\u00e1tica \ny metaan\u00e1lisisRevisi\u00f3n sistem\u00e1tica: 21\nMetaan\u00e1lisis: 162006-07 a 2019-20  -Estudios no intervencionistas \npublicados en revistas revisadas por \npares y literatura gris desde 1997 \nhasta el 15 de julio de 2020, incluidos \nensayos aleatorizados por grupos\n -Conforme a los est\u00e1ndares \nmetodol\u00f3gicos Cochrane y las gu\u00edas \nPRISMA-P \n -Dos revisores extrajeron los datos de \nforma independiente\n -El riesgo de sesgo se evalu\u00f3 mediante \nROBINS-I -aTIV: EV absoluta significativa y \nmejor EVr vs. TIV y QIV\n -aTIV: EVr similar a la vacuna de alta \ndosis en poblaci\u00f3n \u226565 a\u00f1os\nG\u00e4rtner (2022) [13] Revisi\u00f3n sistem\u00e1tica 11 an\u00e1lisis de 9 estudios 2006-07 a 2008-09\n2011-12 a 2019-20 -Ensayo s controlados aleatorizados, \nestudios observacionales y revisiones \nsistem\u00e1ticas publicados entre el 7 de \nfebrero de 2020 y el 6 de septiembre \nde 2021 \n -Los estudios se evaluaron con la \nherramienta Cochrane de riesgo de \nsesgo, ROBINS-I o AMSTAR 2 -9 de l os 11 an\u00e1lisis: aTIV \nsignificativamente m\u00e1s eficaz vs. \nTIV y QIV en reducir los eventos \ncl\u00ednicos relacionados con la gripe y \nlos brotes de gripe\n -7 de los 11 an\u00e1lisis: aTIV eficacia \nsimilar a HD-TIV en reducir los \neventos m\u00e9dicos relacionados con \nla gripe, la duraci\u00f3n de la estancia \nhospitalaria y las hospitalizaciones/\nvisitas a urgencias \n -3 de los 11 an\u00e1lisis: aTIV m\u00e1s eficaz \nque HD-TIV en reducir las consultas \nrelacionadas con la gripe \n -La vacuna adyuvada y la de alta \ndosis son alternativas eficaces para \nlos programas de vacunaci\u00f3n en \nadultos mayores y son preferibles a \nlas vacunas convencionales de dosis \nest\u00e1ndar\nDomnich (2022) \n[34]Revisi\u00f3n sistem\u00e1tica 52 estimaciones de la \nEVr de 10 art\u00edculos2016-17 a 2019-20  -Ensayos controla dos aleatorizados y \nestudios observacionales publicados \nhasta el 08 de abril de 2022\n -Conforme a los est\u00e1ndares \nmetodol\u00f3gicos de las gu\u00edas PRISMA\n -Dos revisores extrajeron los datos de \nforma independiente\n -El riesgo de sesgo se evalu\u00f3 mediante \nROBINS-I\n -La herramie nta GRACE (good research \nfor comparative effectiveness) \nse aplic\u00f3 a los estudios que \ncuantificaban la EVr de aTIV/aQIV \nfrente HD-TIV/HD-QIV -Las vacunas antigripales adyuvadas \ny de alta dosis est\u00e1n actualmente \naprobadas para los adultos mayores\n -Las pruebas comparativas \ndisponibles se limitan a estudios \nobservacionales con datos del \nmundo real\n -Los resultados sobre la eficacia \nrelativa de las dos vacunas contra \nla gripe son inconsistentes\n -Los estudios patrocinados por la \nindustria tienden a informar de \nresultados m\u00e1s favorables\n -Los datos actualmente disponibles \nno apoyan ninguna preferencia de \nuna vacuna sobre otraTabla 4   Revisiones sistem\u00e1ticas y metaan\u00e1lisis de evidencia en vida real con la vacuna antigripal adyuvada en \nadultos \u226560 a\u00f1os\naTIV: vacuna antigripal trivalente adyuvada y de dosis est\u00e1ndar, EV: efectividad vacunal, EVr: efectividad vacunal relativa, HD-TIV: vacuna antigripal trivalente de alta do -\nsis, TIV: vacuna antigripal trivalente sin adyuvar y de dosis est\u00e1ndar. Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-345342lacionadas con la gripe fueron del 13,9 % (4,2\u201323,5; I 2=95,9%; \np<0,01) comparada con TIV, del 13,7% (3,1\u201324,2; I 2=98,8%; \np<0,01) frente a QIV, y del 2,8% (-2,9\u20138,5; I 2=94.5%; p<0,01) \ncomparada con HD-TIV. Se concluy\u00f3 que aTIV mostr\u00f3 una EV \nabsoluta significativa, una mejor EVr en comparaci\u00f3n con la \nvacuna TIV/QIV de dosis est\u00e1ndar, y una EVr similar a HD-TIV en \npoblaci\u00f3n \u226565 a\u00f1os.\nLa segunda revisi\u00f3n sistem\u00e1tica, publicada por G\u00e4rtner et \nal. [13] en 2022, compar\u00f3 la eficacia y la efectividad de las va -\ncunas aTIV/aQIV frente a las de dosis est\u00e1ndar (TIV/QIV) y de \nalta dosis (HD-TIV/QIV) en personas de 65 a\u00f1os o m\u00e1s, para \ncomplementar la revisi\u00f3n sistem\u00e1tica de 2020 de las vacunas \nantigripales mejoradas llevada a cabo por el Centro Europeo \npara la Prevenci\u00f3n y el Control de Enfermedades (ECDC) [12]. \nSe identificaron 11 an\u00e1lisis de 9 estudios que inclu\u00edan 53 mi -\nllones de participantes. En 9 de los 11 an\u00e1lisis la vacuna aTIV \nfue significativamente m\u00e1s efectiva que TIV y QIV en resultados \nrelacionados con la gripe por entorno cl\u00ednico y presuntos bro -\ntes de gripe [EVr de aTIV entre el 7,5% (IC 95%: 4,2\u201310,6%) y el \n25,6% frente a TIV; y del 7,1% (IC 95%: 3,3\u201310,8) y el 36,3% (IC \n95%: 31,0\u201341,2) frente a QIV]. Siete an\u00e1lisis encontraron una \nefectividad similar de aTIV frente a HD-TIV en reducir el n\u00fame -\nro de consultas relacionadas con la gripe, el tiempo de estancia \nhospitalaria y las hospitalizaciones/visitas a urgencias. Y en dos \nan\u00e1lisis aTIV fue significativamente m\u00e1s eficaz que HD-TIV en \nreducir las consultas relacionadas con la gripe [EVr del 6,6% (IC \n95%:2,7\u201310,3% y del 16,6% (IC 95%: 10,8\u201322,0), respectiva -\nmente]. En general no se encontraron diferencias significativas \nentre ambas vacunas para las variables analizadas. El riesgo de \nsesgo de los estudios identificados fue de moderado a alto. \nLa tercera y \u00faltima revisi\u00f3n sistem\u00e1tica, publicada por \nDomnich et al. [34] en 2022, compar\u00f3 la eficacia y la efecti -\nvidad de la vacuna adyuvada (aTIV/aQIV) frente a la de alta \ndosis (HD-TIV/HD-QIV). Durante la b\u00fasqueda se identificaron \n10 estudios que cumpl\u00edan los criterios de inclusi\u00f3n, todos ellos \nobservacionales, con un dise\u00f1o de cohorte retrospectivo y \nelevado tama\u00f1o muestral. Todos fueron realizados en EE.UU. \nentre las temporadas de gripe 2016-2017 y 2019-2020. No \nse encontraron estudios que incluyeran aQIV ni HD-QIV [34]. \nAunque la mayor\u00eda de las estimaciones de EVr agrupada fueron \ncercanas a la nulidad, algunos estudios mostraron una efec -\ntividad ligeramente superior para una vacuna u otra. En con -\ncreto, de las 52 estimaciones de la EVr de aTIV frente a HD-TIV \no viceversa en poblaci\u00f3n \u2265 65 a\u00f1os, la mayor\u00eda (31/52; 59,6%) \nno fueron significativas. Entre las estimaciones significativas, \n13 (25,0%) favorec\u00edan a la vacuna aTIV, mientras que las 8 res -\ntantes (15,4%) eran favorables a HD-TIV. El an\u00e1lisis conjunto \nmostr\u00f3 que la vacuna aTIV fue superior a la HD-TIV (p < 0,05) \nfrente a: todas las consultas m\u00e9dicas relacionadas con la gri -\npe (hospitalizaciones, visitas a urgencias y consultas externas) \n(9,7%; IC 95%: 5,0\u201314,2; I 2=75,6%); consultas hospitalarias \n(tanto hospitalizaciones como visitas a urgencias) por neumo -\nn\u00eda (2,2%; IC 95%: 0,3\u20134,1; I 2=48,0%); asma/EPOC/afecciones \nbronquiales (1,2%; IC 95%: 0,2\u20132,2; I 2 = 0%), eventos cere -\nbrovasculares (2,4%; IC 95%: 0,4\u20134,4; I 2=46,1%) e ictus (2,4%; \nIC 95%: 0,4\u20134,4; I 2=45,2%). Por el contrario, aTIV fue menos efectiva (p < 0,05) que HD-TIV frente a las hospitalizaciones \npor causa respiratoria (-13,9%; IC 95%: -25,4\u20133,4; I 2 = 0%) y \nlas consultas hospitalarias (tanto estancias como visitas a ur -\ngencias) por eventos coronarios (-1,2%; IC 95%: -2,2 \u2013 -0,2; I 2 \n= 0%). No hubo diferencias significativas para otros par\u00e1me -\ntros. Las estimaciones de EVr se limitaron a criterios de valora -\nci\u00f3n cl\u00ednicos no confirmados por laboratorio (consultas m\u00e9di -\ncas, hospitalizaciones, etc.) y el riesgo de sesgo de los estudios \nfue moderado. \nDISCUSI\u00d3N\nEsta revisi\u00f3n de la evidencia sobre la eficacia, efectividad \ny seguridad de la vacuna antigripal adyuvada con MF59 en po -\nblaci\u00f3n de 65 a\u00f1os o m\u00e1s comprende diversos ensayos cl\u00ednicos, \nestudios observacionales y revisiones sistem\u00e1ticas realizados \nen distintas temporadas de gripe. Los resultados demuestran \nque las vacunas adyuvadas generan mayores t\u00edtulos de anti -\ncuerpos y respuestas m\u00e1s sostenidas en el tiempo en compara -\nci\u00f3n con las vacunas no adyuvadas de dosis est\u00e1ndar. \nEl uso de grandes bases de datos del mundo real que in -\ntegran diferentes fuentes de informaci\u00f3n (incluidos datos pro -\ncedentes de hospitales y farmacias) [26,28] permite evaluar \nla efectividad de las vacunas y complementar los resultados \nobtenidos a trav\u00e9s de ECA. Entre los trabajos revisados se in -\ncluyen estudios basados en varias fuentes de datos que explo -\nran m\u00faltiples criterios de valoraci\u00f3n y que permiten ampliar el \nespectro de casos relacionados con la gripe, abarcando desde \ncasos m\u00e1s graves (pacientes hospitalizados) hasta los menos \ngraves (pacientes ambulatorios o sin hospitalizaci\u00f3n). En este \nsentido, los trabajos de Pelton et al. (2021) e Imran et al. (2022) \nindican que la vacuna aTIV parece ser m\u00e1s efectiva en el en -\ntorno ambulatorio al reducir las consultas relacionadas con la \ngripe en comparaci\u00f3n con otras vacunas [26,30].\nCabe destacar los estudios de gran tama\u00f1o muestral rea -\nlizados en pacientes procedentes de bases de datos como Me -\ndicare [20\u201322]. Las fuentes empleadas permitieron analizar re -\nsultados relevantes como las hospitalizaciones en los cuidados \nde rutina en un contexto real, dif\u00edciles de obtener en cualquier \nECA. Estos estudios concluyeron que las vacunas HD-TIV y aTIV \nfueron m\u00e1s efectivas que la QIVe, y apoyan que la cantidad \nde ant\u00edgeno y el uso de adyuvantes pueden contribuir a incre -\nmentar la efectividad vacunal.\nDado que el efecto de la gripe se extiende m\u00e1s all\u00e1 de la \nenfermedad respiratoria, es importante comparar la efectivi -\ndad de las vacunas en cuanto a otros resultados cl\u00ednicos re -\nlevantes, como los eventos cardiovasculares [23,26,27,29]. El \nestudio de Pelton et al. [26] que evalu\u00f3 varios aspectos rela -\ncionados con la enfermedad cardiorrespiratoria, demostr\u00f3 que \nla vacuna aTIV fue similar a la HD-TIV en prevenir hospitaliza -\nciones/visitas a urgencias relacionadas con la gripe, pero m\u00e1s \nefectiva en reducir las hospitalizaciones/visitas a urgencias por \nenfermedad cardiorrespiratoria. Sin embargo, en el estudio de \nVan Aalst et al. [23], los datos agrupados para ambas tempo -\nradas de gripe muestran que la vacuna HD-TIV se asoci\u00f3 a me -Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-345343nos visitas hospitalarias por causa respiratoria que aTIV, lo cual \nrefleja que no existe consistencia entre los distintos estudios \nrevisados. \nDe igual modo, dado que el riesgo de morbilidad y morta -\nlidad por gripe aumenta con la edad entre los adultos mayores \n[35,36], es importante evaluar la efectividad de las vacunas en \neste grupo poblacional. Los estudios analizados en esta revi -\nsi\u00f3n demuestran que las vacunas antigripales adyuvadas pre -\nsentan resultados favorables en la poblaci\u00f3n de 65 a\u00f1os o m\u00e1s, \ngenerando una respuesta inmunitaria m\u00e1s robusta y sostenida \nen el tiempo [17,18] que se traduce en una reducci\u00f3n de las \nhospitalizaciones y las visitas/consultas a urgencias [25\u201327]. \nEsta ventaja se mantiene en los distintos grupos poblacionales \n(65-74 a\u00f1os; 75-84 a\u00f1os y \u226585 a\u00f1os) [30], un aspecto cr\u00edtico \ndada la creciente fragilidad de los pacientes con la edad. \nPor otro lado, con relaci\u00f3n a las variantes v\u00edricas, varios de \nlos estudios revisados demuestran que la vacuna antigripal ad -\nyuvada es m\u00e1s eficaz frente al subtipo A(H3N2) [17,18], cl\u00edni -\ncamente importante en poblaci\u00f3n de 65 a\u00f1os o m\u00e1s, e induce \nuna mejor protecci\u00f3n cruzada que las vacunas no adyuvadas, \nespecialmente la formulaci\u00f3n aQIV, ya que incluye una cepa \nB adicional (B/linaje Yamagata o Victoria). En el ECA de Essink \net al. [16] la vacuna aQIV adyuvada con MF59 cumpli\u00f3 con los \ncriterios de superioridad para la cepa B frente a una vacuna \naTIV-1 y otra aTIV-2 con una cepa B alternativa. Las vacunas \ntetravalentes, que incluyen las cepas A y B recomendadas por \nlas autoridades sanitarias, tienen el potencial de ofrecer una \nprotecci\u00f3n m\u00e1s amplia que las trivalentes.\nAdem\u00e1s, esta revisi\u00f3n muestra que, en temporadas con \nderiva antig\u00e9nica, la vacuna adyuvada mejora los resultados de \ninmunogenicidad en comparaci\u00f3n con otras vacunas est\u00e1ndar. \nEl estudio de Beran et al. [18] avala el beneficio de las vacunas \nantigripales adyuvadas en temporadas con una discrepancia \nsustancial entre las cepas circulantes y vacunales. Levin et al. \ndestacaron que la EVr fue similar entre aTIV y HD-TIV pese a \nque hubo poca o ninguna circulaci\u00f3n significativa de A(H3N2) \ndurante la temporada de 2019-2020, variante que a menudo \ncontribuye de manera importante a las hospitalizaciones y la \nmortalidad relacionadas con la gripe en poblaci\u00f3n de 65 o m\u00e1s \na\u00f1os de edad [27]. En los 2 estudios de Boikos [28,29], la deriva \nantig\u00e9nica de A(H3N2) fue mayor en la temporada 2018-2019 \nque en la 2017-2018, lo cual otorg\u00f3 un mayor beneficio a la \nvacuna aTIV. \nDesde el punto de vista de la seguridad, los resultados del \nestudio de Schmader et al. [19] respaldan el uso de cualquiera \nde las vacunas aTIV o HD-TIV para prevenir la gripe en adultos \nmayores. Este estudio fue el primero en determinar los efectos \nde la vacunaci\u00f3n antigripal en la calidad de vida de los pacien -\ntes, sin diferencias significativas entre ambas. Se confirm\u00f3 la \nseguridad de la vacuna adyuvada, tal y como ya demostraron \nPellegrini et al. en 2009 con datos procedentes de 64 ensayos \ncl\u00ednicos [37].\nEn t\u00e9rminos econ\u00f3micos, el uso de la vacuna adyuvada se \nconsidera una intervenci\u00f3n coste-efectiva [38]. Tal y como se \nestima en el estudio de Fochesato et al. (2022) [38] el coste incremental por a\u00f1o de vida ajustado por calidad que aporta \nla vacuna aQIV frente a la est\u00e1ndar es de 2.240 euros desde la \nperspectiva del pagador, considerando una EVr del 34,6%. El \nuso de vacunas adyuvadas puede suponer un ahorro para el \nSistema de Nacional de Salud espa\u00f1ol, tal y como revelan de \nlos datos de coste-efectividad disponibles [27,38\u201340]. El ahorro \nen costes sanitarios directos con la vacuna adyuvada trivalente \nse ha estimado en 63,6 millones de euros en comparaci\u00f3n con \nla HD-TIV, debido especialmente a la diferencia de precio entre \nambas vacunas [38]. Por otro lado, utilizar la vacuna adyuvada \nen toda la poblaci\u00f3n \u226565 a\u00f1os podr\u00eda suponer un ahorro de \nhasta 82 millones de euros respecto la vacuna no adyuvada \n[39]. La protecci\u00f3n conferida por la vacuna antigripal es fun -\ndamental en t\u00e9rminos econ\u00f3micos si se tiene en cuenta que el \ncoste de una epidemia de gripe puede alcanzar los 56,7 millo -\nnes de euros por mill\u00f3n de habitantes en los pa\u00edses industria -\nlizados [41].\nFinalmente, es preciso mencionar que,  entre los estudios \nanalizados, aportan m\u00e1s valor aquellos realizados en varias \ntemporadas de gripe, pues sus resultados son m\u00e1s f\u00e1cilmen -\nte extrapolables a nuevas temporadas, as\u00ed como aquellos en \nlos que se ha realizado el diagn\u00f3stico virol\u00f3gico de gripe. La \nutilizaci\u00f3n de definiciones de gripe ligeramente distintas en \nlos distintos trabajos y la ausencia de esta confirmaci\u00f3n diag -\nn\u00f3stica de laboratorio en algunos de ellos puede limitar la \ncomparaci\u00f3n de los datos [29\u201331]. Hay muchas variables cu -\nya definici\u00f3n ha cambiado a lo largo del tiempo, por lo que \nlas revisiones e investigaciones deben actualizarse de forma \nconstante. A ello es preciso a\u00f1adir otros factores ligados a la \nsusceptibilidad de las distintas cohortes, los cambios en las va -\ncunas y la deriva antig\u00e9nica de los virus.\nCONCLUSIONES\nLos resultados de ensayos cl\u00ednicos aleatorizados realiza -\ndos con vacunas antigripales adyuvadas con MF59 en diver -\nsas temporadas de gripe demuestran que \u00e9stas generan una \nrespuesta inmunitaria con mayores t\u00edtulos de anticuerpos y \nrespuestas m\u00e1s sostenidas en el tiempo respecto a vacunas no \nadyuvadas. Tambi\u00e9n presenta mejores resultados frente al sub -\ntipo A(H3N2) e induce una mejor protecci\u00f3n cruzada que las \nvacunas sin adyuvante. \nLos datos post-comercializaci\u00f3n reafirman que las vacu -\nnas adyuvadas y las de alta carga presentan una efectividad \nsimilar en cuanto a hospitalizaciones relacionadas con gripe y \nen pacientes de alto riesgo. Adem\u00e1s, demuestran que la vacuna \nantigripal adyuvada es m\u00e1s inmunog\u00e9nica que otras vacunas \nde dosis est\u00e1ndar en temporadas con deriva antig\u00e9nica, y que \npresentan un buen perfil de seguridad. \nCon la evidencia revisada, puede concluirse que las va -\ncunas adyuvadas son alternativas efectivas y seguras para ser \nincluidas en los programas de vacunaci\u00f3n en poblaci\u00f3n de 65 \no m\u00e1s a\u00f1os de edad, y que son preferibles a las vacunas con -\nvencionales de dosis est\u00e1ndar como estrategia de prevenci\u00f3n \nfrente a la gripe.Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-345344AGRADECIMIENTOS \nA Adelphi Targis S.L. por el apoyo de medical writing .\nFINANCIACI\u00d3N\nSeqirus Spain, S.L. ha promovido el desarrollo de este tra -\nbajo financiando los servicios de medical writing . Los autores \nhan desarrollado y consensuado el contenido con independen -\ncia de la fuente de financiaci\u00f3n.\nCONFLICTOS DE INTERESES\nLos autores declaran que han recibido honorarios por la \nparticipaci\u00f3n en grupos asesores que valoraron la informaci\u00f3n \naportada en este manuscrito, y se valor\u00f3 la oportunidad de \nuna revisi\u00f3n narrativa de la evidencia disponible. Los autores \ndeclaran que no han recibido honorarios adicionales derivados \nde su participaci\u00f3n en la elaboraci\u00f3n, escritura, revisi\u00f3n o valo -\nraci\u00f3n cr\u00edtica del manuscrito. \nBIBLIOGRAF\u00cdA\n1. Organizaci\u00f3n Mundial de la Salud (OMS). OMS, 2018 [citado 16 di -\nciembre 2022]. Disponible en: https://www.who.int/es/news-room/\nfact-sheets/detail/influenza-(seasonal). \n2. Iacobucci G. Covid-19: Risk of death more than doubled in people \nwho also had flu, English data show. BMJ. 2020;370:m3720. \ndoi:10.1136/bmj.m3720.\n3. McElhaney JE, Kuchel GA, Zhou X, Swain SL, Haynes L. T-cell immu -\nnity to influenza in older adults: A pathophysiological framework \nfor development of more effective vaccines. Front Immunol. \n2016;7:41. doi:10.3389/fimmu.2016.00041.\n4. Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Meda -\nglini D. Vaccination in the elderly: The challenge of immune chan -\nges with aging. Semin Immunol. 2018;40:83\u201394. doi:10.1016/j.\nsmim.2018.10.010.\n5. Dugan HL, Henry C, Wilson PC. Aging and influenza vaccine-in -\nduced immunity. Cell Immunol. 2020;348:103998. doi:10.1016/j.\ncellimm.2019.103998.\n6. Lang PO, Mendes A, Socquet J, Assir N, Govind S, Aspinall R. Effec -\ntiveness of influenza vaccine in aging and older adults: Compre -\nhensive analysis of the evidence. Clin Interv Aging. 2012;7:55\u201364. \ndoi:10.2147/CIA.S25215.\n7. Rondy M, el Omeiri N, Thompson MG, Lev\u00eaque A, Moren A, Sulli -\nvan SG. Effectiveness of influenza vaccines in preventing severe \ninfluenza illness among adults: A systematic review and meta-\nanalysis of test-negative design case-control studies. J Infect. \n2017;75:381\u201394. doi:10.1016/j.jinf.2017.09.010.\n8. Parodi V, Florentiis D de, Martini M, Ansaldi F. Inactivated Influenza \nVaccines Recent Progress and Implications for the Elderly. Drugs \nAging. 2011;28(2):93-106. doi:10.2165/11586770-000000000-\n00000.9. O\u2019Hagan DT, Ott GS, van Nest G, Rappuoli R, del Giudice G. The \nhistory of MF59 \u00ae adjuvant: A phoenix that arose from the ashes. \nExpert Rev Vaccines. 2013;12:13\u201330. doi:10.1586/erv.12.140.\n10. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Centro \nde Informaci\u00f3n de Medicamentos. Ficha t\u00e9cnica Chiromas. [citado \n16 diciembre 2022]. Disponible en: https://cima.aemps.es/cima/do -\nchtml/ft/63566/FT_63566.html. \n11. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Centro \nde Informaci\u00f3n de Medicamentos. Ficha t\u00e9cnica Fluad Tetra [citado \n16 diciembre 2022]. Disponible en: https://cima.aemps.es/cima/do -\nchtml/ft/1201433001/FT_1201433001.html. Citado 16 diciembre \n2022. \n12. European Centre for Disease Prevention and Control. Systematic \nreview of the efficacy, effectiveness and safety of newer and en -\nhanced seasonal influenza vaccines for the prevention of labora -\ntory-confirmed influenza in individuals aged 18 years and over, \n2020 [citado 16 diciembre 2022]. Disponible en: https://www.ecdc.\neuropa.eu/sites/default/files/documents/seasonal-influenza-vacci -\nnes-systematic-review-efficacy.pdf. \n13. G\u00e4rtner BC, Weinke T, Wahle K, Kwetkat A, Beier D, Schmidt KJ, et \nal. Importance and value of adjuvanted influenza vaccine in the \ncare of older adults from a European perspective \u2013 A systematic \nreview of recently published literature on real-world data. Vaccine \n2022;40:2999\u20133008. doi:10.1016/j.vaccine.2022.04.019.\n14. Par\u00e9 G, Trudel MC, Jaana M, Kitsiou S. Synthesizing information \nsystems knowledge: A typology of literature reviews. Inform Ma -\nnag. 2015;52:183\u201399. doi:10.1016/j.im.2014.08.008.\n15. Frey SE, Reyes MRA-DL, Reynales H, Bermal NN, Nicolay U, Narasi -\nmhan V, et al. Comparison of the safety and immunogenicity of an \nMF59 \u00ae-adjuvanted with a non-adjuvanted seasonal influenza va -\nccine in elderly subjects. Vaccine 2014;32:5027\u201334. doi:10.1016/j.\nvaccine.2014.07.013.\n16. Essink B, Fierro C, Rosen J, Figueroa AL, Zhang B, Verhoeven C, et \nal. Immunogenicity and safety of MF59-adjuvanted quadrivalent \ninfluenza vaccine versus standard and alternate B strain MF59-\nadjuvanted trivalent influenza vaccines in older adults. Vaccine \n2020;38:242\u201350. doi:10.1016/j.vaccine.2019.10.021.\n17. Cowling BJ, Perera RAPM, Valkenburg SA, Leung NHL, Iuliano AD, \nTam YH, et al. Comparative immunogenicity of several enhanced \ninfluenza vaccine options for older adults: A randomized, con -\ntrolled trial. Clin. Infect Dis. 2020;71:1704\u201314. doi:10.1093/cid/\nciz1034.\n18. Beran J, Reynales H, Poder A, Yu CY, Pitisuttithum P, Yuan LL, et \nal. Prevention of influenza during mismatched seasons in older \nadults with an MF59-adjuvanted quadrivalent influenza vaccine: a \nrandomised, controlled, multicentre, phase 3 efficacy study. Lancet \nInfect Dis. 2021;21:1027\u201337. doi:10.1016/S1473-3099(20)30694-\n0.\n19. Schmader KE, Liu CK, Harrington T, Rountree W, Auerbach H, Wal -\nter EB, et al. Safety, Reactogenicity, and Health-Related Quality of \nLife After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated \nInfluenza Vaccines in Older Adults: A Randomized Clinical Trial. \nJAMA Netw Open. 2021;4:e2031266. doi:10.1001/jamanetworko -\npen.2020.31266 .Eficacia, efectividad y seguridad de la vacuna antigripal adyuvada en poblaci\u00f3n de 65 o m\u00e1s a\u00f1os de edad M. P. Arrazola Mart\u00ednez, et al.\nRev Esp Quimioter 2023;36(4): 334-34534520. Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Rela -\ntive Effectiveness of Influenza Vaccines among the United States \nElderly, 2018-2019. J Infect Dis. 2020;222:278\u201387. doi:10.1093/\ninfdis/jiaa080.\n21. Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative \nEffectiveness of Cell-Cultured and Egg-Based Influenza Vaccines \namong Elderly Persons in the United States, 2017-2018. J Infect \nDis. 2019;220:1255\u201364. doi:10.1093/infdis/jiy716.\n22. Izurieta HS, Lu M, Kelman J, Lu Y, Lindaas A, Loc J, et al. Com -\nparative effectiveness of influenza vaccines among U.S. Medicare \nbeneficiaries ages 65 years and older during the 2019-20 season. \nClin Infect Dis. 2021;73:e4251\u20139. doi:10.1093/cid/ciaa1727.\n23. van Aalst R, Gravenstein S, Mor V, Mahmud SM, Wilschut J, Post -\nma M, et al. Comparative effectiveness of high dose versus adju -\nvanted influenza vaccine: A retrospective cohort study. Vaccine \n2020;38:372\u20139. doi:10.1016/j.vaccine.2019.09.105.\n24. McConeghy KW, Davidson HE, Canaday DH, Han L, Saade E, Mor \nV, et al. Cluster-randomized Trial of Adjuvanted Versus Nonadju -\nvanted Trivalent Influenza Vaccine in 823 US Nursing Homes. Clin. \nInfect Dis. 2021;73:e4237\u201343. doi:10.1093/cid/ciaa1233.\n25. Pelton SI, Divino V, Shah D, Mould-Quevedo J, Dekoven M, Kris -\nhnarajah G, et al. Evaluating the relative vaccine effectiveness of \nadjuvanted trivalent influenza vaccine compared to high-dose tri -\nvalent and other egg-based influenza vaccines among older adults \nin the us during the 2017\u20132018 influenza season. Vaccines (Basel) \n2020;8:1\u201317. doi:10.3390/vaccines8030446.\n26. Pelton SI, Divino V, Postma MJ, Shah D, Mould-Quevedo J, DeKo -\nven M, et al. A retrospective cohort study assessing relative effec -\ntiveness of adjuvanted versus high-dose trivalent influenza vacci -\nnes among older adults in the United States during the 2018\u201319 \ninfluenza season. Vaccine 2021;39:2396\u2013407. doi:10.1016/j.vacci -\nne.2021.03.054.\n27. Levin MJ, Divino V, Shah D, Dekoven M, Mould-Quevedo J, Pelton \nSI, et al. Comparing the clinical and economic outcomes associa -\nted with adjuvanted versus high-dose trivalent influenza vaccine \namong adults aged \u2265 65 years in the us during the 2019\u201320 in -\nfluenza season\u2014a retrospective cohort analysis. Vaccines (Basel) \n2021;9:1\u201316. doi:10.3390/vaccines9101146.\n28. Boikos C, Fischer L, O\u2019brien D, Vasey J, Sylvester GC, Mansi JA. Re -\nlative Effectiveness of Adjuvanted Trivalent Inactivated Influenza \nVaccine Versus Egg-derived Quadrivalent Inactivated Influenza \nVaccines and High-dose Trivalent Influenza Vaccine in Preventing \nInfluenza-related Medical Encounters in US Adults \u2265 65 Year. Clin \nInfect Dis. 2021;73:816\u201323. doi:10.1093/cid/ciab152.\n29. Boikos C, Imran M, Nguyen VH, Ducruet T, Sylvester GC, Mansi JA. \nEffectiveness of the adjuvanted influenza vaccine in older adults at \nhigh risk of influenza complications. Vaccines (Basel) 2021;9:862. \ndoi:10.3390/vaccines9080862.\n30. Imran M, Puig-Barbera J, Ortiz JR, Fischer L, O\u2019Brien D, Bonafede \nM, et al. Relative Effectiveness of MF59 Adjuvanted Trivalent In -\nfluenza Vaccine vs Nonadjuvanted Vaccines During the 2019\u20132020 \nInfluenza Season. Open Forum Infect Dis. 2022;9:1\u20138. doi:10.1093/\nofid/ofac167.31. Lapi F, Domnich A, Marconi E, Rossi A, Cricelli C. Adjuvanted ver -\nsus non-adjuvanted standard-dose influenza vaccines in preven -\nting all-cause hospitalizations in the elderly: a cohort study with \nnested case-control analyses over 18 influenza seasons. Expert Rev \nVaccines. 2022;21(11):1647-53. doi:10.1080/14760584.2022.2115\n362.\n32. Blanton. Update: Influenza Activity in the United States During \nthe 2016\u201317 Season and Composition of the 2017\u201318 Influen -\nza Vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(25):668-76. \ndoi:10.15585/mmwr.mm6625a3.\n33. Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness \nof the MF59-adjuvanted trivalent or quadrivalent seasonal in -\nfluenza vaccine among adults 65 years of age or older, a syste -\nmatic review and meta-analysis. Influenza Other Respir Viruses. \n2021;15:813\u201323. doi:10.1111/irv.12871.\n34. Domnich A, de Waure C. Comparative effectiveness of adju -\nvanted versus high-dose seasonal influenza vaccines for older \nadults: a systematic review and meta-analysis. Int J Infect Dis. \n2022;122:855\u201363. doi:10.1016/J.IJID.2022.07.048.\n35. Mart\u00ednez A, Soldevila N, Romero-Tamarit A, Torner N, Godoy P, \nRius C, et al. Risk factors associated with severe outcomes in adult \nhospitalized patients according to influenza type and subtype. \nPLoS One. 2019;14. doi:10.1371/journal.pone.0210353.\n36. P\u00e9rez-Rubio A, Platero L, Eiros Bouza JM. Seasonal influenza \nin Spain: Clinical and economic burden and vaccination pro -\ngrammes. Med Clin (Barc). 2019;153:16\u201327. doi:10.1016/j.med -\ncli.2018.11.014.\n37. Pellegrini M, Nicolay U, Lindert K, Groth N, della Cioppa G. MF59-\nadjuvanted versus non-adjuvanted influenza vaccines: Integrated \nanalysis from a large safety database. Vaccine 2009;27:6959\u201365. \ndoi:10.1016/j.vaccine.2009.08.101.\n38. Fochesato A, Sottile S, Pugliese A, M\u00e1rquez-Pel\u00e1ez S, Toro-Diaz H, \nGani R, et al. An Economic Evaluation of the Adjuvanted Quadri -\nvalent Influenza Vaccine Compared with Standard-Dose Quadri -\nvalent Influenza Vaccine in the Spanish Older Adult Population. \nVaccines (Basel) 2022;10:1360. doi:10.3390/VACCINES10081360.\n39. P\u00e9rez-Rubio A, Eiros Bouza JM. Impacto econ\u00f3mico y sanitario de \nla utilizaci\u00f3n de vacuna antigripal adyuvada con MF59 en pobla -\nci\u00f3n mayor de 65 a\u00f1os en Espa\u00f1a. Rev Esp Quimioter. 2018;31:43-\n52. PMID: 29355006.\n40. Ruiz-Arag\u00f3n J, M\u00e1rquez-Pel\u00e1ez S, Gani R, Alvarez P, Guerrero-Lu -\nduena R. Cost-Effectiveness and Burden of Disease for Adjuvanted \nQuadrivalent Influenza Vaccines Compared to High-Dose Quadri -\nvalent Influenza Vaccines in Elderly Patients in Spain. Vaccines (Ba -\nsel) 2022;10:1\u201312. doi:10.3390/vaccines10020176.\n41. Commission of the European Communities. proposal for a cou -\nncil recommendation on seasonal influenza vaccination, 2018 \n[citado 16 diciembre 2022]. Disponible en: https://op.europa.eu/\nen/publication-detail/-/publication/99fdfdb9-ce99-4064-9711-\n44385d555c1b/language-enISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/002.2023\nRev Esp Quimioter 2023;36(4): 346-379346ment of the sick. The very coexistence among the elderly, the \nfact of sharing caregivers and the very significant exposure \nto third parties, together with the frequent predisposing dis -\neases to infection in this population, make infection frequent \namong residents and also easily transmissible. This leads us to \nask what can be done to prevent infection in this environment \nand more specifically what is the state of the art of the matter \nin a Western European nation such as ours. The Board of Trus -\ntees of the Health Sciences Foundation has asked itself a series \nof questions on the subject of infection prevention in Nursing \nHomes, the structure of procedures, the legislation available, \ncompliance with the measures indicated, the best indicators \nof the processes and therefore, the need to promote in Spain a \ndocument of recommendations to avoid infections in this pop -Infection control in long term care institutions \nfor the elderly: A reflection document on the \nsituation in Spain\n1Servicio de Microbiolog\u00eda Cl\u00ednica y Enfermedades Infecciosas, Hospital General Universitario Gregorio \nMara\u00f1\u00f3n, Departamento de Medicina, Universidad Complutense de Madrid (UCM), Instituto de Investigaci\u00f3n \nSanitaria Gregorio Mara\u00f1\u00f3n, y CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid. \n2Director General del Consorci de Salut i Social de Catalunya. Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda\n3Adjunto al director de LA RAZ\u00d3N y director del suplemento A TU SALUD\n4Hospital San Juan Grande. Jerez\n5POP (Plataforma de organizaciones de pacientes)\n6Consorci Sanitari Integral. Consorci de Salut i Social de Catalunya.\n7Residencia de Personas Mayores Heli\u00f3polis. Junta de Andaluc\u00eda. Sevilla.\n8Secci\u00f3n de Epidemiolog\u00eda y Prevenci\u00f3n. Consejer\u00eda de Sanidad de Canarias. Asociaci\u00f3n Espa\u00f1ola de \nVacunolog\u00eda (AEV).\n9Servicio de Geriatr\u00eda. Hospital Central de la Cruz Roja \u201cSan Jos\u00e9 y Santa Adela\u201d. Universidad \u201cAlfonso X el \nSabio\u201d. Madrid\n10Fundaci\u00f3n de Ciencias de la Salud\n11\u00c1rea de Gesti\u00f3n Cl\u00ednica de Geriatr\u00eda. Hospital Monte Naranco, Oviedo. Instituto de Investigaci\u00f3n Sanitaria \ndel Principado de Asturias (ISPA). Grupo de Trabajo Infecciones y Vacunas de la Sociedad Espa\u00f1ola de \nGeriatr\u00eda y Gerontolog\u00eda.\n12Servicio de Microbiolog\u00eda Cl\u00ednica y E. Infecciosas, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid.\n13Centro Polivalente de recursos para personas mayores El Cristo. Adscrito al Organismo Aut\u00f3nomo ERA \n(Establecimientos Residenciales para Ancianos del Principado de Asturias). Sociedad Espa\u00f1ola de Enfermer\u00eda \nGeri\u00e1trica y Gerontol\u00f3gica.\n14Hospital Cl\u00ednico San Carlos. Grupo de investigaci\u00f3n de urgencias y emergencias del IDiscc. Facultad de \nMedicina de la Universidad Complutense de Madrid. \n15Consultor Senior Instituto de Investigaci\u00f3n. Hospital de la Princesa, Madrid.\n16Servicio de Neumolog\u00eda. Hospital Universitario La Fe, Valencia\n17Departamento de Medicina, Universidad Complutense de Madrid (UCM), Servicio de Microbiolog\u00eda Cl\u00ednica \ny Enfermedades Infecciosas, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n \nSanitaria Gregorio Mara\u00f1\u00f3n, y CIBER de Enfermedades Respiratorias (CIBERES CB06/06/0058), Madrid.\n18Fundaci\u00f3n de Ciencias de la Salud. Madrid. \n19Direcci\u00f3n Asistencial, Badalona Serveis Assistencials.\n20Servicio de Geriatr\u00eda. Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Profesor Titular de Medicina. \nFacultad de Medicina. Universidad Complutense CIBER de Fragilidad y Envejecimiento Saludable (CIBER-FES). \nInstituto de Salud Carlos III. Madrid\n21Programa de Atenci\u00f3n Integrada Social y Sanitaria de Catalu\u00f1a. Departament de Salut. Generalitat de \nCatalunya.\n22Servicio de Geriatr\u00eda. Hospital Universitario de La Ribera. Alcira, Val\u00e9ncia. CIBER de Fragilidad y \nEnvejecimiento Saludable (CIBER-FES). Instituto de Salud Carlos III Madrid\n23Servicio de Geriatr\u00eda, Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Madrid. Jefe de Secci\u00f3n de Geriatr\u00eda. \nHospital General Universitario Gregorio Mara\u00f1\u00f3n. Profesor Asociado. Departamento de Medicina, Universidad \nComplutense. CIBER de Fragilidad y Envejecimiento Saludable (CIBER-FES). Instituto de Salud Carlos III. \nMadrid.Emilio Bouza1*\nJos\u00e9 Augusto Garc\u00eda Navarro2*\nSergio Alonso3\nJuan Carlos Duran Alonso4\nCarina Escobar5\nBenito J. Fontecha G\u00f3mez 6\nMar\u00eda Isabel Galv\u00e1 Borr\u00e1s7\nAm\u00f3s Jos\u00e9 Garc\u00eda Rojas8 \nFrancisco Javier G\u00f3mez Pav\u00f3n 9\nDiego Gracia 10\nJos\u00e9 Guti\u00e9rrez Rodr\u00edguez 11\nMartha Kestler12\nFernando Mart\u00ednez Cuervo13\nFrancisco Javier Mart\u00edn S\u00e1nchez14\nCarlos Melero15\nRosario Men\u00e9ndez Villanueva16\nPatricia Mu\u00f1oz17\nEsteban Palomo18\nJuan Manuel P\u00e9rez-Castej\u00f3n Garrote19\nJos\u00e9 Antonio Serra Rexach20\nSebasti\u00e1n Jos\u00e9 Santaeugenia21\nFrancisco Jos\u00e9 Tarazona Santabalbina22\nMar\u00eda Teresa Vid\u00e1n Astiz23Review\nArticle history\nReceived: 8 January 2023; Accepted:  15 February 2023; Published: 29 March 2023\nABSTRACT\nA progressively increasing percentage of the elderly live \nduring the last years of their lives in nursing homes. Although \nthese institutions are intended to mimic life at home as much \nas possible, they have characteristics that make them quite \nsimilar to a \u201cnosocomiun\u201d, i.e. an establishment for the treat -\nCorrespondence: \nEmilio Bouza MD, PhD. \nInstituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n. \nC/ Dr. Esquerdo, 46 \n28007 Madrid, Espa\u00f1a \nE-mail: emilio.bouza@gmail.com \n*Both authors contributed equally to this manuscript. Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379347nursing homes are also a nosocomium, i.e. a place where the \nsick are cared for and treated and where the transmission of \npathogenic microorganisms is possible and frequent.\nWe know a lot about infection prevention measures in \nother nosocomial facilities, such as hospitals, but we know less \nabout infection prevention in smaller institutions with fewer \nresources for this purpose, such as Long-Term Care Facilities \n(LTCF).\nThe aim of this work has been to try to compile the availa -\nble information on infection control and prevention in LTCF in \na Western European country such as Spain, trying to explore \nwhat room there is for improvement.\nFor this reason, the Board of Trustees of the Health \nSciences Foundation formulated a series of questions on the \nexisting regulations for the prevention of infection in LTCF in \nour country, on their degree of compliance and on the exist -\ning indicators used to monitor this process. The questions were \ndistributed among a multidisciplinary group of experts in this \nfield from very different points of view, including the vision \nof patients\u2019 associations, the media, people responsible for the \nadministration, geriatricians, infectologists, microbiologists \nand other specialists. \nEach question was assigned to a speaker and the conclusions \nwere then discussed by the whole group to reach a summary of \nthe situation accepted by all. What follows are the questions and \nanswers that were asked. All authors have read and re-examined \nthe complete text and gave their approval to it.\nIS THERE A REGIONAL OR NATIONAL PROGRAM \nIN SPAIN ON INFECTION PREVENTION IN LONG-\nTERM CARE FACILITIES (LTCF)?\nThere is no common regional or national program on the \nprevention of nosocomial infection in LTCF, despite the fact \nthat infectious diseases are an important cause of morbidity \nand mortality in the elderly, both in hospital care and in pri -\nmary care consultations and, of course, in nursing homes.\nIn LTCF there is a high prevalence of nosocomial infection \nand colonization by multi-resistant microorganisms (MDR), as \nwell as a high incidence of very often inappropriate antibiotic \nprescription [1].\nIt should also be taken into account that there is a high \nrate of patient transfers to referral hospitals and that there are \nvery few diagnostic resources in nursing homes, making the \nmanagement of nosocomial infection a real health problem.\n The most frequent nosocomial infection is respiratory, \nfollowed by urinary tract, skin and soft tissue, gastrointestinal \ntract and ocular. Outbreaks can also occur relatively frequent -\nly and some centers have relatively high rates of colonization \nby MDR microorganisms, including colonization by methicil -\nlin-resistant Staphylococcus aureus  (MRSA) and the presence \nof bacteria carrying extended-spectrum \u00df-lactamases (ESBL).\nIn order to establish an effective plan for the prevention \nof nosocomial infection in LTCF, it is also necessary to take into ulation whose morbidity and mortality need not be highlight -\ned. To this end, a multidisciplinary group of experts in different \naspects of this problem has been convened and asked the pro -\nposed questions. The questions were discussed by the group as \na whole and led to a series of conclusions agreed upon by the \nparticipants. The results of the meeting are reported below.\nKeywords: Infections in the elderly, infection prevention, nosocomial in -\nfection, urinary tract infection, respiratory infection, skin and soft tissue \ninfection, pneumonia.\nControl de la infecci\u00f3n en residencias de \nancianos: Documento de reflexi\u00f3n sobre la \nsituaci\u00f3n en Espa\u00f1a\nRESUMEN\nUn porcentaje progresivamente creciente de las personas \nmayores viven durante los \u00faltimos a\u00f1os de su vida en residen -\ncias de ancianos. Dichas instituciones, aunque pretenden re -\nmedar lo m\u00e1s posible la vida en el hogar, tienen caracter\u00edsticas \nque las hace bastante parecidas a un nosocomio, es decir a un \nestablecimiento destinado al tratamiento de enfermos. La pro -\npia convivencia entre los ancianos, el hecho de compartir cui -\ndadores y la exposici\u00f3n muy importante a terceras personas, \njunto con las frecuentes enfermedades predisponentes a la in -\nfecci\u00f3n de esta poblaci\u00f3n, hacen que la infecci\u00f3n sea frecuente \nentre los residentes y que adem\u00e1s sea f\u00e1cilmente transmisible. \nEsto nos lleva a preguntarnos qu\u00e9 puede hacerse para prevenir \nla infecci\u00f3n en este medio y m\u00e1s concretamente cu\u00e1l es el es -\ntado del arte de la cuesti\u00f3n en una naci\u00f3n de Europa Occiden -\ntal como la nuestra. El patronato de la Fundaci\u00f3n de Ciencias \nde la Salud se ha formulado una serie de preguntas sobre el \ntema de la prevenci\u00f3n de la infecci\u00f3n en las Residencias de \nMayores, la estructura de la misma, la legislaci\u00f3n vigente, el \ncumplimiento de las medidas indicadas, los indicadores de los \nprocesos y por ende, la necesidad de fomentar en Espa\u00f1a un \ndocumento de recomendaciones para evitar infecciones en \nesta poblaci\u00f3n cuya morbilidad y mortalidad no necesitan ser \nresaltadas. Para ello, se ha convocado a un grupo multidisci -\nplinar de expertos en distintos aspectos de este problema a los \nque se les han formulado las preguntas propuestas. Las pre -\nguntas han sido discutidas por el grupo en su conjunto y han \nconducido a una serie de conclusiones consensuadas entre los \nparticipantes. Pasamos, a continuaci\u00f3n a relatar los resultados \nde la reuni\u00f3n.\nPalabras clave: Infecciones en el anciano, prevenci\u00f3n de la infecci\u00f3n, infec -\nci\u00f3n nosocomial, infecci\u00f3n urinaria, infecci\u00f3n respiratoria, infecci\u00f3n de piel \ny partes blandas, neumon\u00eda\nINTRODUCTION\nNursing homes logically try to reproduce living conditions \nfor their inhabitants as close as possible to those at home. \nHowever, they are still places where people with frequent and \nimportant underlying conditions live in close proximity to each \nother and share caregivers in a common habitat. In this sense, Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379348the acquisition and transmission of infections in residents and \nstaff. Indirectly, some of the legislation inforce in Spain that is \nintended to protect workers against biological hazards in the \nworkplace could be applied, although this is not specifically \nthe focus of our discussion.\nRegarding biosafety, the Biosafety Law (Law 15/1994 of \nJune 3, BOE, 1994) must be applied, which incorporates the \nCommunity Directives (EEC, 90/219 of April 23, 1990) into the \nSpanish legal system. This law was developed in a Royal Decree \n(RD 664/1997, May 12, 1997, BOE, 1997), on the protection of \nworkers against risks related to exposure to biological agents \nat work. The EU has advanced in this protection by including a \ndirective on the protection of workers against risks related to \nexposure to biological agents at work (EEC 2000/54 / EC of the \nEuropean Parliament and the Council of 18 September 2000). \nThere is another legislative block that develops the reg -\nulations on notifiable diseases and epidemic outbreaks but of \nthe autonomous community of Catalonia (Decree 203/2015, of \nSeptember 15) which creates the Epidemiological Surveillance \nNetwork of Catalonia and regulates the notification systems of \nnotifiable diseases and epidemic outbreaks. \nFinally, there are some specific regulations such as the \nprotection against legionellosis (RD 865/2003, of July 4, 2003), \nwhich establishes the hygienic-sanitary criteria for the preven -\ntion and control of this disease in Spain (Decree 352/2004, of \nJuly 27), which establishes the hygienic-sanitary conditions for \nthe prevention and control of legionellosis. Undoubtedly, all \nthe legislative aspects on risk analysis and control of critical \npoints in the food chain (ARCPC) included in different state \nroyal decrees (RD 3484/2000, RD 2207/1995, RD 202/2000) are \nalso applicable to nursing homes. \nConclusion \nThere is no specific legislation for protection against \ninfection in LTCF in Spain. There is general legislation on \naspects such as hygiene and measures against contami -\nnation in the food chain and specific legislation on pro -\ntection against diseases such as legionellosis issued by \nboth the autonomous communities and central govern -\nment authorities.\nWHAT SHOULD BE THE BROAD OUTLINES \nOF A POTENTIAL PREVENTION PLAN FOR \nCOMMUNICABLE INFECTIONS IN LTCF?\nThree major thematic areas can be distinguished in this \npotential plan.\n1.- General prevention measures aimed at reducing the \ngeneric risk of infections related to care or the environment \nwhere there should be sections such as the following [1]: \n- Environmental and surface cleaning and disinfection\n- Hand hygiene\n- Proper use of gloves, gowns or aprons, masks and eye \nprotection.account the atypical presentation of infections in the elderly, \nfor which reason it would be necessary to clearly define the di -\nagnostic standards for infection in this setting. Although there \nhave been attempts to introduce standardized criteria for de -\nfining infection in these centers, they have not been validated \nin our country and are not universally used [2].\nFurthermore, unlike acute care hospitals, where there are \nhigh quality epidemiological studies for the monitoring and \ncontrol of nosocomial infection [3], at this level of care there \nare no quality data that would allow immediate establishment \nof adapted prevention plans.\nIt would be absolutely necessary to establish nosocomi -\nal infection prevention plans to protect the population living \nin LTCF. This population is very vulnerable and is affected by \nother risk factors such as immunosuppression associated with \nadvanced age, comorbidity, the use of immunosuppressive \ntreatments and other risk factors that are very prevalent in the \ninstitutionalized population (pressure ulcers, bladder catheters, \ndysphagia, incontinence, etc.). The training of professionals \ndoes not have the level achieved in our hospitals (there is a \nhigh number of geroculturists with basic training and a very \nsmall number of nurses and physicians), which makes it diffi -\ncult to establish measures to contain the risk of infection both \nin patients/residents and between them and the professionals \nworking in the institutions [4].\nAn infection prevention plan in LTCF should be mandato -\nry in all these centers and be accompanied by an appropriate \ntraining program for the professionals working in them, the \nestablishment of a registry of infections by MDR microorgan -\nisms, the collaboration of the microbiology services and the \nhealth authorities of the area, and effective communication \nbetween these resources and primary and hospital care.\nAs an initial and minimum step, it would be necessary to \ndevelop a surveillance program, with special care in applying \nstandard precautions, with special emphasis on hand hygiene. \nIt is also advisable to measure the infection acquired in the \ncenter, either through point prevalence or incidence studies. It \nis also necessary to propose active policies for the correct use \nof antibiotics in this population.\nConclusion\nThere are no common regional or national nosocomi -\nal infection prevention programs specifically devoted to \nLong Term Care Facilities for the elderly.\nIt is urgent to establish a prevention plan with min -\nimum requirements, at least, that includes training of \nprofessionals, an infection surveillance and registry sys -\ntem, collaboration with reference hospital services and an \nadequate antibiotic use policy.\nIN THE ABSENCE OF A SPECIFIC REGULATION, \nWHAT DOES THE LAW IN SPAIN REQUIRE?\nIt has already been mentioned that there is no specific \nlegislation for LTCF that focuses on specific protection against Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379349that may not require antibiotics, such as viral bronchitis, influ -\nenza or microaspirations.\n3. Avoid treatment of colonizations (especially decubi -\ntus ulcers without infection and bacteriuria).\n4. Avoid unnecessary antimicrobial prophylaxis, espe -\ncially for Urinary Tract Infections.\n5. Avoid unnecessary use of topical antibiotics.\n6. Assess the need for microbiological studies and anti -\nbiotic treatment in some end-of-life care situations.\n7. Reconsider periodically the duration of antibiotic \ntreatments.\n8. Adjust treatments based on available microbiological \nresults.\n9. Promote parenteral-oral sequential therapy.\n10. Use diagnostic and treatment protocols adapted to \nlocal data.\n11. Monitor antimicrobial consumption.\n12. Continuing education.\nConclusion \nThere is a need for a general plan with guidelines for \nthe prevention and management of infections in LTCF \nwith at least three major sections: general prevention \nmeasures, specific protocols for the prevention of the \nmost prevalent infections, and antibiotic management \nplans. The plan should include hand hygiene, urinary \ntract infection, respiratory infection, skin and soft tissue \ninfection, appropriate use of antimicrobials, and C. diffi -\ncile-related infection.\nIS IT NECESSARY FOR EACH LTCF TO HAVE \nA PHYSICIAN OR NURSE RESPONSIBLE FOR \nINFECTION CONTROL?\nWe believe so. To ensure compliance with any protocol \nor procedure in a nursing home, it is essential that it is led \nby a professional, who has the support and recognition of \nthe center\u2019s management, and who is a reference point for \nthe care team for the transmission of information to the rest \nof the professionals of both the center itself and the Public \nHealth Service [15]. \nThe presence of a physician in charge of each LTCF is not \nmandatory in different Spanish autonomous communities \n[16], But in order to be accredited, there must be nursing staff. \nTherefore, the responsible person could be, if there is one, the \nphysician of the residence, or one of the nurses of the center.\nThe person assigned to be responsible for the care team of \nthe LTCF must have sufficient knowledge and experience in the \ncontrol and management of infectious diseases (clinical man -\nifestations, mechanisms of transmission and spread, and pre -\nvention measures); have leadership and communication skills, \nas well as teamwork skills. He/she will be the one who must \ntransmit all the information to the rest of the professionals - Proper handling of personal protective equipment\n- Safe handling of waste and sharps\n- Cleaning system, storage and transport of bed linen and \nuser\u2019s linen\n- Proper handling of invasive devices (intravenous lines, \nbladder catheters, feeding tubes, etc.).\n2.-Specific protocols aimed at the prevention of the most \nprevalent infections in residential centers.\nIn the context of the care of institutionalized frail elderly \npeople, it is necessary to adequately train professionals in the \ndetection and appropriate management of the most prevalent \ninfections in this type of patients. Thus, every residential center \nshould have specific protocols on, at least [5,6]:\n- Immunization schedule for residents and professionals \n(flu, pneumococcus, hepatitis B, SARS-CoV-2, ...).\n- Prevention and management of urinary tract infection \nassociated or not with incontinence-related devices (bladder \ncatheter, absorbents, collectors, ...).\n- Prevention and management of respiratory infection \n(bronchoaspirative, infection in the context of COPD patients, \n...).\n- Prevention of wound infection, pressure ulcers, vascular \nulcers, peripheral venous insufficiency, ...)\n- Prevention of food-borne infections or outbreaks in res -\nidential centers.\n- Prevention and management of colonization and infec -\ntion by MDR microorganisms such as MRSA, BLEE-producing \nbacteria, Clostridoides difficile,  ...)\n3.- Protocols oriented to antimicrobial stewardship. \nImproving antibiotic use in the care of the institutional -\nized elderly in order to protect residents and reduce the threat \nof antibiotic resistance is a global priority. The Centers for Dis -\nease Control (CDC) and others recommends that all nursing \nhomes take steps to improve antibiotic prescribing practices \nand reduce inappropriate antibiotic use [7-10].\nStudies have shown that 40-75% of antibiotics pre -\nscribed in nursing homes may be unnecessary or inappropri -\nate. The harms caused by antibiotic overuse are significant for \nfrail, older adults receiving nursing home care. These harms \ninclude risk of C. difficile  infection (CDI), increased adverse \nevents and drug-drug interactions, and MDR colonization \nand/or infection.\nThere are some experiences in Spain and outside Spain \n[11-13], around PROA interventions (antimicrobial use optimi -\nzation programs) in nursing homes. For example, the Geriatrics \nService of Granollers proposes 12 interventions and measures \nto improve the optimization of antimicrobial treatment in this \npopulation [14]:\n1. Avoid prescribing without a face-to-face medical as -\nsessment. This is related to an increase in the use of broader \nspectrum antimicrobials.\n2.  Reconsider the treatment of respiratory infections Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379350sections referring to environmental conditions that appear \nin the document.\nA.- Material requirements\n- The Centers must be located in healthy and integrated \nareas or close to urban centers.\n- Residential area units will not be admitted in basements \nor crawl spaces.\n- The areas must be sufficiently ventilated and illuminated, \npreferably with natural light.\n- They shall have drinking water, with adequate pressure, \nfrom the public water supply. If it comes from water catchment \nor capacity, they shall have a reserve tank with capacity for at \nleast one day.\n- Hot water in sanitary appliances and kitchen with a tem -\nperature higher than 40\u00baC.\n- Heating that guarantees a temperature equal to or high -\ner than 20\u00baC.\n- Evacuation of water to the municipal sewage system or \nto a sewage treatment plant. In any case, it is forbidden to pour \ninto cesspools.\n- Bedrooms: Usable area of 5.50 square meters per person \nin the case of disabled persons and 7.50 square meters per per -\nson in the case of wheelchair users. \n- The maximum capacity per bedroom will be six people. \nThe bedrooms must have natural light and ventilation.\n- Toilets: When they are collective, they will be differenti -\nated by sex. The minimum endowment will be a toilet, a sink, a \nshower and a bidet for every six people or fraction exceeding \ntwo people. \n- Living quarters: With a minimum area of 1.80 m2, per \nresident, (depending on the recording) with a minimum of 12 \nsquare meters.\n- The resulting surface may be subdivided into smaller \nones and, in any case, when it is larger than 60 m2, it must be \nseparated to allow for different environments: play area, read -\ning area, TV, etc.\n- The living rooms must be exterior.\n- Dining room: It shall have a surface area of at least 1 m2 \nper person, with a minimum of 10 m2.\nB.- Functional requirements\nIt shall be guaranteed that all users receive, by their own \nmeans or those of others, the necessary medical attention.\n- There shall be a first-aid kit conveniently located and \nsignposted, and a correct hygienic-sanitary organization shall \nbe guaranteed.\n- Personnel: They shall be adequate in number and spe -\ncialization to provide the corresponding services. The full-time \nstaff/user ratio will be 0.25 for valid users; and 0.35 for assisted \nusers.\n- Every user will have, in his or her bedroom, a suitable \nlockable closet with shelves and hangers; a bed equipped with of the institution, as well as to the residents and their fami -\nlies, ensuring that all the necessary measures for the preven -\ntion of infections are carried out. On the other hand, he/she \nwill inform the Public Health System of relevant events and \nalso the Primary Care physician responsible for the care of the \nresidence, as well as the Hospital Geriatric Specialized Services \n[17-19].\nTheir work is essential for the early detection of any case \nof transmissible infectious disease, as has been demonstrated \nin the COVID-19 pandemic, as well as for the rapid implemen -\ntation of the contingency and isolation plan to prevent trans -\nmission to the rest of the residents. \nSocial and sanitary coordination is essential for the cor -\nrect functioning of all these protocols, and should be promot -\ned by the competent political authority, with very favorable \nexperiences in different Communities during the present pan -\ndemic [20-23].\nThe SARS-COV-2 pandemic has highlighted the need for \nthe figure of a Coordinator or person in charge in the resi -\ndences for the prevention and control of the infection, being \nrequired by International Institutions (WHO) the State and the \ndifferent Autonomous Communities [18,20,21,24,25]. \nPreviously, there were numerous experiences that focused \non studies of the prevalence of infectious diseases in geriatric \ncenters (EPINGER), prevention of the transmission of MDR mi -\ncroorganisms during the care of colonized/infected residents \nin residential centers of the Junta de Andaluc\u00eda. As well as with \nantibiotic optimization programs to promote their rational use \n(PROA).\nThe experience currently available should be used to pre -\nvent new outbreaks of this or any other infectious disease that \ncan be transmitted in LTCF [23,26-28].\nConclusion\nTo ensure compliance with an infection control plan \nin nursing homes, a person responsible for it should be \nappointed within the LTCF healthcare team. This person \nwill have the support of the institution\u2019s management \nand will be the center\u2019s point of reference, in charge of \ntransmitting all the guidelines to the rest of the col -\nleagues and to the residents and family members, as well \nas acting as a contact person with those responsible for \nhealth care in the Public Health Service. It must be a phy -\nsician, if there is one, or a nurse.\nWHAT MINIMUM ENVIRONMENTAL CONDITIONS \nSHOULD A LICENSED NURSING HOME HAVE? \nIt is necessary to emphasize that the LTCF are con -\nceived as homes, not as health centers. In the specific case \nof the Community of Madrid, there is an order [29], which \ndevelops Decree 91/1990, of October 26, regarding the Au -\nthorization Regime for Services and Centers for Social Ac -\ntion and Social Services, which contains the criteria to be \nmet by the centers. The following paragraphs extract those Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379351Conclusion\nThere is a specific regulation of the Consejer\u00eda de In -\ntegraci\u00f3n Social of the Community of Madrid that con -\ntains the environmental criteria to be met by the centers. \nIn relation to the minimum conditions, the regulation is \nvery clear about the location of the LTCF and the material \nand functional requirements, although it seems too toler -\nant in some other aspects. \nWHAT ARE THE ESSENTIAL DATA IN ASSESSING \nTHE RISK OF INFECTION OF A PERSON LIVING IN \nA LTCF? \nIt is a requirement to have an individual file for each user, \nwhich includes a complete assessment history, treatments, so -\ncial and medical reports. At the time of admission to a nursing \nhome, the resident arrives with an Individual Care Plan pre -\npared by the Dependency Service, drawn up by whomever the \nregional regulations establish. These are usually social work -\ners or multidisciplinary teams. In other countries (Germany) it \nis drawn up by the healthcare field. The user provides all the \nmedical information available to him/her. \nIn the comprehensive geriatric assessment (CGA), for \nwhich different scales can be used, at least the following as -\npects should be included: \n- Personal preferences and advance directives\n- Quality of life\n- Physical status: basic and instrumental activities of daily \nliving, gait and balance, frailty\n- Mental status: cognitive and affective\n- Social status including primary caregiver overload\n- Nutritional status\n- Sense organs (sight, hearing)\n- Complete and up-to-date pharmacological treatment\n- Risk of falls and pressure ulcers\n- Pain\n On the specific point of the subject that concerns us, \nwhich is the assessment of the risk of infection on admission, \nwe have not found standard recommendations, but we believe \nit is necessary to have at least the following data in the pa -\ntient\u2019s file [5]:\nVaccination against influenza [30]\nVaccination against SARS-CoV-2 [31-33]\nVaccination against Varicella-Zoster Virus [34]\nEvaluation of S. aureus  nasal carrier status in specific cir -\ncumstances [35-40]\nPneumococcal vaccination and types of vaccines received \n[41-44].\nVerification of tetanus and pertussis vaccination status.\nPPD and IGRA [45, 46]a bed base, mattress and the corresponding clothing; a bedside \ntable; a light point with a lamp or wall lamp at the head of the \nbed; a power outlet; a mat. \n- Each room will have shutters, blinds or curtains that can \nblock the passage of outside light.\n- Varied menus and dishes will be provided according to \nthe needs of the users. The menus will be previously supervised \nby a physician, in order to ensure adequate dietary and caloric \nintake. In addition to the regular menu, other dietary menus \nwill be prepared for those users who require them. Meals and \ncooked dishes, either with its own service or with an arranged \nservice, will arrive at the appropriate temperature to their re -\ncipients. Likewise, there must be a cold chain to preserve and \nstore food.\n- Daily personal hygiene must be guaranteed for users \nwho cannot look after themselves, and as often as circum -\nstances require.\n- The change of linen and underwear of the users shall \nbe done whenever necessary, and in any case daily. Other gar -\nments shall be changed as often as necessary.\n- The change of bed linen shall be made whenever required \nby circumstances, and in any case weekly, as well as each time \nthere is a new admission. The same periodicity shall be required \nfor towels, napkins, tablecloths and other linen.\n- Special attention shall be paid to the maintenance, up -\nkeep and repair, if necessary, of furniture, installations and \npremises, in order to prevent their deterioration, as well as to \nall machines, boilers, installations or instruments which, if they \ninvolve a high potential risk, shall be handled exclusively by \nauthorized installers.\n- Every Center, in addition to complying with the general \nlegislation in force on hygiene and health, must guarantee, in \na special way:\nThe general and permanent cleaning of the building and \nits dependencies, especially those of more intense use, as well \nas its disinfection. \nThe annual disinsectisation and rat extermination, or as \nmany times as circumstances require.\nThe establishment of specific rules or guidelines for the \npersonnel in matters of hygiene, of obligatory and verifiable \ncompliance. In Centers serving risk sectors, infection and con -\ntagion prevention measures shall be adopted, as well as the \nnecessary periodic sanitary controls.\nCleaning and disinfection of crockery and cutlery after \nuse, as well as other instruments in common use.\nIn centers with a capacity of more than 50 users, there \nshould be a suitable space for the temporary storage of waste \nin closed buckets.\nThis law is clear on the basic environmental requirements \nfor residences for the elderly, although the \u201ctolerance with \n\u201cdormitories for up to 6 people, toilets for 6 people or very low \nstaffing ratios\u201d is surprising.Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379352Conclusion\nElderly people living in residential centers should \nbe properly vaccinated against influenza, pneumococ -\ncus, tetanus and SARS-CoV-2. Likewise, in certain cases \nit would also be advisable to administer vaccines against \ndiphtheria and Varicella-Zoster virus. Likewise, health -\ncare and direct care personnel in the centers should be \nvaccinated, at least, against influenza and SARS-CoV-2. \nWHAT MEASURES HAVE BEEN SHOWN TO \nBE EFFECTIVE IN REDUCING URINARY TRACT \nINFECTION IN THE ELDERLY?\nUrinary tract infection (UTI) is the most frequently re -\nported infection in long-term care facilities. [59] and accounts \nfor 30-40% of healthcare-associated infections. On the oth -\ner hand, the presence of asymptomatic bacteriuria in institu -\ntionalized patients is high, with figures of 25-50% in women \nand 15-40% in men [4]. This bacteriuria is benign, and several \nstudies have shown that the treatment of asymptomatic bac -\nteriuria, whether or not accompanied by pyuria, is of no benefit \nand may even be harmful [60]. Therefore, screening and treat -\nment of asymptomatic bacteriuria is not recommended. How -\never, a frequent problem in nursing homes is that of patients \nwith nonspecific clinical deterioration, without symptoms or \nlocalizing signs and presenting a positive urine culture. The di -\nagnosis of symptomatic UTI requires the presence of dysuria or \nfever, chills or confusion plus some other genitourinary symp -\ntom (urinary frequency, flank pain, hematuria...) [61]. However, \nvery often, those residents who present with altered mental \nstatus, falls, lack of appetite or more awkward mobility and \nhave a positive urine culture are diagnosed with UTI, leading \nto overdiagnosis and inappropriate use of antibiotics, which \nis very common in these centers [62]. In recent years, many \ninitiatives have been developed to improve the management \nof this problem and to optimize the use of antibiotics in resi -\ndential centers. An important randomized study conducted in \nseveral nursing homes demonstrated how the implementation \nof treatment algorithms based on guidelines, i.e. treating only \nthose UTIs (in non-catheterized patients), in which symptoms \nassociated with the genitourinary system were observed, was \nsafe and was associated with a clear reduction in antibiotic use \n[63]. Despite this, the application of these criteria in patients \nwith advanced dementia remains a matter of debate and over -\nuse of antibiotics is especially prevalent in this subgroup of \npatients. A descriptive study in patients with advanced demen -\ntia living in nursing homes showed that only 19% of probable \nUTIs treated with antibiotics met these criteria [64]. Another \nsubsequent study [65,66] found that, although most suspected \ninfections in severely demented and institutionalized patients \nwere treated with antibiotics, this treatment was not associat -\ned with any improvement in survival. \nThe specific measures that have been shown to reduce \nurinary tract infection are well known: treating only symp -\ntomatic infections, minimizing the use of bladder catheters, \ncatheter and perineal hygiene measures, avoiding urinary and History of past international travel\nConclusion\nIn addition to the Comprehensive Geriatric Assess -\nment (CGA), an assessment of the risk of infection should \nbe carried out on admission to nursing homes, the specif -\nic items of which are far from being agreed upon and far \nfrom constituting a standard. In our opinion, they should \ninclude, at least, the vaccination status against prevent -\nable viral diseases such as influenza, SARS-COV-2 and \nVaricella-Zoster, the immunity status against pneumo -\ncoccal infection, the existence or not of latent tubercu -\nlosis and the colonization status against multi-resistant \nbacteria such as MRSA.\n WHAT VACCINES SHOULD BE OFFERED TO \nPERSONS LIVING IN A NURSING HOME?\nIn the elderly, vaccination takes on greater importance \nbecause their immune system is aged and their capacity to \nrespond to infectious processes is diminished, thus increasing \nthe risk of developing serious complications following infec -\ntions.  This statement is especially relevant in people living in \nLTCF for the elderly, where the presence of comorbidity, func -\ntional dependence and cognitive impairment puts them at \ngreater risk of falling ill and, if they do fall ill, more clinical \ncomplications and a higher risk of death [47]. \nThe Spanish Society of Geriatrics and Gerontology [48] \nrecommends systematic vaccination of the elderly against \ninfluenza, pneumococcus and tetanus. Likewise, depending \non personal history and individual risk factors, vaccination \nagainst pertussis and Varicella-Zoster virus infection may \nalso be indicated. Regarding the influenza vaccine, for this \ntype of population and with the aim of increasing its effec -\ntiveness, it is recommended to use vaccines with increased \nimmunogenicity.\nLikewise, in residential centers for the elderly, the objec -\ntive should be to achieve a minimum annual vaccination cov -\nerage against the influenza virus of over 75%, both in institu -\ntionalized persons and in the health and direct care personnel \nof the centers [49-55].\n It should be noted that vaccination of elderly persons \nagainst SARS-CoV-2 (COVID-19) is indicated from the be -\nginning of the year 2021. A considerable number of vaccines \nagainst SARS-CoV-2 are under study and research. In our \ncountry, institutionalized elderly people have been vaccinated \nwith RNA-messenger (RNAm) vaccines [56-58] and they are \ncurrently receiving a booster dose.\n As established in the vaccination strategy against COV -\nID-19 of the Ministry of Health, depending on the results of \nfuture clinical trials, the data registered in the Drug Pharma -\ncovigilance System and the distribution and availability of \nvaccine doses, the most appropriate vaccines for each health \ncondition, age group, risk factors and place of residence can be \nselected from among the different types of vaccines.Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379353number of beds in the residence, but not the lower occupancy \nrate, and 3) the public ownership of the residence, 4) the lower \nnumber of beds in the residence, but not the lower occupancy \nrate, and 5) the lower number of beds in the residence [10,73]. \nThese observed changes could not, however, demonstrate an \nimpact on overall antibiotic utilization or a decrease in MDR \ninfections.\nConclusion\nThe most effective measures to reduce UTI in elderly \nnursing home residents consisted of: treating only symp -\ntomatic urinary tract infections, minimizing the use of \ncatheters, adopting perineal hygiene measures, avoiding \nurinary and fecal retention, avoiding a sedentary life -\nstyle, improving hydration, and not performing antibiotic \nprophylaxis when changing catheters except in cases of \ntraumatic catheterization. \nPrograms to optimize the use of antibiotics, the re -\ncording of infections, the incorporation of a \u201cpreventiv -\nist\u201d or infection consultant, staff education, the existence \nof accessible protocols and the involvement of the medi -\ncal director of the residency are key to its success. \nWHAT MEASURES TO REDUCE RESPIRATORY \nINFECTION HAVE BEEN SHOWN TO BE EFFECTIVE \nIN LTCF?\nRespiratory infections are a very frequent cause of mor -\nbidity and mortality in nursing homes whose etiological diag -\nnosis has improved with the inclusion of new diagnostic tech -\nnologies [74-76]. As for viral etiology, influenza, Respiratory \nSyncytial Virus (RSV) infection, Coronavirus and Metapneu -\nmovirus infections stand out [49,77-81]. The most important \nbacterial pneumonia are pneumococcal pneumonia, [42,82,83] \nand polymicrobial aspiration pneumonia [84]. Legionellosis and \ntuberculosis are less common [45,85]. Finally, fungal infection, \nparticularly Invasive Pulmonary Aspergillosis may occasionally \noccur, especially in immunocompromised patients with COPD \nwho combine the use of corticosteroids and broad-spectrum \nantibiotics [86,87].\nMeasures to prevent respiratory infections in nursing \nhomes for the elderly must take into account intrinsic and ex -\ntrinsic risk factors for infection. \nIn relation to the environment, the effective measures are \nincluded in the World Health Organization (WHO) document, \nwhich brings together the guidelines and recommendations \nto be followed, in addition to incorporating an immunization \nplan for healthcare personnel [88,89]. There are recommen -\ndations for the maintenance of ambient air quality in these \ninstitutions and programs for the control of legionellosis [90].\nThere is literature suggesting that indoor concentrations \nof particulate and gaseous pollutants in nursing homes often \nexceed comparable outdoor environments nearby. Unlike out -\ndoors, indoor air quality (IAQ) in nursing homes is not regulat -\ned by legislation and is rarely monitored. Therefore, an action fecal retention, avoiding a sedentary lifestyle, improving hy -\ndration or performing antibiotic prophylaxis when changing \ncatheters only in cases of traumatic catheterization. However, \nin our opinion, its implementation in the residential setting is \nvariable and subject to improvement.\nMany programs and interventions have been put in place \nto decrease the rate of urinary tract infection in residential fa -\ncilities ranging from different models of staff education, anti -\nbiotic stewardship programs, inclusion of the role of infection \npreventionist or multimodal intervention programs.\nAntibiotic stewardship programs have demonstrated \nclear benefits in hospitals and acute care settings. Some stud -\nies have also demonstrated their effectiveness in residential \ncenters when the program includes education strategies, local \nguidelines and periodic review and feedback on antibiotic use \n[66,67]. In the case of urinary tract infection, these programs \nhave been shown to decrease treatment rates of asymptomat -\nic bacteriuria and improve compliance with antibiotic proph -\nylaxis [68], although they have been insufficient to decrease \nthe total amount of antibiotics used for suspected UTIs [69]. \nIn 2016 the Centers for Medicare and Medicaid Services (CMS) \nregulations [70] included a requirement that nursing homes \nand long-term care facilities develop an infection prevention \nprogram that should include an antibiotic use optimization \nprogram and the inclusion of a trained agent specifically ded -\nicated to infection prevention [71], and list the following as \ncore actions of the program: involved leadership, pharmacy \nknowledge, education, action, collection and periodic report -\ning of infection data. \nIn a baseline analysis, prior to the implementation of this \nstandard in the residencies, it was shown that the most fre -\nquent existing measures were: the existence of written guide -\nlines on antibiotic use and the registry of antibiotics used. The \nmore specific and time-consuming policies, such as the use of \nforms for each antibiotic use, the existence of approval mech -\nanisms or the control of appropriateness of use, were used less \nfrequently and improved when the figure of the trained pre -\nventivist was in place [70]. The lack of nursing knowledge of \nantibiotic policies was a major obstacle to their implementa -\ntion. The involvement in the programs of the medical director \nof the LTCF, the nursing director and the specific preventivist is \nkey to their implementation, for several reasons, including the \nhigh mobility of health personnel in these centers [72].\nIn a survey conducted in different US facilities on infec -\ntion prevention and control programs in residences and the \nchanges between 2014 and 2018 (after the CMS rule) revealed \na clear increase in \u201cantibiotic stewarsdship\u201d programs. In the \nspecific context of UTI the measures that had significantly \nincreased were: the existence of reminders about decreasing \ncatheter use, the use of external collectors, and the use of ul -\ntrasound probes to detect postvoid residual and avoid reten -\ntions. The policies that were associated with the greatest in -\ncrease in these preventive measures were: 1) the existence of \nspecific certified courses and training programs, local certified \ncourses or courses through scientific societies, 2) the lower Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379354HOW IS SKIN AND SOFT TISSUE INFECTION \nPREVENTED IN ELDERLY INSTITUTIONALIZED \nRESIDENTS?\nSkin and soft tissue infections (SSTIs) acquired in residen -\ntial facilities are common, with an estimated prevalence of 5% \n[108], the third most frequent cause of infection after urinary \nand respiratory infections in this group of patients. Overall, \n10% of the elderly who take antibiotics in nursing homes do so \nbecause of a skin or soft tissue infection [109] which are of di -\nverse etiology including viral, bacterial, fungal and, occasional -\nly, parasitic. Institutionalized persons present a greater number \nof risk factors for SSTI due to frequent malnutrition, immuno -\nsuppression, comorbidity and higher cognitive and functional \ndependence, with urinary and fecal incontinence [110]. \nThe most frequent point of entry for skin and soft tissue \ninfections are solutions of continuity due to small wounds, \ntrauma and surgical wounds [111]. Finally, health care centers \nand nursing homes have a high prevalence of skin and soft tis -\nsue infections and colonization by MDRs, among which MRSA \nstands out, with a carrier rate in health care centers and nurs -\ning homes that ranges between 8% and 25% [112].\nFor all these reasons, the prevention and control of SSTIs \nis an important challenge. However, the literature is scarce in \nwell-conducted clinical trials that evaluate the efficacy of the \ndifferent methods for their prevention and the recommen -\ndations are generally based on experiences obtained in other \ngroups or on recommendations based on indirect studies or on \nexpert opinion [113,114].\nIn diabetic patients, it is a fact that poor glycemic control \nincreases the incidence of SSTI [115,116].\nAnother aspect of SSTI prevention is frequent skin cleans -\ning, taking special care of the skin folds (submammary and \ninguinal), which should be dried with soft towel touches, \navoiding the application of alcoholic lotions such as colognes \nor drying substances such as talcum powder, and the use of \ncotton garments is useful. The main problem of the skin of the \nelderly is skin dryness or xerosis, which affects 80 percent of \npeople over 75 years of age, and which is combated with an \nadequate intake of liquids and the application of moisturizing \ncreams all over the body surface on a daily basis.\nThere is data suggesting that periodic chlorhexidine \nshowers decrease the incidence of MRSA infections but this \nhas been done mainly in younger groups such as the military \n[117,118] and there is no evidence of its efficacy in institution -\nalized elderly populations.\nThere is also no evidence of the need for routine nasal \ndecolonization to prevent MRSA infections in patients admit -\nted to nursing homes. It is advisable to evaluate carrier status \nupon admission to the institution, before outbreak situations, \nand in patients who return or go to hospitals or change insti -\ntutions.\nTherefore, it is not necessary to screen for nasal carriers \nof S. aureus in general, unless there is a history of having been plan has been proposed to assess air quality in nursing homes \nand evaluate it periodically. This proactive approach can pave \nthe way for the establishment of mandatory standards for in -\ndoor air quality in nursing homes that will promote the health, \nwell-being and quality of life of LTCF residents and reduce \nmedical costs [91].\n As regards the control of legionellosis in residences for \nthe elderly, there is no uniform legislation in the different \ncountries and, when it exists, it is frequently not complied \nwith. We therefore believe that this regulation and the corre -\nsponding periodic environmental control would be advisable \n[92].\nIn the individual aspects, there is no doubt that the im -\nplementation of vaccination programs for both residents and \ncaregivers is an essential factor for the reduction and control \nof respiratory infection by influenza viruses and SARS-COV-2 \n[30,33,49,55,93-96]. There are also prospects for the use of a \nvaccine against RSV in the elderly population [97].\nAntivirals are not recommended as chemoprophylaxis, ex -\ncept as part of interventions to control institutional outbreaks \nof influenza [98-101]. Its efficacy, for the most widely used \n(Oseltamivir), in a systematic review of 9 randomized clinical \ntrials involving 4,328 patients [102], estimates a 21% reduc -\ntion in symptoms versus placebo in the infected population; \nfewer lower respiratory tract complications requiring antibi -\notics for more than 48 h and fewer hospital admissions for \nany cause. Observational studies find association between the \nuse of Oseltamivir and mortality reduction [103] but no rand -\nomized trial has demonstrated this. All have been conducted in \nhealthy individuals where the mortality rate due to influenza \nis very low.\nThe efficacy of pneumococcal vaccination is linked to its \nantigenic composition [polysaccharide (PPV) and polyvalent \nconjugate (PCV)] and to the impact and application of PCV7, \nPCV10 and PCV13 in individuals over 65 years of age [104,105]. \nPPV23 efficacy data [106] are conclusive for protection from \ninvasive disease, against all-cause pneumonia in low-income \ncountries, and in chronically ill adults. It was not associated \nwith a substantial reduction in all-cause mortality, possibly be -\ncause of heterogeneity or lack of power of the studies.\nIn the CAPiTA trial (Community-Acquired Pneumonia Im -\nmunization Trial in adults) [107] PCV13 was compared in im -\nmunocompetent adults over 65 years of age versus placebo in \na randomized, double-blind trial involving 84,496 adults aged \n65 years or older. The protective efficacy of this vaccine for \ndifferent points was estimated between 45% and 75.0%.\nConclusion\nThere are both environmental (air quality) and indi -\nvidual (vaccines) protective measures capable of reducing \nthe incidence of respiratory infection in nursing homes, \nboth in the case of infections caused by viruses (Influ -\nenza, SARS-COV-2) and bacterial infection (e.g. Pneumo -\ncoccus). In most cases, however, legislation and its imple -\nmentation are necessary.Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379355As we have mentioned, some of the most frequent viral \ninfections are preventable by vaccination, so it is convenient \nto have a record of whether the elderly person has been vac -\ncinated, the date of the last vaccination, whether he/she has \nantibodies or whether he/she needs to be vaccinated. There -\nfore, when the patient is admitted to the nursing home, I be -\nlieve it is convenient to know his serology status against the \nhuman immunodeficiency virus (HIV), and against hepatitis \nA, B and C viruses. We believe that it should also be recorded \nwhen the patient was vaccinated against hepatitis A and B \nand make sure that he has received the previous year\u2019s influ -\nenza vaccine [124], COVID-19 and, as soon as it is available \nin our environment, the Varicella Zoster Virus (VZV) vaccine \nfor adults. \nIn addition to the above, and whenever possible, the per -\ncentage of workers, residents, and visiting family members \nwho have received the influenza vaccine should be recorded \neach year. A recent study (SHELTER study) conducted in 57 \nnursing homes in 7 European countries has shown that both \ncorrect vaccination against influenza and pneumococcus re -\nduce mortality among residents, regardless of their comorbid -\nities and functional and cognitive status [124-126]. This evi -\ndence, together with the reduction in influenza mortality in \nvaccinated patients, makes it an essential quality objective.\nOn the other hand, it is clear that the degree of influen -\nza vaccination among nursing home employees, which ranged \nfrom 15-97% in a North American study, is clearly considered \na quality criterion, since non-compliance with this obligation \nputs residents at unacceptable risk of suffering serious con -\nsequences [127]. It is also highly advisable to insist to family \nmembers that they should not visit their elderly with symp -\ntoms of respiratory infection or having recently been in con -\ntact with a sick person. \nIt is also advisable to record the number of visits to the \nemergency room that the elderly require and their causes \n[128]. Admissions due to upper respiratory infection or pneu -\nmonia and associated mortality should be recorded [129]. \nFinally, it also seems advisable to make sure that absolute -\nly all new workers have received specific training on how to \nprevent and recognize nosocomial infections, as multicenter \nstudies have shown that these training activities substantial -\nly improve the safety of interns and the quality of care [130]. \nThese proposals are summarized in Table 1.\nConclusion \nIndicators of the process of prevention of viral infec -\ntion in nursing homes should include data on previous \ninfection by viruses such as HIV, HBV, HCV, SARS-COV-2, \nInfluenza and RSV on admission to the institution.\nDuring follow-up, parameters such as vaccination \nrates against the different viral pathogens among resi -\ndents and staff, as well as episodes of infection by these \nviruses and the hospital admissions they required, should \nbe available.colonized or infected in close contact with a colonized/infect -\ned case or if the resident has a history of having recently been \nin other centers with an endemic situation or active outbreak \n[17,18,119]. \nColonization of an elderly person by MRSA should not \nbe a reason for exclusion for admission and participation in a \nhealth care center. Patients colonized or infected by MDR mi -\ncroorganisms should, whenever possible, be placed in a single \nroom, not isolated and following universal measures. If this is \nnot possible, they should share a room with another person \nwith the same problem. If this is also not possible, they can \nshare a room with another person who does not have ulcers, \nwounds, catheters, drains or probes. They should never share \na room with an immunosuppressed user. In case of ulcers or \ncolonized skin wounds, these must be well treated and cov -\nered with a dry dressing before sharing activities in common \nrooms of the residence. There should be no restrictions on \nvisitors, since in general, they have a low risk of acquiring \nan infection due to the protection of their saprophytic flora \nand can establish contact, but with the appropriate hygienic \nmeasures (hand washing, use of gloves and disposable gown \nif necessary). Nor are worker controls necessary, except in the \ncase of outbreaks if it is suspected that they may be the epi -\ndemiological cause. \nConclusion\nSkin and soft tissue infections (SSTI) are frequent in \nthe elderly population living in LTCF. Their reduction re -\nquires general hygiene measures and control of predis -\nposing factors such as skin lacerations or uncontrolled \nblood glucose.\nThere is no evidence of the need for routine screen -\ning for S. aureus  carrier status, nor of the efficacy of \nsystematic nasal decontamination or intermittent use of \nchlorhexidine showers.\nWHAT INDICATORS ARE NEEDED TO MONITOR \nTHE PREVENTION OF INFECTION CAUSED BY \nVIRUSES IN NURSING HOMES? HOW OFTEN \nSHOULD THEY BE OBTAINED?\nViral pathogens cause a significant proportion of infec -\ntions in the elderly, mainly respiratory and skin infections. For \nexample, in a recent study, 31.6% of the elderly with respira -\ntory infections had a viral etiology (41.8% among out-of-hos -\npital infections and 25.7% among nosocomial infections) [120] \nand the most frequent was influenza (14% of all patients \nstudied). RSV is also a significant pathogen in this population \n[121,122].\nThe number of patients in a nursing home who get the flu \nand the number of residents and workers who are vaccinat -\ned are, in our opinion, clear indicators of the quality of care \nprovided to the elderly in this respect [123]. These would be \nthe most important indicators, in our opinion. But, if possible, \nsome more could be included, as we will see below.Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-3793562.- The rapid classification of residents, based on their \nCOVID history and diagnostic tests, allows these institutions to \ncreate separate areas and circuits for \u201cpositive\u201d persons who \nhave overcome the disease or who have evidence of disease \nactivity [134].\n3.- Adequate allocation of staff, particularly prior to vac -\ncination, allowed, in these separate units, to assign to a par -\nticular caregiver staff, those unvaccinated and who had not \npassed the disease.\nPrior to vaccination, in non-COVID patient areas, it was \nappropriate to place caregivers who had passed the disease \nand were considered reasonably immunized against it [135]. \n4.- A very severe restriction of visitation is considered to \nbe an effective method for the prevention of COVID in these \ninstitutions [136] and written guidelines for visits should be \navailable.\n5.- Isolation periods for SARS-CoV2 infected patients \nclassically established that residents should remain in isolation \nfor a full 14 days after diagnosis of COVID-19 although it is \npossible that shorter times may be equally valid. It should be \nkept in mind that prolonged isolation predisposes residents to \ngreater physical and mental deconditioning. \n6.- Actions on personnel\nIt is very important to work with caregivers in nursing \nhomes, given that during the COVID pandemic there have been \nhigh levels of dissatisfaction, stress and anxiety among them \n[137,138]. Psychological and professional support policies are \nneeded to complement clear and consistent guidelines on the \nprocedures for handling different situations.\nThe recommendations of the Japanese Geriatric Society \nare interesting in this regard [139].\nConclusion\nThe parameters that can best indicate the situation \nof COVID-19 and its prevention in nursing homes are, in WHAT ARE THE PARAMETERS ON SARS-COV-2 \nINFECTION STATUS THAT SHOULD BE AVAILABLE \nIN NURSING HOMES?\nIt is not the purpose of this discussion to insist on the ter -\nrible impact that COVID has had on the elderly population and \nparticularly among those living in nursing homes but to estab -\nlish what should be the program of action for nursing home \nauthorities to prevent diseases such as COVID-19 and its easy \ntransmission among residents.\nThe challenges that the COVID-19 pandemic has posed to \nLTCF have been analyzed and summarized in several publications. \nGiri et al [131] reported a meta-analysis of publications on the \nsubject. They retrieved 348 articles, of which 76 were included \nin the thematic review. Eight articles referred to asymptomatic \ntransmission, 24 to resident-related factors (e.g., comorbidities, \nnutrition, cognition), 13 to facility characteristics (e.g., physical \nspace, occupancy, facility ownership), 21 to staffing (e.g., staffing \nlevels, staff-to-resident ratio, staff multi-employment), and 10 \nto external factors (e.g., availability of personal protective equip -\nment, health and social care policies in place). The papers also ex -\namine responses to issues that arose including diagnostic testing, \nisolation and grouping of residents, staff protection and support, \npromotion of wellness, and technological innovations [131].\nProper planning and design of the built environment pro -\nmotes infection control strategies in nursing home facilities. \nFindings can be used to guide the redesign, renovation, and \nmodification of nursing home facilities for COVID-19 control \nof future public health emergencies. [132].\nAmong the measures that deserve special mention are:\n1.- The massive use of diagnostic tests that has made it \npossible to identify a high proportion of asymptomatic or ol -\nigosymptomatic patients and to take the pertinent isolation \nmeasures [133]. \nIsolation measures Indicators on admission of the elderly to the nursing home Serology against hepatitis A, B and C, VZV, SARS-CoV-2\nPrevious year\u2019s vaccination status against influenza, COVID-19 and VZV when available.\nAnnually in each patient Annual flu vaccination registry\nWhen available, VZV vaccine registry\nAnnually throughout the residence Influenza cases in the LTCF\nCases of RSV in the residence\nCases of Zoster in the residence\nVisits to the emergency department for upper respiratory tract infections\nPercentage of staff, interns and visiting family members who have received flu vaccine\nPercentage of newly hired staff who have received training in nosocomial infection prevention\nConsumption of alcohol-gel for hand hygiene in the nursing homeTable 1  Indicators related to viral infection in nursing homes.Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379357to have an advance directives document to know the patient\u2019s \ndesire to escalate treatment, referral to hospital, intubation or \nothers. These data should be recorded in the clinical history to \nbe taken into account in decision making for the diagnostic \nand therapeutic management of pneumonia. \nAmong the infection management and evolution indica -\ntors, three related to antibiotic treatment and oxygen therapy \nstand out. In relation to the evolution of the respiratory infec -\ntion, a universal indicator in the management of pneumonia is \nthe use of antibiotics in the first 8 hours after the diagnosis of \npneumonia. This is based on several studies that demonstrate \na higher survival of patients when antibiotics are started in \nthe first 8 hours from diagnosis. For this reason, in the various \nSEPAR regulations [142] and in a consensus on infections in \nthe elderly [143] is a universal recommendation and an indi -\ncator included among those recommended for nursing homes. \nSimultaneously, the measurement of O2 saturation to de -\ntermine the need for oxygen therapy and its subsequent pre -\nscription and delivery is included as an indicator of quality of \ncare. If it is indicated and not prescribed, the reason for this \nshould be indicated in the clinical history, since it may be due \nto the patient\u2019s decision. \nThe third indicator for assessing the evolution is the \nneed for transfer to hospital due to worsening and the need \nfor therapeutic escalation, expressed as a percentage of the \ntotal number of pneumonias or infections. There are some \nprograms developed specifically in nursing homes in the USA \nthat include as an indicator the reduction of hospitalization \nof patients to enhance treatment in the nursing home. This \nprogram called INTERACT (Intervention to reduce acute care \ntransfer) has also been analyzed to determine its safety, given \nthat it could cause complications or have adverse effects if this \nmeasure is promoted and reduces necessary hospitalizations. \nThe study conducted has shown no negative consequences on \npatients [144].\nThe last indicator of evolution and management is the \nchange from intravenous to oral medication when clinical stabil -\nity occurs, as long as there is capacity for oral intake. Clinical sta -\nbility is possibly the best indicator of good therapeutic response our opinion, the following:\n1.- Evolution of the percentages of residents and \nstaff vaccinated against COVID-19.\n2.- Number of new cases detected each month in \nboth residents and staff members, differentiating between \nthose occurring in vaccinated and unvaccinated patients.\n3.- Evolution and number of outbreaks of infection.\n4.- Last date of revision and update of protocols for \nprevention and management of COVID-19.\nIN NURSING HOMES, WHAT ARE THE BEST \nINDICATORS OF THE EVOLUTION OF BACTERIAL \nRESPIRATORY INFECTION?\nSince viral infection and its indicators have already been \ndiscussed in other sections, we will focus on pneumonia as a \nquality parameter to be monitored in nursing homes. \nIn community-acquired pneumonia (CAP), which is the \nmost severe expression, quality of care indicators identify and \nmeasure care that is associated either with a better prognosis \nof the process or with a better use of treatments. Most indica -\ntors have been described in hospitalized patients and in pop -\nulations other than nursing homes. However, for the ACOVE \n(Assessing Care of Vulnerable Elders) expert group, pneumonia \nis one of the target processes for defining indicators and im -\nplementing quality of care [140,141]. In these indicators, they \nexclude the group of patients with advanced cognitive impair -\nment or with a life prognosis of less than 6 months. \nThe indicators selected in pneumonia and/or influenza by \nthis group are eight in total. They comprise infection manage -\nment indicators and infection prevention indicators (Table 2). \nAlthough there have been reviews of pneumonia in the elderly \n[105], There are few studies that analyze the impact of qual -\nity indicators on pneumonia care in nursing homes. In people \nwith advanced dementia, mortality is very high despite the use \nof antibiotics, and even if life is prolonged, it may be only in \ndays, lengthening the dying process.\nAs a starting requirement, in nursing homes, it is essential Management of infection Initial antibiotic in <8 hours in diagnosed pneumonia / Total pneumonias\nPneumonias with hypoxemia treated with O2 /total pneumonias with hypoxemia \nPneumonias referred to hospital /total pneumonias\nChange to oral antibiotic if clinical stability criteria are met/total pneumonias \nPneumonia deaths/ Total pneumonias\nPrevention Influenza vaccination for residents\nPneumococcal vaccination for residents\nVaccination for workersTable 2  Indicators of the pneumonia process in nursing homes for the elderlyInfection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379358WHAT METRICS SHOULD BE USED AS INDICATORS \nOF GASTROINTESTINAL INFECTION IN NURSING \nHOMES?\nGastrointestinal infection is one of the frequent causes \nof infection outbreaks in nursing homes. In addition to immu -\nnosenescence, seniors frequently use medications such as pro -\nton pump inhibitors whose undesirable short- and long-term \neffects are well known [145-147].\nAmong the most frequent causes of enteric infection out -\nbreaks in LTCF are viral pathogens such as Norovirus, Rotavirus, \nCalicivirus and Astrovirus [148] and bacterial such as Clostridium \nperfringes  [149] and Clostridioides difficile  [150, 151]. In a re -\nview of publications on outbreaks of enteric infections in nurs -\ning homes, the publications of 75 outbreaks are used for a me -\nta-analysis. Sixty-nine percent of the outbreaks were associated \nwith viral agents and 31% with bacterial agents. Transmission \nwas mainly foodborne (52%) for those of bacterial origin and \nperson-to-person (71%) for viral outbreaks. Norovirus infection \nwas associated with 58% of hospitalizations but the ones with \nthe highest mortality, however, were enteric infections caused \nby Salmonella sp. The control measures for these outbreaks are \nmainly general and food hygiene measures but none of the 75 \npublished outbreak reports evaluated the effectiveness of the \nrecommendations suggested to control each outbreak [151].\nC. difficile infections (CDI) are often the consequence of \nuntimely antibiotic use, particularly in the elderly who are on \nfluoroquinolones and proton pump inhibitors [152-154]. The \nelderly are a recognized risk group for CDI and outbreaks of \nCDI in institutions for the elderly are well known [155-162].\nThe parameters that, in our opinion, would allow a fol -\nlow-up of gastrointestinal tract infection (GTI) in this popula -\ntion are the following:\n1.- Incidence density of diarrhea in the institution (sum of \npatient days with diarrhea versus total daily stays).\n2.- Evolution of the number of outbreaks of enteric infec -\ntion and their etiology.\n3.- Documented episodes of C. difficile  infection.\n4.- Days of treatment with oral antibiotics and fluoro -\nquinolones per 1,000 stays in the institution.\nConclusion\nGastrointestinal infections can cause outbreaks in nurs -\ning homes. We believe that it is necessary to have specific \nprotocols for their prevention and management. The most \nelementary indicators of these processes seem to us to be \nthe incidence density of diarrhea, outbreaks of enteric infec -\ntion and their causes, episodes of C. difficile  infection and \nconsumption of orally administered antimicrobials.\nHOW SHOULD THE PROBLEM OF URINARY TRACT \nINFECTION BE FOLLOWED UP WITH FIGURES?\nUrinary Tract Infection (UTI) accounts for 49% of all in -and good evolution. Therefore, in daily practice, clinical stability \ncriteria are used for decision making and include the duration of \nantibiotic treatment, among other things [142]. In the published \nguidelines on CAP, it is contemplated that if the patient has a \ntemperature less than or equal to 37.2\u00baC in the last 48-72 hours \nand does not have more than one instability criterion, the antibi -\notic regimen can be terminated. In general, in the use of antibi -\notics, more days than necessary are prescribed with the potential \nproblems of adverse effects such as CDI and others. The different \ncomponents included in these criteria are respiratory rate (RF), \nheart rate (HR), axillary temperature, systolic BP, O2 saturation and \nlevel of consciousness. The cut-off points for establishing clinical \nstability are detailed in Table 3. Clinical stability is usually achieved \nwithin 3-4 days of treatment in patients hospitalized for pneu -\nmonia. It should be considered that in elderly patients or those \nwith multiple pathologies, stability can be delayed until day 5-7 \nwithout this meaning that there is a poor evolution. In fact, a \npublication on people living in nursing homes shows that up to \n57% achieve clinical stability within 5 days of correct treatment. \nIt is also necessary to consider each person\u2019s previous situation. \nIf there were data on the patient\u2019s O2 saturation at baseline, the \ncut-off point established to consider stability should be the return \nto baseline saturation and not necessarily to normal saturation. In \nthe same way, the level of consciousness must be assessed with \nreference to the previous situation.\nAmong the infection management and evolutionary in -\ndicators, those related to early initiation of antibiotic treat -\nment and its de-escalation, oxygen therapy and its subsequent \noutcome in terms of the need for hospitalization or mortality \nstand out.\nConclusion\nNursing homes should have figures on the evolution \nof the incidence density of pneumonia in the population \nthey serve. In addition, the proportion of cases requir -\ning oxygen therapy and hospital referral are desirable \nparameters. The proportion of patients with pneumonia \nwho receive antibiotic treatment within 8 hours of diag -\nnosis, the time to clinical stabilization, the duration of \nantimicrobial treatment and the time to switch to oral \ntreatment should also be known. Undoubtedly, mortality \nshould be included among the process indicators. Heart rate < 100 bpm\nRespiratory rate < 24 rpm\nAxillary temperature \u2264 37.2 \u00baC\nSystolic blood pressure > 90 mmHg\nO2 saturation > 90%\nAdequate level of consciousnessTable 3  Clinical stability criteria in patients \nwith pneumoniaInfection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379359as the number of patients with bladder catheterization or \nother urine diversion procedures, UTI incidence density, \nand the proportion of episodes caused by MDR microor -\nganisms.\nSHOULD THERE BE A REGISTRY TO TRACK \nPRESSURE ULCERS?\nIn a recent systematic review that included 17 valid stud -\nies, the frequency of pressure ulcers is estimated very varia -\nbly in different nations. Prevalence rates ranged from 3.4 to \n32.4% although the large differences in prevalence in different \ncountries are not explained by methodological differences and \ndata from many developed nations are missing [172]. \nIn a study of more than 700 nursing homes in Japan, the \nprevalence of pressure ulcers was 9.6% and the monthly inci -\ndence was 1.9% [173] and in the United States in a sample of \n2,936,146 residents in LTCF had stage 2, 3 or 4 pressure ulcers \nin 8.4% and deep tissue infections in 1.7% [174].\nWe are therefore talking about a frequent problem with \nmultiple risk factors including peripheral vascular disease, \nimmobility and low hemoglobin and albumin blood concen -\ntrations. It is essential to have multidisciplinary teams for \nprevention, specific protocols for assessment and care, and \ntherapeutic and preventive means to address this problem \n[173,175]\nThe minimum data set needed to address pressure ulcer \nfollow-up should include assessment of residents\u2019 risk of pres -\nsure ulcers on admission, quantification and classification of \npressure ulcers, and a management manual with periodic re -\nviews [176]. It is necessary to have the so-called \u201cminimum da -\nta set\u201d (MDS) to be taken into account for the assessment and \nscales such as the PUSH (Pressure Ulcer Scale for Healig), the \nPSST (Pressure Sore Status Tool), the DESING scale, the CODED \nscale or RESVECH 2.0 [177-182]\nFor all these reasons, we believe that the set of parame -\nters aimed at monitoring the problem of pressure ulcers as a \npredisposing element to skin and soft tissue infection should \ninclude the evaluation of the risk of suffering from such ulcers \nboth on admission and periodically, the prevalence of ulcers \nand their categorization, and the verification of the periodic \nreview of a document for their prevention and management. \nIn addition, episodes of skin and soft tissue infections should \nbe recorded, as mentioned in a previous section.\nConclusion\nIt is necessary that follow-up records in nursing \nhomes include the classification of residents according to \nthe risk of pressure ulcers, the evolution of the preva -\nlence of pressure ulcers and their classification by sever -\nity. It is also necessary to record the number of episodes \nof skin and soft tissue infections over time and evidence \nof the periodic review of written protocols for prevention \nand treatment of pressure ulcers.fections in nursing homes and its incidence is estimated to be \naround 1 episode per 1000 stays in studies in Austria [163] and \nGermany [164]. ITU criteria must be strict [165] avoiding over -\ninterpretation of simple positive urine cultures without clearly \nattributable symptomatology. \nThe frequency of indwelling urinary catheters among el -\nderly patients in LTCF varies between 3-12%, being higher in \nmen than in women [60,108]. Urinary catheter-associated UTI \nis a common cause of sepsis, hospital admission and antimi -\ncrobial use that often leads to subsequent colonization with \nmultidrug-resistant microorganisms (MDR) [166,167].\nIn patients with urinary catheters, the prevalence of bac -\nteriuria is 100% and the incidence of symptomatic UTI is es -\ntimated at 3-7 episodes per 1,000 catheterization days [166, \n168]. Symptomatic UTI, defined as the presence of fever not \nattributable to another cause, has been estimated at 6 to 11 \nepisodes per 1,000 catheterization days in institutionalized el -\nderly people [169]. \nIn this regard, it is important to correctly diagnose \nsymptomatic UTI and differentiate it from asymptomatic \nbacteriuria [170]. The Infectious Diseases Society of Amer -\nica (IDSA) guidelines define urinary tract infection as the \ngrowth in culture of \u2265103 CFU/mL of uropathogenic bac -\nteria in the presence of symptoms or signs consistent with \nurinary tract infection with no other identifiable source in \na patient with indwelling urethral, indwelling suprapubic, or \nintermittent urethral catheterization. Compatible symptoms \ninclude fever, suprapubic or costovertebral angle tenderness, \nand unexplained systemic symptoms such as altered mental \nstatus, hypotension, or evidence of a systemic inflammatory \nresponse syndrome. [171]. \nRegarding prevention, there are few randomized con -\ntrolled studies measuring the efficacy of preventive measures \nfor UTI secondary to bladder catheterization. Among the most \nimportant measures are to perform bladder catheterization \nonly when necessary and to remove the catheter as soon as \npossible. Intermittent catheterization may reduce the risk of \nbacteriuria, and is associated with a lower risk of complications \nand bacteremia [108].\nFor the control of UTI in nursing homes [164] surveillance \nof symptomatic UTI episodes (1,000 catheter-days/1,000 resi -\ndent-days) and monitoring of resistant organisms in urine of \ncatheterized patients is recommended in order to detect an \nincrease in incidence or an infectious outbreak. \nThe indices we suggest to monitor this process in nursing \nhomes could be the following:\n1.- Proportion of residents with bladder catheterization or \nother permanent urine diversion procedures.\n2.- UTI episodes per 1000 days of stay.\n3.- Proportion of episodes of UTI caused by MDR.\nConclusion:\nThe effectiveness of surveillance and monitoring of \nUTI in nursing homes should be tracked by indices such Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379360Conclusion\nWe recommend the recording of episodes of in -\nfection caused by multidrug-resistant microorganisms \n(MDR) and not the systematic search for colonization by \nthese microorganisms, which should only be carried out \nas part of actions derived from specific problems. This \nrecommendation is due to the fact that the evidence is \ncurrently insufficient to provide recommendations for or \nagainst any intervention in patients colonized with MDR. \nSHOULD THERE BE A REGISTRY ON THE USE OF \nANTIMICROBIAL AGENTS IN NURSING HOMES?\nImproving the use of antimicrobials in any healthcare set -\nting (human and veterinary) is a national priority, and this ap -\nplies to all settings, hospital and residential [194].\nBetween 40-70% of antibiotics (ATB) prescribed in a \nhealthcare setting are unnecessary and sometimes inappropri -\nate and, as a pharmaceutical group, they are the most pre -\nscribed in a residential facility. \nThe judicious use of antibiotics reduces the emergence of \nresistance, avoids adverse effects and lowers costs [195]. \nIt is recommended that all facilities have a policy on anti -\nbiotic use (PROA program), for which the CDC has developed a \nprogram focused on 7 key elements [196]: \n- Commitment of the center to carry out an antibiotic \npolicy program. \n- Responsible for the program: physician or pharmacist \nwith specific training. \n- Antibiotic expert pharmacist. \n- Documented action plan. \n- Traceability of treatments. \n- Periodic reports of results to prescribers and nurses.\n- Training program. \nThe approach to the use of ATB in institutionalized set -\ntings is not an exclusively local problem; it must be understood \nin territorial terms. The exchange of patients and, therefore, of \nthe microbiota means that the resistance maps of the centers \nmust be drawn up according to the resistance profiles of a \nspecific territory. \nFor infection control in residential centers, there are a \nseries of safe practices that should be \u201cmandatory\u201d, such as \nthe use of gloves, hand hygiene (with its 5 moments) and the \nocclusion of wounds or ulcers. In addition to these practices, \nthere are several measures to implement infection control and \nprevent the spread of MDRs such as the use of closed system \nurine collectors, optimizing oral hygiene, and monitoring of \nhigh prevalence infections: especially urinary tract infections. \nSituations in which ATB use should be avoided are viral \nrespiratory infections, asymptomatic bacteriuria and indis -\ncriminate use of topical ATBs. \nAt the present time, ATB prescribing and administration HOW SHOULD THE PROBLEM OF COLONIZATION \nAND INFECTION BY MULTI-DRUG RESISTANT \n(MDR) BACTERIA IN A NURSING HOME BE \nMONITORED?\nInfections and colonizations by multidrug-resistant microor -\nganisms (MDR) are a worldwide known problem of growing impor -\ntance that is no longer limited to hospitals and is also increasingly \naffecting other healthcare facilities such as nursing homes [73,183-\n187]. The subject has been reviewed in depth by Rodriguez-Villodres \net al. recently [188] showing that the prevalence of colonization by \ndifferent MDRs is highly variable from one continent to another. \nO\u2019Fallon et al. conducted a study with active search for MDRs \nin nursing home residents and found that 22.8%, 0.6% and 11.1% \nwere colonized by MDR gram-negative bacteria, vancomycin-re -\nsistant enterococci and MRSA, respectively. MDR gram-negative \nbacteria were recovered in 3 (1.8%) of the 175 environmental sam -\nples cultured [189].\nElderly residents in these facilities present several risk factors \nfor MDR colonization or infection, in particular, chronic diseases, \nmultimorbidity, immunodeficiencies, limited mobility and frequent \ntransfers between hospital and residence lead to an increased risk \nof healthcare-associated infections and, consequently, MDR carrier \nstatus [164,188,190]. A very important and modifiable risk factor is \nthe high use of antimicrobials during the year in the institution.\nIn addition to the morbidity-mortality aspects, a European \nstudy has recently shown that nursing homes face costs per pa -\ntient with MDR infection estimated at an average of 12,682 euros \nper case (ranging from 2,449 to 153,263 euros per episode). In this \nstudy, the mean duration per case of MDR infection in nursing \nhomes was 163.3 days [191].\nIn general, the literature estimates that the success of decolo -\nnization measures in nursing homes is very low [192]. The reasons \ngiven are, on the one hand, poor health conditions of elderly resi -\ndents combined with poor compliance and, on the other hand, lack \nof hygienic knowledge of nursing staff. \nIn 2019, the European Society for Clinical Microbiology and \nInfectious Diseases (ESCMID) developed a guideline to provide rec -\nommendations on decolonization regimens targeting BGN-MDR \ncarriers in all settings [193].\nWe were not able to find a firm recommendation on the pa -\nrameters that should be systematically obtained to correctly moni -\ntor this problem, nor on the impact that obtaining them has on its \ncontrol. Therefore, our current recommendation does not require a \nsystematic search for MDR colonization in institutions for the care \nof the elderly. However, we believe it is advisable to record infections \ncaused by MDR microorganisms and to monitor them, meaning the \nfollowing: Extended Spectrum Beta-lactamase (ESBL) producing \nEnterobacteriaceae, Carbapenemase producing Enterobacteriaceae, \nMDR Pseudomonas aeruginosa,  MDR Acinetobacter baumanii  and \nMDR Stenotrophomonas maltophilia . Among the gram-positive \nmicroorganisms we should include MRSA, vancomycin-resistant \nEnterococcus  (VRE) and C. difficile  although in the latter case it is \nnot genuinely an MDR.Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379361- Empower professionals. Role of nursing experts in infec -\ntion control. \n- Avoid movement restrictions. \n- Create infection control culture. \n- Implementation of safe practices.\nConclusion\nWe consider the figure of the \u201ctelecounselor\u201d to be \nvery necessary, who should be a professional with ex -\ntensive training in geriatrics and infectious diseases, \nreporting to the territorial Health Services, who can \nact by stimulating and advising on valuable practices, \nmonitoring local and area resistance patterns and lead -\ning-implementing PROA policies in his or her area of \nreference. Given the great variability among the differ -\nent residential centers, this figure must ensure compli -\nance with the recommended guidelines, the follow-up \nof MDR infections, the appearance and control of pos -\nsible outbreaks of infections and the training programs \nfor professionals. \nIS FEVER A GOOD MARKER OF INFECTION IN THE \nELDERLY, AND ARE DAYS WITH FEVER PER YEAR A \nPARAMETER TO BE MEASURED?\nFever, whether present or absent, is not a good marker of \ninfection in the elderly if it is not accompanied by other values. \nUp to 30% of older adults with active bacterial or viral infec -\ntions do not have fever [198,199]. Likewise, the presence of \nfever is not an exclusive marker of infection, as elevated body \ntemperature may be related to other clinical entities such as: \nthe presence of tumors, pharmacological interaction (such as \nneuroleptic malignant syndrome), metabolic causes (such as \nthyrotoxicosis) or fever that appears after excessive sun expo -\nsure, as in the case of heat stroke [198,199].\nGiven the unspecificity of fever as a symptom caused by \nmultiple conditions, fever days per year is not a useful param -\neter in relation to the presence of infections [200]. On the oth -\ner hand, the number of proven annual infections is important \n(those for which there is microbiological evidence as well as \nclinical compatibility). In this case, especially in urinary tract \ninfections, it is possible to implement a non-pharmacological \nprophylaxis or, in case of lack of success of the previous one, \nalso pharmacological prophylaxis.\nConclusion\nFever is not a good marker of infection in the older \nadult as it is neither sufficiently sensitive nor sufficiently \nspecific for the presence of infection. \nWHAT SHOULD A CHECKLIST INCLUDE TO \nPREVENT INFECTION IN ELDERLY PEOPLE LIVING \nIN NURSING HOMES?\nStructured interventions, such as the introduction of in -software can allow systematic recording or analysis of pre -\nscribing profiles. But more important than having or not hav -\ning such a registry is the development of a global program on \ninfection control in the centers. This program, if coordinated \non a territorial basis, is much better, since the resistance pro -\nfiles are linked to a territory and to the reference hospitals of \nthe Health Area. \nIn the implementation of these programs, it can be use -\nful to take as a reference the recommendations of the 7 key \npoints elaborated by the CDC (Centers of Disease Control) for \nhospitals and later adapted to the institutional environment \n[7,196,197]. \nTherefore, to the question of whether there should be a \nregistry on the use of ATB in nursing homes, the answer is yes, \nbut especially within the framework of a global program on \nthe rational use of antibiotics and coordinated with the poli -\ncies and resistance maps of the territory. \nConclusion\nThe consumption of antimicrobials in a nursing home \nshould be a quality indicator. The denominator to be used \ncan be the 1,000 days of stay and the numerator can be \ngiven in total Defined Daily Doses and of the large groups \nof antibiotics.\nIS THERE A NEED FOR A \u201cTELE-ADVISOR\u201d WITH \nEXPERTISE IN INFECTION CONTROL IN THE LTCF? \nWHAT WOULD HIS/HER JOB BE?\nAs we have indicated, the optimal and more than desir -\nable situation is to approach infection control in residential \ncenters from a territorial perspective, which, in our country, \nis articulated around the territorial PROA programs. This \u201ctele -\ncounselor\u201d should play a key role in leading and validating the \ntreatment and infection control programs in the residential \ncenters in his or her area of reference. \nHis task would be to serve as a link between the residen -\ntial centers and the reference hospital of the territory, to elab -\norate and validate the resistance maps of the most frequent \nmicroorganisms in the most prevalent infections (mainly uri -\nnary and cutaneous).\n- Protocolization of the prescription. Analysis of action \nplans.\n- Control of the resistance profile of the center and prepa -\nration of the resistance map of the Health Area. \n- Individualized prescription support in specific cases \n(MultiR, nosocomial outbreaks, restricted ATB policies). \n- Participation in the territorial PROA. \n- Validate and collaborate in the training program of the \nprofessionals of each center. \n- Monitor number of UTIs and most common microorganisms.\n- Monitor bronchoaspirations. \n- Establish empirical treatment protocols. Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379362of signs suggestive of infection in various organs as well \nas the need for maintenance of antimicrobial therapy.\nWHO SHOULD SIT AT A CONSENSUS TABLE TO \nELABORATE A PROGRAM SUCH AS THE ONE WE \nARE DISCUSSING?\nInfection prevention and control should be seen as a team \neffort in which everyone, representatives of institutions and \norganizations, the scientific and medical community, residen -\ntial centers and their direct and indirect care personnel, as well \nas the patient himself, should take part.\nThe public administration is key not only in its regulatory \nrole and as guarantor of the protection and safety of citizens \nand, in particular, of the most vulnerable groups, but also in \nthe monitoring of regulatory compliance. Its role in the dis -\nsemination of guidelines, health recommendations and rigor -\nous information focused on prevention and action in the event \nof infection is also relevant. \nOn the other hand, the role of healthcare professionals is \nfundamental. In addition to doctors, nurses, pharmacists and \nother professionals linked to geriatrics and gerontology, nurses \nand physiotherapists are direct care staff and in addition to \nperforming activities such as administering medication, carry -\ning out cures, rehabilitation exercises and changing catheters, \nthey can provide an assessment of the patient\u2019s condition and \nthe special care that the person needs. In addition to geriatri -\ncians, specialists in infectious diseases and clinical microbiol -\nogy, internists, preventive medicine and other specialists are \nneeded for specific issues. These specialists should be delegates \nof their corresponding Scientific Societies.\nIn addition, health and social workers are knowledgeable \nabout the patient\u2019s situation, the person\u2019s environment and \nthe support required to prevent and control infections.\nPrevention strategies should be developed in routine ger -\niatric care and in any type of health or residential center. The \nmanagement of the centers should be represented to ensure \nthat safety and protection protocols are applied by all staff, \nboth direct and indirect care (kitchen staff, cleaning, main -\ntenance, etc.). In this sense, it is necessary that information \nis disseminated to all levels of the organization and that all \npersonnel working in the facilities, as well as other personnel \nwho may have access to the center, are aware of and apply \nmeasures to guarantee the protection of the resident and the \nrest of the personnel. Likewise, it is necessary to provide these \npersonnel with the necessary resources for the correct devel -\nopment of these protocols and actions.\nPromoting the co-responsibility of the patient and his/her \nenvironment in this area is essential. It is necessary to know \nthe doubts and barriers they face in order to work on a pre -\nventive program that really meets their needs and is effective. \nIt is essential to encourage a health-promoting attitude in its \ndifferent aspects and preventive interventions in gerontolog -\nical clinical practice. In addition, it is necessary to undertake \nawareness and communication actions to explain to residents, fection control packages or checklists, are very useful in in -\ncreasing compliance with infection control measures and de -\ncreasing nosocomial infection rates [201,202].\nA checklist is a tool to assist in the work; it generally con -\nsists of a list of tasks that when performed are verified with \na check mark. It is an instrument with the following positive \nindicators: it improves quality standards and the use of good \npractices, allows critical information to be condensed, helps re -\nduce errors of omission and facilitates reproducible evaluation. \nIt has its limitations and should be avoided as it is time-con -\nsuming to avoid compromising work performance.\nThe \u201cckeck-list\u201d should have the order of workflow and \nroutine established in resident care. For its implementation, it \nis necessary to carry out a series of programs in the organi -\nzational culture of the institution: an educational and train -\ning plan for users of the checklist, support for professionals \nto clarify doubts, piloting before implementation and periodic \nupdating of its content. It should be supported by the person \nor persons responsible for the infection prevention plan of the \nresidential center [203].\nThe \u201ccheck list\u201d can be focused on individual patients but \nit can also be done periodically with the resources of the whole \ninstitution. The one dedicated to assessing the situation of in -\ndividual patients could include, among others, the following \nitems:\nChecking the proper functioning of the hand hygiene de -\nvice closest to the patient\u2019s bed. [114,204,205].\nThe presence of endovascular lines and the question of \nthe need to maintain them.\nThe presence of bladder catheters or other urinary drain -\nage devices and the question of the need to maintain them.\nThe existence of tachypnea or O2 saturation by pulse oxi -\nmetry less than 94%.\nThe existence of pressure ulcers\nThe existence of skin and soft tissue infections.\nAdministration of antimicrobials within the last 24 h.\nRecent deterioration of the patient\u2019s alertness or con -\nsciousness content.\nIndication of any form of isolation\nCommunicating the benefits of implementing a ckeck-list \nto the professionals who carry it out facilitates their incorpo -\nration into their daily tasks since it provides positive reinforce -\nment for their involvement.\nConclusion\nUnderstanding by \u201ccheck-list\u201d the systematic review \nof aspects of infection prevention or detection in resi -\ndents of long-term care facilities, we recommend that a \ndaily check of some items be performed on each individ -\nual. This should include checking the proper functioning \nand availability of hydroalcoholic gels for hand hygiene, \nthe existence and need for maintenance of invasive pro -\ncedures such as IV or urinary catheters, and the presence Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379363and the measures taken to prevent their recurrence should \nalso be made public. Transparent information on the risks of \ninfections in these centers should also be the responsibility of \nthe health authorities.\nAs these centers are mostly privately managed and with \nvery tight financing (in Spain the budget dedicated to long-\nterm care is 0.7% of GDP, compared to an average of 2.5% of \nGDP in the EU-8), any infection control program should be ac -\ncompanied by the corresponding economic report to prevent \ncenters from failing to implement it adequately for economic \nreasons.\nIn addition to the health authorities in the establishment \nof plans and their monitoring and follow-up, the involvement \nof hospital reference services and pharmacy services is very \nimportant for the control of an adequate use of antibiotics in \nthis population.\nIt is also necessary to be very strict in the monitoring of \nthe vaccination schedule in this population, leaving its compli -\nance to the primary health care services.\nPatient organizations should be informed of the estab -\nlishment and monitoring of the control plan, of the incidents \nin its development, of the existence of nosocomial infection \noutbreaks and of the measures to be adopted during visits \nto these centers to minimize the risk. The design of the plan \nshould be technical.\nConclusion\nThe initiative for the establishment of nosocomial in -\nfection control plans in nursing homes is a responsibility \nof the health authorities. The results of the control pa -\nrameters should be in the public domain.\nWHAT CAN BE APPLIED FROM ALL THIS TO THE \nELDERLY LIVING AT HOME?\nThe prevention of infection in the elderly living in their \nown homes, although not primarily the subject that concerns \nus, is also an aspect of the utmost interest. It has many points \nin common with what has been discussed for nursing homes, \nbut also differential aspects. In addition, the place of residence \nof the elderly is variable and there are often changes of resi -\ndence from their own home to long-stay residences and vice \nversa.\nIn view of the need to decide how to apply these meas -\nures in older adults living in the community, we will refer to \nthose pertinent to the prevention of infection and the reduc -\ntion of the risk of communicable diseases. These measures \nmust be coordinated from the Primary Care setting and are an \ninseparable part of the connected fabric of our health system.\nAspects such as the vaccination program and schedule for \nthe elderly do not merit emphasis in this section and readers \nare referred to other sources [47,104].\nThe most common home infection is respiratory infection, \nfollowed by urinary tract infection and skin and soft tissue in -their relatives and caregivers the preventive measures and, al -\nso, the corrective measures in the event of infection, in order \nto encourage the greatest possible collaboration. In this sense, \npatients\u2019 associations become a valuable ally, acting as a chan -\nnel to get the information to these groups and also to convey \nthe needs to public decision-makers and other parties involved.\nFinally, the media become an important source of in -\nformation and play an educational role that cannot be over -\nlooked. The role of the media helps to shape opinion and raises \nawareness, as a preliminary step to a change in behavior fo -\ncused, in this case, on the protection of the individual. \nWe would like to end with a reflection on the commit -\nment of society in general to our elderly and also to their fam -\nilies and caregivers, both formal and informal. We are experi -\nencing an aging population that is leading to a significant and \nprogressive increase in morbidity associated with chronic and \ndegenerative processes, which are often disabling. Therefore, \nthere is an increasing number of elderly people with health \nconditions that require support. For this support to be effec -\ntive, to meet existing needs and to protect the individual, it is \nnecessary for all the agents involved to work in a coordinated \nand cohesive manner, with flexibility and leadership.\nConclusion\nThe elaboration of a document-proposal for the pre -\nvention of infection in nursing homes should include \nhealth professionals, both physicians, pharmacists and \nnurses of different specialties, the most involved scien -\ntific societies, administrators and managers of nursing \nhomes, patients\u2019 associations and representatives of the \nadministration and the media.\nWHO IS RESPONSIBLE FOR SUCH AN \nINITIATIVE? HEALTH AUTHORITIES? SCIENTIFIC \nSOCIETIES? PATIENT ORGANIZATIONS/ SENIORS\u2019 \nASSOCIATIONS?\nThe responsibility for taking the initiative to establish in -\nfection control programs in nursing homes lies with the health \nauthorities.\nIt is the health authorities who should establish what type \nof registers should be set up, clearly indicating their content \n(variables to be collected), the source of the data, the perio -\ndicity, the subsequent analysis and the reports to be issued. It \nshould also be established who is responsible for data collec -\ntion and for establishing infection control programs in these \ncenters.\nThe scientific content of the program should always be \nestablished in collaboration with the country\u2019s scientific soci -\neties and reference experts (research centers and universities) \nto ensure that the latest available knowledge is available at all \ntimes.\nPatients and citizens should be informed of the record of \ninfection in these centers, as well as the programs put in place \nto control it. The reporting of nosocomial infection outbreaks Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379364nursing homes during 2015-2017. Mortality peaked in the first \n4 months after admission, and thereafter, the monthly mor -\ntality rate fluctuated around 3% in men and 2% in women. \nOverall mortality was 34% at one year. The most represented \ncauses of mortality were cardio-cerebrovascular diseases, neu -\nrodegenerative diseases, respiratory diseases and infections. In \nthe table of causes provided by this work, pneumonia appears \nas the cause of 4% of deaths, sepsis with 3.2% and a miscella -\nneous of other infections with 4.2%. In Spain, according to the \n\u201cEnvejecimiento en red\u201d (Ageing network) report, the mortality \nrate due to infections in the total population over 65 years of \nage is about 80 /100,000 inhabitants and year and is one of \nthe few that did not vary between 2006 and 2017 [215]. \nIn a study carried out in public nursing homes in Madrid in \n2013, and published as a doctoral thesis, all the deaths of pa -\ntients living in LTCF were studied, which numbered 713 out of \na total of 5,956 places, representing 12%. The average length \nof stay of the deceased was 37 months. A total of 57.7% died \nin the nursing home and 42.2% in the hospital at a mean age \nof 88.9 years. The principal cause of death was not collected in \n51% of cases and was due to pneumonia and other infectious \nprocesses in 8% of cases, followed by heart failure, tumors \nand dementia. The accompanying chronic diseases were most \nfrequently hypertension, dementia and osteoarticular disease \n[216].\nA study predicting mortality within one year after admis -\nsion to a nursing home does not include infection among the \nmain risk factors [217].\nConclusion:\nThe proportion of elderly dying in nursing homes as \na direct consequence of infection is poorly known since \nthe few studies available have been done on the basis of \ndeath certificates. The data obtained allow us to estimate \nthat infection is a direct cause of death in at least 8 to \n12% of the elderly. Pneumonia and sepsis of urinary ori -\ngin are the leading causes.\nARE THERE DATA ON THE IMPACT OF \nIMPLEMENTING A PROGRAM SUCH AS THE ONE \nWE DISCUSS ON THE QUALITY OF LIFE AND \nSURVIVAL OF THE ELDERLY?\nIn the literature it is possible to find multiple initiatives \ndedicated to improving specific problems related to noso -\ncomial infection in nursing homes. Examples are studies to \noptimize the management and prevention of urinary tract \ninfections [218,219], hand hygiene [220] or the use of in -\ntravenous fluids and antimicrobial agents [221]. There is not \nas much evidence on the effectiveness of global programs \nsuch as those discussed in this paper, let alone their impact \non quality of life and survival [222]. A systematic review of \ndifferent interventions showed that studies with a positive \nimpact on residents tended to change worker behavior, but \nthat such changes in worker practices did not always lead \nto a better prognosis for residents [223]. The authors rec -fection, and in its fundamental aspects the prevention of in -\nfections of these organs follows the same principles as in the \ncase of patients living in nursing homes [206,207].\nA particular aspect of infection prevention in the elderly \nliving at home is the possible acquisition of infections from \nyounger members of the family community. Good examples \nare Influenza, RSV and more recently and dramatically SARS-\nCoV-2.\nAnother very important aspect is the programs to im -\nprove the use of antimicrobials (PROA programs) that exist \nat the community level in Primary Care in some areas, led by \nFamily Physicians [11,28,208-212]. There is evidence that the \ninappropriate use of antibiotics has direct consequences on \nthe increase of infections by MDR microorganisms, taking into \naccount that between 30-50% of antibiotic prescriptions are \ninappropriate. \nIt is therefore interesting to evolve to a system that elim -\ninates all barriers between the patient\u2019s home and the health \nsystem and leads to the use of new technologies to promote \nmultidirectional communication for the benefit of all types of \npatients who at some point in their evolution or permanently \nwill remain in the community.\nConclusion\nInfection prevention programs for the elderly living \nat home are also necessary. They should be coordinated \nby Primary Care and include vaccination programs, pre -\nvention of the most frequent infectious syndromes in the \nelderly, the acquisition of infection from younger people \nin the family environment and finally PROA programs for \nthe rationalization of the use of antibiotics at home.\nDO WE KNOW WHAT PROPORTION OF ELDERLY \nPEOPLE DIE IN NURSING HOMES AS A RESULT OF \nINFECTION?\nIt is difficult to know the causes of death of patients liv -\ning in nursing homes, because there is no reliable registry of \nthem. This is a problem that exists in different countries and is \ndescribed in the literature, so the data are not accurate most \nof the time. In the cases in which the cause of death has been \nevaluated, it is generally taken from death certificates, with \nthe limitations that this implies [213].\nThe main study on this subject, carried out years ago in \nthe USA, evaluated the cause of death in people over 60 years \nof age who lived in nursing homes and during a 15-year fol -\nlow-up. During this period, 75% died, 2,372 of the 3,164 peo -\nple included in the study, with a mean age of 81+/-8 years. \nThe main cause of death was cardiovascular in 63% of cases, \nfollowed by infections in 21%, most of them (15% of the to -\ntal) sepsis of urinary origin, followed by respiratory infections \n[213].\nMore recently, Braggion and co-workers in the Veneto \n(Italy) [214] evaluated mortality rates, their determinants, and \ncauses of death in 19,392 subjects aged \u2265 65 years admitted to Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379365HOW SHOULD THIS INFORMATION BE DISPLAYED \nAND USED IN THE DAILY LIFE OF A NURSING \nHOME?\nThe aspects that we consider key to the knowledge of this \ninformation in the residence are:\n1.  The existence of an education program on infections and on \nthe measures that work, which is periodically given to all the \ntechnical staff, geroculturists, the residents themselves and \ntheir families. These education programs should also involve \nthe health professionals of the health centers responsible \nfor nursing home care.\n2.  The involvement of the medical and care managers in the \nnursing home (medical director, nursing director...) in facili -\ntating participation in infection prevention programs.\n3.  The use of easily visible panels, posters with information, al -\ngorithms useful in decision making (e.g., in case of suspect -\ned urinary tract infection, or in case of fever without clear \nfocus, or in case of a COVID +.....).\n4.  The existence of a registry on infections and antibiotic use \nin each residence, monitored sectorially like the one we are \ndiscussing.\n5.  The inclusion of all these data among the important data to \nbe evaluated in the quality control of the residences:\na) existence of preventive programs,\nb) register of infections both treated in the nursing home \nand referred to the hospital, \nc) record of vaccinations\nd) existence of a consultant\ne) contingency plans for epidemics such as COVID.\n6.  Preparation of an annual report on infection in residences \nby Public Health / General Directorate of Social and Health \nCenters.\nConclusion\nInformation on quality control indicators in nursing \nhomes should be discussed periodically among all levels \nof nursing home workers. They should be transmitted to \nthe health authorities who will anonymously distribute \nthem widely, not only to professionals but also to family \nmembers.\nSHOULD THE HEALTH AUTHORITY REQUIRE A SET \nOF DATA LIKE THE ONES WE ARE TALKING ABOUT \nINTO A CENTRAL DATABASE FOR PROFESSIONAL \nAND PUBLIC KNOWLEDGE?\nManagement to prevent healthcare-associated infections \nis a typical example of the use of one of the general principles \nof quality management in healthcare institutions: each insti -\ntution should compare its own infection rates for defined risk \ngroups of patients with reference data and identify problems \nrelating to specific types of infection in particular clinical care ommended very concrete initiatives (improving oral care, \nfor example). The study demonstrated the most frequently \nencountered challenges (frequent staff turnover, work over -\nload, attitudes, lack of resources, etc.).\nSome of the elements that should be included are re -\ncording of infections and follow-up cultures, hand hygiene, \nisolation precautions, training programs for residents and \nstaff, and a good antimicrobial use control program [201].\nThe results of a program aimed at reducing nosocomial \ninfection in five nursing homes by improving surface clean -\ning and hand hygiene have been published. It included online \ntraining, recording of surface cleaning, monitoring of hand \nhygiene compliance, reporting of diagnosed infections, and \na survey of workers. Only a non-significant reduction in to -\ntal infections (6.7%) and lower respiratory tract infections \n(19.9%) was achieved [224]. There were no significant dif -\nferences in the number of antimicrobial treatments, nor in \nhospitalization rates before and after the intervention. The \nvast majority of workers supported the intervention.\nContinuing education of workers is an aspect that cer -\ntainly deserves great attention. A study conducted in 184 \nAmerican nursing homes with 1,626 participants showed \nthat only 36% knew the meaning of pyuria, only 28% knew \nthe indications for urine culture and less than 30% had \nlearned the correct way to perform hand hygiene [130]. An -\nother study showed that the training and qualifications of \nthe nosocomial infection manager in each residence was \nrelated to indicators of good antimicrobial use, but was not \nrelated to patient survival [225]. \nNursing homes must meet quality criteria, but volun -\ntary inclusion in national surveillance systems, at least in the \nUnited States, did not occur until there was a financial incen -\ntive to report CDI episodes. The residences that signed up first \nwere those that already had more quality criteria, reflected in \na higher rate of pneumococcal vaccination [226]. A U.S. study \nexamined whether voluntary accreditation of nursing homes, \nadopting government quality requirements and undergoing \naudits, had a favorable impact on patient well-being [227]. \nThe variables considered were: vaccination rate against influ -\nenza and pneumococcus; pain; delirium; pressure ulcers and \nhealth inspection scores. A total of 246 accredited nursing \nhomes were compared with 15,393 control nursing homes. \nAccredited nursing homes demonstrated better quality on all \nindicators analyzed.\nConclusion\nIt is not clear which interventions are the most ef -\nfective in improving the quality of life and survival of pa -\ntients in Long Term Care Facilities. The implementation \nof nosocomial infection prevention programs in nursing \nhomes should pursue very specific objectives and include \naspects of training of both workers and residents. It is \nrecommended that nursing homes adhere to official con -\ntrol and audit programs.Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379366Conclusion\nRecording and reporting infections to a central data -\nbase is an effective measure to increase knowledge, de -\nvelop prevention programs, analyze health care and im -\nprove the quality of services provided.\nThe data collected should be publicly available so \nthat their analysis can benefit the center itself, but also \nother residential centers by promoting best care practic -\nes.\nThe participation of a nursing home in an infection \nregistry system and the quality of the data provided, as \nwell as the impact of the prevention measures carried \nout, should be considered as care indicators in the evalu -\nation of a nursing home.\n IS THE PRESS AWARE OF THIS ISSUE AND WHAT \nROLE SHOULD IT PLAY?\nIt is difficult to say whether journalists working in the me -\ndia are sufficiently aware of the situation in nursing homes and \nthe control of infections that can occur in them. In our opin -\nion, the answer is no, and there are several reasons for this. The \nfirst, and fundamental, is the lack of specialization prevailing \nin the written press, radios, televisions and web pages. The pre -\nvious economic and financial crisis had its consequent impact \non the media. The former newsrooms, divided into areas with \nspecialists in different subjects (economics, politics, events, \nreligion, environment, education, health, etc.) were adapting \nto an environment marked by lower sales of copies and/or a \ndrop in advertising revenues. This led to staff reductions and \nthe emergence of the figure of the generalist journalist, a pro -\nfessional who knows everything, but, in reality, hardly knows \nanything. Thus, it is not uncommon that journalists who used \nto report on religion or science have had to start reporting in \nrecent years on television, culture, entertainment, or politi -\ncal parties, to cite just a few examples. The result has been a \nworsening of the quality of reporting that has become more \nacute over time. Not only are the news stories on a variety of \nsubjects worse, but also less information of their own is being \nproduced, which pushes all the media to deal with the same \nsubjects, reducing the information spectrum. The second rea -\nson for the media\u2019s neglect of information on nursing homes \nis purely journalistic. Information on senior centers competes \nfor space in the society and local sections with others on reli -\ngion, education, environment, health, science and, sometimes, \neven events. We know from experience that it is very difficult \nto get a space with these competitors when, on top of that, \nit has been reduced as a consequence of the economic crisis. \nIf there are ten news items on different topics and there are \nonly three pages to publish them, information on residences \nhas all the chances of being left out. And a third factor is the \nintrinsic nature of the information on this type of care for the \nelderly. What is newsworthy in the information on LTCF? There \nis usually little and, moreover, it is a field in which the principle \nof \u201cgood news is not news\u201d applies: in the end, only negative units. This comparison should stimulate a careful analysis of \nthe process of care and options for improvement [228].\nIn order to achieve good infection control management \nwithin health care institutions, surveillance strategies should \nbe designed according to the specific needs of the institutions. \n[229].\nThe implementation of a registration system and the re -\nporting of infections to a central database is a measure that \nhas proven to be effective in increasing knowledge of infec -\ntions and establishing health policies for the control and pre -\nscription of antibiotics [230]. Experience in nursing homes is \nlimited, even at the international level. \nSince 2012 the enrollment of residences for infection re -\nporting to the National Health Safety Network (NHSN) in the \nUnited States has been a national priority since the Centers \nfor Disease Control and Prevention (CDC) put the spotlight on \nLTCF [231]. \nThe assessment made by the nursing homes that have \nregistered in the NHSN is positive: they consider that reporting \nprovides greater awareness of infection prevention, provides \nmotivation to develop a prevention program and improves the \nquality of care in the centers.\nOther advantages that the recording and reporting of in -\nfections can provide are to reinforce the detection of infec -\ntions, to establish a correlation between the infection rate of a \nnursing home or nursing homes in a care area with triggering \nfactors, to facilitate the tracking of an outbreak, to compare \nnursing homes by encouraging best practices, to promote \nstudies to evaluate the impact of prevention measures carried \nout, and to promote patient safety [232].\nIn the United States, it was found that the benefits were \nperceived in centers that participated on a voluntary basis but \nalso in centers that participated on a mandatory basis. The \nmain reason for not wanting to participate was the workload \ninvolved or the absence of a professional to take responsibility \nfor this task [233].\nTherefore, the answer to the question posed is affirmative. \nFrom our point of view, reporting a process makes one respon -\nsible for that process. However, in order for the implemen -\ntation to be successful, an adequate knowledge of the most \nprevalent infections in nursing homes must be obtained be -\nforehand [234], carry out training programs for center profes -\nsionals and provide them with a double support, internal and \nexternal, to clarify doubts, consolidate learning and maintain \nmotivation.\nIn the hospital setting there is more tradition and knowl -\nedge of the importance of submitting information with a \n\u201cfeed-back\u201d. It is very important for motivation that the res -\nidencies obtain information from the data they provide to the \nregistry system, which should be accompanied by an analysis \nof the data collected and a proposal for intervention [234]. The \nsubsequent evaluation should assess the quality of the data \nsubmitted and the suggested intervention. This is a positive \nstimulus for whoever generates the information.Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379367different places, but the average figure is around 5,000-3,000 \nBC. The second, the so-called industrial revolution, began in \nEngland in the mid-19th century, but did not become glob -\nal until well into the 20th century. Between these two dates, \nthe human species remained in a type of society that is often \nreferred to as \u201cagricultural culture\u201d. The basic occupation was \nthe cultivation of the land, a task assigned to men. These were \nthe so-called \u201cproductive\u201d activities. The other major sector \nwas that of \u201creproductive\u201d activities, reserved for women, who \nwere responsible, among other things, for raising children and \ncaring for the elderly. This was carried out in dwellings that \ntoday are called \u201cpatriarchal\u201d (think of the Catalan farmhous -\nes, the Galician pazos or the Castilian manor houses), in which \nthree or even four generations coexisted, and in which there \nwas a permanent system of care for children, the elderly and \nthe sick. The elder, on the other hand, was the most revered \nmember of the community, if only because he was the ori -\ngin, not only biologically but also economically, of the whole \ngroup.\nThis is what sociologists usually call the \u201cpatriarchal fam -\nily\u201d. In it there were several very significant facts. One, that \nthere were always elders in it. Another, that they were respect -\ned and revered for their own condition. And a final one, that \nthey all considered it natural that they should be cared for in \ntheir own home. To throw them out or send them elsewhere \nwould have been considered socially and morally execrable.\nThings began to change with the industrial revolution. In -\ndustrial warehouses appeared in the suburbs of the cities, if \nonly because cheap labor was plentiful there. The large patri -\narchal dwellings gave way to apartments or city apartments, \nin which only one generation, or at most two, can live. This \nis the so-called \u201cnuclear family\u201d. Since both members of the \nfamily need to work, caring for children, the elderly and the \nsick is almost impossible. Exceptionally, acute situations can be \ntaken care of, but certainly not chronic ones. In such cases, \nthe support of other institutions is necessary. In the case of \nillnesses, these are hospitals, which are now taking on a new \nrole, taking on a special role. And in the case of the elderly, the \nsolution has been found in the establishment of an extensive \nnetwork of assisted living facilities. The very organization of \nlife in modern society has made them indispensable.\nThe old man usually looks at these institutions with a \nsidelong glance and with caution. He is well aware that in \nthe traditional society, the one in which he was born, the old \npeople\u2019s home was judged as morally and humanly negative. \nThe old man had dedicated his life to his family, and it seemed \nlogical that the family should not abandon him when he was \nno longer useful. In fact, the impossibility of caring for the el -\nderly in the family has generated an enormous guilt complex \nin many families, who continue to consider themselves obliged \nnot to abandon their elders, despite the near impossibility of \ndoing so in the situation of nuclear families.\nIt is clear that families cannot be blamed. But the problem \ndoes not end there. We have organized modern society around \nthe basic principle of the economy, efficiency. This became the news ends up being published or disseminated. Positive news \nhas no place.\nThe outbreak of the pandemic in March 2020 brought in -\nformation about nursing homes and the elderly out of ostra -\ncism and suddenly became front page news, especially during \nthe first wave. In our opinion, the information disseminated \nabout what happened in them was biased by political confron -\ntation and conditioned by the three evils I mentioned above, \nproducing a sort of \u201cperfect storm\u201d. The image that was finally \ntransmitted to the public by the media was that the facilities \nwere a perfect breeding ground for the spread of the virus, \ngoverned by satrap and exploitative businessmen, and left to \ntheir own devices by the health authorities. This image does \nnot coincide with reality despite the avalanche of deaths al -\nlegedly due to Covid-19 that occurred inside them, especial -\nly during the first wave of the pandemic. The residences have \nbeen in the news again since the third wave, coinciding with \nthe vaccination process against the SARS-CoV-2 virus that has \nbeen carried out in them since December 27th. The authorities \njudiciously decided to start inoculating the doses in this group \nbecause it is the one with the highest case fatality rate. Spe -\ncifically, from June 22 to the present day, 22% of those over \n90 years of age who were infected have died from Covid, a \npercentage which stands at 14.2% among those aged 80 to 89 \nyears and 5.3% among those aged 70 to 79 years, according \nto data compiled by the Carlos III Health Institute and the Na -\ntional Epidemiological Surveillance Network.\nConclusion\nThe mass media has little and deficient information \non the problems of infection transmission in nursing \nhomes and on the possibilities of reducing these risks. \nThe reasons for this are to be found in the decrease of \nspecialized health sections in many media since more \nthan a decade ago.\nWHAT ETHICAL ISSUES ARE RAISED BY THE \nTOPICS AND POSITIONS THAT HAVE BEEN \nDISCUSSED THROUGHOUT THIS MEETING?\nOur era is peculiar for several reasons. One of them is \nthat people\u2019s average life expectancy has more than doubled \ncompared to earlier times, such as the beginning of the 20th \ncentury. This phenomenon has been accompanied by others \nno less significant: the secondary and tertiary sectors of the \neconomy have come to occupy most of the population, so that \nas the countryside was depopulated, urban concentrations \nbecame megacities. Another phenomenon of no lesser impor -\ntance has been the access of women to productive work. All \nthis has created a new situation, unprecedented in the annals \nof human history, which no one could have foreseen and for \nwhich no one was prepared.\nLet us briefly recall the previous situation, which, with no \ngreat variations, had been maintained over several millennia, \nat least from the Neolithic revolutions until the arrival of the \nindustrial revolution. The first took place at different dates in Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379368not that citizens consciously and intentionally undervalue the \nelderly. It is an unconscious process, and therefore much more \nsubtle and difficult to control. In the age of efficiency, the el -\nderly are seen as a hindrance, a burden or a burden. This leads, \nalso unconsciously, to their discrimination. To the point that \none does not know what to call an elderly person, because the \nterms all end up having negative connotations. The Latin term \nfor old is senex, whose opposite is iuvenis. One is either iuvenis \nor senex. These are terms that in classical Latin were applied \nonly to living beings, and especially to people. For things other \nterms were used, vetus and novus. A book is new or old, etc. guiding category of human activity from the 18th century on -\nwards, when, with Adam Smith and his disciples, economics \nbecame a scientific discipline. And this is the criterion that \ngoverns industrial work, which revolutionized human life from \nthat same century onwards. In industrial society, in contrast to \nagricultural society, the culture of efficiency dominates. Thus, \ninefficient people become part of the debit side, not the credit \nside, together with the sick, the lazy, the thugs, etc.\nThe old, by definition, is inefficient. In modern culture, this \nhas a very negative social and even moral connotation. It is Country Date Approach to \nmeasuring COVID-19 \nlinked deaths in care \nhomesTotal number \ndeaths linked to \nCOVID-19*Number of deaths \nof care home \nresidents linked to \nCOVID-19Number of \ndeaths in care \nhomes linked to \nCOVID-19Number of care home \nresident deaths as \n% of all COVID-19 \ndeathsNumber of deaths in \ncare homes as % of \nall COVID-19 deaths\nAustralia 22/01/2021 C 909 685 75%\nAustria 24/01/2021 C 7,328 3,243 44%\nBelgium 19/01/2021 C + P 20,457 11,722 8,854 57% 43%\nCanada 23/01/2021 C + P 18,974 11,114 59%\nDenmark 19/01/2021 C 1,837 719 39%\nFinland 22/01/2021 C 644 243 33%\nFrance 20/01/2021 C + P 71,342 30,395 21,646 43% 30%\nGermany 22/01/2021 C 50,642 14,066 28%\nHong Kong 25/01/2021 C 169 32 0 19% 0%\nHungary 27/08/2020 C 612 142 23%\nIreland 13/12/2020 C + P 2,110 1,084 51%\nIsrael 25/10/2020 C 2,404 861 36%\nNetherlands 15/01/2021 C 12,774 6,529 51%\nNew Zealand 12/01/2021 C + P 25 16 64%\nNorway 20/01/2021 C 533 318 60%\nPortugal 10/01/2021 Unclear 7,803 2,254** 29%**\nSingapore 24/01/2021 C 29 4 0 14% 0%\nSlovenia 17/01/2021 C 3,371 1,875 56%\nSouth Korea 07/09/2020 C 336 27 0 8% 0%\nSpain 22/01/2021 C + P 66,557 26,328 40%\nSweden 18/01/2021 C + P 9,949 4,656 4,249 47% 43%\nEngland (UK) 15/01/2021 C + P 88,674 29,381 21,615 33% 24%\nWales (UK) 15/01/2021 C + P 5,884 1,470 1,267 25% 22%\nN. Ireland (UK) 15/01/2021 C + P 2,124 862 642 41% 30%\nScotland (UK) 17/01/2021 C + P 7,448 3,266 2,867 44% 38%\nUnited Kingdom As above C + P 104,130 34,979 26,391 34% 25%\nUnited States 07/01/2021 C + P 357,124 139,699 39%Table 4  Mortality in nursing homes. Adapted from Glette et al [15].\nC: confirmed; P: probableInfection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379369of 26,299 people (10.56% of the total number of dependent \npeople cared for in nursing homes). While highlighting that \nsuch excess was concentrated\u0301 in the months of March-May, \nwhile in June 2020-January 2021 excess mortality was similar \nregardless of the place of provision, except in October 2020 \nand from February 2021 where there was lower excess mortal -\nity in people with residential care than in home support\u201d [235].\n (The total number of deaths due to COVID-19 includes \nonly those confirmed, so the figures may be lower than the \nreal ones, particularly in the first part of the pandemic).\nA certain percentage of deaths in nursing homes, not easy \nto quantify, is due to the biological condition of the elderly, \nwith a clear decrease in biological reserves and immune re -\nsponse. But another percentage, not negligible, has to do with \nthe lack of specialized care, sometimes with overcrowding and, \nfinally, with the fact that in certain places they have been dis -\ncriminated against, denying them transfer to health centers. \nIn the case of Spain, this has even been stated in guidelines \nissued by some autonomous communities.\nConclusion. \nThe great moral problem in the elderly population is \ndiscrimination, which ends up being mistreatment, and \nwhich is sometimes overt, but other times it is subtle and, \non certain occasions, is even unknown even to the people \nwho practice it. Hence the need to educate the popula -\ntion in general, and particularly those who are directly \ninvolved in nursing home care.\nTRANSPARENCY DISCLOSURE\nFor transparency purposes, please note that GSK has con -\ntributed to the funding of this publication. Its contents reflect \nthe authors\u2019 own opinions, criteria, conclusions and/or find -\nings, which may not necessarily coincide with those of GSK. \nGSK always recommends the use of its products in accordance \nwith the data sheet approved by the health authorities.\nREFERENCES\n1. Department of Health and Health Protection Agency UK. Prevention \nand control of infection in care homes - an information resource. \n2013. Available at: https://assetspublishingservicegovuk/govern -\nment/uploads/system/uploads/attachment_data/file/214930/Care-\nHome-Resource-Summary-Feb14-2013pdf . \n2. Department of Health and Human resources, Agency for Helthcare \nResearch and Quality. A Unit Guide To Infection Prevention for \nLong-Term Care Staff. 2017. Available at: https://wwwahrqgov/hai/\nquality/tools/cauti-ltc/modules/resources/guides/infection-pre -\nventhtml . Publication No. 16(17)-0003-4-EF March 2017. \n3. Serrano M, Barcenilla F, Lim\u00f3n E. [Nosocomial infections in long-\nterm health care facilities]. Enfermedades infecciosas y microbio -\nlogia clinica. 2014;32(3):191-8. DOI: 10.1016/j.eimc.2013.11.007\n4. Dwyer LL, Harris-Kojetin LD, Valverde RH, Frazier JM, Simon \nAE, Stone ND, et al. Infections in long-term care populations in Well, in the modern world, unlike what happened in all pre -\nvious centuries, the old man will be called \u201cold\u201d (derived from \nvetus), so that \u201csenecto\u201d (derived from senex) will be relegated \nto the category of cultism. And since old is a clearly deroga -\ntory term when applied to human beings, others have been \nsought to replace it. One is \u201celder\u201d, which comes directly from \nthe French, and the other from the Latin antiquus. Despite ap -\npearances, it is no less discriminatory than vetus, because it is \nalso a term referring to things, not people.\nSo what to call them? From this point on, the proliferation \nof euphemistic terms began. There has been talk of \u201cpassive \nclasses\u201d, of \u201cthird age\u201d, of \u201csenior citizens\u201d, of \u201celderly people\u201d, \netc. Basically, we do not know what to call them properly, be -\ncause the terms, although at first they may seem correct, soon \ntake on a negative meaning, which brings back the specter of \ndiscrimination.\nIt is also a problem to properly name discrimination \nagainst the elderly. In English, the term \u201cageism\u201d has taken \nhold and was soon imported into our language as \u201cageism\u201d. \nSome, more purist, proposed as an alternative \u201ceta\u00edsmo\u201d or \n\u201ceda\u00edsmo\u201d. The Fund\u00e9u of the Real Academia Espa\u00f1ola says \nthat the correct term is \u201cedadismo\u201d, which, however, has not \nyet been incorporated into the official dictionary.\nFrom all that has been said so far, it would seem natural \nthat the mistreatment of the elderly would take place in fam -\nily homes, given their precarious conditions. But the Covid-19 \npandemic has shown that discrimination is so subtle and so \nwidespread that it also affects those institutionalized in assist -\ned living facilities, and that those who are trained to care for \nand assist this type of person are not exempt from it. In this \nregard, the data that have just become known are very reveal -\ning. Of every 100 institutionalized in nursing homes, 17 have \ndied during the pandemic in the Community of Madrid, 14 in \nthose of Castilla la Mancha and 11 in those of Castilla-Le\u00f3n \nand Extremadura. The number of deaths in homes for the el -\nderly is close to 30,000, according to provisional data from the \nMinistries of Social Rights, Health and Science and Innovation.\nAccording to IMSERSO data, during the first wave it is \npossible to \u201cestimate as plausible a range between 47% and \n50% of deaths in residences with respect to the total number \nof deaths due to COVID-19 disease in the first wave. If this \nestimate is valid, and according to some preliminary interna -\ntional studies, the Spanish case would be situated in terms of \npercentage of deaths of users of residential centers with re -\nspect to the total number of COVID-19 deaths in intermediate \nparameters for the first wave, similar to those of the United \nKingdom (45%), France (46%), Sweden (46%), Scotland (47%) \nor Northern Ireland (49%); significantly below Belgium (61%), \nAustralia (75%), Canada (80%) or Slovenia (81%) and above \nDenmark (35%), Austria (36%), Israel (39%) or Germany (39%) \n[18] (Table 4).\nThe total number of deaths in nursing homes has not yet \nbeen calculated, but according to IMSERSO data, as of May \n31, 2021, \u201cthere is a very high impact on excess mortality in \npeople with care in nursing homes, with an excess of deaths Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379370Mayores. DGdP. Normativa sobre Centros Residenciales de Perso -\nnas Mayores. Consejer\u00eda de Igualdad y Bienestar Social. Junta de \nAndaluc\u00eda. Disponible en: https://wwwjuntadeandaluciaes/export/\ndrupaljda/Normativa_centros_mayorespdf . 2007:1- 78. \n17. Organizaci\u00f3n Mundial de la Salud. Prevenci\u00f3n y control de infec -\nciones en los centros de atenci\u00f3n de larga estancia en el contexto \nde la COVID-19. 2020:6. \n18. Ministerio de derechos sociales y agenda 2030. Secretar\u00eda de Es -\ntado. Informe del grupo de trabajo de Covid en Residencias. Min -\nisterio de Derechos Sociales y Agenda 2030. Available at: https://\nwwwmscbsgobes/ssi/imserso/docs/GTCOVID_19_RESIDENCIASpdf . \n2020:115.\n19. Ministerio de Sanidad Consumo y Bienestar Social. Gu\u00eda de pre -\nvenci\u00f3n y control frente al COVID-19 en residencias de mayores y \notros centros de servicios sociales de car\u00e1cter residencial. 2020. \n20. Junta de Andalucia. Consejer\u00eda de Salud y Familia. Estrategia de \nactuaci\u00f3n en residencias de mayores y centros sociosanitarios de \nla consejer\u00eda de salud y familias Plan de actuaci\u00f3n en Residencias, \nConsejer\u00eda de Salud Junta de Andaluc\u00eda Available at: https://ww -\nwjuntadeandaluciaes/export/drupaljda/SyF-DocumentoPlanActua -\ncionResidenciaspdf . 2020:34. \n21. SERGAS. Medidas de prevenci\u00f3n y control de riesgo de diseminaci\u00f3n \ndel covid-19 y otras enfermedades infecciosas de transmisi\u00f3n por \ncontacto (incluido gotas) en las residencias de ancianos. Availa -\nble at https://coronavirussergasgal/Contidos/Documents/263/\nIRR_060420_Residencias_Control_infecci%c3%b3npdf . 2020:9. \n22. M\u00e9dicos sin Fronteras. Plan de contingencia para residencias. Or -\nganizaci\u00f3n de servicios y estructuras.5. \n23. Gobierno de Arag\u00f3n, Departamento de Sanidad y Departamento \nde Ciudadan\u00eda y Derechos Sociales. Gu\u00eda para la elaboraci\u00f3n del \nplan de contingencia destinado a centros de servicios sociales \nde naturaleza residencial para la atenci\u00f3n de personas mayores \ny personas con discapacidad. 2020. Available at: https://www.\naragon.es/documents/20127/2523242/Guia+de+Plan+de+con -\ntingencia+residencias+240720-.pdf/c3a443b7-b0c6-07e1-ad78-\nc9819119405d?t=1596625169\n24. World Health Organization. Prevenci\u00f3n y control de infec -\nciones en los centros de atenci\u00f3n de larga estancia en el con -\ntexto de la COVID-19 . Available at http://appswhoint/iris/bit -\nstream/10665/112656/1/9  7892 41507134_engpdf. 2020.\n25. Ministerio de Sanidad. Documento t\u00e9cnico Recomendaciones a \nResidencias de Mayores y Centros Sociosanitarios para el Covid-19. \nMinisterio de Sanidad. 2020:9. Available at: https://www.sanidad.\ngob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/doc -\numentos/Centros_sociosanitarios.pdf\n26. Men\u00e9ndez R. La Geriatr\u00eda de Enlace con residencias en la \u00e9poca \nde la Covid-19. Un nuevo modelo de coordinaci\u00f3n que ha llega -\ndo para quedarse. Revista Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. \n2021;56:157-65. DOI: https://doi.org/10.1016/j.regg.2021.01.002\n27. Organizaci\u00f3n M\u00e9dica Colegial. Covid-19 y las residencias y cen -\ntros sociosanitarios. Organizaci\u00f3n M\u00e9dica Colegial.17. Available at: \nhttps://www.cgcom.es/covid-19/informacion-y-documentacion/\ncomision-asesorathe United States. Journal of the American Geriatrics Society. \n2013;61(3):342-9. DOI: 10.1111/jgs.12153\n5. Chami K, Gavazzi G, de Wazi\u00e8res B, Lejeune B, Carrat F, Piette F, \net al. Guidelines for infection control in nursing homes: a Delphi \nconsensus web-based survey. The Journal of hospital infection. \n2011;79(1):75-89. DOI: 10.1016/j.jhin.2011.04.014\n6. Tinelli M, Tiseo G, Falcone M. Prevention of the spread of multi -\ndrug-resistant organisms in nursing homes. Aging Clin Exp Res. \n2021;33(3):679-87. DOI: 10.1007/s40520-020-01746-2\n7. Gouin KA, Kabbani S, Anttila A, Mak J, Mungai E, McCray TT, et al. \nImplementation of core elements of antibiotic stewardship in nurs -\ning homes-National Healthcare Safety Network, 2016-2018. Infec -\ntion control and hospital epidemiology. 2021:1-5. DOI: 10.1017/\nice.2021.209\n8. Crespo-Rivas JC, Guisado-Gil AB, Pe\u00f1alva G, Rodr\u00edguez-Villodres \u00c1, \nMart\u00edn-Gandul C, Pach\u00f3n-Ib\u00e1\u00f1ez ME, et al. Are antimicrobial stew -\nardship interventions effective and safe in long-term care facili -\nties? A systematic review and meta-analysis. Clinical microbiology \nand infection : the official publication of the European Society of \nClinical Microbiology and Infectious Diseases. 2021. DOI: 10.1016/j.\ncmi.2021.06.003\n9. Aliyu S, Travers JL, Heimlich SL, Ifill J, Smaldone A. Antimicrobi -\nal Stewardship Interventions to Optimize Treatment of Infec -\ntions in Nursing Home Residents: A Systematic Review and Me -\nta-Analysis. J Appl Gerontol. 2021:7334648211018299. DOI: \n10.1177/07334648211018299\n10. Agarwal M, Estrada LV, Stone PW. Nursing Home Antibiotic Stew -\nardship Policy and Antibiotics Use: 2013-2017. Journal of the \nAmerican Medical Directors Association. 2021. DOI: 10.1016/j.jam -\nda.2021.06.031\n11. Serrano M, Barcenilla F, Lim\u00f3n E, Pujol M, Gudiol F. Prevalence of \nhealthcare-associated infections in long-term care facilities in Cat -\nalonia. VINCat Program. Enfermedades infecciosas y microbiologia \nclinica. 2017;35(8):505-10. DOI: 10.1016/j.eimc.2015.11.011\n12. Ricchizzi E, Latour K, K\u00e4rki T, Buttazzi R, Jans B, Moro ML, et al. \nAntimicrobial use in European long-term care facilities: results \nfrom the third point prevalence survey of healthcare-associat -\ned infections and antimicrobial use, 2016 to 2017. Euro Surveill. \n2018;23(46). DOI: 10.2807/1560-7917.Es.2018.23.46.1800394\n13. Morrill HJ, Caffrey AR, Jump RL, Dosa D, LaPlante KL. Antimicrobial \nStewardship in Long-Term Care Facilities: A Call to Action. Journal \nof the American Medical Directors Association. 2016;17(2):183.e1-\n16. DOI: 10.1016/j.jamda.2015.11.013\n14. Hospital Geaneral de Granollers. Doce intervenciones PROA en Cen -\ntros Sociosanitarios. . Available at https://wwwsaludcastillayleones/\nportalmedicamento/es/boletines/boletin-mensual/noticias-destac -\nadas/12-intervenciones-proa-centros-sociosanitarios . 2019. \n15. Glette MK, R\u00f8ise O, Kringeland T, Churruca K, Braithwaite J, Wiig S. \nNursing home leaders\u2019 and nurses\u2019 experiences of resources, staff -\ning and competence levels and the relation to hospital readmis -\nsions - a case study. BMC health services research. 2018;18(1):955. \nDOI: 10.1186/s12913-018-3769-3\n16. Junta de Andaluc\u00eda, Consejer\u00eda para la Igualdad y Bienestar Social, Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-37937140. Brugnaro P, Fedeli U, Pellizzer G, Buonfrate D, Rassu M, Boldrin C, \net al. Clustering and risk factors of methicillin-resistant Staphy -\nlococcus aureus carriage in two Italian long-term care facilities. \nInfection. 2009;37(3):216-21. DOI: 10.1007/s15010-008-8165-1\n41. Stevenson CG, McArthur MA, Naus M, Abraham E, McGeer AJ. \nPrevention of influenza and pneumococcal pneumonia in Ca -\nnadian long-term care facilities: how are we doing? Cmaj. \n2001;164(10):1413-9. \n42. Thomas RE. Pneumococcal Pneumonia and Invasive Pneumococcal \nDisease in Those 65 and Older: Rates of Detection, Risk Factors, \nVaccine Effectiveness, Hospitalisation and Mortality. Geriatrics (Ba -\nsel). 2021;6(1). DOI: 10.3390/geriatrics6010013\n43. McConeghy KW, Davidson HE, Canaday DH, Han L, Saade E, Mor V, \net al. Cluster-randomized trial of adjuvanted vs. non-adjuvanted \ntrivalent influenza vaccine in 823 U.S. nursing homes. Clinical in -\nfectious diseases : an official publication of the Infectious Diseases \nSociety of America. 2020. DOI: 10.1093/cid/ciaa1233\n44. Ino H. Vaccine mandate in long-term care facilities. Geriatr Geron -\ntol Int. 2020;20(10):995-6. DOI: 10.1111/ggi.14023\n45. Arnedo-Pena A, Juan-Cerd\u00e1n JV, Romeu-Garcia M, Sorribes-Segura \nS, Tirado-Balaguer M, Gil-Fortu\u00f1o M, et al. Vitamin D status and la -\ntent tuberculosis infection: conversion in nursing homes, Spain. Int \nJ Tuberc Lung Dis. 2020;24(3):278-86. DOI: 10.5588/ijtld.19.0365\n46. Khan A, Rebhan A, Seminara D, Szerszen A. Enduring Challenge of \nLatent Tuberculosis in Older Nursing Home Residents: A Brief Re -\nview. J Clin Med Res. 2019;11(6):385-90. DOI: 10.14740/jocmr3763\n47. Bouza E, Ancochea-Berm\u00fadez J, Campins M, Eir\u00f3s-Bouza JM, Far -\ngas J, Garc\u00eda Rojas A, et al. The situation of vaccines for the pre -\nvention of infections in adults: An opinion paper on the situation \nin Spain. Rev Esp Quimioter. 2019;32(4):333-64. PMC: 6719651\n48. Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. Recomendaciones \nde vacunaci\u00f3n para adultos y mayores y calendarios vacunales \n2019-2020. . Available at https://wwwsegges/media/descargas/VA -\nCUNAS-SEGG-2019-2020pdf . 2019. \n49. Thomas RE. Reducing Morbidity and Mortality Rates from COV -\nID-19, Influenza and Pneumococcal Illness in Nursing Homes and \nLong-Term Care Facilities by Vaccination and Comprehensive In -\nfection Control Interventions. Geriatrics (Basel). 2021;6(2). DOI: \n10.3390/geriatrics6020048\n50. Boey L, Roelants M, Vandermeulen C. Increased vaccine up -\ntake and less perceived barriers toward vaccination in long-term \ncare facilities that use multi-intervention manual for influenza \ncampaigns. Hum Vaccin Immunother. 2021;17(3):673-80. DOI: \n10.1080/21645515.2020.1788327\n51. Kenny E, McNamara \u00c1, Noone C, Byrne M. Barriers to seasonal in -\nfluenza vaccine uptake among health care workers in long-term \ncare facilities: A cross-sectional analysis. Br J Health Psychol. \n2020;25(3):519-39. DOI: 10.1111/bjhp.12419\n52. Bechini A, Lorini C, Zanobini P, Mand\u00f2 Tacconi F, Boccalini S, Grazz -\nini M, et al. Utility of Healthcare System-Based Interventions in Im -\nproving the Uptake of Influenza Vaccination in Healthcare Workers \nat Long-Term Care Facilities: A Systematic Review. Vaccines (Basel). \n2020;8(2). DOI: 10.3390/vaccines802016528. Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. Recomendaciones \npara el manejo de la epidemia Covid en Residencias de Mayores. \nSociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda. 2020:4. \n29. Consejer\u00eda de Integraci\u00f3n Social de la Comunidad Aut\u00f3noma de \nMadrid. Orden 612/1990, de 6 de noviembre, por la que se desar -\nrolla el Decreto 91/1990, de 26 de octubre, relativo al R\u00e9gimen de \nAutorizaci\u00f3n de Servicios y Centros de Acci\u00f3n Social y Servicios \nSociales. Available at http://wwwmadridorg/wleg_pub/secure/nor -\nmativas/contenidoNormativajsf ? 1990. \n30. Spreckelsen O, Luque Ramos A, Freitag M, Hoffmann F. Influenza \nvaccination rates before and after admission to nursing homes in \nGermany. Aging Clin Exp Res. 2018;30(6):609-16. DOI: 10.1007/\ns40520-017-0825-5\n31. Ye P, Fry L, Liu H, Ledesma S, Champion JD. COVID outbreak after \nthe 1st dose of COVID vaccine among the nursing home residents: \nWhat happened? Geriatr Nurs. 2021;42(5):1105-8. DOI: 10.1016/j.\ngerinurse.2021.06.022\n32. Unroe KT, Evans R, Weaver L, Rusyniak D, Blackburn J. Willing -\nness of Long-Term Care Staff to Receive a COVID-19 Vaccine: A \nSingle State Survey. Journal of the American Geriatrics Society. \n2021;69(3):593-9. DOI: 10.1111/jgs.17022\n33. Salmer\u00f3n R\u00edos S, Mas Romero M, Cort\u00e9s Zamora EB, Tabernero Sa -\nhuquillo MT, Romero Rizos L, S\u00e1nchez-Jurado PM, et al. Immuno -\ngenicity of the BNT162b2 vaccine in frail or disabled nursing home \nresidents: COVID-A study. Journal of the American Geriatrics Soci -\nety. 2021;69(6):1441-7. DOI: 10.1111/jgs.17153\n34. Senderovich H, Grewal J, Mujtaba M. Herpes zoster vaccination \nefficacy in the long-term care facility population: a qualitative \nsystematic review. Curr Med Res Opin. 2019;35(8):1451-62. DOI: \n10.1080/03007995.2019.1600482\n35. Sasahara T, Ae R, Yoshimura A, Kosami K, Sasaki K, Kimura Y, et al. \nAssociation between length of residence and prevalence of MRSA \ncolonization among residents in geriatric long-term care facilities. \nBMC geriatrics. 2020;20(1):481. DOI: 10.1186/s12877-020-01885-1\n36. Harrison EM, Ludden C, Brodrick HJ, Blane B, Brennan G, Morris D, \net al. Transmission of methicillin-resistant Staphylococcus aureus  \nin long-term care facilities and their related healthcare networks. \nGenome Med. 2016;8(1):102. DOI: 10.1186/s13073-016-0353-5\n37. Szab\u00f3 R. [Prevalence and predisposing factors of methicil -\nlin-resistant Staphylococcus aureus  in long-term care facilities. \nAn international view]. Orv Hetil. 2016;157(27):1071-8. DOI: \n10.1556/650.2016.30427\n38. Schora DM, Boehm S, Das S, Patel PA, O\u2019Brien J, Hines C, et al. \nImpact of Detection, Education, Research and Decolonization \nwithout Isolation in Long-term care (DERAIL) on methicillin-re -\nsistant Staphylococcus aureus  colonization and transmission at \n3 long-term care facilities. American journal of infection control. \n2014;42(10 Suppl):S269-73. DOI: 10.1016/j.ajic.2014.05.011\n39. Evans ME, Kralovic SM, Simbartl LA, Freyberg RW, Obrosky DS, \nRoselle GA, et al. Nationwide reduction of health care-associated \nmethicillin-resistant Staphylococcus aureus  infections in Veterans \nAffairs long-term care facilities. American journal of infection con -\ntrol. 2014;42(1):60-2. DOI: 10.1016/j.ajic.2013.06.004Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379372icine. 2014;174(10):1660-7. DOI: 10.1001/jamainternmed.2014.3918\n65. Dufour AB, Shaffer ML, D\u2019Agata EM, Habtemariam D, Mitchell SL. \nSurvival After Suspected Urinary Tract Infection in Individuals with \nAdvanced Dementia. Journal of the American Geriatrics Society. \n2015;63(12):2472-7. DOI: 10.1111/jgs.13833\n66. Monette J, Miller MA, Monette M, Laurier C, Boivin JF, Sourial N, \net al. Effect of an educational intervention on optimizing antibi -\notic prescribing in long-term care facilities. Journal of the Amer -\nican Geriatrics Society. 2007;55(8):1231-5. DOI: 10.1111/j.1532-\n5415.2007.01250.x\n67. Pettersson E, Vernby A, M\u00f6lstad S, Lundborg CS. Can a multifacet -\ned educational intervention targeting both nurses and physicians \nchange the prescribing of antibiotics to nursing home residents? \nA cluster randomized controlled trial. The Journal of antimicrobial \nchemotherapy. 2011;66(11):2659-66. DOI: 10.1093/jac/dkr312\n68. Zabarsky TF, Sethi AK, Donskey CJ. Sustained reduction in inap -\npropriate treatment of asymptomatic bacteriuria in a long-term \ncare facility through an educational intervention. American \njournal of infection control. 2008;36(7):476-80. DOI: 10.1016/j.\najic.2007.11.007\n69. Nicolle LE. Antimicrobial stewardship in long term care facilities: \nwhat is effective? Antimicrobial resistance and infection control. \n2014;3(1):6. DOI: 10.1186/2047-2994-3-6\n70. Centers for Medicare & Medicaid Services (CMS) H. Medicare and \nMedicaid Programs; Reform of Requirements for Long-Term Care \nFacilities. Final rule. Fed Regist. 2016;81(192):68688-872. \n71. Rummukainen ML, Jakobsson A, Matsinen M, J\u00e4rvenp\u00e4\u00e4 S, Nissinen \nA, Karppi P, et al. Reduction in inappropriate prevention of urinary \ntract infections in long-term care facilities. American journal of in -\nfection control. 2012;40(8):711-4. DOI: 10.1016/j.ajic.2011.09.013\n72. Crnich CJ, Jump R, Trautner B, Sloane PD, Mody L. Optimizing Anti -\nbiotic Stewardship in Nursing Homes: A Narrative Review and Rec -\nommendations for Improvement. Drugs & aging. 2015;32(9):699-\n716. DOI: 10.1007/s40266-015-0292-7\n73. Agarwal M, Dick AW, Sorbero M, Mody L, Stone PW. Changes in \nUS Nursing Home Infection Prevention and Control Programs From \n2014 to 2018. Journal of the American Medical Directors Associa -\ntion. 2020;21(1):97-103. DOI: 10.1016/j.jamda.2019.10.020\n74. Checovich MM, Barlow S, Shult P, Reisdorf E, Temte JL. Evaluation of \nViruses Associated With Acute Respiratory Infections in Long-Term \nCare Facilities Using a Novel Method: Wisconsin, 2016\u03012019. Jour -\nnal of the American Medical Directors Association. 2020;21(1):29-\n33. DOI: 10.1016/j.jamda.2019.09.003\n75. Childs A, Zullo AR, Joyce NR, McConeghy KW, van Aalst R, Moyo P, et \nal. The burden of respiratory infections among older adults in long-\nterm care: a systematic review. BMC geriatrics. 2019;19(1):210. \nDOI: 10.1186/s12877-019-1236-6\n76. Carnahan JL, Shearn AJ, Lieb KM, Unroe KT. Pneumonia Manage -\nment in Nursing Homes: Findings from a CMS Demonstration \nProject. J Gen Intern Med. 2021;36(2):570-2. DOI: 10.1007/s11606-\n020-05885-0\n77. Rios P, Radhakrishnan A, Williams C, Ramkissoon N, Pham B, \nCormack GV, et al. Preventing the transmission of COVID-19 and 53. Tan HY, Lai E, Kunasekaran M, Chughtai AA, Trent M, Poulos CJ, et \nal. Prevalence and predictors of influenza vaccination among res -\nidents of long-term care facilities. Vaccine. 2019;37(43):6329-35. \nDOI: 10.1016/j.vaccine.2019.09.021\n54. Shireman TI, Ogarek J, Gozalo P, Zhang T, Mor V, Davidson HE, et \nal. Cost Benefit of High-Dose vs Standard-Dose Influenza Vaccine \nin a Long-Term Care Population During an A/H1N1-Predominant \nInfluenza Season. Journal of the American Medical Directors Asso -\nciation. 2019;20(7):874-8. DOI: 10.1016/j.jamda.2018.12.003\n55. Campbell J. Influenza vaccination for healthcare workers who care \nfor people aged 60 or older living in long-term care institutions. Int \nJ Nurs Pract. 2019;25(3):e12730. DOI: 10.1111/ijn.12730\n56. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, \net al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-\n19 and BNT162b2 against SARS-CoV-2 infection in residents of \nlong-term care facilities in England (VIVALDI): a prospective cohort \nstudy. The Lancet Infectious diseases. 2021. DOI: 10.1016/s1473-\n3099(21)00289-9\n57. Munitz A, Yechezkel M, Dickstein Y, Yamin D, Gerlic M. BNT162b2 \nvaccination effectively prevents the rapid rise of SARS-CoV-2 \nvariant B.1.1.7 in high-risk populations in Israel. Cell Rep Med. \n2021;2(5):100264. DOI: 10.1016/j.xcrm.2021.100264\n58. Mor V, Gutman R, Yang X, White EM, McConeghy KW, Feifer RA, \net al. Short-term impact of nursing home SARS-CoV-2 vaccina -\ntions on new infections, hospitalizations, and deaths. Journal of the \nAmerican Geriatrics Society. 2021. DOI: 10.1111/jgs.17176\n59. Matthews SJ, Lancaster JW. Urinary tract infections in the elderly \npopulation. Am J Geriatr Pharmacother. 2011;9(5):286-309. DOI: \n10.1016/j.amjopharm.2011.07.002\n60. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. \nInfectious Diseases Society of America guidelines for the diagnosis \nand treatment of asymptomatic bacteriuria in adults. Clinical in -\nfectious diseases : an official publication of the Infectious Diseases \nSociety of America. 2005;40(5):643-54. DOI: 10.1086/427507\n61. Loeb M, Bentley DW, Bradley S, Crossley K, Garibaldi R, Gantz N, \net al. Development of minimum criteria for the initiation of anti -\nbiotics in residents of long-term-care facilities: results of a con -\nsensus conference. Infection control and hospital epidemiology. \n2001;22(2):120-4. DOI: 10.1086/501875\n62. Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness \nPH, Tinetti M. Clinical features to identify urinary tract infection \nin nursing home residents: a cohort study. Journal of the Amer -\nican Geriatrics Society. 2009;57(6):963-70. DOI: 10.1111/j.1532-\n5415.2009.02227.x\n63. Loeb M, Brazil K, Lohfeld L, McGeer A, Simor A, Stevenson K, et \nal. Effect of a multifaceted intervention on number of antimi -\ncrobial prescriptions for suspected urinary tract infections in \nresidents of nursing homes: cluster randomised controlled trial. \nBMJ (Clinical research ed). 2005;331(7518):669. DOI: 10.1136/\nbmj.38602.586343.55\n64. Mitchell SL, Shaffer ML, Loeb MB, Givens JL, Habtemariam D, Kiely DK, \net al. Infection management and multidrug-resistant organisms in \nnursing home residents with advanced dementia. JAMA internal med -Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-37937389. Dey P, Halder S, Collins S, Benons L, Woodman C. Promoting uptake \nof influenza vaccination among health care workers: a randomized \ncontrolled trial. Journal of public health medicine. 2001;23(4):346-\n8. DOI: 10.1093/pubmed/23.4.346\n90. Lynch RM, Goring R. Practical Steps to Improve Air Flow in \nLong-Term Care Resident Rooms to Reduce COVID-19 Infec -\ntion Risk. Journal of the American Medical Directors Association. \n2020;21(7):893-4. DOI: 10.1016/j.jamda.2020.04.001\n91. Reddy M, Heidarinejad M, Stephens B, Rubinstein I. Adequate in -\ndoor air quality in nursing homes: An unmet medical need. Sci Total \nEnviron. 2021;765:144273. DOI: 10.1016/j.scitotenv.2020.144273\n92. Barker KA, Whitney EA, Blake S, Berkelman RL. A Review of Guide -\nlines for the Primary Prevention of Legionellosis in Long-Term Care \nFacilities. Journal of the American Medical Directors Association. \n2015;16(10):832-6. DOI: 10.1016/j.jamda.2015.05.015\n93. Nisbet LC, Cobbledick AM, Smith TE, Bryant PA, Lawrence J. Op -\nportunistic influenza vaccination in the home: broadening access \nin isolated times. Arch Dis Child. 2020. DOI: 10.1136/archdis -\nchild-2020-320273\n94. Frentzel E, Jump RLP, Archbald-Pannone L, Nace DA, Schweon SJ, \nGaur S, et al. Recommendations for Mandatory Influenza Vaccina -\ntions for Health Care Personnel From AMDA\u2019s Infection Advisory \nSubcommittee. Journal of the American Medical Directors Associa -\ntion. 2020;21(1):25-8.e2. DOI: 10.1016/j.jamda.2019.11.008\n95. Men\u00e9ndez Colino R, Merello de Miguel A, Argentina F, Barcons \nMarqu\u00e9s M, Chaparro Jim\u00e9nez B, L\u00f3pez Hern\u00e1ndez P, et al. [Evolu -\ntion of COVID-19 at nursing homes from the second wave to vac -\ncination. Description of a coordination program between Primary \nCare, Geriatrics and Public Health.]. Rev Esp Salud Publica. 2021;95. \n96. McConaghy M, Sartaj M, Conway BR, Aldeyab MA. An assessment \nof the impact of the vaccination program on coronavirus disease \n2019 (COVID-19) outbreaks in care homes in Northern Ireland-A \npilot study. Infection control and hospital epidemiology. 2021:1-2. \nDOI: 10.1017/ice.2021.169\n97. Stephens LM, Varga SM. Considerations for a Respiratory Syncyt -\nial Virus Vaccine Targeting an Elderly Population. Vaccines (Basel). \n2021;9(6). DOI: 10.3390/vaccines9060624\n98. Rubin MS, Nivin B, Ackelsberg J. Effect of timing of amanta -\ndine chemoprophylaxis on severity of outbreaks of influenza a \nin adult long-term care facilities. Clinical infectious diseases : an \nofficial publication of the Infectious Diseases Society of America. \n2008;47(1):47-52. DOI: 10.1086/588658\n99. Dolamore MJ. Influenza prophylaxis in the long-term care facility: \na case-control study of the risk factors for adverse drug reactions \nto amantadine. Curr Ther Res Clin Exp. 2003;64(9):753-63. DOI: \n10.1016/j.curtheres.2003.11.001\n100. Stewart RJ, Flannery B, Chung JR, Gaglani M, Reis M, Zimmerman \nRK, et al. Influenza Antiviral Prescribing for Outpatients With an \nAcute Respiratory Illness and at High Risk for Influenza-Associated \nComplications During 5 Influenza Seasons-United States, 2011-\n2016. Clinical infectious diseases : an official publication of the \nInfectious Diseases Society of America. 2018;66(7):1035-41. DOI: \n10.1093/cid/cix922other coronaviruses in older adults aged 60 years and above liv -\ning in long-term care: a rapid review. Syst Rev. 2020;9(1):218. DOI: \n10.1186/s13643-020-01486-4\n78. Kain DC, McCreight LJ, Johnstone J. Dealing with coronavirus dis -\nease 2019 (COVID-19) outbreaks in long-term care homes: A proto -\ncol for room moving and cohorting. Infection control and hospital \nepidemiology. 2020:1-2. DOI: 10.1017/ice.2020.1302\n79. Dosa D, Jump RLP, LaPlante K, Gravenstein S. Long-Term Care Facil -\nities and the Coronavirus Epidemic: Practical Guidelines for a Pop -\nulation at Highest Risk. Journal of the American Medical Directors \nAssociation. 2020;21(5):569-71. DOI: 10.1016/j.jamda.2020.03.004\n80. Bosco E, van Aalst R, McConeghy KW, Silva J, Moyo P, Eliot MN, \net al. Estimated Cardiorespiratory Hospitalizations Attributable to \nInfluenza and Respiratory Syncytial Virus Among Long-term Care \nFacility Residents. JAMA Netw Open. 2021;4(6):e2111806. DOI: \n10.1001/jamanetworkopen.2021.11806\n81. Liao RS, Appelgate DM, Pelz RK. An outbreak of severe respirato -\nry tract infection due to human metapneumovirus in a long-term \ncare facility for the elderly in Oregon. J Clin Virol. 2012;53(2):171-3. \nDOI: 10.1016/j.jcv.2011.10.010\n82. Poscia A, Collamati A, Carf\u00ec A, Topinkova E, Richter T, Denkinger \nM, et al. Influenza and pneumococcal vaccination in older adults \nliving in nursing home: a survival analysis on the shelter study. Eur \nJ Public Health. 2017;27(6):1016-20. DOI: 10.1093/eurpub/ckx150\n83. Black CL, Williams WW, Arbeloa I, Kordic N, Yang L, MaCurdy T, \net al. Trends in Influenza and Pneumococcal Vaccination Among \nUS Nursing Home Residents, 2006-2014. Journal of the Ameri -\ncan Medical Directors Association. 2017;18(8):735.e1-.e14. DOI: \n10.1016/j.jamda.2017.05.002\n84. Omura T, Matsuyama M, Nishioka S, Sagawa S, Seto M, Naoe M. As -\nsociation Between the Swallowing Reflex and the Incidence of As -\npiration Pneumonia in Patients with Dysphagia Admitted to Long-\nterm Care Wards. Arch Phys Med Rehabil. 2021. DOI: 10.1016/j.\napmr.2021.06.012\n85. Cristino S, Legnani PP, Leoni E. Plan for the control of Legionel -\nla infections in long-term care facilities: role of environmental \nmonitoring. Int J Hyg Environ Health. 2012;215(3):279-85. DOI: \n10.1016/j.ijheh.2011.08.007\n86. Machado M, Valerio M, \u00c1lvarez-Ur\u00eda A, Olmedo M, Veintimilla C, \nPadilla B, et al. Invasive pulmonary aspergillosis in the COVID-19 \nera: An expected new entity. Mycoses. 2021;64(2):132-43. DOI: \n10.1111/myc.13213\n87. Guinea J, Torres-Narbona M, Gij\u00f3n P, Mu\u00f1oz P, Pozo F, Pel\u00e1ez T, \net al. Pulmonary aspergillosis in patients with chronic obstructive \npulmonary disease: incidence, risk factors, and outcome. Clinical \nmicrobiology and infection : the official publication of the Eu -\nropean Society of Clinical Microbiology and Infectious Diseases. \n2010;16(7):870-7. DOI: 10.1111/j.1469-0691.2009.03015.x\n88. World Health Organization. WHO Guidelines Approved by the \nGuidelines Review Committee. Infection Prevention and Control \nof Epidemic- and Pandemic-Prone Acute Respiratory Infections in \nHealth Care. Geneva: World Health Organization Copyright \u00a9 World \nHealth Organization 2014.; 2014.Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379374Braekeveld P, et al. Infection prevention and control challenges \nin Flemish homecare nursing: a pilot study. Br J Community Nurs. \n2020;25(3):114-21. DOI: 10.12968/bjcn.2020.25.3.114\n114. McNeil JC, Fritz SA. Prevention Strategies for Recurrent Commu -\nnity-Associated Staphylococcus aureus  Skin and Soft Tissue In -\nfections. Curr Infect Dis Rep. 2019;21(4):12. DOI: 10.1007/s11908-\n019-0670-0\n115. Hine JL, de Lusignan S, Burleigh D, Pathirannehelage S, McGov -\nern A, Gatenby P, et al. Association between glycaemic control and \ncommon infections in people with Type 2 diabetes: a cohort study. \nDiabet Med. 2017;34(4):551-7. DOI: 10.1111/dme.13205\n116. Wasson NJ, Varley CD, Schwab P, Fu R, Winthrop KL. \u201cSerious skin \n& soft tissue infections in rheumatoid arthritis patients taking an -\nti-tumor necrosis factor alpha drugs: a nested case-control study\u201d. \nBMC Infect Dis. 2013;13:533. DOI: 10.1186/1471-2334-13-533\n117. Morrison SM, Blaesing CR, Millar EV, Chukwuma U, Schlett CD, \nWilkins KJ, et al. Evaluation of methicillin-resistant Staphylococcus \naureus  skin and soft-tissue infection prevention strategies at a mil -\nitary training center. Infection control and hospital epidemiology. \n2013;34(8):841-3. DOI: 10.1086/671278\n118. Millar EV, Schlett CD, Law NN, Whitman TJ, Ellis MW, Tribble \nDR, et al. Opportunities and Obstacles in the Prevention of Skin \nand Soft-Tissue Infections Among Military Personnel. Mil Med. \n2019;184(Suppl 2):35-43. DOI: 10.1093/milmed/usz105\n119. Junta de Andaluc\u00eda. Secreatar\u00eda Genral de Salud P\u00fablica y Consu -\nmo. Direcci\u00f3n General de Salud P\u00fablica y Ordenaci\u00f3n Farmac\u00e9utica. \nServicio de Vigilancia y Salud Laboral. Recomendaciones para la \nprevenci\u00f3n de la transmisi\u00f3n de microorganismos multirresistentes \ndurante la atenci\u00f3n a residentes colonizados/infectados en centros \nresidenciales. 2017:75. \n120. Ye C, Zhu W, Yu J, Li Z, Fu Y, Lan Y, et al. Viral pathogens among \nelderly people with acute respiratory infections in Shanghai, \nChina: Preliminary results from a laboratory-based surveillance, \n2012-2015. Journal of medical virology. 2017;89(10):1700-6. DOI: \n10.1002/jmv.24751\n121. Kestler M, Mu\u00f1oz P, Mateos M, Adrados D, Bouza E. Respirato -\nry syncytial virus burden among adults during flu season: an \nunderestimated pathology. The Journal of hospital infection. \n2018;100(4):463-8. DOI: 10.1016/j.jhin.2018.03.034\n122. Falsey AR, McElhaney JE, Beran J, van Essen GA, Duval X, Esen M, \net al. Respiratory syncytial virus and other respiratory viral infec -\ntions in older adults with moderate to severe influenza-like illness. \nThe Journal of infectious diseases. 2014;209(12):1873-81. DOI: \n10.1093/infdis/jit839\n123. Sloss EM, Solomon DH, Shekelle PG, Young RT, Saliba D, MacLean \nCH, et al. Selecting target conditions for quality of care improve -\nment in vulnerable older adults. Journal of the American Geriat -\nrics Society. 2000;48(4):363-9. DOI: 10.1111/j.1532-5415.2000.\ntb04691.x\n124. Pu Y, Dolar V, Gucwa AL. A comparative analysis of vaccine ad -\nministration in urban and non-urban skilled nursing facilities. BMC \ngeriatrics. 2016;16:148. DOI: 10.1186/s12877-016-0320-4\n125. Grosholz JM, Blake S, Daugherty JD, Ayers E, Omer SB, Polivka-West 101. Havers FP, Campbell AP, Uyeki TM, Fry AM. Commentary: A His -\ntorical Review of Centers for Disease Control and Prevention An -\ntiviral Treatment and Postexposure Chemoprophylaxis Guidance \nfor Human Infections With Novel Influenza A Viruses Associated \nWith Severe Human Disease. The Journal of infectious diseases. \n2017;216(suppl_4):S575-s80. DOI: 10.1093/infdis/jix065\n102. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment \nfor influenza in adults: a meta-analysis of randomised controlled \ntrials. Lancet (London, England). 2015;385(9979):1729-37. DOI: \n10.1016/s0140-6736(14)62449-1\n103. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud \nJ, et al. Antiviral therapy and outcomes of influenza requiring hos -\npitalization in Ontario, Canada. Clinical infectious diseases : an \nofficial publication of the Infectious Diseases Society of America. \n2007;45(12):1568-75. DOI: 10.1086/523584\n104. Bouza E, Brenes FJ, D\u00edez Domingo J, Eiros Bouza JM, Gonz\u00e1lez J, \nGracia D, et al. The situation of infection in the elderly in Spain: \na multidisciplinary opinion document. Revista espanola de quimi -\noterapia : publicacion oficial de la Sociedad Espanola de Quimioter -\napia. 2020;33(5):327-49. DOI: 10.37201/req/057.2020\n105. Henig O, Kaye KS. Bacterial Pneumonia in Older Adults. Infec -\ntious disease clinics of North America. 2017;31(4):689-713. DOI: \n10.1016/j.idc.2017.07.015\n106. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for \npreventing pneumococcal infection in adults. The Cochrane da -\ntabase of systematic reviews. 2013;2013(1):Cd000422. DOI: \n10.1002/14651858.CD000422.pub3\n107. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault \nS, et al. Polysaccharide conjugate vaccine against pneumococ -\ncal pneumonia in adults. The New England journal of medicine. \n2015;372(12):1114-25. DOI: 10.1056/NEJMoa1408544\n108. Jump RLP, Crnich CJ, Mody L, Bradley SF, Nicolle LE, Yoshikawa TT. \nInfectious Diseases in Older Adults of Long-Term Care Facilities: \nUpdate on Approach to Diagnosis and Management. Journal of the \nAmerican Geriatrics Society. 2018;66(4):789-803. DOI: 10.1111/\njgs.15248\n109. Yogo N, Gahm G, Knepper BC, Burman WJ, Mehler PS, Jenkins TC. \nClinical Characteristics, Diagnostic Evaluation, and Antibiotic Pre -\nscribing Patterns for Skin Infections in Nursing Homes. Frontiers in \nmedicine. 2016;3:30. DOI: 10.3389/fmed.2016.00030\n110. Hahnel E, Blume-Peytavi U, Trojahn C, Dobos G, Jahnke I, Kanti V, \net al. Prevalence and associated factors of skin diseases in aged \nnursing home residents: a multicentre prevalence study. BMJ open. \n2017;7(9):e018283. DOI: 10.1136/bmjopen-2017-018283\n111. LeBlanc K, Woo KY, VanDenKerkhof E, Woodbury MG. Skin tear \nprevalence and incidence in the long-term care population: a \nprospective study. J Wound Care. 2020;29(Sup7):S16-s22. DOI: \n10.12968/jowc.2020.29.Sup7.S16\n112. Abizanda Pea. Vacunaci\u00f3n y pol\u00edticas de prevenci\u00f3n y manjeo de \ninfecciones en el medio residencial. Tratada de medicina geri\u00e1trica \n2nd Edition. Fundamentos de la atenci\u00f3n sanitaria a los mayores. \nElsevier Espa\u00f1a 2020:1019-27. \n113. Maelegheer K, Dumitrescu I, Verpaelst N, Masson H, Broucke C, Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379375u\u0142kowicz M, et al. Mental Health Impact of SARS-COV-2 Pandem -\nic on Long-Term Care Facility Personnel in Poland. Journal of the \nAmerican Medical Directors Association. 2020;21(11):1576-7. DOI: \n10.1016/j.jamda.2020.09.020\n139. Kuzuya M, Aita K, Katayama Y, Katsuya T, Nishikawa M, Hirahara \nS, et al. The Japan Geriatrics Society consensus statement \u201crecom -\nmendations for older persons to receive the best medical and long-\nterm care during the COVID-19 outbreak-considering the timing \nof advance care planning implementation\u201d. Geriatr Gerontol Int. \n2020;20(12):1112-9. DOI: 10.1111/ggi.14075\n140. Saliba D, Solomon D, Rubenstein L, Young R, Schnelle J, Roth C, et \nal. Quality indicators for the management of medical conditions \nin nursing home residents. Journal of the American Medical Di -\nrectors Association. 2005;6(3 Suppl):S36-48. DOI: 10.1016/j.jam -\nda.2005.03.022\n141. Saliba D, Solomon D, Rubenstein L, Young R, Schnelle J, Roth C, \net al. Quality indicators for the management of medical condi -\ntions in nursing home residents. Journal of the American Medi -\ncal Directors Association. 2004;5(5):297-309. DOI: 10.1097/01.\nJam.0000136960.25327.61\n142. Men\u00e9ndez R, Torres A, Aspa J, Capalastegui A, Prat C, Rodr\u00edguez de \nCastro F. Neumon\u00eda adquirida en la comunidad. Normativa de la \nSociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR). Ac -\ntualizaci\u00f3n 2020 Community-Acquired Pneumonia Spanish Society \nof Pulmonology and Thoracic Surgery (SEPAR) Guidelines 2020 Up -\ndate. 2020:10. DOI: 10.1016/j.arbres.2020.01.014\n143. Gonz\u00e1lez-Castillo J, Mart\u00edn-S\u00e1nchez FJ, Llinares P, Men\u00e9ndez R, \nMujal A, Navas E, et al. Guidelines for the management of commu -\nnity-acquired pneumonia in the elderly patient. Revista espanola \nde quimioterapia : publicacion oficial de la Sociedad Espanola de \nQuimioterapia. 2014;27(1):69-86. \n144. Tappen RM, Newman D, Huckfeldt P, Yang Z, Engstrom G, Wolf DG, \net al. Evaluation of Nursing Facility Resident Safety During Imple -\nmentation of the INTERACT Quality Improvement Program. Journal \nof the American Medical Directors Association. 2018;19(10):907-\n13.e1. DOI: 10.1016/j.jamda.2018.06.017\n145. Durazzo M, Campion D, Fagoonee S, Pellicano R. Gastrointestinal \ntract disorders in the elderly. Minerva Med. 2017;108(6):575-91. \nDOI: 10.23736/s0026-4806.17.05417-9\n146. Freedberg DE, Kim LS, Yang YX. The Risks and Benefits of Long-term \nUse of Proton Pump Inhibitors: Expert Review and Best Practice Ad -\nvice From the American Gastroenterological Association. Gastroen -\nterology. 2017;152(4):706-15. DOI: 10.1053/j.gastro.2017.01.031\n147. Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari \nRM, et al. Proton pump inhibitors: Risks of long-term use. J Gastro -\nenterol Hepatol. 2017;32(7):1295-302. DOI: 10.1111/jgh.13737\n148. \u0160ubelj M, U \u010dakar V. An outbreak of acute gastroenteritis associated \nwith group A Rotavirus in long-term care facility in Slovenia. Wien \nKlin Wochenschr. 2015;127(11-12):415-20. DOI: 10.1007/s00508-\n014-0672-8\n149. Utsumi M, Makimoto K, Quroshi N, Ashida N. Types of infectious \noutbreaks and their impact in elderly care facilities: a review of \nthe literature. Age and ageing. 2010;39(3):299-305. DOI: 10.1093/L, et al. Accuracy of influenza vaccination rate estimates in Unit -\ned States nursing home residents. Epidemiology and infection. \n2015;143(12):2588-95. DOI: 10.1017/s0950268814003434\n126. Hutt E, Reznickova N, Morgenstern N, Frederickson E, Kramer AM. \nImproving care for nursing home-acquired pneumonia in a man -\naged care environment. The American journal of managed care. \n2004;10(10):681-6. \n127. Daugherty JD, Blake SC, Grosholz JM, Omer SB, Polivka-West L, \nHoward DH. Influenza vaccination rates and beliefs about vaccina -\ntion among nursing home employees. American journal of infec -\ntion control. 2015;43(2):100-6. DOI: 10.1016/j.ajic.2014.08.021\n128. Hsieh VC, Hsieh ML, Chiang JH, Chien A, Hsieh MS. Emergency \nDepartment Visits and Disease Burden Attributable to Ambulato -\nry Care Sensitive Conditions in Elderly Adults. Scientific reports. \n2019;9(1):3811. DOI: 10.1038/s41598-019-40206-4\n129. Warshaw G, Mehdizadeh S, Applebaum RA. Infections in nursing \nhomes: assessing quality of care. The journals of gerontology Series \nA, Biological sciences and medical sciences. 2001;56(2):M120-3. \nDOI: 10.1093/gerona/56.2.m120\n130. Trautner BW, Greene MT, Krein SL, Wald HL, Saint S, Rolle AJ, et \nal. Infection Prevention and Antimicrobial Stewardship Knowledge \nfor Selected Infections Among Nursing Home Personnel. Infection \ncontrol and hospital epidemiology. 2017;38(1):83-8. DOI: 10.1017/\nice.2016.228\n131. Giri S, Chenn LM, Romero-Ortuno R. Nursing homes during the \nCOVID-19 pandemic: a scoping review of challenges and responses. \nEur Geriatr Med. 2021:1-10. DOI: 10.1007/s41999-021-00531-2\n132. Wang Z. Use the Environment to Prevent and Control COVID-19 in \nSenior-Living Facilities: An Analysis of the Guidelines Used in China. \nHerd. 2021;14(1):130-40. DOI: 10.1177/1937586720953519\n133. Sanchez GV, Biedron C, Fink LR, Hatfield KM, Polistico JMF, Meyer \nMP, et al. Initial and Repeated Point Prevalence Surveys to Inform \nSARS-CoV-2 Infection Prevention in 26 Skilled Nursing Facilities \n- Detroit, Michigan, March-May 2020. MMWR Morb Mortal Wkly \nRep. 2020;69(27):882-6. DOI: 10.15585/mmwr.mm6927e1\n134. Blain H, Rolland Y, Schols J, Cherubini A, Miot S, O\u2019Neill D, et al. \nAugust 2020 Interim EuGMS guidance to prepare European Long-\nTerm Care Facilities for COVID-19. Eur Geriatr Med. 2020;11(6):899-\n913. DOI: 10.1007/s41999-020-00405-z\n135. Collison M, Beiting KJ, Walker J, Huisingh-Scheetz M, Pisano J, Chia \nS, et al. Three-Tiered COVID-19 Cohorting Strategy and Implications \nfor Memory-Care. Journal of the American Medical Directors Asso -\nciation. 2020;21(11):1560-2. DOI: 10.1016/j.jamda.2020.09.001\n136. Paananen J, Rannikko J, Harju M, Pirhonen J. The impact of Cov -\nid-19-related distancing on the well-being of nursing home resi -\ndents and their family members: a qualitative study. Int J Nurs Stud \nAdv. 2021;3:100031. DOI: 10.1016/j.ijnsa.2021.100031\n137. McGilton KS, Escrig-Pinol A, Gordon A, Chu CH, Z\u00fa\u00f1iga F, Sanchez \nMG, et al. Uncovering the Devaluation of Nursing Home Staff Dur -\ning COVID-19: Are We Fuelling the Next Health Care Crisis? Journal \nof the American Medical Directors Association. 2020;21(7):962-5. \nDOI: 10.1016/j.jamda.2020.06.010\n138. Senczyszyn A, Lion KM, Szcze \u015bniak D, Trypka E, Mazurek J, Ci -Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379376162. Asempa TE, Nicolau DP. Clostridium difficile infection in the el -\nderly: an update on management. Clinical interventions in aging. \n2017;12:1799-809. DOI: 10.2147/cia.S149089\n163. K\u00f6nig E, Medwed M, Pux C, Uhlmann M, Schippinger W, Krause R, \net al. Prospective Surveillance of Healthcare-Associated Infections \nin Residents in Four Long-Term Care Facilities in Graz, Austria. An -\ntibiotics (Basel). 2021;10(5). DOI: 10.3390/antibiotics10050544\n164. Engelhart ST, Hanses-Derendorf L, Exner M, Kramer MH. Pro -\nspective surveillance for healthcare-associated infections in Ger -\nman nursing home residents. The Journal of hospital infection. \n2005;60(1):46-50. DOI: 10.1016/j.jhin.2004.09.037\n165. McGeer A, Campbell B, Emori TG, Hierholzer WJ, Jackson MM, Nicol -\nle LE, et al. Definitions of infection for surveillance in long-term \ncare facilities. American journal of infection control. 1991;19(1):1-\n7. DOI: 10.1016/0196-6553(91)90154-5\n166. Nicolle LE. Infection prevention issues in long-term care. Current \nopinion in infectious diseases. 2014;27(4):363-9. DOI: 10.1097/\nqco.0000000000000071\n167. Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et \nal. Clinical Practice Guideline for the Management of Asymptomat -\nic Bacteriuria: 2019 Update by the Infectious Diseases Society of \nAmerica. Clinical infectious diseases : an official publication of the \nInfectious Diseases Society of America. 2019;68(10):1611-5. DOI: \n10.1093/cid/ciz021\n168. Stevenson KB, Moore J, Colwell H, Sleeper B. Standardized infec -\ntion surveillance in long-term care: interfacility comparisons from \na regional cohort of facilities. Infection control and hospital epide -\nmiology. 2005;26(3):231-8. DOI: 10.1086/502532\n169. Pigrau C. [Nocosomial urinary tract infections]. Enfermedades \ninfecciosas y microbiologia clinica. 2013;31(9):614-24. DOI: \n10.1016/j.eimc.2012.11.015\n170. Bagchi S, Watkins J, Norrick B, Scalise E, Pollock DA, Allen-Bridson \nK. Accuracy of catheter-associated urinary tract infections reported \nto the National Healthcare Safety Network, January 2010 through \nJuly 2018. American journal of infection control. 2020;48(2):207-\n11. DOI: 10.1016/j.ajic.2019.06.006\n171. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice \nJC, et al. Diagnosis, prevention, and treatment of catheter-associated \nurinary tract infection in adults: 2009 International Clinical Practice \nGuidelines from the Infectious Diseases Society of America. Clinical \ninfectious diseases : an official publication of the Infectious Diseases \nSociety of America. 2010;50(5):625-63. DOI: 10.1086/650482\n172. Anthony D, Alosoumi D, Safari R. Prevalence of pressure ulcers in \nlong-term care: a global review. J Wound Care. 2019;28(11):702-9. \nDOI: 10.12968/jowc.2019.28.11.702\n173. Igarashi A, Yamamoto-Mitani N, Gushiken Y, Takai Y, Tanaka M, \nOkamoto Y. Prevalence and incidence of pressure ulcers in Japanese \nlong-term-care hospitals. Arch Gerontol Geriatr. 2013;56(1):220-6. \nDOI: 10.1016/j.archger.2012.08.011\n174. Ahn H, Cowan L, Garvan C, Lyon D, Stechmiller J. Risk Factors for \nPressure Ulcers Including Suspected Deep Tissue Injury in Nurs -\ning Home Facility Residents: Analysis of National Minimum Data \nSet 3.0. Adv Skin Wound Care. 2016;29(4):178-90; quiz E1. DOI: ageing/afq029\n150. Taslim H. Clostridium difficile infection in the elderly. Acta Med In -\ndones. 2009;41(3):148-51. \n151. Greig JD, Lee MB. Enteric outbreaks in long-term care facilities and \nrecommendations for prevention: a review. Epidemiology and in -\nfection. 2009;137(2):145-55. DOI: 10.1017/s0950268808000757\n152. Bermejo Boixareu C, Tutor-Ureta P, Ramos Mart\u00ednez A. [Updated \nreview of Clostridium difficile infection in elderly]. Rev Esp Geriatr \nGerontol. 2020;55(4):225-35. DOI: 10.1016/j.regg.2019.12.003\n153. Felsen CB, Dodds Ashley ES, Barney GR, Nelson DL, Nicholas JA, \nYang H, et al. Reducing Fluoroquinolone Use and Clostridioides \ndifficile Infections in Community Nursing Homes Through Hospi -\ntal-Nursing Home Collaboration. Journal of the American Medical \nDirectors Association. 2020;21(1):55-61.e2. DOI: 10.1016/j.jam -\nda.2019.11.010\n154. Appaneal HJ, Caffrey AR, Beganovic M, Avramovic S, LaPlante KL. \nPredictors of Clostridioides difficile recurrence across a national \ncohort of veterans in outpatient, acute, and long-term care set -\ntings. Am J Health Syst Pharm. 2019;76(9):581-90. DOI: 10.1093/\najhp/zxz032\n155. Novakova E, Kotlebova N, Gryndlerova A, Novak M, Vladarova M, \nWilcox M, et al. An Outbreak of Clostridium (Clostridioides) difficile \nInfections within an Acute and Long-Term Care Wards Due to Mox -\nifloxacin-Resistant PCR Ribotype 176 Genotyped as PCR Ribotype \n027 by a Commercial Assay. J Clin Med. 2020;9(11). DOI: 10.3390/\njcm9113738\n156. Marincu I, Bratosin F, Vidican I, Cerbu B, Turaiche M, Tirnea L, et al. \nPredictive Factors for the First Recurrence of Clostridioides difficile \nInfection in the Elderly from Western Romania. Medicina (Kaunas). \n2020;56(9). DOI: 10.3390/medicina56090439\n157. Grace E, Chahine EB. Updates on Clostridioides (Clostridium) dif -\nficile Infection With Emphasis on Long-Term Care. Sr Care Pharm. \n2019;34(1):29-42. DOI: 10.4140/TCP.n.2019.29\n158. Endres BT, Dotson KM, Poblete K, McPherson J, Lancaster C, Bass\u00e8res \nE, et al. Environmental transmission of Clostridioides difficile ribo -\ntype 027 at a long-term care facility; an outbreak investigation \nguided by whole genome sequencing. Infection control and hospi -\ntal epidemiology. 2018;39(11):1322-9. DOI: 10.1017/ice.2018.230\n159. Donskey CJ, Sunkesula VCK, Stone ND, Gould CV, McDonald LC, \nSamore M, et al. Transmission of Clostridium difficile from asymp -\ntomatically colonized or infected long-term care facility residents. \nInfection control and hospital epidemiology. 2018;39(8):909-16. \nDOI: 10.1017/ice.2018.106\n160. Mallia G, Van Toen J, Rousseau J, Jacob L, Boerlin P, Greer A, et \nal. Examining the epidemiology and microbiology of Clostridium \ndifficile carriage in elderly patients and residents of a healthcare \nfacility in southern Ontario, Canada. The Journal of hospital infec -\ntion. 2018;99(4):461-8. DOI: 10.1016/j.jhin.2018.01.020\n161. Guh AY, Mu Y, Baggs J, Winston LG, Bamberg W, Lyons C, et al. \nTrends in incidence of long-term-care facility onset Clostridium \ndifficile infections in 10 US geographic locations during 2011-\n2015. American journal of infection control. 2018;46(7):840-2. \nDOI: 10.1016/j.ajic.2017.11.026Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379377Factors for Multidrug-Resistant Organisms Colonization in Long-\nTerm Care Facilities Around the World: A Review. Antibiotics (Basel). \n2021;10(6). DOI: 10.3390/antibiotics10060680\n189. O\u2019Fallon E, Schreiber R, Kandel R, D\u2019Agata EM. Multidrug-resistant \ngram-negative bacteria at a long-term care facility: assessment \nof residents, healthcare workers, and inanimate surfaces. Infec -\ntion control and hospital epidemiology. 2009;30(12):1172-9. DOI: \n10.1086/648453\n190. Peters C, Schablon A, Bollongino K, Maa\u00df M, Ka\u00df D, Dulon M, et al. \nMultiresistant pathogens in geriatric nursing - infection control in \nresidential facilities for geriatric nursing in Germany. GMS hygiene \nand infection control. 2014;9(3):Doc22. DOI: 10.3205/dgkh000242\n191. Huebner C, Roggelin M, Flessa S. Economic burden of multidrug-re -\nsistant bacteria in nursing homes in Germany: a cost analysis based \non empirical data. BMJ open. 2016;6(2):e008458. DOI: 10.1136/\nbmjopen-2015-008458\n192. Ruscher C, Schaumann R, Mielke M. [The challenge of infections \nand multiresistant bacteria among the elderly living in long-term \ncare facilities]. Bundesgesundheitsblatt, Gesundheitsforschung, \nGesundheitsschutz. 2012;55(11-12):1444-52. DOI: 10.1007/\ns00103-012-1555-7\n193. Tacconelli E, Mazzaferri F, de Smet AM, Bragantini D, Eggimann \nP, Huttner BD, et al. ESCMID-EUCIC clinical guidelines on decol -\nonization of multidrug-resistant Gram-negative bacteria carriers. \nClinical microbiology and infection : the official publication of the \nEuropean Society of Clinical Microbiology and Infectious Diseases. \n2019;25(7):807-17. DOI: 10.1016/j.cmi.2019.01.005\n194. The White House. NATIONAL STRATEGY FOR COMBATING AN -\nTIBIOTICRESISTANT BACTERIA. 2014:37. Available at: http:// \nobamawhitehouse.archives.gov/sites/default/files/docs/carb_na -\ntional_strategy.pdf\n195. Lim CJ, Kong DC, Stuart RL. Reducing inappropriate antibiotic pre -\nscribing in the residential care setting: current perspectives. Clinical \ninterventions in aging. 2014;9:165-77. DOI: 10.2147/cia.S46058\n196. Centers for Diseases Control and Prevention. Core Elements of Hos -\npital Antibiotic Stewardship Programs. 2019. \n197. Palms DL, Kabbani S, Bell JM, Anttila A, Hicks LA, Stone ND. Imple -\nmentation of the Core Elements of Antibiotic Stewardship in Nurs -\ning Homes Enrolled in the National Healthcare Safety Network. \nClinical infectious diseases : an official publication of the Infectious \nDiseases Society of America. 2019;69(7):1235-8. DOI: 10.1093/cid/\nciz102\n198. Norman DC, Yoshikawa TT. Fever in the elderly. Infectious disease \nclinics of North America. 1996;10(1):93-9. DOI: 10.1016/s0891-\n5520(05)70288-9\n199. Norman DC, Grahn D, Yoshikawa TT. Fever and aging. Journal of the \nAmerican Geriatrics Society. 1985;33(12):859-63. DOI: 10.1111/\nj.1532-5415.1985.tb05441.x\n200. Outzen M. Management of fever in older adults. Journal of \ngerontological nursing. 2009;35(5):17-23; quiz 4-5. DOI: \n10.3928/00989134-20090331-02\n201. Montoya A, Cassone M, Mody L. Infections in Nursing Homes: Epi -\ndemiology and Prevention Programs. Clinics in geriatric medicine. 10.1097/01.Asw.0000481115.78879.63\n175. Lee YJ, Kim JY, Dong CB, Park OK. Developing risk-adjusted quality \nindicators for pressure ulcers in long-term care hospitals in the Re -\npublic of Korea. Int Wound J. 2019;16 Suppl 1(Suppl 1):43-50. DOI: \n10.1111/iwj.13024\n176. Ayello EA. CMS MDS 3.0 Section M Skin Conditions in Long-term \nCare: Pressure Ulcers, Skin Tears, and Moisture-Associated Skin \nDamage Data Update. Adv Skin Wound Care. 2017;30(9):415-29. \nDOI: 10.1097/01.Asw.0000521920.60656.03\n177. Bates-Jensen BM, Cadogan M, Osterweil D, Levy-Storms L, Jorge J, \nAl-Samarrai N, et al. The minimum data set pressure ulcer indicator: \ndoes it reflect differences in care processes related to pressure ulcer \nprevention and treatment in nursing homes? Journal of the Amer -\nican Geriatrics Society. 2003;51(9):1203-12. DOI: 10.1046/j.1532-\n5415.2003.51403.x\n178. Stotts NA, Rodeheaver GT. Revision of the PUSH Tool using an \nexpanded database. Pressure Ulcer Scale for Healing. Adv Wound \nCare. 1997;10(5):107-10. \n179. Maklebust J. PUSH Tool reality check: audience response. Pressure \nUlcer Scale for Healing. Adv Wound Care. 1997;10(5):102-6. \n180. Thomas DR, Rodeheaver GT, Bartolucci AA, Franz RA, Sussman C, \nFerrell BA, et al. Pressure ulcer scale for healing: derivation and \nvalidation of the PUSH tool. The PUSH Task Force. Adv Wound Care. \n1997;10(5):96-101. \n181. Sussman C. Presenting a draft pressure ulcer scale to monitor heal -\ning. Adv Wound Care. 1997;10(5):92. \n182. Bates-Jensen BM. The Pressure Sore Status Tool a few thousand \nassessments later. Adv Wound Care. 1997;10(5):65-73. \n183. Pfingsten-W\u00fcrzburg S, Pieper DH, Bautsch W, Probst-Kepper M. \nPrevalence and molecular epidemiology of meticillin-resistant \nStaphylococcus aureus  in nursing home residents in northern Ger -\nmany. The Journal of hospital infection. 2011;78(2):108-12. DOI: \n10.1016/j.jhin.2011.02.011\n184. Greenland K, Rijnders MI, Mulders M, Haenen A, Spalburg E, van \nde Kassteele J, et al. Low prevalence of methicillin-resistant Staph -\nylococcus aureus  in Dutch nursing homes. Journal of the Amer -\nican Geriatrics Society. 2011;59(4):768-9. DOI: 10.1111/j.1532-\n5415.2011.03325.x\n185. Reynolds C, Quan V, Kim D, Peterson E, Dunn J, Whealon M, et al. \nMethicillin-resistant Staphylococcus aureus  (MRSA) carriage in 10 \nnursing homes in Orange County, California. Infection control and \nhospital epidemiology. 2011;32(1):91-3. DOI: 10.1086/657637\n186. Rooney PJ, O\u2019Leary MC, Loughrey AC, McCalmont M, Smyth B, \nDonaghy P, et al. Nursing homes as a reservoir of extended-spec -\ntrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant \nEscherichia coli. The Journal of antimicrobial chemotherapy. \n2009;64(3):635-41. DOI: 10.1093/jac/dkp220\n187. Murphy CR, Quan V, Kim D, Peterson E, Whealon M, Tan G, et al. \nNursing home characteristics associated with methicillin-resistant \nStaphylococcus aureus  (MRSA) Burden and Transmission. BMC In -\nfect Dis. 2012;12:269. DOI: 10.1186/1471-2334-12-269\n188. Rodr\u00edguez-Villodres \u00c1, Mart\u00edn-Gandul C, Pe\u00f1alva G, Guisado-Gil \nAB, Crespo-Rivas JC, Pach\u00f3n-Ib\u00e1\u00f1ez ME, et al. Prevalence and Risk Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379378envejecimiento.csic.es/estqadisticas/indicadores/residencias/indez.htlm\n216. Campos-Dompedro JR, JM. RC. Mortalidad en centros residenciales \npara mayores dependientes: estudio de variables asociadas. . Tesis \ndoctoral T38413 Disertaci\u00f3n 2016 Available at: Universidad com -\nplutense de Madrid Servicio de tesis doctorales y publicaciones \nacad\u00e9micas https://ucmonworldcatorg/ . 2016. \n217. van Dijk PT, Mehr DR, Ooms ME, Madsen R, Petroski G, Frijters DH, \net al. Comorbidity and 1-year mortality risks in nursing home resi -\ndents. Journal of the American Geriatrics Society. 2005;53(4):660-\n5. DOI: 10.1111/j.1532-5415.2005.53216.x\n218. Nace DA, Hanlon JT, Crnich CJ, Drinka PJ, Schweon SJ, Anderson G, \net al. A Multifaceted Antimicrobial Stewardship Program for the \nTreatment of Uncomplicated Cystitis in Nursing Home Residents. \nJAMA internal medicine. 2020;180(7):944-51. DOI: 10.1001/ja -\nmainternmed.2020.1256\n219. Mody L, Greene MT, Meddings J, Krein SL, McNamara SE, Trautner \nBW, et al. A National Implementation Project to Prevent Cathe -\nter-Associated Urinary Tract Infection in Nursing Home Residents. \nJAMA internal medicine. 2017;177(8):1154-62. DOI: 10.1001/ja -\nmainternmed.2017.1689\n220. Lai CC, Lu MC, Tang HJ, Chen YH, Wu YH, Chiang HT, et al. Imple -\nmentation of a national quality improvement program to enhance \nhand hygiene in nursing homes in Taiwan. Journal of microbiol -\nogy, immunology, and infection = Wei mian yu gan ran za zhi. \n2019;52(2):345-51. DOI: 10.1016/j.jmii.2018.09.007\n221. Rom\u00f8ren M, Gjelstad S, Lindb\u00e6k M. A structured training pro -\ngram for health workers in intravenous treatment with fluids \nand antibiotics in nursing homes: A modified stepped-wedge \ncluster-randomised trial to reduce hospital admissions. PloS one. \n2017;12(9):e0182619. DOI: 10.1371/journal.pone.0182619\n222. Simmons S, Schnelle J, Slagle J, Sathe NA, Stevenson D, Carlo M, \net al. AHRQ Comparative Effectiveness Technical Briefs. Resident \nSafety Practices in Nursing Home Settings. Rockville (MD): Agency \nfor Healthcare Research and Quality (US); 2016.\n223. Low LF, Fletcher J, Goodenough B, Jeon YH, Etherton-Beer C, \nMacAndrew M, et al. A Systematic Review of Interventions to \nChange Staff Care Practices in Order to Improve Resident Out -\ncomes in Nursing Homes. PloS one. 2015;10(11):e0140711. DOI: \n10.1371/journal.pone.0140711\n224. McConeghy KW, Baier R, McGrath KP, Baer CJ, Mor V. Implement -\ning a Pilot Trial of an Infection Control Program in Nursing Homes: \nResults of a Matched Cluster Randomized Trial. Journal of the \nAmerican Medical Directors Association. 2017;18(8):707-12. DOI: \n10.1016/j.jamda.2017.03.003\n225. Stone PW, Herzig CTA, Agarwal M, Pogorzelska-Maziarz M, Dick \nAW. Nursing Home Infection Control Program Characteristics, \nCMS Citations, and Implementation of Antibiotic Stewardship Pol -\nicies: A National Study. Inquiry : a journal of medical care organ -\nization, provision and financing. 2018;55:46958018778636. DOI: \n10.1177/0046958018778636\n226. Dick AW, Bell JM, Stone ND, Chastain AM, Sorbero M, Stone PW. \nNursing home adoption of the National Healthcare Safety Network \nLong-term Care Facility Component. American journal of infection 2016;32(3):585-607. DOI: 10.1016/j.cger.2016.02.004\n202. Smith PW, Bennett G, Bradley S, Drinka P, Lautenbach E, Marx J, \net al. SHEA/APIC guideline: infection prevention and control in the \nlong-term care facility, July 2008. Infection control and hospital \nepidemiology. 2008;29(9):785-814. DOI: 10.1086/592416\n203. Hales B, Terblanche M, Fowler R, Sibbald W. Development of med -\nical checklists for improved quality of patient care. International \njournal for quality in health care : journal of the International So -\nciety for Quality in Health Care. 2008;20(1):22-30. DOI: 10.1093/\nintqhc/mzm062\n204. Fuentes. V ea. Recomendaciones para la Prevenci\u00f3n de la Trans -\nmisi\u00f3n de Microorganismos Multirresistentes durante la Atenci\u00f3n \na Residentes Colonizados/Infectados en Centros Residenciales. \n2017:75. \n205. World Health Organization. Hand hygiene in outpatient and home-\nbased care and long-term care facilities: a guide to the application \nof the WHO multimodal hand hygiene improvement strategy and \nthe \u201cMy Five Moments For Hand Hygiene\u201d approach. 2012. \n206. Torres A, El-Ebiary M, Riquelme R, Ruiz M, Celis R. Commu -\nnity-acquired pneumonia in the elderly. Semin Respir Infect. \n1999;14(2):173-83. \n207. Torres OH, Gil E, Comas MT, Saez ME, Clotet S, Ramirez HD, et al. \n[Impact of a multidimensional intervention in elderly patients \nwith community-acquired pneumonia: IMIEPCAP clinical tri -\nal]. Rev Esp Geriatr Gerontol. 2016;51(1):37-43. DOI: 10.1016/j.\nregg.2015.09.004\n208. F\u00fcri J, Widmer A, Bornand D, Berger C, Huttner B, Bielicki JA. The \npotential negative impact of antibiotic pack on antibiotic steward -\nship in primary care in Switzerland: a modelling study. Antimicro -\nbial resistance and infection control. 2020;9(1):60. DOI: 10.1186/\ns13756-020-00724-7\n209. Giry M, Pulcini C, Rabaud C, Boivin JM, Mauffrey V, Birg\u00e9 J. Ac -\nceptability of antibiotic stewardship measures in primary care. Med \nMal Infect. 2016;46(6):276-84. DOI: 10.1016/j.medmal.2016.02.001\n210. Zetts RM, Stoesz A, Garcia AM, Doctor JN, Gerber JS, Linder JA, et \nal. Primary care physicians\u2019 attitudes and perceptions towards anti -\nbiotic resistance and outpatient antibiotic stewardship in the USA: \na qualitative study. BMJ open. 2020;10(7):e034983. DOI: 10.1136/\nbmjopen-2019-034983\n211. Zetts RM, Garcia AM, Doctor JN, Gerber JS, Linder JA, Hyun DY. Pri -\nmary Care Physicians\u2019 Attitudes and Perceptions Towards Antibiot -\nic Resistance and Antibiotic Stewardship: A National Survey. Open \nForum Infect Dis. 2020;7(7):ofaa244. DOI: 10.1093/ofid/ofaa244\n212. Badalona Serveis Assistencials. PROA atenci\u00f3n Primaria 2021. \n213. Aronow WS. Clinical causes of death of 2372 older persons in a \nnursing home during 15-year follow-up. Journal of the American \nMedical Directors Association. 2000;1(3):95-6. \n214. Braggion M, Pellizzari M, Basso C, Girardi P, Zabeo V, Lamattina MR, \net al. Overall mortality and causes of death in newly admitted nurs -\ning home residents. Aging Clin Exp Res. 2020;32(2):275-80. DOI: \n10.1007/s40520-019-01441-x\n215. Envejecimiento en Red - EnR. Un perfil de las personas mayores en \nEspa\u00f1a, 2019 Indicadores estad\u00edsticos b\u00e1sicos. 2019:38. Available at: Infection control in long term care institutions for the elderly:  A reflection document on the situation in \nSpainE. Bouza, et al.\nRev Esp Quimioter 2023;36(4): 346-379379control. 2019;47(1):59-64. DOI: 10.1016/j.ajic.2018.06.018\n227. Wagner LM, McDonald SM, Castle NG. Impact of voluntary accred -\nitation on short-stay rehabilitative measures in U.S. nursing homes. \nRehabilitation nursing : the official journal of the Association of \nRehabilitation Nurses. 2013;38(4):167-77. DOI: 10.1002/rnj.94\n228. Gastmeier P, Behnke M, Reichardt C, Geffers C. [Quality man -\nagement for preventing healthcare-acquired infections. The im -\nportance of surveillance]. Bundesgesundheitsblatt, Gesundheits -\nforschung, Gesundheitsschutz. 2011;54(2):207-12. DOI: 10.1007/\ns00103-010-1200-2\n229. Gudiol F. [Prudent use of antibiotics and suggestions for improve -\nment in long-term-care facilities]. Enfermedades infecciosas y \nmicrobiologia clinica. 2010;28 Suppl 4:32-5. DOI: 10.1016/s0213-\n005x(10)70040-9\n230. European Centre for Disease Prevention and Control (ECD). Pro -\ntocol for point prevalence surveys of healthcare-associated infec -\ntions and antimicrobial use in European log-term care facilties. \nVersion 2.1. 2015:60. \n231. Fu CJ, Agarwal M, Dick AW, Bell JM, Stone ND, Chastain AM, et \nal. Self-reported National Healthcare Safety Network knowledge \nand enrollment: A national survey of nursing homes. American \njournal of infection control. 2020;48(2):212-5. DOI: 10.1016/j.\najic.2019.08.016\n232. Stone PW, Chastain AM, Dorritie R, Tark A, Dick AW, Bell JM, et \nal. The expansion of National Healthcare Safety Network enroll -\nment and reporting in nursing homes: Lessons learned from a \nnational qualitative study. American journal of infection control. \n2019;47(6):615-22. DOI: 10.1016/j.ajic.2019.02.005\n233. Mukamel DB, Ye Z, Glance LG, Li Y. Does mandating nursing home \nparticipation in quality reporting make a difference? Evidence from \nMassachusetts. Medical care. 2015;53(8):713-9. DOI: 10.1097/\nmlr.0000000000000390\n234. S\u00e1nchez Ferr\u00edn P, Fontecha G\u00f3mez BJ. [Infection epidemiology in \ngerontology centers]. Rev Esp Geriatr Gerontol. 2011;46(2):61-2. \nDOI: 10.1016/j.regg.2010.12.003\n235. Comas-Herrera A, Fernandez JL, Hancock R, Hatton C, Knapp M, \nMcDaid D, et al. COVID-19: Implications for the Support of People \nwith Social Care Needs in England. J Aging Soc Policy. 2020;32(4-\n5):365-72. DOI: 10.1080/08959420.2020.1759759ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/023.2023\nRev Esp Quimioter 2023;36(4): 380-391380Reducci\u00f3n del riesgo de progresi\u00f3n en \nreceptores de trasplantes infectados por SARS-\nCoV-2 tratados con anticuerpos monoclonales.\nRESUMEN\nLos receptores de trasplantes de \u00f3rganos s\u00f3lidos (TOS) \npresentan un alto riesgo de infecci\u00f3n por el virus SARS-CoV-2 \ndebido al tratamiento inmunosupresor y m\u00faltiples comorbili -\ndades. La COVID-19 puede ser potencialmente mortal en re -\nceptores de TOS, con un aumento de la probabilidad de pro -\ngresi\u00f3n a enfermedad grave. Este trabajo presenta una revisi\u00f3n \nactualizada del impacto de la COVID-19 en receptores de TOS. \nEn los receptores de TOS no vacunados, la COVID-19 se asocia \ncon una alta tasa de mortalidad, hospitalizaci\u00f3n, ingreso en la \nUCI y deterioro del injerto o rechazo. En los pacientes vacuna -\ndos, incluso con pauta de vacunaci\u00f3n completa, se reduce el \nriesgo de mortalidad, pero el curso de la COVID-19 puede con -\ntinuar siendo grave en funci\u00f3n del tiempo desde el trasplante, \nel estado neto de inmunosupresi\u00f3n y haber sufrido rechazo o \ndisfunci\u00f3n del injerto. Los receptores de TOS presentan una \nbaja inmunogenicidad a las vacunas de ARNm y respuesta su -\nb\u00f3ptima. El tratamiento con anticuerpos monoclonales (AMC) \nen receptores de TOS no hospitalizados con alto riesgo de en -\nfermedad grave, se asocia con menores tasas de hospitaliza -\nci\u00f3n, visitas a urgencias, ingreso en UCI, progresi\u00f3n a enferme -\ndad grave y muerte. Sin embargo, se requieren nuevas vacunas \ny opciones terap\u00e9uticas, teniendo en cuenta la tendencia del \nvirus SARS-CoV-2 a adaptarse y a evadir tanto la inmunidad \nnatural como la inducida por la vacuna.\nPalabras clave:  trasplante de \u00f3rgano s\u00f3lido, COVID-19, SARS-CoV-2, inmunosu -\npresi\u00f3n, vacunas, anticuerpos monoclonales, sotrovimab.Reduction in the risk of progression of solid organ \ntransplant recipients infected by SARS-CoV-2 \ntreated with monoclonal antibodies\n1Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica, Coordinaci\u00f3n de Trasplantes, Banco de Tejidos, Hospital Cl\u00ednico San \nCarlos, Hospital Cl\u00ednico Universitario San Carlos, Madrid, Spain. \n2Unidad de Enfermedades Infecciosas (\u00c1rea Cl\u00ednica M\u00e9dica). Grupo de Investigaci\u00f3n de Infecci\u00f3n Grave, Instituto de In -\nvestigaci\u00f3n Sanitaria (IIS) La Fe, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain. \n3Medical Department, GSK, Madrid, Spain. Francisco Javier Candel1\nMiguel Salavert2\nDavid Lorite Mingot3\nMarta Manzano Crespo3\nPaula P\u00e9rez Portero3\nRafael Cuervo Pinto3Review\nArticle history\nReceived: 1 March 2023; Accepted: 23 March 2023; Published: 24 April 2023\nABSTRACT\nRecipients of solid organ transplants (SOT) are at higher \nrisk of infection by SARS-CoV-2 virus especially due to chronic \nimmunosuppression therapy and frequent multiple comorbid \nconditions. COVID-19 is a potentially life-threatening disease \nin SOT recipients, with an increased likelihood of progressing \nto severe disease, with the need of hospitalization, admission \nto the intensive care unit (ICU) and mechanical ventilatory \nsupport. This article presents an updated review of different \naspects related to the outcome of COVID-19 in SOT recipients. \nIn unvaccinated SOT recipients, COVID-19 is associated with a \nhigh mortality rate, in-patient care and ICU admission, and im -\npaired graft function or rejection in severe disease. In vaccinat -\ned SOT recipients even after full vaccination, there is a reduc -\ntion of the risk of mortality, but the course of COVID-19 may \ncontinue to be severe, influenced by the time from transplant, \nthe net state of immunosuppression and having suffered graft \nrejection or dysfunction. SOT recipients develop lower immu -\nnity from mRNA vaccines with suboptimal response. Treatment \nwith mAbs provides favorable outcomes in non-hospitalized \nSOT recipients at high risk for severe disease, with lower rates \nof hospitalization, emergency department visits, ICU care, pro -\ngression to severe disease, and death. However, broad vaccina -\ntion and therapeutic options are required, particularly in light \nof the tendency of the SARS-CoV-2 virus to adapt and evade \nboth natural and vaccine -induced immunity.\nKeywords: solid organ transplant, COVID-19, SARS-CoV-2, vaccines, immu -\nnosuppression, monoclonal antibodies, sotrovimab.\nCorrespondence: \nDr. Francisco Javier Candel.\nEnfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica, Coordinaci\u00f3n de Trasplantes, Banco de Teji -\ndos, Hospital Cl\u00ednico San Carlos, Hospital Cl\u00ednico Universitario San Carlos, \nC/ Profesor Mart\u00edn Lagos s/n, E-28040 Madrid, Spain. \nE-mail:  franciscojavier.candel@salud.madrid.orgReduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-391381(kidney, liver, and heart) being transplantation a safe practice, \nwith a low risk of transmission, regardless of the presence of \nsymptoms at the time of procurement [8]. \nFrom another perspective, transplant recipients may be \nat a higher risk of infection by SARS-CoV-2 due to the use of \nimmunosuppression, underlying comorbidities, and frequent \ncontact with the healthcare system. However, they are al -\nso more likely to be diagnosed early because of a more overt \nsymptomatology than immunocompetent subjects or due to \ncloser follow-up at the hospital or the transplant center. In \nSpain, in SOT (n = 665) and hematopoietic stem cell transplant \n(HSCT) (n = 113) recipients diagnosed with COVID-19 until \n13 July 2020, the incidence of COVID-19 was twofold higher \ncompared to the Spanish general population [9]. The mortality \nrate was 27%, with age > 60 years, lung transplantation, and \nhospital-acquired COVID-19 as risk factors for death. However, \nduring the ongoing pandemic, from 2020 to 2021 mortality \nin SOT recipients has decreased from 20-25% to 8-10% as a \nresult of increased and early availability of SARS-CoV-2 test -\ning, adherence to non-pharmaceutical interventions (face cov -\nering, hand hygiene, physical distancing) to control spread of \ninfection, development of novel treatments, and vaccination \n[10]. Nevertheless, transplant patients have less post-vaccina -\ntion protection than the general population, this condition of \nlower protection should have implications for treatment [8].\nAlthough the COVID-19 pandemic is likely to move to \nan endemic phase, with vaccination and novel therapeutic \noptions potentially reducing infection rates in SOT recipients \n[11-13], there are still limited data on the risk of poor out -\ncomes and progression of SARS-CoV-2 infection, response to \nvaccination, or efficacy of monoclonal antibody therapy in \nSOT. Therefore, an updated review of recently published rel -\nevant studies addressing these aspects is here presented. The \naim of the review is to provide clinicians involved in organ \ndonation and transplantation with some updated evidence for \nan optimal approach to the care of SOT patients in daily prac -\ntice, in particular in reference to how COVID-19 impacts on INTRODUCTION\nThe current pandemic of SARS-CoV-2 infection posed \nunprecedented threats to global healthy populations, sick \npatients with any disease, healthcare systems, economic bur -\nden, and governments\u2019 responsibilities to ensure the health \nand safety of their communities. The coronavirus disease \n2019 (COVID-19) had also had a major impact on solid organ \ntransplantation (SOT), specially on the mortality of these pa -\ntients, since they are more likely to develop severe forms of the \ndisease as compared to the general population. This may be \nbecause they are unable to mount a robust immunity against \nSARS-CoV-2.\nAlthough effective treatment options and vaccines have \nbeen a game changer, the ongoing pandemic continues to \npose unique challenges to fully resume disrupted transplan -\ntation activities. A population-based study of nationwide co -\nhorts of consecutive kidney, liver, lung, and heart transplants \nfrom 22 countries estimated an overall 16% reduction in \ntransplant activity comparing rates in 2020 and 2019 [1]. An \nanalysis of the impact of COVID-19 pandemic on the size of \nUS transplant waiting lists showed an increase in waiting list \nmortality and decreased transplant and candidate listings [2].  \nA review of data provided by the US United Network of Organ \nSharing (UNOS) [3] comparing monthly transplants in January \nand February 2020 with those performed during the entire \nmonth of April 2020 demonstrated a 35.9% decrease in organs \ntransplanted, with the largest reduction seen in kidney and \nlung transplants; moreover, increases in waitlist deaths. The \nimpact on organ transplantation also varied with respect to \norgan type with preferential deferral of kidney transplant can -\ndidates who were stable on renal replacement therapy and/or \nhad lower immunologic barriers to transplantation [4]. Howev -\ner, the majority of reports noted a decline in SOT in all organ \ntypes, with living donor programs generally suspended or cur -\ntailed in many sites [5-7], recent evidence has also shown that \nthere is low risk for a transplant recipient to get infected from \nan already infected donor, especially in non-pulmonary organs \nFigure 1  Different aspects of SARS-CoV-2 infection in solid organ transplantation \n(SOT) recipients include the severity of the disease in unvaccinated in \ncomparison to vaccinated patients, the immune response to vaccines, and \nthe effect of treatment with monoclonal antibodies on the course of the \ndisease.\nReduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-391382The systematic review and meta-analysis [14] included 14 \nretrospective and 1 prospective studies which had been pub -\nlished in 2020 that provided clinical outcomes of COVID-19 \ntransplant recipients (n = 1485) vs. non-transplant controls. \nThe overall quality of the evidence, according to Newcastle-Ot -\ntawa Scale (NOS) ranging from 7 to 9, was moderate. SOT re -\ncipients were predominantly male and more likely to present \nwith higher proportions of comorbidities. Transplant recipients \nwith COVID-19 showed as compared with non-transplanted \npatients a higher risk of admission to the intensive care unit \n(ICU) (odds ratio [OR] 1.57, 95 % confidence interval [CI] 1.07-\n2.31, p = 0.02) and mortality (hazard ratio [HR] 1.54, 95 % CI \n1.03-2.32, p = 0.037) (1.40-fold increase odds of mortality than \nnon-SOT recipients). In addition, in three studies that matched \nSOT recipients with the general population by age, sex, and \ncomorbidities, SOT recipients also showed an increased risk of \nmortality (HR 1.42, 95% CI 1.01-2.0, p = 0.046).\nIn a structured review of cohort studies, case series, \ncase-control studies, and case reports published in 2020, 164 \npublications were identified with 3,451 cases of SARS-CoV-2-\ninfected SOT recipients, in which data on outcome were avail -\nable for 3,353 patients (97.2%) [15]. Main outcomes included \nhospitalization in 84 % of patients (with SARS-CoV-2 infec -\ntion recovery in 53.6%), mortality rate of 21.1%, changes in \nimmunosuppressive medication in 57.9%, and disease progres -\nsion involving an impaired allograft function in 22.6%.\nIn a study of the largest database on COVID-19 in the \nUnited States (National COVID Cohort Collaborative) [16] based \non SOT patients who were tested for COVID-19 between Janu -\nary and November 2020, 18,121 SOT patients were identified, \n1,925 (10.6%) of whom had a positive test for SARS-CoV-2. \nThe outcome in the 90 days after COVID-19 positivity was ana -\nlyzed. The presence of COVID-19, compared to SOT patients \nwithout COVID-19 positivity, significantly increased the risk of \na composite variable (myocardial infarction, stent occlusion/\nthrombosis, angina, stroke, transient ischemic attack, chronic \nheart failure or death of any cause) (OR 1.92), as well as the \nrisk of graft loss (OR 79.7), rejection (OR 31.8), death (OR 8.43), \nacute kidney injury (AKI) (OR 2.35), and graft failure (OR 1.23). \nCompared with all other organ types, kidney transplant recipi -\nents had the highest risk of AKI and graft loss.\nCOVID-19 is a life-threatening disease for unvaccinated \nlung transplant recipients. In a single German high-volume \nlung transplantation center [17], clinical outcomes of 31 re -\ncipients with SARS-CoV-2 infection among 1,046 patients fol -\nlowed between March 2020 and May 2021 showed a mortal -\nity rate of 39%, and 84% of patients required in-patient care. \nPulmonary function parameters worsened significantly, and in \npatients with pre-existing chronic lung allograft dysfunction, \nthere was a substantial deterioration in graft function, with \na mortality rate of 43%. The Charlson Comorbidity Index was \na predictor of mortality (4/5.5) (HR 1.5, 95% CI 1.5-2.2, p = \n0.023).\nIn a review of eight studies published from January 2020 \nto January 2021, that evaluated COVID-19 infection in 494 liv -the overall management of SOT recipients and the use of mAbs \nas an available treatment to reduce the risk of progression of \nthese patients (Figure 1). It should be noted that even though \nthis review focuses on monoclonal antibodies, there are other \ntreatments available against COVID-19, such as antivirals.\nMETHODS\nA narrative review was carried out to cover all the points \nof interest to be reflected, being these both the risk of COV -\nID-19 disease progression of SOT patients when infected by \nSARS-CoV-2 and the use of mAbs as early treatment to avoid \nCOVID-19 progression. The information of interest was divided \ninto four blocks, including: 1) outcomes in unvaccinated SOT \nrecipients, 2) response to SARS-CoV-2 vaccine of SOT recipi -\nents, 3) outcomes in vaccinated SOT recipients, and 4) effect of \ntreatment with monoclonal antibodies on the course of COV -\nID-19 in SOT recipients.  \nThe literature search was conducted in MEDLINE/PubMed \ndatabase in May 2022 using MeSH terms and the following \nstrategy: ((covid[Title/Abstract]) OR (sars-cov-2[Title/Abstract])) \nAND ((solid organ transp*[Title/Abstract]) OR (transpl*[Title/Ab -\nstract]) OR (SOT[Title/Abstract])) AND ((risk[Title/Abstract]) OR \n(bad outcome*[Title/Abstract]) OR (progno*[Title/Abstract]) OR \n(hospit*[Title/Abstract]) OR (death[Title/Abstract]) OR (mortal*[ -\nTitle/Abstract])). Also, (vaccin*[Title/Abstract]) was added in the \nsearch of the second and third blocks, and ((monoclonal anti -\nbody [Title/Abstract]) OR (mab [Title/Abstract]) OR (treatment \n[Title/Abstract])) in the search of the fourth block. The search \nperiod ranged from June 2021 to May 2022 and was limited \nto articles published in English. In September 2022, the fourth \nblock search was actualized, extending the search date to that \nmoment. Also, due to updated vaccination programs leading \nto booster doses, especially in immunocompromised patients, \nrelevant publications that provide key information for the aim \nof this review, were also allowed to be included. Hematopoie -\ntic cell transplant recipients were excluded. Regarding \u2018article \ntype\u2019, no limits were established, although reviews, system -\natic reviews, and meta-analysis with the largest number of \npatients and participating centers were prioritized. Reference \nlists of retrieved articles were checked for additional potential -\nly eligible studies. Full texts were obtained from all articles in -\ncluded in the present review. After excluding publications with \nthe other formats, such as editorials, comments on articles, or \nopinion studies, the authors met via teleconference for discus -\nsion and agreement of the selected bibliography. The authors \nwere not blinded to the authors, institutions, or journals while \nselecting studies or extracting data.\n1. OUTCOMES IN UNVACCINATED SOT RECIPIENTS\nIn this block, three studies, a systematic review and me -\nta-analysis [14], a structured review [15], and a cohort study [16] \nwere focused on the outcomes of SARS-CoV-2 infection in SOT, \nwhereas another three studies each assessed COVID-19 in spe -\ncific lung [17], liver [18], and kidney [19] transplant recipients.Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-391383The use of calcineurin inhibitors, antimetabolites, and corti -\ncosteroids were associated with higher non-response rates or \nlower antibody titers. Non-responder status was also associ -\nated with older age and lower estimated glomerular filtration \nrate. The authors found inconsistency in the results with re -\ngards to the impact of time since transplantation on vaccine \nresponse.\nThe seroconversion after second dose of COVID-19 mRNA \nvaccines was evaluated in a systematic review and meta-anal -\nysis of 26 studies conducted in 2021 in 3,207 immunocom -\npromised patients and 1,726 healthy controls [21]. Thirteen \nstudies were focused on immunocompromised patients due \nto SOT, showing that transplant recipients were less likely to \ndevelop seroconversion than controls (relative risk reduction \n[RRR] 0.67, 95% CI 0.53-0.76, p < 0.01). No significant differ -\nences ( p = 0.55) were observed in the subgroup analysis based \non the type of transplantation (kidney vs. others [heart, lung, \nand liver]).\nA descriptive review based on 24 studies in SOT recipients \n[22], suboptimal humoral immune responses following two \ndoses of mRNA SARS-CoV-2 vaccine was reported, particular -\nly in kidney and lung transplant recipients (seropositivity rates \nfrom 8.2% to 66% and from 10% to 47.4% for kidney and \nlung transplant recipients, respectively). However, seropositivi -\nty rates were higher for liver (37.5 % to 80%) and heart (18.2% \nto 62%) transplant patients. Among 148 kidney transplant re -\ncipients, 35% developed neither humoral nor cellular immune \nresponses. Advanced age and magnitude of immunosuppres -\nsion correlated to the immune response. \nIn a single-center prospective observational cohort study \nof 200 SOT recipients (liver, kidney and lung) and 200 age- and \nsex-matched controls [23], in which anti-receptor-binding \ndomain (RBD) immunoglobulin IgG was measured after two \ndoses of BNT162b2 vaccine, humoral (36% SOT vs 97.5% con -\ntrols with positive response, p<0.001) and cellular responses \n(13.1% SOT vs 59.4% controls with positive response, p<0.001) \n6 months after vaccination were inferior in SOT recipients \nthan in healthy controls. Antibody levels increased from first \nvaccine dose to 2 months but declined from 2 months to 6 \nmonths. Statistically significant risk factors ( p < 0.001) for \nhumoral non-response 6 months after the first vaccine dose \nwere increasing age (risk ratio [RR] 1.23 per decade increase), \nbeing less than 1 year from transplantation (RR 1.55), lung (RR \n1.63), and kidney (RR 1.70) as type of organ transplantation \nwith liver as reference, the use of mycophenolate (RR 1.54) or \ncorticosteroids (RR 1.45) as immunosuppressive therapy, and \nde nov o non-skin cancer as comorbidity (RR 1.52).\nOther studies have evaluated the immune response in kid -\nney transplant patients [24-27]. In a systematic review of 18 \nprospective cohort studies with 2,453 patients, 693 of which \nwere kidney transplant recipients, the antibody response was \nevaluated 1-6 weeks after receiving the second dose of a mR -\nNA vaccine [24]. The seroconversion rate ranged between 2.5% \nand 37.5% (overall 27.2%), with advanced age, high-dose \ncorticosteroids in the last 12 months, and maintenance im -er transplant recipients, 80% required hospital admission and \n17% ICU care (of which 21% required mechanical ventilation) \n[18]. The overall mortality rate was 17%. Finally, in a systematic \nreview and meta-analysis of 48 observational studies compris -\ning 3,137 kidney transplant recipients with COVID-19 [19], the \nmortality rate for hospitalized patients was 21%, increasing to \n53% among patients admitted to the ICU ( p < 0.0001) and up \nto 68% in those who required mechanical ventilation support. \nIn addition, the pooled prevalence of acute respiratory distress \nsyndrome (ARDS) and AKI was 58% and 48%, respectively. \nThere was a higher mortality risk associated with ARDS (OR \n19.59), need of ICU care (OR 13.39), mechanical ventilation (OR \n3.80), and age \u2265 60 years (OR 3.90). \nTake home message\n\u2022 Unvaccinated SOT recipients with COVID-19 have a sig -\nnificant high risk of progression to severe COVID-19 \ndisease and mortality.\n\u2022 Impaired allograft function, graft rejection or graft loss \nare consequences of the severity of SARS-CoV-2 infec -\ntion.\n\u2022 Intensive surveillance is necessary in unvaccinated SOT \npatients for severe clinical outcomes.\n2. RESPONSE TO SARS-COV-2 VACCINE OF SOT \nRECIPIENTS\nVaccines against SARS-CoV-2 have been shown to con -\nstitute an important preventive option against COVID-19, es -\npecially in fragile patients, such as transplant patients. How -\never, available data indicate that COVID-19 vaccines may be \nless effective in immunocompromised populations such as SOT \nrecipients, although vaccines are safe and not related to re -\njection or other major adverse events. For this section of the \nreview, selected reports included two systematic reviews (one \nwith meta-analysis) [20,21], a descriptive review [22], a com -\nparison of antibody titers between SOT recipients and healthy \ncontrols [23], three reviews in kidney transplant patients [24-\n26], one review and meta-analysis in the subgroup of patients \nreceiving anti-CD20 therapies [27], and a retrospective study \nin liver transplant recipients [28]. Additionally, two prospective \ncohort study in renal patients [29,32], and two studies in SOT \nrecipients [30,31] were also included to give information about \nthe effect of a third or fourth dose.\nA systematic review that assessed the immunogenicity \nof COVID-19 vaccine after primary complete vaccination in \nimmunocompromised populations, based on 157 studies in \n25,209 patients, including 47 studies in 5,974 SOT recipients \n(23.7%) until August 2021 [20]. Non-response rates, defined \nas no presence of anti-SARS-CoV-2 spike protein antibodies or \nabsence of neutralizing antibodies, ranged from 19% to 100%, \nwith 35-98% in recipients of kidney transplantation, 19-63% \nin liver transplantation, 25-88% in heart transplantation, and \n59-100% in lung transplantation. Also, most studies found \nlower non-response rates in cellular than in antibody response. Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-391384in antibody titer was observed after third dose (overall mean \nincrease 831.0 BAU/mL). Factors associated with poor response \nwere increased age, shorter time since transplantation and \ntreatment with prednisolone and proliferation inhibitors [31].\nIn a further publication, the SENCOVAC study group, ana -\nlyzed the impact of a fourth dose of vaccine, 12 months af -\nter primary vaccination. They included 396 kidney transplant \npatients (278 with three doses and 118 with four doses). The \nfourth dose increased the antibody titers in patients with he -\nmodialysis and non-dialyzed patients with chronic kidney dis -\nease, but not in kidney transplant patients. Additionally, being \na kidney transplant patient was shown to be an independent \npredictor factor of negative humoral response at 12 months \n(OR 7.8; p<0.001) [32].\nSteroids and mycophenolate mofetil were found to be \nassociated with lower anti-Spike antibody titers (p=0.030 and \np=0.004, respectively) [32].\nTake home message\n\u2022 SOT recipients develop poor response to two doses of \nCOVID-19 mRNA vaccines, with a lower seroconversion \nrate as compared to healthy population.\n\u2022 Older age, burden of immunosuppressive regimen, \nmaintenance with mycophenolic acid and corticos -\nteroids, less than 1 year after transplantation, and \nimpaired renal function are risk factors for humoral \nnon-response.\n\u2022 Kidney transplant patients increased antibody titers \nand seroconversion after third dose. However, 20 % \nof patients did not respond at all and those that did \nrespond had lower antibody titers than other popula -\ntions. \n\u2022 Fourth dose of vaccine does not seem to meaningful \nimprove the response in kidney transplant patients.\n\u2022 Given the suboptimal immune response to two doses \nof vaccine, vaccination by at least three doses would be \ndesirable.\n3. OUTCOMES IN VACCINATED SOT RECIPIENTS\nThe evidence of whether effective anti-SARS-CoV-2 \nvaccines may significantly reduce the risk of morbidity and \nmortality-associated with COVID-19 in SOT recipients is un -\nclear [33]. Relevant studies assessed in this block included a \nretrospective registry-based analysis [34], a cohort study [35], \na retrospective multicenter study [36], an observational data \nlinkage cohort analysis [37], and a population-based cohort \nstudy [38].\nA study that linked four national registries in the United \nKingdom was conducted to identify outcomes within 28 days \nof a laboratory confirmed SARS-CoV-2 infection in unvacci -\nnated SOT recipients and those who had received 2 doses of \nPfizer-BioNTech BNT162b2 or Oxford-AstraZeneca ChAdOx1-S \nvaccine [34]. Vaccination was not associated with reduction munosuppression regiments including mycophenolate mofetil \n(MMF) as variables associated with low or absent antibody \nresponse. In another review [25], immune response after two \ndoses of anti-SARS-CoV-2 vaccine ranged between 11% and \n48%, with longer time from transplantation, first kidney trans -\nplant, better kidney function, and less immunosuppression re -\nlated to more likely to seroconvert. In a meta-analysis of 27 \ncohort and case-control studies with 1,452 kidney transplant \npatients and 477 healthy controls, humoral and cellular im -\nmune responses ranged from 2.6% to 29.87% and from 5.13% \nto 59.84%, respectively, for up to 4 weeks post-vaccination \ncompletion with mRNA vaccines, whereas all healthy controls \nmaintained \u2265 93% of both responses [26]. Moreover, another \nmeta-analysis of immune responses in patients treated with \nanti-CD20 antibodies showed a low humoral response rate of \n14% for the subset of kidney transplant recipients, which was \na lower level of response than other conditions also treated \nwith anti-CD20 such as hematological malignancies or auto -\nimmune diseases. [27]. In patients receiving a liver transplant, \nalcohol-induced cirrhosis as underlying disease and MMF for \nimmunosuppression have been identify as risk factors for se -\nronegativity [28]. \nSENCOVAC is a prospective, multicentric study of four co -\nhorts of vaccinated patients with different status of chronic \nkidney disease (CKD). In an analysis of vaccine response (by \nmeasurement of antibody titers), 6 months after the primary \nvaccination, the authors included 175 kidney transplant recip -\nients who have received, at least, two doses of mRNA vaccine. \n118 patients received a third dose. At 6 months, 80% of kidney \ntransplant patients among those who had received a third dose \nof vaccine (median 125 days after second dose) were catego -\nrized as responders vs only 53% of responders among those \nwith only two doses (p=0.002). However, 20% of patients did \nnot respond after a third those [29]. After third dose, patients \nhad higher anti spike antibody titers than those without the \nthird dose (p< 0.001). In addition, 62% of kidney transplant \npatients that did not respond after two doses, seroconverted \nafter third those. Thus, a third antigenic event seems relevant \nin this population although still a meaningful size keeps not \nwell protected, not responding to vaccine [29]. \nSimilar results were reported by Kamar et al. after stud -\nying, retrospectively, 101 SOT patients (78 kidney, 12 liver, 8 \nlung-heart, 3 pancreas). There were 40% of SOT patients with \ndetectable anti SARS-CoV-2 IgG before the third dose. After \nthe third those, this percentage increased up to 68%. Among \npatients that remained seronegative after second dose (n=59), \n44% seroconverted 4 weeks after third dose [30].\nIn a prospective study in Denmark, SOT patients (kidney \n73.2%, liver 16.2%, heart 4.7%, lung 3.7%) were included for \nstudy of humoral response after BNT162b2 vaccination. 395 \nand 335 patients were studied after second and third dose \nrespectively. SARS-CoV-2 spike IgG antibodies were detect -\ned in 49.4% of patients after two doses and 77.9% after the \nthird dose. The rate of seroconversion was 47.5% after the \nthird dose for those who remained seronegative after second \ndose (n=200). In terms of quantification, an overall increased Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-391385Vaccine effectiveness against severe outcomes (hospitalization \nor mortality) was shown, again, to be lower in this population \nvs general population, for both two (54%) and three (67%) \ndoses. However, it was notably improved with the third admin -\nistration [38].\nTake home message\n\u2022 The level of protection provided by vaccination from \nsymptomatic SARS-CoV-2 disease in SOT recipients is \nlower than in the general population. \n\u2022 A primary vaccine course of two doses appears to have \na limited effect on COVID-19 and its complications, in -\ncluding hospitalization and fatal outcome.\n\u2022 A third dose notably improves vaccine effectiveness in \nSOT patients.  \n\u2022 Alternative immunization schemes (booster dose, high -\ner doses) and modulation of immunosuppression dur -\ning vaccination need to be more extensively assessed in \nSOT recipients.\n4. EFFECT OF TREATMENT WITH MONOCLONAL \nANTIBODIES ON THE COURSE OF COVID-19 IN \nSOT RECIPIENTS \nSOT recipients are candidates for the use of anti-spike \nSARS-CoV-2 monoclonal antibodies (mAbs) for early treatment \nor prevention of COVID-19 because of special characteristics \nof this population, particularly chronic use of immunosup -\npression treatment, multiple underlying medical comorbidities, \nsuboptimal immunogenic response to complete vaccination \nscheme, and, occasionally, the age of the transplant patient. \nFor all these main reasons, SOT recipients are at higher risk of \ndeveloping severe COVID-19 with the potential need of care \nin the hospital including ICU admission, and ultimately to die \nfrom the disease. Neutralizing antibodies targeting the spike \nprotein of SARS-CoV-2, such as bamlanivimab-etesevimab, \ncasirivimab-imdevimab, tixagevimab-cilgavimab or sotrovimab \nhave been approved for the treatment of mild-to-moderate \nCOVID-19 in non-hospitalized patients with laboratory-con -\nfirmed SARS-CoV-2 infection, who are at high risk of progres -\nsion or severe disease and/or hospitalization. It is recommend -\ned that treatment should be started as soon as possible after a \npositive test and within 10 days of symptom onset. Also, some \nmAbs can be used for post-exposure prophylaxis (PEP) (casiriv -\nimab-imdevimab) or pre-exposure prophylaxis (PreP) (casiriv -\nimab-imdevimab and tixagevimab-cilgavimab). \nA number of clinical reviews of the general implications of \nmAbs against SARS-CoV-2 have been recently published (fig -\nure 2) [47-58]. In the particular group of SOT recipients, the \nuse of mAbs, recommended in the outpatient management \nof mild-moderate COVID-19, has been associated with a low -\ner risk of hospitalizations, emergency department (ED) visits, \nneed for ICU care, mechanical ventilation, and fatal outcomes. \nSimilar benefits have been reported for PEP, treatment of SOT \npatients with recurrent episodes of COVID-19 and possible of the risk of testing positive (incidence risk ratio [IRR] 1.29, \n95% CI 1.03-1.61), the incidence rate of SARS-CoV-2 infec -\ntion was 34.4 and 39.2 per 100,000 person-days for unvac -\ncinated and vaccinated SOT recipients respectively. However, \nvaccinated patients showed a higher chance of survival at \n28 days as compared with unvaccinated patients (91.8% vs. \n88.8%, p = 0.002); after risk adjustment (for type of organ re -\nceived, time since transplant, sex, age, ethnicity, NHS region, \ncalendar month and, in some analyses, vaccine type), vaccinat -\ned patients showed a 20% reduction in the risk of death (HR \n0.80, 95% CI 0.63-1.00, p = 0.05). Older age, Black ethnicity, \nlung transplantation, and care location were associated with a \nhigher risk of death.\nA cohort study of 449 SOT patients vaccinated with one \nof the two approved mRNA vaccines at the moment of study \n(BNT162b2 and mRNA-1273), observed severe course of COV -\nID-19 was common in a small number of SOT recipients (n=15) \nwho tested positive for COVID-19 even after their full vaccina -\ntion (two doses of mRNA vaccine at the moment of the study) \n[35]. Fifteen patients (3.3%) tested positive using SARS-CoV-2 \nPCR, with negative antibody titers in 9 (60%) of them. Sev -\nen patients had mild COVID-19, but the remaining 8 (53.3%) \nrequired hospitalization, 7 of which had severe disease and \n2 of them died. These findings were confirmed in a review of \n18,215 fully vaccinated SOT recipients at 17 transplant centers \n[36], in which there were 151 breakthrough infections (0.83%) \ndefined per Centers of Disease Control and Prevention criteria \n\u2265 14 days after completing all recommended vaccine doses. \nOf these 151 cases of breakthrough infections, 87 (57.6%) re -\nquired hospitalization and 14 patients died, with a mortality \nrate of 9.3%. Compared with the general population of 101 \nmillion fully vaccinated adults in the United States through \nApril 30, 2021, SOT recipients in this study had 82-fold higher \nrisk of breakthrough SARS-CoV-2 infection and 485-fold high -\ner risks of breakthrough infection with associated hospitaliza -\ntion and death.\nIn kidney transplant recipients, an observational cohort \nstudy linking national datasets in Scotland reported that as \nof September 19, 2021, 5,281 had received two doses of ap -\nproved SARS-CoV-2 vaccine [37]. There were 814 (15.4%) \ncases of SARS-CoV-2 infection. Vaccine effectiveness rates \nwere 39% (95% CI 2-58) against infection and 40% (95% CI \n0-59) against hospitalization. Within 28 days of a SARS-CoV-2 \npositive PCR test, the mortality rate among kidney transplant \nrecipients was 10% (compares to < 0.1% of the vaccinated \ngeneral Scottish population admitted to the hospital or dying \ndue to COVID-19 during the same period). In the multivariate \nanalysis, predictors of breakthrough infection following two \ndoses of SARS-CoV-2 vaccine were kidney transplant (vs. dial -\nysis) and socioeconomic deprivation.\nNaylor et al. conducted a population-based cohort study, \nincluding 12,842 SOT patients in Canada (kidney, liver, lung, \nheart and pancreas). Patients were included as for Decem -\nber 2020 and were followed-up until November 2021, as the \nvaccine program were developed in this population. 54.1% \nreceived three doses, with 12.7% who remain unvaccinated. Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-391386was provided to 17 kidney transplant recipients and 17 liver \ntransplant recipients. Only 5 patients required hospitalization, \nnone required ICU admission, and all 34 patients survived [50]. \nIn a comparison of outcomes of abdominal transplant recipi -\nents who would have been qualified for mAbs therapy but did \nnot receive the treatment, mAbs reduced the rates of hospi -\ntalization from 32% to 15% ( p = 0.045) and death from 13% \nto 0% ( p < 0.04). There were no major adverse reactions [50].\nIn a single-center analysis of 95 kidney transplant recipi -\nents diagnosed with COVID-19 from March 2020 to April 2021, \n20 (21%) of which were treated with mAbs (15 bamlanivimab, \n1 bamlanivimab-etesevimab, 3 casirivimab-imdevimab and 1 \nmAb treatment not known). The primary endpoints were hos -\npitalization or ED visits [51]. Antiviral treatment with mAbs \nwas associated with a marked decrease in hospitalization or ED \nvisits (15% vs. 76%, p < 0.001; HR 0.216, p = 0.04 after adjust -\nment for potential confounders and time-dependent symp -\ntom variable). In the multivariate analysis, age, chronic kidney \ndisease, and Hispanic ethnicity were independent factors for \nhospitalization or ED visits. There were no deaths in the 20 pa -\ntients treated with mAb whereas there were 8 (10.7%) in the \n75 not treated with mAbs.\n4.2 Sotrovimab\nSeveral groups have reported their experiences regarding \nthe use of sotrovimab in SOT recipients. In a report of 51 SOT \npatients who received sotrovimab (during both the Delta- and \nOmicron-predominant periods), 1 patient experienced pro -\ngression of COVID-19 symptoms and required 5-days hospi -\ntalization. None of the patients required ICU care or died [52]. \nIn this study, patients received sotrovimab on an average of \n3.5 days after the onset of symptoms and 2 days after labora -\ntory confirmation of SARS-CoV-2 positivity. 35% of patients \nin this study were vaccinated with 3 doses, and 45% had an \nincomplete vaccination regimen (less than 3 doses) with the \nremained 10% unvaccinated. In another single-center study \n[53] based on 15 SOT recipients diagnosed with SARS-CoV-2 \ninfection between December 2021 and January 2022 and with \na mild to moderate disease, 13 (86.7%) of which had received \ntwo or three doses of mRNA COVID-19 vaccines, 2 patients \n(13.3%) required hospitalization because of rapidly progres -\nsive respiratory distress symptoms requiring oxygen therapy. \nThere were no deaths. Sotrovimab infusion was well-tolerat -\ned with no reported adverse events. In another single-center \nprospective cohort study of 300 SOT patients infected with \nSARS-CoV-2 (51 treated with sotrovimab, of which 80% were \nvaccinated), it was observed that vaccination \u22653 doses and \ntreatment with sotrovimab are independently protective fac -\ntors in the progression to severe COVID-19 disease. Regard -\ning sotrovimab treatment, the number needed to treat (NNT) \nto prevent a patient from requiring supplemental oxygen was \n6.64 (95% CI, 4.56 to 13.66), and to prevent one hospitaliza -\ntion was 8.5 (95% CI, 4.83 to 59.1). Once again, there were no \ndeaths in the group of patients treated with sotrovimab [54].\nIn kidney transplant recipients, a comparison of the clin -\nical outcome of 25 patients with mild-to-moderate Omicron vaccine-breakthrough infection [46]. Studies of mAbs in SOT \nrecipients collected from the literature were divided according \nto the type of mAbs used: bamlanivimab and casirivimab-im -\ndevimab [47-51], patients were include from March 2020 to \nSeptember 2021, when the prevalent VOCs and VOIs were \nthose before Omicron (mainly Alpha, Beta Gamma, Epsilon \nand Delta), and sotrovimab, including patients from Septem -\nber 2021 to August 2022, when the prevalent VOCs were Delta \nand Omicron BA.1 and BA.2 [52-58]. Most data referred to ret -\nrospective case series reports of relatively small study popula -\ntions.\n4.1. Bamlanivimab and casirivimab-imdevimab\nSeveral studies have evaluated bamlanivimab and ca -\nsirivimab-imdevimab as emergency use in SOT recipients. In \na retrospective review from the Mayo Clinic of 73 SOT pa -\ntients treated with mAbs, between November 2020 and Jan -\nuary 2021, most commonly with bamlanivimab monotherapy \n(75.3%) and completing the full 28-day follow-up period, \nthe rates of ED consultation and hospitalization were 15.1% \n(63.6% for respiratory symptoms) and 12.3%, respectively \n[47]. There was one ICU admission not related to COVID-19, no \ndeaths, or advanced respiratory support, and minimal adverse \nevents were reported. Notably, in patients who were hospital -\nized, mAb administration was later than in those who did not \nrequire hospitalization (median 6 days from symptom onset vs \n4 days, p=0.03), reinforcing the importance of early interven -\ntion with these treatments. The same group of authors also re -\nported data of 28 SOT recipients who presented mild-to-mod -\nerate COVID-19 after full vaccination (defined as two doses of \nmRNA vaccine; except one patient who underwent vaccination \nwith Johnson & Johnson and 4 patients who received a third \ndose), all patients received casirivimab-imdevimab, with a me -\ndian time of infusion of 3 days after symptoms onset. ED visits \nwere reported by 4 patients (14.3%) and only 1 patient (3.6%) \nrequired hospital admission. No ICU admission or deaths were \nreported [48].\nThese results are similar to those obtained in another sin -\ngle-center retrospective analysis of 165 SOT recipients with \nno records of covid vaccination, 93 of which received mAbs \n(76.3% bamlanivimab and 22% casirivimab-imdevimab) and \n72 did not (comparator cohort) [49]. The 30-day hospitaliza -\ntion rate was 8.7% in the study cohort vs. 15.3% in the com -\nparator cohort, but differences after adjusting for age did \nnot reach statistical significance (OR 0.49, 95% CI 0.18-1.32, \np = 0.16). None of the patients that received casirivimab-im -\ndevimab were hospitalized but all patients hospitalized in the \nmAbs group had received bamlanivimab monotherapy. Two \nepisodes of biopsy-proven acute rejection were observed in \nthe mAbs group, but it was unknown whether they could be \nattributed to mAbs therapy, COVID-19, or immunosuppression \nadjustments. There were 2 deaths in the comparator cohort \nand none in the mAbs-treated cohort.\nIn a single center retrospective review of abdominal trans -\nplant patients between February 2020 and February 2021, an -\nti-SARS-CoV-2 mAbs therapy (33/34 received bamlanivimab) Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-391387one dose of mRNA vaccine, with 76% and 86% vaccinated \nwith three or four doses in the sotrovimab and control group \nrespectively.\nIn a Spanish multicenter retrospective cohort study [56], a \ntotal of 82 kidney transplant recipients with SARS-CoV-2 Omi -\ncron BA.1 infection were treated with sotrovimab, of which \nwas administered early ( \u2264 5 days from the onset of symptoms) \nin 46 patients (56.1%). Overall, more than 86.8% of patients \nhad received three doses of vaccine before their COVID-19 di -\nagnosis and 42.6% had an oxygen saturation < 95% at ad -\nmission. Early treatment was associated with a reduced risk of \nprogression to severe disease with need of mechanical ventila -\ntion (2.2% vs. 36.1%, p < 0.001), ICU admission (2.2% vs. 25%, COVID-19 who received sotrovimab with 100 patients who did \nnot receive sotrovimab showed a reduced rate of hospitaliza -\ntion (4 patients, 16% vs. 35 patients, 35%) and ICU admission \n(1 patients, 4% vs. 17 patients, 17%), and no patient died as \ncompared to 11% in non-sotrovimab-treated patients. The \nKaplan-Meier analysis showed significant differences in mor -\ntality ( p = 0.044) and severity (measured as mortality and/or \nICU admission) of Omicron COVID-19 disease ( p = 0.045) be -\ntween kidney transplant recipients treated or not treated with \nsotrovimab [55]. Notably, median time from symptoms onset \nand sotrovimab administration were 5 days, however the 1 \npatient who suffered COVID-19 progression was administered \nafter 11 days. Overall, 92% of patients had received at least Figure 2  COVID-19 progression rates in each study based on treatment or not with mAb\nColors indicate mAb used for treatment, red: bamlanivimab or casirivimab+imdevimab; green: casirivimab + imdevimab; blue: sotrovimab. Solid fill: mAb treatment (trea -\nted group); not solid fill: not mAb treatment (control group). Circles size: hospitalization rate, bigger the circle, higher hospitalization rate:\nThe numbers of the studies correspond to the reference included in the bibliography section. The patients included in the different studies present different vaccination \nstatus. In addition, the outcomes were collected at different dates from the treatment administration, the majority at one-month post-treatment, however, in some stu -\ndies it is not specified. Three of the publications included in the sotrovimab treatment block have not been included in this graph, one of them is Villanego F, et al. Clin \nKidney J. 2022;15(10):1847-55 [56], which at the beginning of the study, 81.7% of the patients were hospitalized, so progression is measured as COVID-19 mortality, \nbeing 8.5%. Furthermore, 42% had an oxygen saturation < 95% at admission, and 43,9% of patients were administered >5 days from symptom onset, representing a \nmore severe population and suboptimal administration. Differences were observed between patients treated \u22645 days from the onset of symptoms and those treated >5 \ndays (2.2% vs 16.7%; p=0.020 mortality). The second one, Vathsala A, et al. Transpl Infect Dis. 2022:e13930 [57], where hospitalization is not determined; COVID-19 \nprogression is determined by the need for supplemental oxygen (21.6%; <4 days 14.3% vs \u22654 days 55.6%; p=0.015) and mortality (9.8%). The third publication not \nincluded is Negin Farhadian, et al. Immunopharmacol Immunotoxicol. 2022;1-7 [58], since it is a meta-analysis where several publications are included, indicating that \nsotrovimab treatment reduces the risk of hospitalization (OR 0.29, p<0.001), ICU admission (OR 0.17, p = 0.009) and death (OR 0.15, p=0.010) compared to the control \ngroup without mAb treatment.\nReduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-391388able therapeutic options, mAbs have been shown to be both \neffective and safe in this population. Treatment of COVID-19 \nwith mAbs in SOT recipients, in particular early treatment af -\nter diagnosis, is associated with a reduced likelihood of pro -\ngression to severe COVID-19. Reduction of the risk of severe \ndisease entails decreases in hospitalization, ICU care, ventila -\ntory support, ED visits, mortality, and, very especially to take \ninto account in this immunosuppressed population, the re -\nduction or avoidance of the risk of opportunistic infections \nby multiresistant hospital bacteria and by fungi that cause \ninvasive fungal infection (CAPA, CAM) with high intrinsic \nmortality promoted by SARS-CoV-2.\nAlthough neutralizing capacity of some mAbs have been \nreported to be reduced against new circulating variants, it is \nnot known, how in vitro neutralization data correlates with \nclinical efficacy. This is specially noting in the case of sotro -\nvimab, a mAb that has a double mechanism of action, not only \nneutralizing but also with effector function that is mediated \nby the Fc region of the mAb [59]. This effector function has \nbeen shown, in animal models, to be an additional protection \nmechanism beyond virus neutralization, being critical for the \nmaintenance of its activity against SARS-CoV-2 variants that \nreduced its neutralizing activity such us BA.2 [60-66]. Several \nrecent studies in real practice, have shown the same effective -\nness data of the antibody against Omicron BA.2 vs BA.1, being \nBA.1 a variant against which sotrovimab neutralization capac -\nity is not impacted [60, 61]. In addition, some preprints have \nbeen published showing maintained clinical efficacy for BA.5 \nalso [62]. Same kind of not peer reviewed works, have report -\ned that effector function is maintained for other variants with \nhigher fold changes such us BQ.1.1 [63], and that sotrovimab \nis able to reduce viral load in animal models for this variant \n[63,64]. Although more evidence and continuous surveillance \nis needed, to monitor a potential impact in the effectiveness \nof these therapeutic mAbs, they are an important therapeutic \noption, especially in SOT patients, who can be excluded from \nother therapeutic options because of interactions with con -\ncomitant medications.\nFindings of the present review are timely and informative \nto the transplant community. The ability to draw firm conclu -\nsions is limited by the retrospective nature of data collection, \nthe absence of a control group and the limited number of \nparticipants in most studies. It is difficult to use this data to \nestimate comparative effectiveness of mAbs therapies in SOT \nrecipients exposed to or infected with SARS-CoV-2 and at high \nrisk of developing severe COVID-19, however the weight of \nevidence is in favor of a benefit of mAb treatment. It is nec -\nessary to continue to explore the best approach in preventing \nsevere COVID-19 in this vulnerable SOT patient population in \nthe context of limited immunogenicity of vaccines and possi -\nble surge of COVID-19 infections.\nSuccessful utilization of anti-SARS-CoV-2 mAbs requires \na multidisciplinary team approach, close monitoring for effica -\ncy and tolerability, and awareness of circulating variants.p = 0.002), and mortality due to COVID-19 (2.2% vs. 16.7%, p \n= 0.02). In the multivariate analysis, early use of sotrovimab \nwas the only protective risk factor (OR 0.026) for a composite \noutcome defined as the need for ventilatory support or ICU \ncare or COVID-19-related mortality. There was a good safety \nprofile, even in patients with multiple comorbidities or ad -\nvanced chronic kidney disease stage. \nIn another retrospective study of 51 SARS-CoV-2-infected \n(49% Delta and 51% Omicron BA.1 variants) kidney transplant \nrecipients treated with sotrovimab, 11 (21.6%) progressed to \nsevere COVID-19 disease and 5 (9.8%) patients died. Those \nwho had earlier administration of sotrovimab were less likely \nto have more severe disease (14.3% of patients administered \nsotrovimab at < 4 days after symptom onset needed supple -\nmental oxygen therapy vs. 55.6% among those treated at \u2265 4 \ndays [ p = 0.015]) [57]. \nFinally, in a meta-analysis of 6 cohort studies which re -\nports the clinical outcomes of SOT patients treated with sotro -\nvimab vs a control group between January 2021 and August \n2022, it was shown that treated patients had a lower frequen -\ncy of COVID-19 disease progression (Figure 2). Sotrovimab \ntreatment was shown to reduce the risk of hospitalization (OR \n0.29, p < 0.001), ICU admission (OR 0.17, p = 0.009) and death \n(OR 0.15, p = 0.010) compared to the control group without \nmAb treatment [58].\nTake home message:\n\u2022 Treatment with the anti-spike available mAbs formula -\ntions provides favorable outcomes in SOT recipients at \nhigh risk for severe COVID-19 disease.\n\u2022 SOT recipients with SARS-CoV-2 infection treated with \nmAbs as compared with untreated comparator groups \nhad lower rates of hospitalization, ICU admissions, pro -\ngression to severe disease, and death.\n\u2022 Early administration ( \u2264 4-5 days of symptom onset) \nseems to improve benefits of mAbs treatment.\n\u2022 Treatment with mAbs is safe with a few adverse events \ngenerally mild, and no effect on graft losses or rejec -\ntion.\nCONCLUDING REMARKS\nThe available evidence based on relevant studies pub -\nlished in the literature reinforces the importance of an ear -\nly diagnosis of COVID-19 in SOT recipients and completion \nof a fully anti-SARS-CoV-2 vaccination schedule. Despite a \nlower rate of humoral and cellular immune response, com -\npared to general population. All studies reviewed, find that \nrepeated doses of vaccination increase the humoral response \nup to 70 - 80% of transplant patients with detectable anti -\nbodies after 3 doses. The third dose seems to be key for this \npopulation, with remarkable rates of seroconversion after its \nadministration. However, despite vaccination, a considerable \npercentage of this group remains at high risk and should be \ntreated soon after COVID-19 diagnosis. Among current avail -Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-39138910.1111/ajt.16369\n10. Nimmo A, Gardiner D, Ushiro-Lumb I, Ravanan R, Forsythe JLR. The \nglobal impact of COVID-19 on solid organ transplantation: Two \nyears into a pandemic. Transplantation. 2022;106(7):1312-29. doi: \n10.1097/TP.0000000000004151\n11. Bartelt L, van Duin D. An overview of COVID-19 in solid organ \ntransplantation. Clin Microbiol Infect. 2022;28(6):779-84. doi: \n10.1016/j.cmi.2022.02.005\n12. Laracy JC, Miko BA, Pereira MR. The solid organ transplant re -\ncipient with SARS-CoV-2 infection. Curr Opin Organ Transplant. \n2021;26(4):412-8. doi: 10.1097/MOT.0000000000000888\n13. Opsomer R, Kuypers D. COVID-19 and solid organ transplan -\ntation: Finding the right balance. Transplant Rev (Orlando). \n2022;36(3):100710. doi: 10.1016/j.trre.2022.100710\n14. Ao G, Wang Y, Qi X, Nasr B, Bao M, Gao M, Sun Y, Xie D. The asso -\nciation between severe or death COVID-19 and solid organ trans -\nplantation: A systematic review and meta-analysis. Transplant Rev \n(Orlando). 2021;35(3):100628. doi: 10.1016/j.trre.2021.100628\n15. Quante M, Brake L, Tolios A, Della Penna A, Steidle C, Gruendl M, \net al. SARS-CoV-2 in solid organ transplant recipients: A struc -\ntured review of 2020. Transplant Proc. 2021;53(8):2421-34. doi: \n10.1016/j.transproceed.2021.08.019\n16. Vinson AJ, Agarwal G, Dai R, Anzalone AJ, Lee SB, French E, et al. \nCOVID-19 in solid organ transplantation: Results of the National \nCOVID Cohort Collaborative. Transplant Direct. 2021;7(11):e775. \ndoi: 10.1097/TXD.0000000000001234\n17. Kamp JC, Hinrichs JB, Fuge J, Ewen R, Gottlieb J. COVID-19 in lung \ntransplant recipients-Risk prediction and outcomes. PLoS One. \n2021;16(10):e0257807. doi: 10.1371/journal.pone.0257807\n18. Kullar R, Patel AP, Saab S. COVID-19 in liver transplant recip -\nients. J Clin Transl Hepatol. 2021;9(4):545-50. doi: 10.14218/\nJCTH.2020.00098\n19. Jayant K, Reccia I, Bachul PJ, Al-Salmay Y, Pyda JS, Podda M, et al. \nThe Impact of COVID-19 on kidney transplant recipients in pre-vac -\ncination and delta strain era: A systematic review and meta-analy -\nsis. J Clin Med. 2021;10(19):4533. doi: 10.3390/jcm10194533\n20. Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop \nL, Loubet P, et al. Immunological and clinical efficacy of COVID-19 \nvaccines in immunocompromised populations: a systematic re -\nview. Clin Microbiol Infect. 2022;28(2):163-77. doi: 10.1016/j.\ncmi.2021.09.036\n21. Mehrabi Nejad MM, Moosaie F, Dehghanbanadaki H, Haji Ghadery \nA, Shabani M, Tabary M, et al. Immunogenicity of COVID-19 mRNA \nvaccines in immunocompromised patients: a systematic review and \nmeta-analysis. Eur J Med Res. 2022;27(1):23. doi: 10.1186/s40001-\n022-00648-5\n22. Grupper A, Katchman H. SARS-CoV-2 vaccines: Safety and immu -\nnogenicity in solid organ transplant recipients and strategies for \nimproving vaccine responses. Curr Transplant Rep. 2022;9(1):35-\n47. doi: 10.1007/s40472-022-00359-0\n23. Hamm SR, M\u00f8ller DL, P\u00e9rez-Al\u00f3s L, Hansen CB, Pries-Heje MM, Heft -\ndal LD, et al. Decline in antibody concentration 6 months after two \ndoses of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant ACKNOWLEDGMENTS\nThe authors thank Grupo SANED, S.L., for logistic support \nand Marta Pulido, MD, PhD, for editing the manuscript and ed -\nitorial assistance.\nFUNDING\nThis review was funded by GSK (GSK4182-REV-00064354).\nCONFLICTS OF INTEREST\nF.J. Candel has presented conferences in meetings spon -\nsored by GSK, MSD, Pfizer, Correvio, Astellas, Gilead, Meiji and \nShionogi; M. Salavert has presented conferences in meetings \nsponsored by Angelini, Gilead, GSK, MSD, Menarini, Pfizer, Te -\ndec-Meiji and Shionogi; D. Lorite Mingot, M. Manzano Crespo, \nP. P\u00e9rez Portero and R. Cuervo Pinto are employees of GSK, \nand hold shares in the company.\nREFERENCES\n1. Aubert O, Yoo D, Zielinski D, Cozzi E, Cardillo M, D\u00fcrr M, et al. COV -\nID-19 pandemic and worldwide organ transplantation: a popula -\ntion-based study. Lancet Public Health. 2021;6(10):e709-19. doi: \n10.1016/S2468-2667(21)00200-0\n2. Miller J, Wey A, Valapour M, Hart A, Musgrove D, Hirose R, et al. \nImpact of COVID-19 pandemic on the size of US transplant waiting \nlists. Clin Transplant. 2022;36(5):e14596. doi: 10.1111/ctr.14596\n3. Cholankeril G, Podboy A, Alshuwaykh OS, Kim D, Kanwal F, Esquivel \nCO, Ahmed A. Early impact of COVID-19 on solid organ transplan -\ntation in the United States. Transplantation. 2020;104(11):2221-\n24. doi: 10.1097/TP.0000000000003391\n4. Danziger-Isakov L, Blumberg EA, Manuel O, Sester M. Impact of \nCOVID-19 in solid organ transplant recipients. Am J Transplant. \n2021;21(3):925-37. doi: 10.1111/ajt.16449\n5. Angelico R, Trapani S, Manzia TM, Lombardini L, Tisone G, Cardillo \nM. The COVID-19 outbreak in Italy: Initial implications for organ \ntransplantation programs. Am J Transplant. 2020;20(7):1780-4. \ndoi: 10.1111/ajt.15904\n6. Gumber L, Gumber A. COVID-19 and \u2018lockdown\u2019 in organ trans -\nplantation in the UK. Public Health. 2020;185:55-6. doi: 10.1016/j.\npuhe.2020.06.017\n7. Dom\u00ednguez-Gil B, Coll E, Fern\u00e1ndez-Ruiz M, Corral E, Del R\u00edo \nF, Zaragoza R, et al. COVID-19 in Spain: Transplantation in the \nmidst of the pandemic. Am J Transplant. 2020;20(9):2593-8. doi: \n10.1111/ajt.15983\n8. Candel FJ, Pardo Rey C, Torres-Gonz\u00e1lez JI, Fern\u00e1ndez-Vega P, Frag -\niel M, Oteo D, et al. COVID-19 in donation and transplant. Rev Esp \nQuimioter. 2022;35(Suppl3):54\u201362. Doi: 10.37201/req/s03.13.2022\n9. Coll E, Fern\u00e1ndez-Ruiz M, S\u00e1nchez-\u00c1lvarez JE, Mart\u00ednez-Fern\u00e1ndez \nJR, Crespo M, Gayoso J, et al. COVID-19 in transplant recipients: \nThe Spanish experience. Am J Transplant. 2021;21(5):1825-37. doi: Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-3913902022;54(6):1405-8. doi: 10.1016/j.transproceed.2021.12.012\n36. Qin CX, Moore LW, Anjan S, Rahamimov R, Sifri CD, Ali NM, et al. \nRisk of breakthrough SARS-CoV-2 infections in adult transplant \nrecipients. Transplantation. 2021;105(11):e265-6. doi: 10.1097/\nTP.0000000000003907\n37. Bell S, Campbell J, Lambourg E, Watters C, O\u2019Neil M, Almond A, et \nal. The impact of vaccination on incidence and outcomes of SARS-\nCoV-2 infection in patients with kidney failure in Scotland. J Am \nSoc Nephrol. 2022;33(4):677-86. doi: 10.1681/ASN.2022010046\n38. Naylor KL, Kim SJ, Smith G, McArthur E, Kwong JC, Dixon SN, et \nal. Effectiveness of first, second, and third COVID-19 vaccine dos -\nes in solid organ transplant recipients: A population-based cohort \nstudy from Canada. Am J Transplant. 2022;22(9):2228-2236. doi: \n10.1111/ajt.17095\n39. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, \nTuccori M. Monoclonal antibody therapies against SARS-CoV-2. \nLancet Infect Dis. 2022;22(11):e311-26. doi: 10.1016/S1473-\n3099(22)00311-5\n40. Quiros-Roldan E, Amadasi S, Zanella I, Degli Antoni M, Storti S, \nTiecco G, et al. Monoclonal antibodies against SARS-CoV-2: Cur -\nrent scenario and future perspectives. Pharmaceuticals (Basel). \n2021;14(12):1272. doi: 10.3390/ph14121272\n41. Chatterjee S, Choudhury S, Das D. An update of antispike severe \nacute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclo -\nnal antibodies. Indian J Pharmacol. 2022;54(1):51-7. doi: 10.4103/\nijp.ijp_519_21\n42. El Abd Y, Tabll A, Smolic R, Smolic M. Mini-review: The market \ngrowth of diagnostic and therapeutic monoclonal antibodies - \nSARS CoV-2 as an example. Hum Antibodies. 2022;30(1):15-24. \ndoi: 10.3233/HAB-211513\n43. Hwang YC, Lu RM, Su SC, Chiang PY, Ko SH, Ke FY, et al. Monoclonal \nantibodies for COVID-19 therapy and SARS-CoV-2 detection. J Bi -\nomed Sci. 2022;29(1):1. doi: 10.1186/s12929-021-00784-w\n44. Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et \nal. SARS-CoV-2-neutralising monoclonal antibodies for treatment \nof COVID-19. Cochrane Database Syst Rev. 2021;9(9):CD013825. \ndoi: 10.1002/14651858.CD013825.pub2\n45. Martin-Blondel G, Marcelin AG, Souli\u00e9 C, Kaisaridi S, Lusivika-Nzin -\nga C, Dorival C, et al. Outcome of very high-risk patients treated \nby sotrovimab for mild-to-moderate COVID-19 Omicron, a pro -\nspective cohort study (the ANRS 0003S COCOPREV study). J Infect. \n2022;84(6):e101-4. doi: 10.1016/j.jinf.2022.04.010\n46. Dhand A, Razonable RR. COVID-19 and solid organ transplantation: \nRole of anti-SARS-CoV-2 monoclonal antibodies. Curr Transplant \nRep. 2022;9(1):26-34. doi: 10.1007/s40472-022-00357-2\n47. Yetmar ZA, Beam E, O\u2019Horo JC, Ganesh R, Bierle DM, Brumble L, \net al. Monoclonal antibody therapy for COVID-19 in solid organ \ntransplant recipients. Open Forum Infect Dis. 2021;8(6):ofab255. \ndoi: 10.1093/ofid/ofab255\n48. Yetmar ZA, Bhaimia E, Bierle DM, Ganesh R, Razonable RR. Break -\nthrough COVID-19 after SARS-CoV-2 vaccination in solid organ \ntransplant recipients: An analysis of symptomatic cases and mono -\nclonal antibody therapy. Transpl Infect Dis. 2022;24(2):e13779. doi: recipients and healthy controls. Front Immunol. 2022;13:832501. \ndoi: 10.3389/fimmu.2022.832501\n24. Akyol M, \u00c7evik E, Ucku D, Tanr\u0131\u00f6ver C, Af\u0301ar B, Kanbay A, et al. \nImmunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and \nkidney transplant patients: A systematic review. Tuberk Toraks. \n2021;69(4):547-60. doi: 10.5578/tt.20219612\n25. Devresse A, De Greef J, Yombi JC, Belkhir L, Goffin E, Kanaan N. \nImmunosuppression and SARS-CoV-2 infection in kidney trans -\nplant recipients. Transplant Direct. 2022;8(3):e1292. doi: 10.1097/\nTXD.0000000000001292\n26. Swai J, Gui M, Long M, Wei Z, Hu Z, Liu S. Humoral and cellular \nimmune response to severe acute respiratory syndrome coronavi -\nrus-2 vaccination in haemodialysis and kidney transplant patients. \nNephrology (Carlton). 2022;27(1):7-24. doi: 10.1111/nep.13974\n27. Schietzel S, Anderegg M, Limacher A, Born A, Horn MP, Maurer B, \net al. Humoral and cellular immune responses on SARS-CoV-2 vac -\ncines in patients with anti-CD20 therapies: a systematic review and \nmeta-analysis of 1342 patients. RMD Open. 2022;8(1):e002036. \ndoi: 10.1136/rmdopen-2021-002036\n28. Timmermann L, Globke B, Lurje G, Schmelzle M, Sch\u00f6ning W, \n\u00d6llinger R, et al. Humoral immune response following SARS-\nCoV-2 vaccination in liver transplant recipients. Vaccines (Basel). \n2021;9(12):1422. doi: 10.3390/vaccines9121422\n29. Quiroga B, Soler MJ, Ortiz A, Orero E, Tejedor S, et al. Humoral Re -\nsponse to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum. \nCJASN. 2022;17(6):872-876. doi:10.2215/CJN.01770222\n30. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. \nThree Doses of an mRNA Covid-19 Vaccine in Solid-Organ Trans -\nplant Recipients. N Engl J Med. 2021;385:661-662. doi: 10.1056/\nNEJMc2108861\n31. Balsby D, Nilsson AC, M\u00f6ller S, Lindvig SO, Davidsen JR, Abazi R, et al. \nDeterminants of Antibody Response to a Third SARS-CoV-2 mRNA \nVaccine Dose in Solid Organ Transplant Recipients: Results from \nthe Prospective Cohort Study COVAC-Tx. Vaccines. 2022;10(4):565. \nDoi: 10.3390/vaccines10040565\n32. Quiroga B, Soler MJ, Ortiz A, Jarava Mantec\u00f3n CJ, Gomes P\u00e9rez \nVO, Bordils A, et al. Humoral response after the fourth dose of the \nSARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis \nof the SENCOVAC study. Nephrol Dial Transplant. 2022;24:gfac307. \ndoi: 10.1093/ndt/gfac307. Epub ahead of print. PMID: 36423334.\n33. Giannella M, Pierrotti LC, Helanter\u00e4 I, Manuel O. SARS-CoV-2 vac -\ncination in solid-organ transplant recipients: What the clinician \nneeds to know. Transpl Int. 2021;34(10):1776-88. doi: 10.1111/\ntri.14029\n34. Callaghan CJ, Mumford L, Curtis RMK, Williams SV, Whitaker \nH, Andrews N, et al. Real-world effectiveness of the Pfizer-Bi -\noNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vac -\ncines against SARS-CoV-2 in solid organ and islet transplant \nrecipients. Transplantation. 2022;106(3):436-46. doi: 10.1097/\nTP.0000000000004059\n35. Marinaki S, Xagas E, Tsoutsoura P, Katsaros D, Korogiannou M, \nBoletis IN. Occurrence of severe SARS-CoV-2 infection in ful -\nly vaccinated solid organ transplant recipients. Transplant Proc. Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated \nwith monoclonal antibodiesF.J. Candel,, et al.\nRev Esp Quimioter 2023;36(4): 380-39139110.1111/tid.13779\n49. Sarrell BA, Bloch K, El Chediak A, Kumm K, Tracy K, Forbes RC, et \nal. Monoclonal antibody treatment for COVID-19 in solid organ \ntransplant recipients. Transpl Infect Dis. 2022;24(1):e13759. doi: \n10.1111/tid.13759\n50. Ahearn AJ, Thin Maw T, Mehta R, Emamaullee J, Kim J, Blodget E, \net al. A programmatic response, including bamlanivimab or casiriv -\nimab-imdevimab administration, reduces hospitalization and death \nin COVID-19 positive abdominal transplant recipients. Transplan -\ntation. 2022;106(2):e153-7. doi: 10.1097/TP.0000000000003953\n51. Klein EJ, Hardesty A, Vieira K, Farmakiotis D. Use of anti-spike \nmonoclonal antibodies in kidney transplant recipients with COV -\nID-19: Efficacy, ethnic and racial disparities. Am J Transplant. \n2022;22(2):640-5. doi: 10.1111/ajt.16843\n52. Dhand A, Okumura K, Wolfe K, Lobo SA, Nog R, Keller M, et al. \nSotrovimab for treatment of COVID-19 in solid organ transplant \nrecipients. Transplantation. 2022;106(7):e336-e337. doi: 10.1097/\nTP.0000000000004136\n53. Pinchera B, Buonomo AR, Scotto R, Carrano R, Salemi F, Galluc -\ncio F, et al. Sotrovimab in solid organ transplant patients with \nearly, mild/moderate SARS-CoV-2 infection: A single-center ex -\nperience. Transplantation. 2022;106(7):e343-e345. doi: 10.1097/\nTP.0000000000004150\n54. Solera JT, \u00c1rbol BG, Alshahrani A, Bahinskaya I, Marks N, Humar A, \net al. Impact of Vaccination and Early Monoclonal Antibody Ther -\napy on Coronavirus Disease 2019 (COVID-19) Outcomes in Organ \nTransplant Recipients During the Omicron Wave. Clinical Infectious \nDiseases. 2022; ciac324. Doi: 10.1093/cid/ciac324\n55. Chavarot N, Melenotte C, Amrouche L, Rouzaud C, Sberro-Soussan \nR, Pavie J, et al. Early treatment with sotrovimab monoclonal anti -\nbody in kidney transplant recipients with Omicron infection. Kidney \nInt. 2022;101(6):1290-3. doi: 10.1016/j.kint.2022.04.003\n56. Villanego F, Mazuecos A, Cubillo B, Merino MJ, Poveda I, Saura \nIM, et al. Treatment with sotrovimab for SARS-CoV-2 infection in \na cohort of high-risk kidney transplant recipients. Clin Kidney J. \n2022;15(10):1847-55. doi: 10.1093/ckj/sfac177\n57. Vathsala A, Somani J, Ross D\u2019Costa M, Lum L, Wong ET, Sran HK. \nComparative outcomes after early sotrovimab administration in \nvaccinated and unvaccinated kidney transplant recipients with \nSARS-CoV-2 infection during the Delta and Omicron BA.1 surges. \nTranspl Infect Dis. 2022:e13930. doi: 10.1111/tid.13930\n58. Farhadian N, Farhadian M, Zamanian MH, Taghadosi M, Vaziri S. \nSotrovimab therapy in solid organ transplant recipients with mild \nto moderate COVID-19: a systematic review and meta-analy -\nsis. Immunopharmacol Immunotoxicol. 2022 Dec 27:1-7. doi: \n10.1080/08923973.2022.2160733.\n59. Pinto, D., Park, YJ., Beltramello, M. et al. Cross-neutralization of \nSARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. \n2020;583:290\u2013295. Doi: 10.1038/s41586-020-2349-y\n60. Martin-Blondel G, Marcelin A-G, Souli\u00e9 C, Kaisaridi S, Lusivi -\nka-Nzinga C, Dorival C, et al. Sotrovimab to prevent severe COV -\nID-19 in high-risk patients infected with Omicron BA.2. J Infect. \n2022;85(4): e104\u2013e108. Doi: 10.1016/j.jinf.2022.06.03361. Zheng B, Green ACA, Tazare J, Curtis HJ, Fisher L, Nab L, et al. Com -\nparative effectiveness of sotrovimab and molnupiravir for preven -\ntion of severe covid-19 outcomes in patients in the community: \nobservational cohort study with the OpenSAFELY platform. BMJ. \n2022;379 :e071932. doi:10.1136/bmj-2022-071932\n62. The OpenSAFELY Collaborative, Zheng B, Campbell J, Carr EJ, \nTazare J, Nab L, et al. Comparative effectiveness of sotrovimab \nand molnupiravir for preventing severe COVID-19 outcomes in \nnon-hospitalised patients on kidney replacement therapy: obser -\nvational cohort study using the OpenSAFELY-UKRR linked plat -\nform and SRR database. medRxiv. 2022. Unpublished results. doi: \n10.1101/2022.12.02.22283049\n63. Addetia A, Piccoli L, Case JB, Park YJ, Beltramello M, Guarino B, et \nal.  Therapeutic and vaccine-induced cross-reactive antibodies with \neffector function against emerging Omicron variants. bioRxiv 2023. \nUnpublished results. doi: 10.1101/2023.01.17.523798\n64. Driouich, J.-S., Bernardin, O., Touret, F., de Lamballerie, X., Nou -\ngair\u00e8de A., In vivo activity of Sotrovimab against BQ.1.1 Omi -\ncron sublineage. bioRxiv 2023. Unpublished results. doi: \n10.1101/2023.01.04.522629\n65. Bruel T, St\u00e9fic K, Nguyen Y, Toniutti D, Staropoli I, Porrot F, et al. \nLongitudinal analysis of serum neutralization of SARS-CoV-2 Omi -\ncron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibod -\nies. Cell Rep Med. 2022;3(12): 100850. doi: 10.1016/ 2022.100850.\n66. Case JB, Mackin S, Errico JM, Chong Z, Madden EA et al. Resilience \nof S309 and AZD7442 monoclonal antibody treatments against \ninfection by SARS-CoV-2 Omicron lineage strains. Nat Commun. \n2022;13(1):3824. doi: 10.1038/s41467-022-31615-7ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/138.2022\nRev Esp Quimioter 2023;36(4): 392-399392Management of COVID-19 pandemic in \nhospital at home in two regional Spanish \nhospitals. what it meant, who we cared for, \nwho died and how assistance has evolved over \ntime\nABSTRACT\nIntroduction.  Home Hospitalization (HH) is an alterna -\ntive hospitalization modality that can be very useful in times \nof health stress such as the COVID-19 pandemic. This paper \nincludes the management of patients admitted with COVID-19 \nin HH in two county spanish hospitals for two years. \nMethods.  A descriptive, observational and retrospective \nstudy of all patients admitted at HH with a diagnosis of COV -\nID-19 disease was carried out. Subsequently, further analysis \nwas carried out to characterize the patients who died in HH \nor 30 days after discharge and another to compare the man -\nagement between the first phase of the study (2020) and the \nsecond one (2021 and part of 2022). \nResults. A total of 167 patients were recruited. A 52.1% \nmoved to watch that the recovery continued compared to \n40.7% in which it was done to watch that they did not worsen. \nThe patients who died in HAD were older (mean 87.5 years), \nmore comorbid and more likely to have do-not resucitate or -\nders (DNR) in case of cardiac arrest (85%). In the second phase \nof the study, older patients, more comorbid patients and with \na greater degree of DNR orders were admitted than those ad -\nmitted throughout 2020. \nConclusions. HAD is a useful resource to increase the re -\nsilience of health systems in cases of stress such as the disease \ncaused by COVID-19. The development and growth of existing \nunits, as well as the creation of new ones where they do not \nexist, could be a basic tool for the medicine of the future.\nKeywords: Home Care Services, Hospital-Based; COVID-19; Coronavirus; \nMortality; Epidemics; Pandemics. Manejo de la pandemia de COVID-19 en \nhospitalizaci\u00f3n domiciliaria en dos hospitales \ncomarcales espa\u00f1oles: qu\u00e9 signific\u00f3, qui\u00e9nes \natendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la \nasistencia a lo largo del tiempo\n1Servicio de Medicina Interna, Hospital Reina Sof\u00eda de Tudela (Espa\u00f1a).\n2Servicio de Neumolog\u00eda, Hospital Reina Sof\u00eda de Tudela (Espa\u00f1a).\n3Servicio de Medicina Interna, Hospital Garc\u00eda Orcoyen de Estella (Espa\u00f1a).\n4Servicio de Digestivo, Hospital Obispo Polanco de Teruel (Espa\u00f1a).David S\u00e1nchez Fabra1\nTina Herrero Jord\u00e1n2\nAlicia Alda Lozano1\nVictoria Duro Su\u00e1rez3\nNuria Saura Blasco4\nIsabel Torres Courchoud1Original\nArticle history\nReceived: 5 December 2022; Revision Requested: 27 January 2023; Revision Received: 27 January 2023;  \nAccepted: 9 March 2023; Published: 3 May 2023\nRESUMEN\nIntroducci\u00f3n. La Hospitalizaci\u00f3n a Domicilio (HAD) es una \nmodalidad de ingreso alternativa que puede resultar de gran \nutilidad en momentos de estr\u00e9s sanitario como la pandemia \nde COVID-19. En el presente trabajo se recoge el manejo de los \npacientes ingresados con COVID-19 en HAD en dos hospitales \ncomarcales espa\u00f1oles durante dos a\u00f1os.\nM\u00e9todos. Se realiz\u00f3 un estudio descriptivo, observacional \ny retrospectivo de los pacientes ingresados en HAD con CO -\nVID-19. Posteriormente se realiz\u00f3 un an\u00e1lisis para caracterizar \na los pacientes que fallecieron en HAD o a 30 d\u00edas del alta y \notro para comparar el manejo entre la primera fase del estudio \n(2020) y la segunda (2021 y parte de 2022).\nResultados. Se reclutaron 167 pacientes. Un 52,1% se \ntrasladaron para vigilar que continuaban mejorando frente a \nun 40,7% en los que se hizo para vigilar que no empeoraran. \nLos pacientes que fallecieron en HAD resultaron m\u00e1s ancianos \n(87,5 a\u00f1os de media), m\u00e1s com\u00f3rbidos y con mayor probabili -\ndad de ser no reanimables en caso de paro cardiaco (No RCP) \n(85%). En la segunda fase del estudio se ingresaron pacientes \nm\u00e1s ancianos, m\u00e1s com\u00f3rbidos y en mayor grado No RCP que \nlos ingresados en 2020.\nConclusiones.  La HAD es un recurso \u00fatil para aumentar \nla resiliencia de los sistemas sanitarios en casos de estr\u00e9s como \nsupuso la enfermedad por COVID-19. El desarrollo y crecimien -\nto de las unidades ya existentes, as\u00ed como la creaci\u00f3n de otras \nnuevas all\u00e1 donde no existan, puede ser una herramienta b\u00e1si -\nca para la medicina del futuro.\nPalabras clave: Hospitalizaci\u00f3n a Domicilio; COVID-19; Coronavirus; Mor -\ntalidad; Epidemia; Pandemia. \nCorrespondencia:\nDavid S\u00e1nchez Fabra. \nC/ San Rafael 42, 3\u00baB, Zaragoza (50017) Espa\u00f1a.\nE-mail: davidsanchezfabra@gmail.comManejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: \nqu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al.\nRev Esp Quimioter 2023;36(4): 392-399393motivo de ingreso en el hospital, motivo de traslado a HAD y \nestado en ese momento, de uso de oxigenoterapia, de indi -\ncaci\u00f3n de No Reanimaci\u00f3n cardiopulmonar en caso de paro \ncard\u00edaco (No RCP) o Limitaci\u00f3n del Esfuerzo Terap\u00e9utico (LET) \ny de resultados (estancia, mortalidad durante el ingreso, re -\ningreso en el hospital desde HAD y mortalidad o reingreso a \nlos 30 d\u00edas del alta; todo ello para causa relacionada o no con \nla COVID-19). Las variables de mejor\u00eda antes del traslado se \ndieron como afirmativas si quedaba reflejado o impl\u00edcito en \nla historia cl\u00ednica o los registros inform\u00e1ticos que durante la \nestancia en planta se dio mejor\u00eda cl\u00ednica, gasom\u00e9trica (pO2 \no SaO2), radiol\u00f3gica (radiograf\u00edas sucesivas) o de laboratorio \n(descenso de reactantes); y negativa si hubo empeoramien -\nto o, simplemente, no pudo objetivarse mejor\u00eda (el paciente \nse traslad\u00f3 en un estado similar al ingreso, el paciente fue \ndirectamente a domiciliaria sin pasar un solo d\u00eda en el hos -\npital o no se pidieron pruebas de control antes de trasladarlo \na HAD). Rellenamos las variables de No RCP o LET gracias a \nla interpretaci\u00f3n de la lectura comprensiva de la historia y \ncurso evolutivo de cada paciente, dejando como datos perdi -\ndos aquellos en los que no fue sencillo determinarlo. Para las \nvariables de motivo de traslado a HAD en cada paciente pudo \ndarse m\u00e1s de una. La recopilaci\u00f3n de datos se realiz\u00f3 por va -\nrios investigadores m\u00e9dicos a trav\u00e9s de la lectura de historias \ncl\u00ednicas y registros inform\u00e1ticos.\nRealizamos un estudio descriptivo, observacional y re -\ntrospectivo. Posteriormente llevamos a cabo dos an\u00e1lisis adi -\ncionales de inter\u00e9s cient\u00edfico. En primer lugar, comparamos \nlas caracter\u00edsticas de los casos que hab\u00edan fallecido durante el \ningreso en HAD o a los 30 d\u00edas del alta de HAD frente a los \nque no, en aras de intentar objetivar qu\u00e9 tipo de paciente de \nHAD ha fallecido en este periodo de estudio. En segundo lugar, \nrealizamos un estudio comparativo entre la primera fase de la \npandemia respecto a la segunda, tomando como punto de cor -\nte el 1/1/2021. Se decidi\u00f3 esta fecha en particular por ser con -\nsiderada por los autores como un punto de inflexi\u00f3n en la pan -\ndemia por tres motivos: la superaci\u00f3n de la primera y segunda \nolas, el inicio de la vacunaci\u00f3n en diciembre de 2020 y la po -\nsibilidad de asumir que la informaci\u00f3n cl\u00ednica y la experiencia \nde los facultativos a la hora de tratar la COVID-19 resultaron \nsignificativamente superiores a lo largo de 2021. Para este \u00falti -\nmo an\u00e1lisis excluimos al HGO por existir datos perdidos.\nPara el an\u00e1lisis descriptivo usamos porcentajes, medias y \ncuartiles. Para el contraste de hip\u00f3tesis se utilizamos Chi cua -\ndrado para las variables cualitativas y T de student para las \nvariables normales cuantitativas. Empleamos el programa es -\ntad\u00edstico SPSS\u00a9 versi\u00f3n 15. Se obtuvo autorizaci\u00f3n del Comit\u00e9 \n\u00c9tico de Navarra.\nRESULTADOS\nCaracter\u00edsticas de los pacientes y del curso en hospi -\ntalizaci\u00f3n convencional. Se reclutaron 167 pacientes. El HRS \naport\u00f3 el 85,6% de la muestra. Ambos hospitales se consideran \ncomarcales y atienden un \u00e1rea rural de similares caracter\u00edsti -\ncas. La comorbilidad m\u00e1s frecuente fue la demencia (35,9%) y INTRODUCCI\u00d3N\nLa Hospitalizaci\u00f3n a Domicilio (HAD) se ha definido como \nuna modalidad de ingreso alternativa a la hospitalizaci\u00f3n con -\nvencional que puede producir similares o mejores resultados en \ncuanto a mortalidad, reingreso o estancia [1]. Su utilidad para \nreducir el consumo de los recursos del hospital ha sido demos -\ntrada tambi\u00e9n en episodios de epidemia de gripe [2]. En 2020, la \npandemia de COVID-19 fue un \u00abcisne negro\u00bb que puso a prueba \nlos sistemas sanitarios mundiales, haci\u00e9ndose necesario cono -\ncer si la HAD pudo ser o ser\u00e1 en el futuro un elemento decisivo \na la hora de afrontar tales retos.\nHasta la fecha, y pese a la enorme bibliograf\u00eda existente \nsobre la COVID-19, son pocos los trabajos que analizaron su \nmanejo en r\u00e9gimen de HAD. Al inicio de la pandemia ya se vio \nque la HAD tambi\u00e9n pod\u00eda tener utilidad y ser segura a la hora \nde tratar la COVID-19 [3,4]. Aunque fueron series peque\u00f1as y \npreliminares se pudo elaborar el primer documento de consen -\nso [5]. Otros estudios posteriores intentaron dirimir los factores \nde riesgo asociados a reingreso y la verdadera magnitud de la \ndescarga hospitalaria que produjo [6-8].\nSin embargo, la mayor\u00eda de los trabajos analizaron solo el \nmanejo de la HAD en etapas incipientes de la pandemia y, sobre \ntodo, como factor de reducci\u00f3n de ingresos. Pese a la enorme \npotencialidad de la HAD para hacer m\u00e1s resilientes los sistemas \nsanitarios durante momentos de estr\u00e9s como la pandemia de \nCOVID-19 [9], todav\u00eda se hace necesario aumentar el conoci -\nmiento de lo que supuso la HAD durante la pandemia.\nEn el presente trabajo exponemos los datos del manejo real \nde la HAD en dos hospitales comarcales que dan cobertura a la \nzona sur de Navarra durante un periodo que comprende tanto \n\u00e9pocas de estr\u00e9s como otras de menor presi\u00f3n asistencial (des -\nde marzo de 2020 hasta marzo de 2022). Se registraron todos \nlos pacientes atendidos en HAD con diagn\u00f3stico de COVID-19. \nLos objetivos del mismo son detallar qu\u00e9 tipo de pacientes se \natendieron, cu\u00e1les fueron los resultados y qu\u00e9 modelos men -\ntales de toma de decisiones llevaron a cabo los facultativos en \ndicho contexto.\nPACIENTES Y M\u00c9TODOS\nInclu\u00edmos todos los casos mayores de 18 a\u00f1os con diag -\nn\u00f3stico de presunci\u00f3n de COVID-19, infecci\u00f3n por coronavi -\nrus o SARS-COV-2 ingresados en r\u00e9gimen de HAD entre marzo \nde 2020 y marzo de 2022. Excluimos aquellos pacientes en los \nque, finalmente, e independientemente de las pruebas, el m\u00e9 -\ndico cl\u00ednico decidi\u00f3 que no ten\u00edan infecci\u00f3n por coronavirus. \nLos criterios de ingreso en HAD fueron los mismos que se em -\npleaban en la pr\u00e1ctica cl\u00ednica habitual para otras enfermeda -\ndes. Los casos se reclutaron del Hospital Reina Sof\u00eda de Tudela \n(HRS) y del Hospital Garc\u00eda Orcoyen de Estella (HGO), ambas \npoblaciones sitas en Navarra.\nRegistramos variables demogr\u00e1ficas, cl\u00ednicas, de comor -\nbilidades, de procedencia de ingreso (desde urgencias, des -\nde planta de hospitalizaci\u00f3n o directamente en el domicilio), Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: \nqu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al.\nRev Esp Quimioter 2023;36(4): 392-399394Manejo en HAD . La mayor\u00eda de traslados se hicieron por \npatolog\u00eda respiratoria por COVID-19 (77,2%) con un tiempo \nmedio de 10 d\u00edas desde el inicio de los s\u00edntomas. Objetivar al -\ng\u00fan tipo de mejor\u00eda no fue necesario para los cl\u00ednicos en un \n41,3% de los casos. Un 52,1% de los pacientes se trasladaron \npara vigilar que continuaba la recuperaci\u00f3n frente a un 40,7% un 46,5% de los pacientes fueron claramente No RCP desde el \nprincipio del ingreso. La estancia media en el hospital fue de \n5,4 d\u00edas, siendo de 7,1 en HAD. Respecto al uso de ox\u00edgeno, un \n65,9% de los pacientes precisaron oxigenoterapia en HAD, la \nmayor\u00eda de ellos con flujos bajos. En las Tablas 1 y 2 se recoge \ninformaci\u00f3n m\u00e1s detallada.Variable Valor\nHospital; HRS n (%) 143 (85,6)\nSexo mujer; n (%) 80 (47,9)\nEdad; media (p25/p50/p75) 75,5 (63/81/88)\nHAD fuera de su domicilio habitual; n (%) 8 (4,8)\n\u00cdndice de Charlson; media (p25/p50/p75) (n=165) 4,5 (0/5/7)\nDemencia; n (%) 60 (35,9)\nInsuficiencia card\u00edaca; n (%) 46 (27,5)\nDiabetes; n (%) 40 (24)\nInstitucionalizados; n (%) 57 (34,1)\nIngresa en el hospital por NAC COVID; n (%) 100 (59,9)\nIngresa en el hospital por causa respiratoria asociada a COVID; n (%) 135 (80,8)\nOtras causas de ingreso hospitalario\nNAC bacteriana; n (%) 24 (14,4)\nOtras infecciones; n (%) 21 (12,6)\nFiebre; n (%) 15 (9)\nCardiol\u00f3gica; n (%) 14 (8,4)\nFracaso renal agudo; n (%) 12 (7,2)\nDigestivas; n (%) 11 (6,6)\nETEV; n (%) 5 (3)\nCOVID nosocomial; n (%) 10 (6)\nCOVID fue un hallazgo casual; n (%) 22 (13,2)\nIngreso en UCI; n (%) 1 (0,6)\nDesaislado durante la estancia; n (%) 5 (3)\nEstancia en el hospital; media (p25/p50/p75) (n=109) 5,4 (2/5/8)\nEstancia en HAD; media (p25/p50/p75) (n=137) * 7,1 (4,5/6/8)\nPacientes no RCP e indicaci\u00f3n de LET**\nPaciente claramente no RCP desde el principio; n (%) (n=159) 74 (46,5)\nPaciente en el que se indica LET desde el principio; n (%) (n=166) 24  (14,5)\nPaciente en el que se indica LET en alg\u00fan momento del curso evolutivo; n (%) 17 (10,2)\nPaciente en el que se indica LET desde el principio o en alg\u00fan momento del curso evolutivo; n (%) 39 (23,4)Tabla 1  Caracter\u00edsticas generales de los pacientes. \nSalvo que se especifique con contrario la n ser\u00e1 de 167 pacientes. Siglas: HRS, Hospital Reina Sof\u00eda; p25/p50/p75, percentiles \n25, 50 y 75; HAD, Hospitalizaci\u00f3n a Domicilio; NAC, Neumon\u00eda Adquirida en la Comunidad; ETEV, Enfermedad Tromboemb\u00f3li -\nca Venosa; UCI, Unidad de Cuidados Intensivos; RCP, Reanimaci\u00f3n Cardiopulmonar; LET, Limitaci\u00f3n del Esfuerzo Terap\u00e9utico. \n*Para el c\u00e1lculo se excluyen exitus durante su estancia en el hospital. ** Se excluyen los casos en los que fue dif\u00edcil precisar o \nresponder a dicha pregunta.Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: \nqu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al.\nRev Esp Quimioter 2023;36(4): 392-399395muy avanzada edad, muy com\u00f3rbido y en la mayor\u00eda de los \ncasos considerado No RCP o LET. La inercia de manejo en la \nsegunda parte del periodo respecto a la primera, lo que tradu -\ncir\u00eda un cambio de comportamiento a la hora de usar la HAD, \nsugiere que con el paso del tiempo la HAD se ha empleado m\u00e1s \npara pacientes de mayor edad, m\u00e1s com\u00f3rbidos y en fases m\u00e1s \ntempranas de la enfermedad, muchas veces sin haber com -\nprobado mejor\u00eda antes de cursar el ingreso en la misma. Esto \nimplicar\u00eda que se ha optimizado su uso para los pacientes que \nrealmente lo necesitaban, a diferencia del principio de la pan -\ndemia, cuando todav\u00eda no se ten\u00eda tanta experiencia sobre el \nmanejo de la enfermedad.\nEn comparaci\u00f3n con otros art\u00edculos similares, nuestro tra -\nbajo comprende un periodo mucho m\u00e1s largo que los dem\u00e1s. \nLos datos recogidos en dichos trabajos son muy heterog\u00e9neos \naunque en algunos supuestos coinciden con los nuestros. En \nel trabajo de Lwin et al [3], muy precoz al inicio de la pande -\nmia, con una edad media similar a la de nuestra muestra, 7 de \nlos 23 los pacientes ingresados en HAD requirieron reingreso \nen el hospital y solo uno falleci\u00f3. El uso de ox\u00edgeno fue ex -\nclusivamente hospitalario. En la serie de Peric\u00e0s et al [4], ya \ncon 63 pacientes, solo uno recibi\u00f3 ox\u00edgeno en HAD. La edad \nmedia de la muestra fue 51 a\u00f1os, un 4,8% de los pacientes \nreingresaron y ninguno falleci\u00f3, lo que contrasta con nuestros \ndatos (edad media de 75,5 a\u00f1os, 10,2% de reingresos y 24% \nde mortalidad). En otra serie espa\u00f1ola de gran tama\u00f1o [8] se \nobjetiv\u00f3 la gran capacidad de HAD para aumentar la resiliencia \nde los sistemas sanitarios. La muestra fue de 917 casos, los re -\ningresos fueron un 6,2% y solo falleci\u00f3 una paciente, aunque, \nnuevamente, los criterios de admisi\u00f3n de ingresos selecciona -\nron pacientes m\u00e1s j\u00f3venes y menos graves que los recogidos \nen nuestro trabajo. En otros estudios internacionales [10] se \nvio asimismo pacientes m\u00e1s j\u00f3venes y con mejores resultados. \nCabe rese\u00f1ar tambi\u00e9n en este punto la utilidad de los hoteles \ny otros edificios que se medicalizaron durante la pandemia y \nque resultaron de utilidad para aliviar la presi\u00f3n hospitalaria. en los que se hizo para vigilar que no empeoraran. El 10,2% \nde los casos tuvieron que reingresar en el hospital. La mayor\u00eda \nde reingresos y exitus hospitalarios fueron producidos por la \nCOVID-19 (Tabla 3).\nCaracter\u00edsticas del paciente diagnosticado de CO -\nVID-19 que falleci\u00f3 en HAD. El paciente fallecido en HAD \ntuvo m\u00e1s edad, comorbilidades, demencia y probabilidad de \nestar institucionalizado que el que sobrevivi\u00f3. Asimismo, tuvo \nm\u00e1s estancia en el hospital, sin existir diferencias en cuanto a \nla estancia en HAD; y fue menos probable objetivar en \u00e9l alg\u00fan \ntipo de mejor\u00eda antes del traslado. La probabilidad de ser No \nRCP o iniciar LET desde el principio o durante el curso fue mu -\ncho mayor en los pacientes fallecidos (Tabla 4).\nComparativa entre fases de la epidemia. Para el an\u00e1li -\nsis solo se incluyeron los casos de HRS. Los pacientes diagnos -\nticados de COVID-19 e ingresados en r\u00e9gimen de HAD durante \n2020 fueron m\u00e1s j\u00f3venes, menos com\u00f3rbidos, llevaban m\u00e1s \nd\u00edas desde el inicio de los s\u00edntomas y fue m\u00e1s probable en -\ncontrar mejor\u00eda en ellos antes de trasladarlos a HAD respecto \na los pacientes ingresados en 2021 y principios de 2022. Fue \ntambi\u00e9n mucho menos probable que se consideraran No RCP \no se iniciaran medidas de LET al principio o durante el ingre -\nso, sin que se encontraran diferencias en cuanto a la estancia \nhospitalaria o en HAD. Aunque hubo cierta tendencia a encon -\ntrar un mayor grado de mortalidad en los pacientes de 2021 \ny principios de 2022, esta no alcanz\u00f3 significaci\u00f3n estad\u00edstica \n(Tabla 5).\nDISCUSI\u00d3N\nEn el presente trabajo encontramos datos muy rese\u00f1ables \nsobre la pr\u00e1ctica real de asistencia a los pacientes con CO -\nVID-19 en r\u00e9gimen de HAD durante un largo periodo de tiem -\npo, objetivando que el prototipo de paciente fallecido fue de Variable Valor\nOCD previa; n (%) 16 (9,6)\nPrecis\u00f3 ox\u00edgeno en HAD; n (%) 110 (65,9)\nPrecis\u00f3 prescripci\u00f3n de ox\u00edgeno al alta; n (%) (n=137)* 38 (27,7)\nD\u00edas con oxigenoterapia durante el ingreso (hospital y HAD); media (p25/p50/p75) (n=117) 10,4 (6/10/14)\nNecesidad de oxigenoterapia (litros por minuto) Basal <2 2 a 5 5 a 10 10 a 15 OAF\nFlujo m\u00e1ximo de ox\u00edgeno administrado en el hospital; n (%)(n=128) 36 (28,1) 40 (31,3) 33 (25,8) 10 (7,8) 8 (3,3) 1 (0,8)\nFlujo de ox\u00edgeno necesario al traslado a HAD; n (%) 86 (51,5) 44 (26,3) 29 (17,4) 6 (3,6) 1 (0,6) 0\nFlujo m\u00e1ximo de ox\u00edgeno administrado en HAD; n (%) (n=156) 47 (29,9) 67 (43) 34 (21,8) 5 (3,2) 3 (1,9) 0Tabla 2  Uso de oxigenoterapia\nSalvo que se especifique con contrario la n ser\u00e1 de 167 pacientes. OCD, Oxigenoterapia Cr\u00f3nica Domiciliaria; HAD, Hospitalizaci\u00f3n a Domicilio; p25/p50/p75, percentiles \n25, 50 y 75. OAF, Ox\u00edgeno a Alto Flujo. \n*Se excluyeron pacientes fallecidos o reingreso al hospital.Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: \nqu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al.\nRev Esp Quimioter 2023;36(4): 392-399396Variable Valor\nIngreso directo desde urgencias; n (%) 7 (4,2)\nIngreso directo en el domicilio sin pasar por el hospital; n (%) 58 (34,7)\nIngreso desde planta de hospitalizaci\u00f3n; n (%) 102 (61,1)\nMotivo de traslado asociado a problemas por COVID respiratorios; n (%) 129 (77,2)\nMotivo de traslado asociado a problemas por COVID no respiratorios; n (%) 32 (19,2)\nIngreso para vigilar si hay empeoramiento en fases muy incipientes de la enfermedad o cuando no hay suficiente informaci\u00f3n del curso; n (%) 74 (44,3)\nAntes del traslado se objetiv\u00f3 alg\u00fan tipo de mejor\u00eda; n (%) 98 (58,7)\nCl\u00ednica; n (%) 95 (56,9)\nDe laboratorio; n (%) 70 (41,9)\nGasom\u00e9trica; n (%) (n=144) 36 (25)\nRadiol\u00f3gica; n (%) (n=144) 36 (25)\nD\u00edas desde s\u00edntomas hasta ingreso en HAD; media (p25/p50/p75) (n=148) 10 (5/10/13,7)\nD\u00edas desde la positivizaci\u00f3n de la PCR hasta el ingreso en HAD; media (p25/p50/p75) (n=165) 8,3 (3/7/12)\nMotivo de traslado a HAD (un paciente puede tener varios)\nVigilancia por parte de un especialista de que contin\u00faa la recuperaci\u00f3n; n (%) 87 (52,1)\nVigilancia estrecha por si hay empeoramiento relacionado con la NAC o SDRA estrictamente relacionados con el COVID; n (%) 68 (40,7)\nContinuar tratamientos con posolog\u00eda o uso hospitalario no relacionados con el COVID, incluyendo TADE; n (%) 46 (27,6)\nContinuar tratamientos con posolog\u00eda o uso hospitalario relacionados con el COVID; n (%) 38 (22,8)\nDescompensaci\u00f3n de comorbilidades; n (%) 21 (12,6)\nCuidados paliativos; n (%) 13 (7,8)\nSobreinfecci\u00f3n o aparici\u00f3n de nuevas enfermedades infecciosas; n (%) 13 (7,8)\nNecesidad de oxigenoterapia a altos flujos; n (%) 8 (4,8)\nTratamiento y control de la ETEV; n (%) 6 (3,6)\nOtros; n (%) 5 (3)\nReingreso en el hospital desde HAD; n (%) 17 (10,2)\nRelacionado con el COVID; n (%) 9 (52,9)\nNo relacionado con el COVID; n (%) 7 (41,2)\nPetici\u00f3n del paciente o familiares; n (%) 1 (5,9)\nD\u00edas hasta reingreso; media (P25/50/75) 4,4 (2/3/5,5)\nExitus en el hospital o en HAD; n (%) 31 (18,6)\nProducido por COVID; n (%) 25 (80,6)\nD\u00edas desde ingreso en HAD hasta exitus en el hospital o en HAD; media (p25/p50/p75) 9,3 (3/8/15)\nExitus a 30 d\u00edas del alta; n (%) (n=135) 9 (6,7)\nProducido por COVID; n (%) 5 (55,6)\nD\u00edas desde alta hasta exitus a 30 d\u00edas; media (P25/50/75) 13,25 (7,25/11,5/20,5)\nReingreso a 30 d\u00edas del alta; n (%) (n=132) 10 (7,6)\nProducido por COVID; n (%) 5 (50)\nD\u00edas desde alta hasta reingreso; media (P25/50/75) 10,3 (2/10,5/14)Tabla 3  Manejo en Hospitalizaci\u00f3n a Domicilio\nSalvo que se especifique con contrario, la n ser\u00e1 de 167 pacientes. Siglas: HAD, Hospitalizaci\u00f3n a Domicilio; PCR, Reacci\u00f3n en Cadena de la Polimerasa; NAC, Neumon\u00eda \nAdquirida en la Comunidad; SDRS, S\u00edndrome de Distr\u00e9s Respiratorio del Adulto; TADE, Tratamiento Antibi\u00f3tico Domiciliario Endovenoso; ETEV, Enfermedad Tromboemb\u00f3li -\nca Venosa; p25/p50/p75, percentiles 25, 50 y 75.Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: \nqu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al.\nRev Esp Quimioter 2023;36(4): 392-399397Fallecidos \n(n=40)No fallecidos \n(n=127)p\nEdad; media (p25/p50/p75) 87,5 (83,8/88,5/92,0) 71,7 (61/76/86) <0,001\n\u00cdndice de Charlson; media (p25/p50/p75) 7,1 (6/7/8) 3,6 (0/4/6) <0,001\nDemencia; n (%) 29 (72,5) 31 (24,4) <0,001\nInstitucionalizados; n (%) 28 (70) 29 (22,8) <0,001\nD\u00edas desde s\u00edntomas hasta ingreso en HAD; media (n=148) (p25/p50/p75) 6,9 (1/7/12) 11 (6/11/14) 0,007\nEstancia en el hospital; media 8,3 (3/8/10,5) 5 (2/4/7) 0,017\nIngresa en el hospital por NAC COVID; n (%) 18 (45) 82 (64,6) <0,028\nAntes del traslado se objetiv\u00f3 mejor\u00eda; n (%)* 11 (27,5) 87 (68,5) <0,001\nPaciente claramente no RCP desde el principio; n (%) (n=159) 34 (85) 40 (31,5) <0,001\nPaciente en el que se indica LET desde el principio; n (%) (n=166) 14 (35) 10 (7,9) <0,001\nPaciente en el que se indica LET en alg\u00fan momento del curso evolutivo; n (%) 16 (40) 1 (0,8) <0,001\nPaciente en el que se indica LET desde el principio o en alg\u00fan momento del curso evolutivo; n (%) 28 (70) 11 (8,1) <0,001Tabla 4  An\u00e1lisis de la mortalidad: Exitus durante el ingreso o a los 30 d\u00edas del alta de HAD.\nEjemplo de lectura de tabla: la demencia se dio en 29 (72,5%) de los fallecidos respecto a 31 (24,4%) en los no fallecidos con una p <0,001. Salvo que se especifique con \ncontrario la n ser\u00e1 de 167 pacientes.  p25/p50/p75, percentiles 25, 50 y 75; HAD, Hospitalizaci\u00f3n a Domicilio; NAC, Neumon\u00eda Adquirida en la Comunidad; RCP, Reanima -\nci\u00f3n Cardiopulmonar; LET, Limitaci\u00f3n del Esfuerzo Terap\u00e9utico; No hubo diferencias en cuanto a sexo, a si el COVID fue un hallazgo casual, si el COVID fue nosocomial, a la \nestancia en r\u00e9gimen de HAD o a los d\u00edas desde positividad de la PCR hasta ingreso en HAD. \n* La significaci\u00f3n estad\u00edstica se dio para las cuatro variables de mejor\u00eda cl\u00ednica (cl\u00ednica, de laboratorio, gasom\u00e9trica o radiol\u00f3gica).\nNosotros tuvimos un 4,8% de la muestra en dicha situaci\u00f3n \n(teniendo en cuenta que solo un peque\u00f1o porcentaje de nues -\ntros pacientes derivados a los hoteles estaban cubiertos por un \ningreso de HAD), pero existe tambi\u00e9n una serie espa\u00f1ola con \n516 pacientes con dicho r\u00e9gimen de ingreso de los cuales solo \nun 5,4% reingresaron [11].\nSobre el manejo de la oxigenoterapia, con un 65,9% de \nprescripci\u00f3n durante el ingreso en HAD en nuestro trabajo des -\ntacamos haber hecho un amplio uso de la misma, muy superior \nal de las otras series publicadas [3,4,6,8].\nRespecto al an\u00e1lisis de las caracter\u00edsticas asociadas a los \ntraslados a HAD, creemos haber aportado datos no recogidos \nen la bibliograf\u00eda consultada y que son de gran utilidad para \ncomprender lo que ha significado dicha modalidad de ingreso \ndurante este periodo en nuestro medio. Resulta rese\u00f1able que \nsolo se objetiv\u00f3 mejor\u00eda en un 58,7% de los casos antes del \ntraslado, y que la mejor\u00eda gasom\u00e9trica o radiol\u00f3gica solo fue \nnecesaria un 25% de las ocasiones para los facultativos. No \nen vano, respecto a los dos principales motivos de traslado a \nHAD, frente a un 52,1% de los casos en los que se hizo para \nvigilar que continuaba la recuperaci\u00f3n, en un 44,3% pareci\u00f3 \nhacerse sabiendo que el paciente pod\u00eda empeorar pero prefi -\nriendo tenerlo en HAD pese a ello respecto a la hospitalizaci\u00f3n \nconvencional o al manejo ambulatorio (alta), lo que pudo tener \ngran importancia a la hora de aliviar la presi\u00f3n asistencial. En \nrelaci\u00f3n con las variables de reingreso y exitus durante la es -\ntancia o a 30 d\u00edas, aunque son superiores a los de otras series, creemos que son unos resultados esperables asumiendo las \ncaracter\u00edsticas de la poblaci\u00f3n atendida (edad avanzada, co -\nmorbilidad\u2026). En el caso de la mortalidad, y enlazando con la \nTabla 4, encontramos que los pacientes que fallecieron en HAD \nfueron aquellos de los que cabr\u00eda esperar un exitus en caso de \ncontraer la COVID-19, ya no solo por tener una media de edad \ny de \u00cdndice de Charlson de 87,5 a\u00f1os y 7,1 puntos, respecti -\nvamente, sino por el hecho tambi\u00e9n de que un 85% fueron \nclaramente No RCP desde el inicio y en un 70% de los casos se \nindic\u00f3 LET durante alg\u00fan momento del curso evolutivo. Estos \ndatos son, a nuestro parecer, novedosos y de gran relevancia, \nya que este tipo de variables no suelen recogerse en los traba -\njos observacionales de cualquier enfermedad que estudian la \nmortalidad y, sin ellas, ser\u00eda imposible evaluar adecuadamente \n\u00abqui\u00e9n se est\u00e1 muriendo realmente\u00bb en cada supuesto. En este \ncaso, por ejemplo, los datos parecen orientar a que los resul -\ntados adversos del ingreso en HAD (reingreso o mortalidad), \nestuvieron controlados o asumidos por las decisiones cl\u00ednicas \nque se tomaron al respecto, primando, quiz\u00e1, el confort perso -\nnal y familiar o la salvaguarda del \u00edndice de ocupaci\u00f3n hospita -\nlario sobre otra serie de medidas que, seg\u00fan se interpreten, po -\ndr\u00edan considerarse desde f\u00fatiles hasta obstinaci\u00f3n terap\u00e9utica.\nPor \u00faltimo, en lo tocante a las diferencias entre ambos \nperiodos (2020 o 2021 en adelante), creemos haber detecta -\ndo las diferencias de manejo de la COVID-19 en r\u00e9gimen de \nHAD secundarias a los factores que fueron diferentes entre un \nmomento y otro, a saber, el conocimiento recabado, la inmu -Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: \nqu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al.\nRev Esp Quimioter 2023;36(4): 392-399398Periodos de estudio 2020 2021 y 2022 p\nN\u00famero de pacientes, n (%) 74 (51,7) 69 (48,3) -\nEdad; media (p25/p50/p75) 68,5 (53/67,5/86) 81 (75,5/86/90) <0,001\n\u00cdndice de Charlson; media (p25/p50/p75) 2,85 (0/0/6) 5,6 (4/6/8) <0,001\nDemencia; n (%) 11 (14,9) 31 (44,9) <0,001\nInstitucionalizados; n (%) 11 (14,9) 25 (36,2) 0,003\nD\u00edas desde s\u00edntomas hasta ingreso en HAD; media (n=148) (p25/p50/p75) 11,8 (9/12/14) 8,4 (1,5/6/12) 0,003\nIngresa en el hospital por NAC COVID; n (%) 58 (78,4) 37 (53,6) 0,002\nAntes del traslado se objetiv\u00f3 mejor\u00eda; n (%) 55 (74,3) 37 (53,6) 0,01\nCl\u00ednica; n (%) 55 (74,3) 34 (49,3) 0,002\nDe laboratorio; n (%) 40 (54,1) 24 (34,8) 0,021\nGasom\u00e9trica; n (%) (n=122)* 30 (44,1) 2 (3,7) <0,001\nRadiol\u00f3gica; n (%)  (n=122) * 25 (36,8) 8 (14,8) 0,007\nPaciente claramente no RCP desde el principio; n (%) (n=143) 20 (27) 35 (50,7) <0,001\nPaciente en el que se indica LET en alg\u00fan momento del curso evolutivo; n (%) 2 (2,7) 14 (20,7) 0,001\nPaciente en el que se indica LET desde el principio o en alg\u00fan momento del curso evolutivo; n (%) 5 (6,8) 14 (20,3) 0,017\nExitus en el hospital o en HAD; n (%) 8 (10,8) 14 (20,3) 0,116\nExitus a los 30 d\u00edas del alta; n (%) 2 (3) 6 (10,9) 0,082Tabla 5  Comparativa entre periodos, 2020 (1/3/20 \u2013 31/12/20) frente 2021 y 2022 (1/1/21 \u2013 31/3/22).\nSalvo que se especifique con contrario la n ser\u00e1 de 167 pacientes. p25/p50/p75, percentiles 25, 50 y 75; HAD, Hospitalizaci\u00f3n a Domicilio; NAC, Neumon\u00eda Adquirida en \nla Comunidad; RCP, Reanimaci\u00f3n Cardiopulmonar; LET, Limitaci\u00f3n del Esfuerzo Terap\u00e9utico. No hubo diferencias en cuanto a sexo, que el COVID fuera un hallazgo casual, \nCOVID nosocomial, inicio de LET desde el principio, traslado a HAD con oxigenoterapia, reingreso al hospital desde HAD, reingreso a 30 d\u00edas del alta, estancia hospitalaria \no en HAD, d\u00edas de oxigenoterapia o d\u00edas hasta exitus extrahospitalario y reingreso.\n*Se excluyeron los casos en los que las pruebas gasom\u00e9tricas o radiol\u00f3gicas no fueron relevantes para evaluar el curso de la enfermedad.\nnidad adquirida por la poblaci\u00f3n (natural o tras la vacunaci\u00f3n), \nla presi\u00f3n asistencial o la posible atenuaci\u00f3n de la virulencia \ndel virus. A este respecto, es necesario destacar que pese a que \nhubo una tendencia no significativa a encontrar mayor mor -\ntalidad en la segunda fase del periodo de estudio, tambi\u00e9n es -\ntos pacientes fueron m\u00e1s mayores, m\u00e1s com\u00f3rbidos o tuvieron \nmayor indicaci\u00f3n de No RCP o LET, todo esto \u00faltimo siendo \nestad\u00edsticamente significativo. La interpretaci\u00f3n que hacemos \nde estos datos ser\u00eda que durante 2020 la HAD se emple\u00f3 para \npacientes con menores probabilidades basales de fallecer, que \nestaban menos graves, llevaban m\u00e1s d\u00edas de evoluci\u00f3n o en los \nque se hab\u00eda constatado con mayor frecuencia mejor\u00eda cl\u00ednica \ndurante el periodo de hospitalizaci\u00f3n. Por el contrario, en el \nperiodo de 2021 y principios de 2022 la HAD tuvo mayor uti -\nlidad para atender a pacientes m\u00e1s fr\u00e1giles en los que poder \nindicar LET o asistencia al final de la vida. Al tratarse de un es -\ntudio observacional de todos los casos atendidos en el hospital \nHRS, creemos que en esta tabla se recoge con fidelidad c\u00f3mo \nse adapt\u00f3 la HAD a las necesidades del hospital en cada fase de \nla pandemia.\nNuestro trabajo tiene algunas limitaciones. Adem\u00e1s de \ntodas las asumibles a la naturaleza de los estudios observa -cionales, el hecho de haber incluido solo los datos de dos hos -\npitales comarcales, perdiendo incluso los pacientes de uno de \nellos para el an\u00e1lisis de la Tabla 5, no recoge los usos que se \nhayan podido hacer en otros lugares de Espa\u00f1a. Sin embargo, \nel trabajo tiene algunas fortalezas como el disponer de un ta -\nma\u00f1o muestral importante, el haber recogido todos los casos \ndurante un largo periodo de tiempo, el examen del prototipo \nde paciente que falleci\u00f3 a trav\u00e9s de la lupa de las \u00f3rdenes de \nNo RCP o LET, elemento que se echa en falta en la mayor\u00eda de \nestudios observacionales, especialmente en relaci\u00f3n con esta \npandemia, o la gran cantidad de datos aportados, pese a que \nalgunos sean interpretativos, sobre lo que ha supuesto este \nmanejo hol\u00edstico de la COVID-19 en r\u00e9gimen de HAD.\nA modo de conclusi\u00f3n, la HAD supuso en nuestro medio \nun elemento crucial a la hora de luchar contra la pandemia \nde COVID-19, tanto en sus momentos m\u00e1s crudos como en las \nfases posteriores, en las que la enfermedad ha sido integrada \ncomo \u00abuna m\u00e1s\u00bb dentro de nuestra pr\u00e1ctica cl\u00ednica habitual. \nCompartimos los pensamientos de otros autores que han de -\nfinido la HAD como un recurso indispensable de cara al futuro \npor su capacidad de aumentar la resiliencia de los sistemas sa -\nnitarios, su seguridad, su versatilidad, su r\u00e1pida escalabilidad y Manejo de la pandemia de COVID-19 en hospitalizaci\u00f3n domiciliaria en dos hospitales comarcales espa\u00f1oles: \nqu\u00e9 signific\u00f3, qui\u00e9nes atendimos, qui\u00e9n falleci\u00f3 y como evolucion\u00f3 la asistencia a lo largo del tiempoD. S\u00e1nchez Fabra, et al.\nRev Esp Quimioter 2023;36(4): 392-399399su mayor coste-efectividad [9,12]. Integrar los enormes ade -\nlantos tecnol\u00f3gicos en cuanto a telemedicina podr\u00eda potenciar \ntodav\u00eda m\u00e1s la mejora los resultados de la atenci\u00f3n de pacien -\ntes en HAD [13]. Consideramos que el desarrollo y crecimiento \ntanto de las unidades ya existentes de HAD como la creaci\u00f3n \nde otras nuevas en las \u00e1reas de salud donde no existen pue -\nde resultar de vital importancia a la hora de hacer a nuestro \nsistema sanitario m\u00e1s robusto, especialmente en los tiempos \nvenideros en lo referente tanto a la aparici\u00f3n de nuevos retos \nde salud como a la probable necesidad de practicar la medicina \nen un contexto econ\u00f3mico y social de menor flujo de recursos.\nFINANCIACI\u00d3N\nLos autores declaran que no han recibido financiaci\u00f3n para \nla realizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener conflicto de intereses \nBIBLIOGRAF\u00cdA\n1.  Leong MQ, Lim CW, Lai YF. Comparison of Hospital-at-Home \nmodels: a systematic review of reviews. BMJ Open. 2021 Jan \n29;11(1):e043285. doi: 10.1136/bmjopen-2020-043285..\n2.  Salmer\u00f3n R\u00edos S, Lozoya Moreno S, Sol\u00eds Garc\u00eda Del Pozo J, Salme -\nr\u00f3n R\u00edos R, Plaza Carmona L, Abizanda Soler P. Unidad domiciliaria \nde atenci\u00f3n integral: Reducci\u00f3n de recursos hospitalarios durante \nbrotes de gripe [Comprehensive Care Home Unit: reduction of hos -\npital resources during influenza outbreaks]. Rev Esp Salud Publica. \n2018 Nov 2;92:e201811080. PMID: 30394367.\n3.  Lwin N, Burgess J, Johnston C, Johnson N, Chung S. Hospital-in-\nthe-Home experience of first 23 COVID-19 patients at a regional \nNSW hospital. Intern Med J. 2020 Oct;50(10):1271-1273. doi: \n10.1111/imj.15016. \n4.  Peric\u00e0s JM, Cucchiari D, Torrallardona-Murphy O, Calvo J, Serra -\nlab\u00f3s J, Alv\u00e9s, et al. Hospital at home for the management of CO -\nVID-19: preliminary experience with 63 patients. Infection. 2021 \nApr;49(2):327-332. doi: 10.1007/s15010-020-01527-z. \n5.  Bryant PA, Rogers BA, Cowan R, Bowen AC, Pollard J; Hospital-in-\nthe-Home Society Australasia. Planning and clinical role of acu -\nte medical home care services for COVID-19: consensus position \nstatement by the Hospital-in-the-Home Society Australasia. Intern \nMed J. 2020 Oct;50(10):1267-1271. doi: 10.1111/imj.15011. \n6.  Chou SH, McWilliams A, Murphy S, Sitammagari K, Liu TL, Hole C, \net al. Factors Associated With Risk for Care Escalation Among Pa -\ntients With COVID-19 Receiving Home-Based Hospital Care. Ann \nIntern Med. 2021 Aug;174(8):1188-1191. doi: 10.7326/M21-0409..\n7.  Llorens P, Moreno-P\u00e9rez O, Espinosa B, Garc\u00eda T, Pay\u00e1 AB, Sola S, et \nal. J. An integrated emergency department/hospital at home model \nin mild COVID-19 pneumonia: feasibility and outcomes after dis -\ncharge from the emergency department. Intern Emerg Med. 2021 \nSep;16(6):1673-1682. doi: 10.1007/s11739-021-02661-8. 8.  Nogu\u00e9s X, S\u00e1nchez-Martinez F, Castells X, D\u00edez-P\u00e9rez A, Sabat\u00e9 RA, \nPetit I, et al. Hospital-at-Home Expands Hospital Capacity During \nCOVID-19 Pandemic. J Am Med Dir Assoc. 2021 May;22(5):939-\n942. doi: 10.1016/j.jamda.2021.01.077. \n9.  Nicol\u00e1s D, Coloma E, Peric\u00e0s JM. Alternatives to conventional hos -\npitalisation that enhance health systems\u2019 capacity to treat CO -\nVID-19. Lancet Infect Dis. 2021 May;21(5):591-593. doi: 10.1016/\nS1473-3099(21)00093-1. \n10.  Sitammagari K, Murphy S, Kowalkowski M, Chou SH, Sullivan M, \nTaylor S, et al. Insights From Rapid Deployment of a \u201cVirtual Hospi -\ntal\u201d as Standard Care During the COVID-19 Pandemic. Ann Intern \nMed. 2021 Feb;174(2):192-199. doi: 10.7326/M20-4076. \n11.  Torrallardona-Murphy O, Peric\u00e0s JM, Rabaneda-Lombarte N, Cube -\ndo M, Cucchiari D, Calvo J, et al. Medicalized Hotel as an Alternati -\nve to Hospital Care for Management of Noncritical COVID-19. Ann \nIntern Med. 2021 Sep;174(9):1338-1340. doi: 10.7326/M21-1873. \n12.  Coloma E, Nicol\u00e1s D. Hospital at Home units in the post-COVID \n19 era. Eur J Clin Invest. 2020 Nov;50(11):e13390. doi: 10.1111/\neci.13390. \n13.  Silva AF, Tavakoli M. Domiciliary Hospitalization through Wea -\nrable Biomonitoring Patches: Recent Advances, Technical Cha -\nllenges, and the Relation to Covid-19. Sensors (Basel). 2020 Nov \n29;20(23):6835. doi: 10.3390/s20236835.ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/017.2023\nRev Esp Quimioter 2023;36(4): 400-407400Influencia de factores epidemiol\u00f3gicos y \ncl\u00ednicos en la reactogenicidad a la vacuna \nComirnaty\u00ae en trabajadores sanitarios de \nun hospital universitario espa\u00f1ol (estudio \nCOVIVAC)\nRESUMEN\nIntroducci\u00f3n.  Comirnaty\u00ae es una vacuna de ARNm con -\ntra el COVID-19 que se ha administrado a millones de personas \ndesde finales de 2020. Nuestro objetivo fue estudiar los facto -\nres epidemiol\u00f3gicos y cl\u00ednicos que influyen en la reactogeni -\ncidad y la limitaci\u00f3n funcional asociadas tras las dos primeras \ndosis de la vacuna en trabajadores de la salud.\nMetodolog\u00eda. Estudio de cohorte prospectivo post-auto -\nrizaci\u00f3n para evaluar la seguridad y eficacia de la vacuna. \nResultados . Los efectos secundarios locales fueron leves \ny se presentaron tanto con la primera como con la segunda \ndosis de Comirnaty. Los efectos secundarios sist\u00e9micos fueron \nm\u00e1s frecuentes despu\u00e9s de la segunda dosis. No obstante, la \ninfecci\u00f3n previa por SARS-CoV-2 se asoci\u00f3 con efectos sist\u00e9 -\nmicos tras la primera dosis de la vacuna (OR de 2 a 6). No se \ninformaron efectos adversos graves. El an\u00e1lisis multivariante \ndemostr\u00f3 que el grado de limitaci\u00f3n funcional tras la primera \ndosis aument\u00f3 con la edad, el sexo femenino, contacto previo \ncon COVID-19, la infecci\u00f3n previa por SARS CoV-2 y el \u00edndi -\nce de comorbilidad de Charlson (ICC). Tras la segunda dosis, el \ngrado de limitaci\u00f3n funcional observado fue menor en aque -\nllos con infecci\u00f3n previa por SARS-CoV-2, y se asoci\u00f3 positi -\nvamente al grado de limitaci\u00f3n funcional tras la primera dosis.\nConclusi\u00f3n.  Los efectos adversos sist\u00e9micos fueron m\u00e1s \nfrecuentes despu\u00e9s de la segunda dosis de Comirnaty. La infec -\nci\u00f3n previa por SARS-CoV-2 se asoci\u00f3 con efectos sist\u00e9micos \ndespu\u00e9s de la primera dosis. La edad, el sexo femenino, infec -\nci\u00f3n por COVID-19 previa, el aislamiento previo por contacto \nde COVID-19 y el ICC se mostraron como predictores inde -Influence of epidemiological and clinical factors \nin the reactogenicity to Comirnaty\u00ae vaccine \nin health care workers of a Spanish university \nteaching hospital (COVIVAC study)\n1Internal Medicine Departmente Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.\n2Queen Mary University, London, United Kingdom \n3Medical Assistant Direction. Complejo Asistencial de \u00c1vila, \u00c1vila, Spain.\n4Internal Medicine Deparment, Hospital Universitario HM Montepr\u00edncipe, HM Hospitales, Madrid, Spain.\n5Intensive Care Service, HM Sanchinarro University Hospital. Hospitales Madrid. Madrid, Spain. Carlos Risco-Risco1\nDiego Mart\u00ednez-Urbistondo1\nRafael Su\u00e1rez del Villar1\nLuis Ayerbe Garc\u00eda-Monz\u00f3n2\nAlberto P\u00e9rez-Rubio3\nJos\u00e9 Barber\u00e1n-L\u00f3pez4\nDavid Andaluz-Ojeda5\nPaula Villares Fern\u00e1ndez1Original\nArticle history\nReceived: 1 Febriary 2023; Revision Requested: 23 March 2023; Revision Received: 24 March 2023; Accepted: 30 March 2023; \nPublished: 29 April 2023\nABSTRACT\nIntroduction . Comirnaty\u00ae is an mRNA vaccine against COV -\nID-19 which has been administered to millions of people since the \nend of 2020. Our aim was to study epidemiological and clinical \nfactors influencing reactogenicity and functional limitation after \nthe first two doses of the vaccine in health care workers (HCWs). \nMaterial and methods. Prospective post-authorization co -\nhort study to monitor safety and effectiveness of the vaccine. \nResults.  Local side effects were mild and presented both with \nfirst and second dose of Comirnaty. Systemic side effects were \nmore frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 \ninfection was associated with systemic effects after the first dose \nof the vaccine (OR ranging from 2 to 6).  No severe adverse effects \nwere reported. According to multivariate analysis, the degree of \nself-reported functional limitation after the first dose increased \nwith age, female sex, previous COVID-19 contact, previous SARS-\nCoV-2 infection, and Charlson Comorbidity Index (CCI). After the \nsecond dose, the degree of functional limitation observed was \nlower in those with previous SARS-CoV-2 infection, and it was \npositively associated to the degree of functional limitation after \nthe first dose.\nConclusion.  Systemic adverse effects were more frequent \nafter the second dose of Comirnaty. Previous SARS-CoV-2 in -\nfection was associated with systemic effects after the first dose. \nAge, female sex, previous COVID-19, previous isolation due to  \nCOVID-19 contact, and CCI showed to be independent predictors \nof the degree of functional limitation after the 1st dose of Comir -\nnaty\u00ae. After the 2nd dose, the degree of functional limitation was \nlower in those who previously had SARS-CoV-2 infection.\nKeywords: COVID-19, Vaccines, Comirnaty, reactogenicity\nCorrespondence: \nDavid Andaluz-Ojeda\nIntensive Care Department, HM Sanchinarro University Hospital, Madrid, Spain.  \nE-mail: davidandaluz78@yahoo.esInfluence of epidemiological and clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care \nworkers of a Spanish university teaching hospital (COVIVAC study)C. Risco-Risco, et al.\nRev Esp Quimioter 2023;36(4): 400-407401workers answered an online questionnaire about previous \nhealth conditions (including comorbidities, previous exposure \nto COVID-19 at home or at work, previous COVID-19 infection, \nor previous isolation due to COVID-19 contact), age, sex, eth -\nnicity, blood group, date of administration of each dose, and \npossible adverse effects, from mild to severe. All participants \nagreed to enter the study (informed consent) at the time of \nreceiving the second dose of vaccine.  The study was approved \nby the Ethics Advisory Board of HM hospitals. \nQuantitative data were presented with mean and stand -\nard deviation, or median and interquartile range in case of \nnon-parametric data. Qualitative data were presented with \nproportions and percentages. Association was studied with \nPearson coefficient for normal quantitative data, and chi \nsquare test in case of parametric qualitative data. In non-para -\nmetric data, Spearman coefficient and Fisher\u2019s exact test were \napplied, respectively. Logistic regression was applied to study \nthe association of the different secondary effects to previous \nCOVID-19 infection or exposure, and linear regression (multi -\nvariate) was used to study the association of clinical and ep -\nidemiological factors to the degree of functional limitation \nwith each dose of the vaccine. Data analysis was performed \nwith STATA software version 16.1.\nRESULTS\nUp to 278 HCW answered the questionnaire (85 male, 193 \nfemale). The mean age was 39.34 years in men, and 36.31 years \nin women (p<0.05). The complete description of the character -\nistics of participants is presented in Table 1.  \nRegarding previous exposure to SARS-CoV-2, more than \n60% of HCW reported previous exposure to COVID-19 pa -\ntients without adequate protection in the laboral environment, \naround 15% at home, and around 15% had been isolated be -\nfore the vaccination due to COVID-19 contact. 19 per cent \nof them reported previous SARS-CoV-2 infection The list of \nsymptoms in those with previous COVID-19, as well as oth -\ner more concrete data about previous exposure to COVID-19 \nmight be consulted in Table 2.\nThe most frequent adverse effect was local pain, signif -\nicantly slightly more common after first dose (83 vs 78%, \np<0.05). On the other hand, systemic symptoms including fever \n(from mild to severe), dysthermia, use of antipyretic, headache, \ncough, vomiting, diarrhoea, adenopathy, myalgia, arthralgia, \nand work absenteeism, were significantly more frequent after \nthe second dose of the vaccine (p<0.05). More concrete details \nmight be consulted in Table 3. The degree of post-vaccine lim -\nitation was significatively higher after the second dose of the \nvaccine (Figure 1). \nPrevious COVID-19 was significantly associated with high -\ner incidence of low-grade fever (OR 2.96), asthenia (OR 2.48), \nheadache (OR 2.8), dysthermia (OR 4.36), myalgia (OR 5.69), \nuse of antipyretic (OR 3.46), and post-vaccine functional limi -\ntation, after the first dose of Comirnaty\u00ae.  On the other hand, \nafter the second dose of Comirnaty\u00ae, previous COVID-19 was pendientes del grado de limitaci\u00f3n funcional tras la 1\u00aa dosis \nde Comirnaty\u00ae. Despu\u00e9s de la 2.\u00aa dosis, el grado de limitaci\u00f3n \nfuncional fue menor en los que previamente ten\u00edan infecci\u00f3n \npor SARS-CoV-2.\nPalabras clave: COVID-19, Vacunas, Comirnaty, reactogenicidad\nINTRODUCTION\nSince December 2019 more than 295 million COVID-19 \ncases and almost 5.5 million deaths have been reported world -\nwide [1]. The magnitude of the health problem has driven the \nfocus of public health efforts to the development of effective \nand safe vaccines with an unprecedented celerity [2]. Comir -\nnaty\u00ae, an mRNA BNT162b2 vaccine, developed by Pfizer-BI -\nONTech, has been one of the first vaccines in being approved \nby EMA (European Medicines Agency) and FDA (USA Food and \nDrug Administration) [3,4]. This vaccine showed to be reason -\nable safe, and evidenced a high efficacy in preventing sympto -\nmatic (over 90%) and severe COVID-19 (over 95 %) in clinical \ntrials conducted in adults, younger people (from 12-15 years \nold) and lately, in children (from 5 to 11 years) [5-8]. In differ -\nent post-authorization studies conducted in Israel, the vaccine \nshowed an effectiveness over 95% in preventing symptomat -\nic COVID-19, and even higher in preventing severe illness or \ndeath [9,10] \nIn the different clinical trials conducted (adult people, ad -\nolescents, children), the safety profile of the vaccine showed to \nbe acceptable, reporting mild to moderate side effects, such as \ninjection site pain, fatigue, and headache, though some seri -\nous allergic reactions were observed [5,7,8]. In other post-au -\nthorization studies, less frequent side effects, (with around 1 \nper 10,000 incidence rate) such as myocarditis, and pericar -\nditis, more common in young male people, have been report -\ned [11,12]. Other possible less frequent side effects are under \nstudy. Further observational post-emergency use authoriza -\ntion studies are needed in order to more precisely define the \nsafety profile of these new vaccines [13].\nThe COVIVAC-1 is a prospective cohort investigation on \nthe safety and effectiveness of Comirnaty\u00ae vaccine in health \ncare workers of a university teaching Spanish hospital who re -\nceived two doses of the vaccine, taking into account epidemi -\nological and clinical variables such as age, sex, ethnicity, blood \ngroup, comorbidities, previous COVID-19 infection, or previous \nexposure to COVID-19. \nMATERIAL AND METHODS\nCOVIVAC-1 is a prospective cohort study about safety and \neffectiveness of mRNA BNT162b2 vaccine (Comirnaty\u00ae). This \ninvestigation was conducted in health care workers (HCW) of \nthe HM Sanchinarro, a university teaching hospital in Madrid \n(Spain), who had received two doses of the vaccine.  The first \nphase of the study, concerning safety, was carried out after \nreception of both doses of the vaccine. In this phase, which \nwas focused on safety issues of the vaccine, the health care Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care \nworkers of a Spanish university teaching hospital (COVIVAC study)C. Risco-Risco, et al.\nRev Esp Quimioter 2023;36(4): 400-407402Finally, we employed linear regression analysis to study \nthe predictive capacity of different factors and covariables in \nthe degree of self-reported (from 0 to 5) functional limitation \nafter each dose of the vaccine. Neither ethnicity, blood group, \nor body mass index revealed themselves as significant predic -associated with lower incidence of moderate fever (0R 0.13) \nand cough (OR 0.16), and, as with the first dose, with greater \nincidence of asthenia (OR 2.48).  The rest of adverse effects \nstudied did not show significative association with previous \nCOVID-19 (Table 4).Sex n (%) Men 85 (30.58) Women 193 (69.42)\nAge mean (IC 95%) 39.34 (36.58-42.10) 36.31 (34.93-37.70) p = 0.031\nBMI mean (IC 95%) 25.37 (24.69-26.09) 22.63 (22.10-23.17) p < 0.0001\nEthnicity n (%) Caucasian 76 (89.41)\nAsian 0 (0)\nLatin 9 (10.59) \nBlack 0 (0) \nOther 0 (0)Caucasian 166 (86.01)\nAsian 2 (1.04)\nLatin 23 (11.92)\nBlack 1 (0.52)\nOther 1 (0.52) p=0.749\nBlood Group n (%) 0- 8 (12.12)\n0+ 23 (34.85)\nA+ 31 (46.97)\nB+ 4 (6.06)0- 12 (7.55)\n0+ 53 (33.33)\nA+ 76 (47.80)\nB+ 18 (11.32) p=0.483\nComorbidities n (%)\n  COPD- Asthma\n  Acute Myocardial Infarction\n  Cardiac Failure\n  Vascular Peripheric Disease\n  Stroke\n  Dementia\n  Rheumatologic Disease\n  Ulcus\n  Hepatic steatosis\n  Hepatic Cirrhosis\n  DM with target organ damage\n  DM without target organ damage\n  Hemiplegia\n  Kidney Chronic Disease\n  Tumour\n  Leukaemia\n  Lymphoma\n  Metastasis\n  AIDS3 (3.53)\n0 (0)\n0 (0)\n4 (2.07)\n0 (0)\n0 (0)\n4 (2.07)\n0 (0)\n0 (0)\n0 (0)\n0 (0)\n4 (2.07)\n0 (0)\n0 (0)\n3 (1.55)\n0 (0)\n0 (0)\n0 (0)\n0 (0)14 (7.25)\n0 (0)\n0 (0) \n2 (1.18)\n0 (0)\n0 (0)\n0 (0)\n2 (2.35)\n2 (2.35)\n0 (0)\n0 (0)\n2 (2.35)\n0 (0)\n0 (0)\n1 (1.18)\n0 (0)\n0 (0)\n0 (0)\n0 (0)p=0.234\np=0.606\np=0.182\np=0.0325\np=0.0325\np=0.883\np=0.808\nCharlson Index  n (%) 0\n1\n2\n375 (88.24)\n8 (9.41)\n2 (2.35)\n0 (0)167 (86.53)\n21 (10.08)\n4 (2.07)\n1 (0.52)p=0.896Table 1  Descriptive summary of Health Care Workers fully vaccinated with ComirnatyInfluence of epidemiological and clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care \nworkers of a Spanish university teaching hospital (COVIVAC study)C. Risco-Risco, et al.\nRev Esp Quimioter 2023;36(4): 400-407403Comirnaty \u00ae, around 90% did experience at least one side ef -\nfect. Most of the self-reported side effects were mild to mod -\nerate. The main adverse effect observed after the first and sec -\nond dose of Comirnaty \u00ae was local pain. In general, systemic \nside effects were significatively more intense after the second \ndose of the vaccine. The degree of self-reported functional \nlimitation (from 0 to 5) after vaccination was also significantly \nhigher after the second dose of the vaccine (p<0.05).   \nThis echoes the results of the clinical trial conducted by \nPolack [5], and the cohort study by Chapin-Bardales [14], with \nover three and half million participants, using the V-safe Ac -\ntive Surveillance System, in USA.\nOn the contrary, another evidence from our study was \nthat in those with previous SARS-CoV-2 infection, systemic \nside effects were more intense after first dose of Comirnaty\u00ae.  \nThese findings were in congruence with those reported by Me -tors of functional limitation after the first or second dose of \nComirnaty\u00ae.  After the first dose of Comirnaty\u00ae, in the mul -\ntivariate model, we found a positive independent association \nbetween degree of functional limitation and age (years), fe -\nmale sex, previous SARS-CoV-2 infection, previous isolation \ndue to COVID-19 contact, and Charlson Comorbidity Index \nPunctuation. By contrast, after the second dose of the vaccine, \nin the multivariate model, the degree of functional limitation \nwas positively associated with the degree of functional lim -\nitation (0 to 5) after the first dose of vaccine (p<0.001), and \nit was significatively lower in people with previous COVID-19 \n(Table 5)\nDISCUSSION\nIn our group of health care workers fully vaccinated with COVID-19 Laboral contact n (%) 167 (60.07)\nCOVID-19 Cohabiting Contact n (%) 40 (14.39)\nIsolation due to COVID-19 contact n (%) 42 (15.11)\nN. isolations due to COVID-19 contact\n      1 isolation n (%)\n      2 isolations n (%)\n      3 isolations n (%)29 (70.73)\n9 (21.95)\n3 (7.32)\nPrevious COVID-19 diagnose n (%)\n      PCR                   n (%)\n      Ag test             n (%)\n      Serology          n (%)53 (19.06)\n31 (11.15)\n3 (1.08)\n19 (6.83)\nHospitalization due to COVID-19 1 (0.36)\nICU admission due to COVID-19 1 (0.36)\nSymptoms in previous COVID-19 cases in vaccinated health care workers n (%)\nFever\nCough\nDyspnoea\nDiarrhoea\nHeadache\nDysgeusia\nAnosmia\nAsthenia\nMyalgia\nOdynophagia\nChest tightness\nExtreme weakness\nRash24 (45.28)\n21 (39.62)\n9 (16.98)\n10 (18.87)\n33 (62.26)\n28 (52.83)\n33 (62.26)\n44 (83.02)\n26 (49.06)\n8 (15.09)\n9 (16.98)\n1 (1.89)\n2 (3.77)Table 2  Previous exposure to SARS-CoV2 in HCWs receptors of \nCOVID-19 mRNA BNT162b2 (n =278)Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care \nworkers of a Spanish university teaching hospital (COVIVAC study)C. Risco-Risco, et al.\nRev Esp Quimioter 2023;36(4): 400-407404of 278 HCW.  No deaths or other serious adverse events were \nreported in our study. \nA strength of our study is the attention paid to different \nepidemiological and clinical factors and their influence in the \nreactogenicity to Comirnaty \u00ae. In this way, in the multivari -\nate linear regression analysis we found that age, female sex, \nCharlson Comorbidity Index Punctuation, previous SARS CoV-\n2 infection, and previous isolation due to COVID-19 contact Adverse effect 1st Dose n (%) 2nd Dose n (%) P\nNone 31 (11.15) 27(9.71) 0.48\nLocal erythema 35 (12.59) 30 (10.79) 0.25\nLocal swelling 51 (18.35) 51 (18.35) 1\nLocal pain 232 (83.45) 217 (78.06) 0.025\nLow grade fever (under 38\u00baC) 18 (6.47) 62 (22.30) <0.0001\nFever >38\u00baC & < 39\u00baC 6 (2.16) 31 (11.15) <0.0001\nFever >39\u00baC 0 (0)  7 (2.52) <0.01\nAsthenia 72(25.90) 72 (25.90) 1\nHeadache 60 (21.58) 104 (37.41) <0.0001\nDysthermia 39 (14.03) 97 (34.89) <0.0001\nCough 13 (4.68) 46 (16.55) <0.0001\nVomiting 1 (0.36) 16 (5.76) <0.001\nDiarrhoea  6 (2.16) 20 (7.19) 0.002\nAdenopathy 11 (3.96) 27 (9.71) 0.002\nMyalgia 23 (8.27)  80 (28.78) <0.0001\nArthralgia 16 (5.76)  46 (16.55) <0.0001\nAntipyretic use 44 (15.83) 95 (34.17) <0.0001\nUrgent care need 0 (0) 0 (0)\nWork absenteeism 4 (1.44) 16 (5.76) 0.003\nPost-vaccine limitation\nNone (0)\nVery Mild (1)\nMild (2)\nModerate (3)\nSevere (4)\nVery Severe (5)182 (65.70)\n45 (16.25)\n22 (7.94)\n12 (4.33)\n13 (4.69)\n3 (1.08)122 (43.88)\n38 (13.67)\n34 (12.23)\n38 (13.67)\n34 (12.23)\n12 (4.32)< 0.001Table 3  Adverse effects after 1st and 2nd dose of \nCOVID-19 mRNA BNT162b2 vaccine  \n(n =278)\nni [15] in the British COVID Symptom Study and D\u2019Arminio [16] \non HCW in Italy. \nA very rare adverse effect attributed to mRNA vaccines \n(Pfizer and Moderna) has been the development of myocar -\nditis and/or pericarditis, mainly in the first week after the sec -\nond dose, as reported by Kim [17], Montgomery [18], Marshall \n[19] or Boehmer [20].  No events of pericarditis or myocarditis \npost-vaccination with Comirnaty \u00ae were reported in our series Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care \nworkers of a Spanish university teaching hospital (COVIVAC study)C. Risco-Risco, et al.\nRev Esp Quimioter 2023;36(4): 400-407405Adverse effect* Dose 1\nOR (IC 95%)p Dose 2\nOR (IC 95%)p\nLow grade fever (<38\u00baC) 2.96 (1.08-8.04) 0.033 0.66 (0.30-1.45) 0.303\nFever >38\u00baC & < 39\u00baC 0.85 (0.10-7.40) 0.880 0.13 (0.02-0.94) 0.043\nAsthenia 2.48 (1.32-4.67) 0.005 2.48 (1.32-4.67) 0.005\nHeadache 2.80 (1.46-5.38) 0.002 0.83 (0.44-1.56) 0.565\nDysthermia 4.36 (2.11-9.00) <0.0001 0.77 (0.40-1.47) 0.425\nCough 1.29 (0.34-4.86) 0.71 0.16 (0.04-0.69) 0.014\nMyalgia 5.69 (2.35-13.78) <0.0001 0.97 (0.50-1.88) 0.932\nArthralgia 4.82 (1.72-13.52) 0.003 1.04 (0.47-2.31) 0.925\nAntipyretic use 3.46 (1.71-6.99) 0.001 0.89 (0.47-1.69) 0.721\nPost-vaccine limitation\nNone (0)\nVery Mild (1)\nMild (2)\nModerate (3)\nSevere (4)\nVery Severe (5)1\n2.28 (1.04-5.01)\n2.35 (0.84-6.59)\n6.28 (1.88-21.01)\n2.80 (0.80-9.75)0.039\n0.103\n0.003\n0.1081 \n0.63 (0.24-1.66)\n0.45 (0.15-1.38)\n1.20 (0.52-2.77)\n0.32 (0.09-1.14)\n0.67 (0.14-3.24)0.349\n0.162\n0.671\n0.080\n0.620Table 4  OR of previous COVID-19 and adverse effects after mRNA \nBNT162b2 vaccine (n =278) \n*The rest of adverse effects did not show significant association (OR) with previous COVID-19, nor with 1st \ndose, neither with 2nd dose. \nFigure 1  Degree of functional limitation (0 to 5) in HCWs after 1st & 2nd dose of \nComirnatyInfluence of epidemiological and clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care \nworkers of a Spanish university teaching hospital (COVIVAC study)C. Risco-Risco, et al.\nRev Esp Quimioter 2023;36(4): 400-407406Model after 2nd dose\nCoef. CI 95% P Wald\nAge (each year) 0.00003 -0.001 to 0.001 0.963\nMale Sex -0.20 -0.60 to 0.20 0.332\nCharlson Index -0.04 -0.45 to 0.38 0.859\nPrevious COVID-19 -0.55 -1.03 to -0.06 0.027\nIsolation due to COVID-19 contact -0.11 -0.64 to 0.42 0.687\nFunctional limitation after 1st dose (0 to 5) 0.48 0.31 to 0.64 <0.001Model after 1st dose\nCoef. CI 95% P Wald\nAge (each year) 0.0016 0.001 to 0.002 <0.001\nMale Sex -0.34 -0.62  to - 0.05 0.021\nCharlson Index  0.35 0.05 to 0.65 0.020\nPrevious COVID-19  0.61 0.27 to 0.95 <0.001\nIsolation due to COVID-19 contact  0.47 0.09 - 0.84 0.015Table 5  Multivariate Linear regression model of post-\nvaccine limitation after 1st & 2nd dose of \nComirnaty\u00ae\nwere independent predictors of a higher degree of functional \nlimitation after the first dose of Comirnaty \u00ae. After the second \ndose, previous COVID-19 was associated with a lower func -\ntional limitation, and only the degree of functional limitation \nafter the first dose revealed itself as an independent predic -\ntor of greater impairment.  Other evidences from our analyses \nnot published in previous works include that no differences in \nfunctional limitation post-vaccination were observed accord -\ning to body mass index, ethnicity, or blood group.   \nA limitation of our study was the limited number of \nparticipants, though this could be counterbalanced with the \nhigher degree of precision in the answer to the questionnaire \ndue to the fact that all of them were HCW. Although this lim -\nitation, we obtained results in congruence with much great -\ner studies, such as the ones conducted by Chapin Bardales or \nMenni [14,15]. \nCONCLUSION\nIn conclusion, in the same way as other studies, global -\nly we found a higher incidence of systemic side effects with \nthe second dose of Comirnaty \u00ae than with the first dose, while \nin those previously infected by SARS-CoV-2 systemic adverse \neffects were more intense after the first dose. No events of \nmyocarditis neither pericarditis were reported in our HCW \npopulation.  No deaths or major severe adverse events were \nreported. The degree of functional limitation after the first \ndose was independently associated with age, female sex, pre -\nvious COVID-19 isolation, previous SARS-CoV-2 infection, and punctuation in the Charlson Comorbidity Index. The degree of \nfunctional limitation after the first dose showed to be an inde -\npendent predictor of a higher degree of functional limitation \nafter the second dose, while previous SARS-CoV-2 infection \nwas associated with a lower functional limitation after the \nsecond dose.  Further post-emergency use authorization stud -\nies are still needed in order to define more precisely the safety \nprofile of these new vaccines against COVID-19. \nFUNDING\nNone to declare.\nCONFLICT OF INTEREST\nAuthors declare no have conflict of interest\nREFERENCES\n1.   WHO, COVID-19 Dashboard, 4 th January 2022, from https://cov -\nid19.who.int/ .  Last access 5 th february 2022\n2.  Our World in Data. \u2018\u2018Coronavirus (COVID-19) Vaccinations.\u201d from \nhttps://ourworldindata.org/covid-vaccinations . last access 5 th Jan-\nuary 2022\n3.  EMA Comirnaty authorization for Emergency Authorized Use, 21 st  \nDecember 2020, available at https://www.ema.europa.eu/en/news/\nema-recommends-first-covid-19-vaccine-authorisation-eu , last \naccess 5 th January 2022Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty\u00ae vaccine in health care \nworkers of a Spanish university teaching hospital (COVIVAC study)C. Risco-Risco, et al.\nRev Esp Quimioter 2023;36(4): 400-4074074.  FDA full approval in people of sixteen years or older for Comir -\nnaty vaccine, 23 rd August 2021. Available at https://www.fda.\ngov/emergency-preparedness-and-response/coronavirus-dis -\nease-2019-covid-19/comirnaty-and-pfizer-biontech-cov -\nid-19-vaccine , last access 5 th January 2022\n5.  Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial \nGroup. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vac -\ncine. N Engl J Med. 2020 Dec 31; 383(27):2603-2615. doi: 10.1056/\nNEJMoa2034577.\n6.  Chagla Z. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% effica -\ncy against COVID-19 \u22657 days after the 2nd dose. Ann Intern Med. \n2021 Feb;174(2):JC15. Doi: 10.7326/ACPJ202102160-015.\n7.   Frenck RW Jr, Klein NP, Kitchin N, et al; Safety, Immunogenicity, \nand Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N \nEngl J Med. 2021;385(3):239-250. doi: 10.1056/NEJMoa2107456.\n8.  Walter EB, Talaat KR, Sabharwal C, et al; C4591007 Clinical Trial \nGroup. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 \nto 11 Years of Age. N Engl J Med. 2022;386(1):35-46. doi: 10.1056/\nNEJMoa2116298.\n9.  Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness \nof mRNA BNT162b2 vaccine against SARS-CoV-2 infections and \nCOVID-19 cases, hospitalisations, and deaths following a nation -\nwide vaccination campaign in Israel: an observational study using \nnational surveillance data. Lancet. 2021 May 15;397(10287):1819-\n1829. doi:: 10.1016/S0140-6736(21)00947-8. \n10.  Dagan N, Barda N, Kepten E, et al.  BNT162b2 mRNA Covid-19 \nVaccine in a Nationwide Mass Vaccination Setting, New England \nJournal of Medicine 2021;384(15):1412-1423. doi:\n11.  EMA update on safety profile of Comirnaty, December 2021, \nfrom https://www.ema.europa.eu/en/documents/covid-19-vac -\ncine-safety-update/covid-19-vaccine-safety-update-comir -\nnaty-9-december-2021_en.pdf , last access 5 th January 2022\n12.  Rathore SS, Rojas GA, Sondhi M, et al. Myocarditis associated with \nCovid-19 disease: a systematic review of published case reports \nand case series. Int J Clin Pract . 2021;75(11):e14470. doi: 10.1111/\nijcp.14470\n13.  Patel, M. K., Bergeri, I., Bresee, J. S et al.  Evaluation of post-in -\ntroduction COVID-19 vaccine effectiveness: Summary of inter -\nim guidance of the World Health Organization. Vaccine, S0264-\n410X(21)00707-6. doi: 10.1016/j.vaccine.2021.05.099.\n14.  Chapin-Bardales J, Gee J, Myers T. Reactogenicity Following Re -\nceipt of mRNA-Based COVID-19 Vaccines. JAMA. 2021 Jun \n1;325(21):2201-2202. doi: 10.1001/jama.2021.5374. \n15.  Menni, C., Klaser, K., May, A., et al (2021). Vaccine side-effects \nand SARS-CoV-2 infection after vaccination in users of the COV -\nID Symptom Study app in the UK: a prospective observational \nstudy. The Lancet Infectious Diseases, 21(7). 00224-3. doi: 10.1016/\nS1473-3099(21)00224-3\n16.  D\u2019Arminio Monforte, A; Tavelli, A; Perrone, PM., et al. Associ -\nation between previous infection with SARS CoV-2 and the risk \nof self-reported symptoms after mRNA BNT162b2 vaccina -\ntion: Data from 3,078 health care workers, EClinicalMedicine, \n2021;36:100914. doi: 10.1016/j.eclinm.2021.100914.17.  Kim HW, Jenista ER, Wendell DC et al. Patients With Acute My -\nocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol. \n2021;6(10):1196-1201. doi: 10.1001/jamacardio.2021.2828.\n18.  Montgomery J, RyanM, Engler R, et al. Myocarditis following im -\nmunization with mRNA COVID-19 vaccines in members of the \nUS military. JAMA Cardiol. 2021;6(10):1202-1206 19. Marshall M, \nFerguson ID, Lewis P, et al. Symptomatic acute myocarditis in sev -\nen adolescents following Pfizer-BioNTech COVID-19 vaccination. \nPediatrics. Published online June 4, 2021. doi: 10.1001/jamacar -\ndio.2021.2833\n20.  Boehmer TK, Kompaniyets L, Lavery AM, et al. Association Be -\ntween COVID-19 and Myocarditis Using Hospital-Based Adminis -\ntrative Data \u2014 United States, March 2020\u2013January 2021. MMWR \nMorb Mortal Wkly Rep 2021;70:1228\u20131232. doi: 10.15585/mmwr.\nmm7035e5.ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/008.2023\nRev Esp Quimioter 2023;36(4): 408-415408Agust\u00edn Juli\u00e1n-Jim\u00e9nez1*\nRafael Rubio-D\u00edaz1*\nJuan Gonz\u00e1lez del Castillo2\nEric Jorge Garc\u00eda-Lamberechts2\nItziar Huarte Sanz3 \nCarmen Navarro Bustos4\nFrancisco Javier Candel5\nPedro \u00c1ngel de Santos6\nRa\u00fal Alonso Avil\u00e9s6\nen nombre del grupo INFURG-\nSEMES**\nAbility of qSOFA1-lactate to predict 30-day \nmortality in patients seen for infection in the \nEmergency Department\nABSTRACT\nObjectives. To evaluate lactate and the Quick Sepsis-Re -\nlated Organ Failure Assessment (qSOFA) and compare their \nability to predict 30-day mortality in patients treated for infec -\ntion in emergency departments (ED).\nMethods. Prospective multicenter observational cohort \nstudy. We enrolled a convenience sample of patients aged 18 \nyears or older attended in 71 Spanish ED from October 1, 2019, \nto March 31, 2020. Each model\u2019s predictive power was analyz -\ned with the area under the receiver operating characteristic \ncurve (AUC), and its values of sensitivity (Se), specificity (Sp), \npositive predictive value (PPV) and negative (NPV).\nResults. A total of 4439 patients with a mean (SD) age \nof 18 years were studied; 2648 (59.7%) were men and 459 \n(10.3%) died within 30 days. For 30-day mortality, the AUC-\nCOR obtained with the qSOFA = 1 model plus 2 mmol/l lac -\ntate was 0.66 (95% CI, 0.63-0.69) with Se: 68%, Es: 70% and \nNPV:92%, while qSOFA = 1 obtained AUC-COR of 0.52 (95% CI, \n0.49-0.55) with a Se:42%, Es:64% and NPV:90%.\nConclusions. To predict 30-day mortality in patients pre -\nsenting to the ED due to an episode of infection, the qSOFA =1 \n+ lactate\u22652 mmol/L model significantly improves the predictive \npower achieved individually by qSOFA1 and becomes very sim -\nilar to qSOFA \u22652.\nKeywords: Sepsis, Lactic acid, Prognosis, Mortality, Quick Sepsis-Related \nOrgan Failure Assessment (qSOFA), Emergency Department,Capacidad del qSOFA1-lactato para predecir \nmortalidad a 30 d\u00edas en los pacientes atendidos \npor infecci\u00f3n en urgencias\n1Servicio de Urgencias, Complejo Hospitalario Universitario de Toledo, Universidad de Castilla La Mancha, Toledo, \nEspa\u00f1a.\n2Servicio de Urgencias, Hospital Universitario Cl\u00ednico San Carlos, IDISSC, Madrid, Espa\u00f1a.\n3Servicio de Urgencias, Hospital Universitario de Donosti, Espa\u00f1a.\n4Servicio de Urgencias, Hospital Universitario Virgen de la Macarena, Sevilla, Espa\u00f1a.\n5Servicio de Microbiolog\u00eda Cl\u00ednica, Hospital Universitario Cl\u00ednico San Carlos, IDISSC, Madrid, Espa\u00f1a \n6Servicio de Urgencias, Hospital Cl\u00ednico Universitario de Valladolid, Espa\u00f1a.Original breve\nArticle history\nReceived: 19 January 2023; Revision Requested: 27 February 2023; Revision Received: 27 February 2023;  \nAccepted: 22 March 2023; Published: 8 May 2023 \nRESUMEN\nObjetivo. Evaluar y comparar la capacidad del lactato y \ndel quick Sepsis-related Organ Failure Assessment (qSOFA) \npara predecir mortalidad a 30 d\u00edas en los pacientes que acuden \nal servicio de urgencias (SU) por un episodio de sospecha de \ninfecci\u00f3n. \nM\u00e9todo. Estudio observacional de cohortes, multic\u00e9ntrico, \nprospectivo. Se incluy\u00f3 por oportunidad a pacientes \u226518 a\u00f1os \natendidos por sospecha de infecci\u00f3n en 71 SU espa\u00f1oles del \n01/10/2019 al 31/03/2020. Se analiz\u00f3 la capacidad predictiva \ncon el \u00e1rea bajo la curva (ABC) de la caracter\u00edstica operativa del \nreceptor (COR) y los valores de sensibilidad (Se), especificidad \n(Es), valor predictivo positivo (VPP) y negativo (VPN).\nResultados. Se incluyeron 4.439 pacientes con edad me -\ndia de 67 (DE:18) a\u00f1os, 2.648 (59,7%) fueron hombres y fa -\nllecieron a los 30 d\u00edas 459 (10,3%). Para la mortalidad a 30 \nd\u00edas el ABC-COR obtenida con el modelo qSOFA=1 m\u00e1s lacta -\nto 2 mmol/l fue de 0,66 (IC 95%: 0,63-0,69) con una Se:68%, \nEs:70% y VPN:92%, mientras que qSOFA=1 obtuvo ABC-COR \nde 0,52 (IC 9%: 0,49-0,55) con una Se:42%, Es:64% y VPN:90%.\nConclusiones. Para predecir mortalidad a los 30 d\u00edas en \nlos pacientes que acuden al SU por un episodio de infecci\u00f3n, \nel modelo qSOFA=1 + lactato \u22652 mmol/L mejora significativa -\nmente el poder predictivo conseguido de forma individual por \nqSOFA1 y llega a ser muy similiar al de qSOFA \u22652.\nPalabras clave: Sepsis, Lactato, Pron\u00f3stico, Mortalidad, qSOFA, Servicio de \nUrgencias, \nCorrespondencia: \nDr. Agust\u00edn Juli\u00e1n-Jim\u00e9nez\nServicio de Urgencias-Coordinador de Docencia, Formaci\u00f3n, Investigaci\u00f3n y Calidad.\nComplejo Hospitalario Universitario de Toledo, Toledo, Espa\u00f1a. \nAvda. R\u00edo Guadiana s/n. C.P: 45.071. Toledo. Espa\u00f1a.\nE-mail: agustinj@sescam.jccm.es\n*Ambos autores han contribuido de igual forma a la preparaci\u00f3n de este manuscritoCapacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n \nen urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al.\nRev Esp Quimioter 2023;36(4): 408-415409SEMES(Grupo de Infecciones de la Sociedad Espa\u00f1ola de \nMedicina de Urgencias y Emergencias)(ver adenda) a los que \nse realiz\u00f3 un seguimiento durante 30 d\u00edas. Del 01/10/2019 al \n31/03/2020 se incluyeron con un muestreo por oportunidad \na pacientes \u226518 a\u00f1os diagnosticados de un proceso infec -\ncioso y en los que, por sus caracter\u00edsticas epidemiol\u00f3gicas \ny presentaci\u00f3n cl\u00ednica, los m\u00e9dicos responsables indicaron \nla obtenci\u00f3n de muestras anal\u00edticas con determinaci\u00f3n de \nbiomarcadores (lactato) y cultivos microbiol\u00f3gicos. Se ex -\ncluyeron las pacientes de obstetricia-ginecolog\u00eda (ver crite -\nrio inclusi\u00f3n y exclusi\u00f3n completos en publicaciones previas) \n[9,19].\nComo variable dependiente se consider\u00f3 la mortalidad cru -\nda a los 30 d\u00edas. Como variables independientes aquellas que se \nconsideraron cl\u00ednicamente relevantes, las que pudieran influir \nen el pron\u00f3stico y evoluci\u00f3n, sociodemogr\u00e1ficas, de comorbi -\nlidad y anal\u00edticas (se asumieron y adoptaron las definiciones, \nt\u00e9cnicas, m\u00e9todos establecidos para la recogida de muestras, \nvalores de referencia y variables estudiadas del estudio primi -\ngenio) [9,19].\nSe aplicaron los criterios de selecci\u00f3n de pron\u00f3stico de \npacientes en las definiciones del qSOFA y las variables que la \nconstituyen seg\u00fan la tercera conferencia de consenso de sepsis \n(Sepsis-3) [7].\nPara el an\u00e1lisis estad\u00edstico se utilizaron medias y sus des -\nviaciones est\u00e1ndar (DE) para variables cuantitativas y n\u00fameros \nabsolutos y porcentajes para las cualitativas. Las comparacio -\nnes se realizaron con la pruebas de ji cuadrado o exacta de \nFisher, la t de Student y la U de Mann-Whitney, seg\u00fan el tipo \nde variable. Se consider\u00f3 significativo un valor de p<0,05. Los \ncontrastes fueron bilaterales. La eficacia para la predicci\u00f3n de \nmortalidad a los 30 d\u00edas se estudi\u00f3 mediante el an\u00e1lisis del \u00e1rea \nbajo la curva (ABC) de la caracter\u00edstica operativa del receptor \n(COR) con el intervalo de confianza al 95(IC 95%) y se compar\u00f3 \nfrente al valor neutro (0,5). Se calcul\u00f3 el rendimiento pron\u00f3s -\ntico de estas y de los nuevos modelos elegidos con los c\u00e1lculos \nde sensibilidad (Se), la especificidad (Es), el valor predictivo po -\nsitivo (VPP) y el valor predictivo negativo (VPN), as\u00ed como sus \nIC 95% por m\u00e9todos binomiales exactos. Los errores est\u00e1ndar \nde las ABC se calcularon por m\u00e9todos no param\u00e9tricos. La \ncomparativa entre ABC-COR de las variables y nuevos modelos \ncombinados predictivos se realiz\u00f3 por la prueba de ji cuadra -\ndo para comparar ABC-COR respecto a ABC-COR de referencia \nelegidas. Por su parte, las proporciones se compararon con el \ntest de McNemar para muestras independientes (accesible en \nla calculadora: http://home.ubalt.edu/ntsbarsh/business-stat/\notherapplets/pairedprop.htm). El an\u00e1lisis estad\u00edstico se realiz\u00f3 \ncon los programas IBM-SPSS Statistics 22 para Windows y STA -\nTA/MP 16.0. \nEl estudio ha seguido la Declaraci\u00f3n de Helsinki y fue \naprobado por el Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica (CEIC) \ndel Complejo Hospitalario Universitario de Toledo (398/2109), \nas\u00ed como por los CEIC/CEIm de referencia de los centros par -\nticipantes. INTRODUCCI\u00d3N\nLa atenci\u00f3n a pacientes con sospecha de infecci\u00f3n en los \nservicios de urgencias (SU) se increment\u00f3 significativamente \nantes de la pandemia COVID-19 hasta un 15-20% de las aten -\nciones diarias en 2019 [1]. Adem\u00e1s, en 2020-2021 por el im -\npacto del SARS-CoV-2, estas cifras han podido elevarse hasta el \n50-80% [2]. Asimismo, la gravedad cl\u00ednica (pacientes con sep -\nsis, comorbilidad, neutrop\u00e9nicos, ancianos, sospecha de bacte -\nriemia, etc.) y la mortalidad a corto plazo (30 d\u00edas) tambi\u00e9n \nhan sufrido un incremento en la \u00faltima d\u00e9cada [2,3]. En este \ncontexto, la sepsis representa uno de los mayores problemas de \nsalud p\u00fablica en todo el mundo, por su incidencia y mortalidad \na 30 d\u00edas (24,4% para la sepsis y 34,7% para el shock s\u00e9ptico) \n[2,3]. Hoy en d\u00eda, el SU representa un eslab\u00f3n clave ya que es \ndonde se realiza la sospecha de sepsis, su reconocimiento, la \ntoma de muestras microbiol\u00f3gicas y se debe comenzar un tra -\ntamiento precoz y adecuado, lo que determinar\u00e1 la evoluci\u00f3n \ncl\u00ednica del enfermo [2,4-6].\nEn 2016, los criterios de Sepsis-3 recomendaron el em -\npleo del quick Sepsis-related Organ Failure Assessment (qSO -\nFA) en pacientes no ingresados en medicina intensiva [7]. \nInmediatamente se suscit\u00f3 una gran controversia ya que q-\nSOFA mostraba una pobre sensibilidad para detectar pacien -\ntes con posible mala evoluci\u00f3n, lo que impuls\u00f3 que m\u00faltiples \nestudios compararan el rendimiento del qSOFA con otras es -\ncalas y algunos biomarcadores [8-12]. Por este motivo, se ha \nrecomendado la utilizaci\u00f3n conjunta de escalas y biomarca -\ndores para determinar el diagn\u00f3stico de infecci\u00f3n bacteria -\nna, sepsis y el pron\u00f3stico de mortalidad [9,10-13]. Se con -\nsidera al lactato como el mejor marcador de hipoperfusi\u00f3n \ne hipoxia tisular y valores \u22652 mmol/L constituyen un factor \nindependiente de mortalidad, incluso sin hipotensi\u00f3n [11-13]. \nSin embargo, durante el desarrollo de los estudios de cara a \nestablecer los criterios de Sepsis-3, el lactato no cumpli\u00f3 con \nlos umbrales estad\u00edsticos para su inclusi\u00f3n en la construcci\u00f3n \ndel modelo de qSOFA, lo que podr\u00eda justificarse por la gran \ncantidad de valores ausentes en el registro [7,14]. Fruto de \nestas consideraciones, la \u00faltima actualizaci\u00f3n de la Campa\u00f1a \nSobrevivir a la Sepsis no recomend\u00f3 como screening de sepsis \nel empleo de q-SOFA de manera aislada, comparado con otras \nescalas [5]. Algunos autores han propuesto a\u00f1adir el lactato a \nq-SOFA (qSOFA-lactato), ya que se consigue un mayor rendi -\nmiento diagn\u00f3stico, sobre todo para los pacientes de te\u00f3rico \nbajo riesgo inicial (qSOFA1) [9,14,18].\nEl objetivo de este estudio fue evaluar la capacidad del \nlactato para mejorar el rendimiento predictivo de mortalidad a \ncorto plazo en pacientes de riesgo bajo (qSOFA=1) del SU con \nsospecha de infecci\u00f3n.\nM\u00c9TODOS\nAn\u00e1lisis secundario del registro MPB-INFURG-SEMES \n[9,19], que es un estudio observacional, multic\u00e9ntrico, pros -\npectivo, descriptivo y anal\u00edtico de pacientes atendidos por \nsospecha de infecci\u00f3n en 71 SU de la Red del Grupo INFURG-Capacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n \nen urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al.\nRev Esp Quimioter 2023;36(4): 408-415410DATOS DEMOGR\u00c1FICOS-EPIDEMIOL\u00d3GICOSTotal\nn=4.439 Valores \nperdidos Supervivientes \na 30 d\u00edas\nn=3.980 (89,7%)Fallecidos \na 30 d\u00edas\nn= 459 (10,3%)Valor p\nEdad (a\u00f1os), media (DE) 67 (18) 0 (0,0)  66 (19) 77 (14) <0,001\nEdad >65 a\u00f1os n (%) 2.661 (59,9) 0 (0,0) 2.293 (57,6) 368 (80,2) <0,001\nG\u00e9nero masculino n (%) 2.648 (59,7) 0 (0,0)  2.370 (59,5) 278 (60,6) 0,356\nInstitucionalizado n (%) 382 (8,6) 0 (0,0) 274 (6,9)  108 (23,5) <0,001\nCOMORBILIDADES\nNeoplasia s\u00f3lida, n (%)  523 (11,8) 0 (0,0) 459 (11,5) 64 (13,9) 0,077\nLeucemia/Linfoma, n (%) 199 (4,5) 104 (2,3) 174 (4,4) 25 (5,4) 0,183\nEnfermedad hep\u00e1tica, n (%) 119 (2,7) 0 (0,0) 111 (2,8) 8 (1,7) 0,119\nEnfermedad cardiaca cr\u00f3nica, n (%) 502 (11,3) 0 (0,0) 384 (9,6) 118 (25,7) <0,001\nHTA 2.001 (45,1) 0 (0,0) 1753 (44,0) 248 (54,0) <0,010\nEnfermedad renal cr\u00f3nica, n (%) 431 (9,7) 0 (0,0) 358 (9,0) 73 (15,9) <0,001\nEnfermedad cerebrovascular, n (%) 447 (10,1) 0 (0,0) 371 (9,3) 76 (16,6) <0,001\nDemencia, n (%) 490 (11,0) 0 (0,0) 368 (9,2) 122 (26,6) <0,001\nEPOC, n (%) 724 (16,3) 0 (0,0) 634 (15,9) 90 (19,6) 0,027\nDiabetes Mellitus, n (%)  867 (19,5) 0 (0,0) 720 (18,1) 147 (32,0) <0,001\n\u00cdndice de Charlson [media (DE)] 2,8 (2,6) 0 (0,0) 2,6 (2,5) 4,2 (2,8) <0,001\n\u00cdndice de Charlson \u22653 2.039 (45,9) 0 (0,0) 1.722 (43,3) 317 (69,1) <0,001\n\u00cdndice de Barthel [media (DE)] 83 (30) 148 (3,3) 86 (28) 58 (40) <0,001\n\u00cdndice de Barthel \u226460, n (%) 813 (18,9) 148 (3,3) 601 (15,1) 212 (46,2) <0,001\nDATOS CL\u00cdNICOS Y DE GRAVEDAD\nTemperatura en grados cent\u00edgrados [media (DE)] 37,4 (7,9) 14 (0,3) 37,4 (7,9) 37,3 (6,5) 0,704\nTemperatura > 38,3\u00b0C, n (%) 1.505 (34,0) 14 (0,3) 1.361 (34,2) 144 (31,4) 0,120\nFC en lpm [media (DE)] 99,9 (20,6) 67 (1,5) 99,4 (20,1) 104,1 (24,0) <0,001\nFC > 90 lpm 3.014 (68,9) 67 (1,5) 2.673 (67,2) 341 (74,3) 0,001\nFR en rpm [media (DE)] 21,2 (13,1) 306 (6,9) 21,01 (11,81) 23,28 (16,62) <0,001\nFR \u2265 22 rpm 1.640 (39,7) 306 (6,9) 1.355 (34,0) 285 (62,1) <0,001\nAlteraci\u00f3n de la consciencia ECG \u226414, n (%) 832 (19,1) 91 (2,1) 589 (14,8) 243 (52,9) <0,001\nPAS en mmHg [media (DE)] 122,3 (27,4) 30 (0,7) 123,7 (26,8) 110,6 (30,1) <0,001\nPAS \u2264 100 mmHg, n (%) 1.005 (22,8) 30 (0,7) 805 (20,2) 200 (43,6) <0,001\nCriterios de sepsis-2 (SRIS \u22652), n (%) 2.928 (71,06) 319 (7,2) 2.579 (64,8) 349 (76,0) <0,001\nqSOFA = 0, n (%) 1.623 (40,07) 386 (8,7) 1.594 (40,1) 29 (6,3) <0,001\nqSOFA = 1, n (%) 1.606 (39,65) 386 (8,7) 1.410 (35,4) 196 (42,7) <0,001\nqSOFA = 2, n (%) 646 (15,95) 386 (8,7) 504 (12,7) 142 (30,9) <0,001\nqSOFA = 3, n (%) 178 (4,39) 386 (8,7)  86 (2,2) 92 (20,0) <0,001\nCriterios de sepsis-3: qSOFA \u22652, n (%)  824 (20,34) 386 (8,7) 590 (14,8) 234 (51,0) <0,001\nCriterios Shock s\u00e9ptico (Sepsis-3), n (%)  405 (10,0) 389 (8,8)  282 (7,1) 123 (26,8) <0,001Tabla 1  Caracter\u00edsticas cl\u00ednico-epidemiol\u00f3gicas, de evoluci\u00f3n, anal\u00edticas y de destino \nla muestra global y estudio univariable en funci\u00f3n de la existencia o no de \nfallecimiento del paciente a 30 d\u00edasCapacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n \nen urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al.\nRev Esp Quimioter 2023;36(4): 408-415411DATOS DE EVOLUCI\u00d3N Y DESTINOTotal\nn=4.439 Valores \nperdidos Supervivientes \na 30 d\u00edas\nn=3.980 (89,7%)Fallecidos \na 30 d\u00edas\nn= 459 (10,3%)Valor p\nDestino inicial de los pacientes, n (%) 0 (0,0)  <0,001\n Alta 748 (16,9) 0 (0,0) 730 (18,3) 18 (3,9)\n Observaci\u00f3n y unidad corta estancia 335 (7,6) 0 (0,0) 327 (8,2) 8 (1,7)\n Planta de hospitalizaci\u00f3n convencional 2.722 (61,3) 0 (0,0) 2404 (60,4)  318 (69,3)\n Unidad de Cuidados Intensivos 284 (6,4) 0 (0,0) 226 (5,7) 58 (12,6)\n Fallecimiento en urgencias 38 (0,9) 0 (0,0) 0 (0,0) 38 (8,3)\nMortalidad a los 30 d\u00edas 459 (10,3) 0 (0,0) 0 (0,0) 459 (100,0)\nHALLAZGOS ANAL\u00cdTICOS Y MICROBIOL\u00d3GICOS \nBacteriemia verdadera n (%) 899 (20,5) 0 (0,0) 753 (18,9) 146 (31,8) <0,001\nCreatinina \u2265 2 mg/dl n (%) 588 (13,3) 26 (0,6) 444 (11,2) 144 (31,4) <0,001\nLeucocitos por mm3 [media (DE)] 14.144 (11.639) 0 (0,0) 14.024 (11.435) 15.191 (13.255) 0,043\n Leucocitosis > 12.000/ mm32.681 (60,4) 0 (0,0) 2.370 (59,5) 311 (67,8) <0,001\nCayados (bandas) > 10%, n(%) 238 (7,4) 1.225 (27,6) 199 (5,0) 39 (8,5) 0,001\nPlaquetas por mm3 [media (DE)] 219.800 (106.892) 26 (0,6) 218.092 (102.998) 227.500 (136.116) 0,105\n Trombopenia < 150.000/mm3, n(%) 999 (22,6) 26 (0,6) 881 (22,1) 118 (25,7) 0,042\nLactato s\u00e9rico en mmol/l ([media (DE)] 2,75 (2,96) 747 (16,8) 2,64 (2,93) 3,65 (3,09) <0,001\n Lactato \u2265 2 mmol/L, n (%) 1.562 (42,3) 747 (16,8) 1.292 (32,5) 270 (58,8) <0,001\nProcalcitonina en ng/ml [media (DE)] 3,41 (10,17) 139 (3,1) 3,06 (9,38) 6,24 (15,05) <0,001\nProte\u00edna C reactiva en mg/l [media (DE)] 15,01 (12,08) 362 (8,15) 14,67 (11,86) 18,16 (13,57) <0,001Tabla 1  Caracter\u00edsticas cl\u00ednico-epidemiol\u00f3gicas, de evoluci\u00f3n, anal\u00edticas y de destino \nla muestra global y estudio univariable en funci\u00f3n de la existencia o no de \nfallecimiento del paciente a 30 d\u00edas (cont.)\nDE: desviaci\u00f3n est\u00e1ndar; n: n\u00famero casos; AB: antibi\u00f3ticos; EPOC: Enfermedad pulmonar obstructiva cr\u00f3nica; C: cent\u00edgrados; FC: frecuencia \ncardiaca; lpm: latidos por minuto; FR: frecuencia respiratoria; rpm: respiraciones por minuto. ECG: escala del coma de Glasgow; PAS: presi\u00f3n \narterial sist\u00f3lica; SRIS: s\u00edndrome de respuesta inflamatoria sist\u00e9mica; qSOFA: quick Sepsis-related; Criterios de sepsis (SRIS\u00b3 2) seg\u00fan conferencia \nde Consenso de 2001 (Sepsis-2) (Descritos en referencia 1); Criterios de sepsis (qSOFA \u00b3 2) seg\u00fan la tercera conferencia de consenso (Sepsis-3) \n(Descritos en referencia 7)\nRESULTADOS\nDe los 4.923 pacientes seleccionados, finalmente se inclu -\nyeron 4.439 (se excluyeron 484 por perder su seguimiento o \ncambiar a otro diagn\u00f3stico en los 30 d\u00edas tras visitar urgencias), \ncon una edad media de 67 (DE 18) a\u00f1os, rango 18-103 a\u00f1os. \nEl 59,9% (2.661) ten\u00edan m\u00e1s de 65 a\u00f1os y 2.648 (59,6%) eran \nvarones. \nEn la primera evaluaci\u00f3n, seg\u00fan la puntuaci\u00f3n de la escala \nqSOFA, se clasificaron 1.623 pacientes (40,07%) como qSO -\nFA=0, 1.606 (39,65%) con qSOFA=1 y 824 pacientes (20,34%) \nen el grupo qSOFA \u22652 [646 (15,95%) qSOFA=2 y 178 (4,39%) \nqSOFA=3], consider\u00e1ndose 386 (8,7%) como valores perdidos al \nno estar registrado uno de sus tres criterios. \nEn el seguimiento de los 4.439 pacientes durante 30 d\u00edas fallecieron 459 (10,3%), de estos 38 (0,9%) durante su estancia \nen urgencias y seg\u00fan puntuaci\u00f3n de la qSOFA: 29 (1,8%) con \npuntuaci\u00f3n qSOFA=0; 196 (12,2%) con qSOFA=1; 142 (21,98%) \ncon qSOFA=2 y 234 (28,4%) con un qSOFA \u22652.\nEn la tabla 1 se muestran las caracter\u00edsticas \nsociodemogr\u00e1ficas, epidemiol\u00f3gicas, comorbilidades, funciona -\nles, cl\u00ednicas, de gravedad, de evoluci\u00f3n y destino de los pacien -\ntes, as\u00ed como los resultados de las determinaciones anal\u00edticas y \nde microbiolog\u00eda de la muestra global del estudio con los datos \ndel estudio comparativo de los casos de los pacientes que falle -\ncieron o no a los 30 d\u00edas.\nEn la figura 1 se muestra la capacidad predictiva de mor -\ntalidad a los 30 d\u00edas en pacientes atendidos en el servicio de \nurgencias por sospecha de infecci\u00f3n, as\u00ed como los par\u00e1metros \nde rendimiento pron\u00f3stico (Se, Es, VPP y VPN) de qSOFA=1, Capacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n \nen urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al.\nRev Esp Quimioter 2023;36(4): 408-415412\nMortalidad a corto plazo \n(30 d\u00edas)ABC-COR (IC 95%)\nValor pSe %\n(IC 95%)Es %\n(IC 95%)VPP %\n(IC 95%)VPN %\n(IC 95%)Comparativa de\nproporciones*\nqSOFA \u2265 2 + lactato \u2265 2 mmol/L0,74 (0,71-0,77)\np<0,00160\n(35-45)91\n(90-92)35\n(31-40)93\n(92-94)\np < 0,01\nqSOFA \u2265 20,69 (0,66-0,72)\np<0,00151\n(46-56)85\n(84-86)28\n(25-32)94\n(93-95)\nqSOFA=1 + lactato \u2265 2 mmol/L0,66 (0,63-0,69)\np<0,00168\n(61-75)70\n(67-73)20\n(17-22)92\n(90-94)\np < 0,01\nqSOFA=10,52 (0,49-0,55)\np = 0,38642\n(38-47)64\n(62-65)12\n(10-13)90\n(89-92)\nLactato \u2265 2 mmol/L  0,63 (0,61-0,66)\np<0,00168\n(63-72)61\n(59-63)18\n(16-20)94\n(93-95)\n Rendimiento para la predicci\u00f3n de mortalidad de los criterios definitorios de sepsis 2 (SRIS \u2265 2) y qSOFA=1 y su comparativa con los nuevos modelos combinados al a\u00f1adir \nel lactato\nABC-COR: \u00e1rea bajo la curva de la caracter\u00edstica operativa del receptor; IC 95%: intervalo de confianza al 95%; IC: intervalo de confianza; Se: sensibilidad; Es: \nespecificidad; VPP: valor predictivo positivo; VPN: valor predictivo negativo; qSOFA \u22652: Criterios de sepsis 3 (quick Sepsis Related Organ Failure Assessment) seg\u00fan la \ntercera conferencia de consenso (Sepsis-3) (referencia 7).\n*Nota: la comparativa de proporciones se realiz\u00f3 con el test de McNemar. Los valores p reflejados en la columna \u201ccomparativa de proporciones*\u201d se refiere a las diferencias \nencontradas entre los modelos combinados y los valores de qSOFA: (qSOFA \u2265 2 + lactato \u2265 2 mmol/L con qSOFA \u22652 y por otro lado qSOFA=1 + lactato \u2265 2 mmol/L con \nqSOFA =1)Figura 1  Rendimiento para la predicci\u00f3n de mortalidad de los criterios definitorios de sepsis 2 (SRIS \u2265 2) y \nqSOFA=1 y su comparativa con los nuevos modelos combinados al a\u00f1adir el lactatoCapacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n \nen urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al.\nRev Esp Quimioter 2023;36(4): 408-415413qSOFA \u22652 y los nuevos modelos combinados con lactacidemia \n\u22652 mmol/L. \nDISCUSI\u00d3N\nLos resultados del presente estudio nos permiten confir -\nmar la mejora del rendimiento predictivo de riesgo de mor -\ntalidad a 30 d\u00edas que ofrece el lactato en pacientes con qSO -\nFA=1, para los pacientes atendidos en los SU con sospecha de \nun proceso infeccioso. Este hecho ya hab\u00eda sido se\u00f1alado por \notros autores, as\u00ed como para los mayores de 75 a\u00f1os [9,11-\n15,17,18], aunque, en la mayor\u00eda de las ocasiones en pacientes \ncon qSOFA \u22652, es decir, los clasificados como de alto riesgo de \nmala evoluci\u00f3n y en los que se activa el \u201cc\u00f3digo sepsis\u201d y se \nindica su ingreso [1,9,12-14] . Todo ello, en la nueva l\u00ednea re -\ncomendada de no utilizar como screening de sepsis el q-SOFA \nde manera aislada, comparado con otras escalas, por su baja \nSe [5,16] . En nuestro estudio, qSOFA muestra una insuficiente \nSe (51% y 42% para qSOFA \u22652 y qSOFA=1, respectivamente) y \nmejor Es (85% y 64%), similar a los resultados en distintos me -\ntan\u00e1lisis (Se: 45-55% y Es 85-88%) [8,20] . Asimismo, el nuevo \nmodelo (qSOFA \u22652 + lactato \u22652 mmol/L) consigue un mayor \nrendimiento predictivo de mortalidad a 30 d\u00edas (ABC de 0,74 \ny Es de 91%) que qSOFA \u2265 2 aislado (0,69 y 85%). Y, por su \nparte, (qSOFA =1 + lactato \u22652 mmol/L) consigue tambi\u00e9n un \nmejor resultado (ABC de 0,66 y Es de 70%) que qSOFA=1 aisla -\ndo (0,52 y 64%), pero tambi\u00e9n mejora significativamente la Se \n(68% vs. 42%) y el VPN (92%  vs. 90%), siendo el responsable \nde ello la incorporaci\u00f3n del lactato. En este sentido, Seymour \net al [14], en el mismo art\u00edculo que valid\u00f3 el qSOFA, publicaron \nque la mortalidad hospitalaria de los pacientes q-SOFA=1 con \nniveles de lactato s\u00e9rico \u22652 mmol/L era similar a los pacientes \ncon q-SOFA \u22652. El estudio de Churpek et al [15], propuso bajar \nel umbral de positividad a q-SOFA \u22651 (q-SOFA1), ya que estos \npacientes ten\u00edan un comportamiento similar a los SIRS \u22652. Y \nDe Santos Castro PA, et al [17] encuentran que la baja Se del \nqSOFA1 de 42% aumentaba al 78% con una Es de 70% al a\u00f1a -\ndir el lactato (qSOFA-lactato). Por lo tanto, el qSOFA-lactato \npuede representar una \u00fatil herramienta de ayuda a la hora de \nreclasificar aquellos pacientes con qSOFA=1, para as\u00ed optimizar \nlas decisiones inmediatas que se deben tomar en los SU: indi -\ncaci\u00f3n de extracci\u00f3n de hemocultivos, administrar una terapia \nantimicrobiana adecuada y precoz y el ingreso hospitalario o el \nalta domiciliaria, entre otras [1,4,5,16] . \nNuestro estudio tiene distintas limitaciones. En primer \nlugar, el reclutamiento de casos fue por oportunidad (cuan -\ndo los investigadores estaban de guardia), con el componente \nde sesgo de inclusi\u00f3n introducido. En segundo lugar hubo da -\ntos perdidos (lactato en el 16,8% y alguno de los criterios de \nqSOFA en el 8,7%). Adem\u00e1s, el 9,8% de los pacientes incluidos \ninicialmente fueron excluidos en los 30 d\u00edas de seguimiento. \nEn tercer lugar, el momento y el tipo de tratamiento no se eva -\nluaron, y estos aspectos pueden condicionar el desenlace de la \nenfermedad. \nA pesar de estas limitaciones, creemos que el estudio es un \nreflejo de la realidad cl\u00ednica de nuestros SU. Como conclusi\u00f3n de este estudio podemos se\u00f1alar que \npara predecir mortalidad a los 30 d\u00edas en los pacientes que acu -\nden al SU por un episodio de infecci\u00f3n, el modelo qSOFA=1 + \nlactato\u22652 mmol/L mejora significativamente el poder predictivo \nconseguido de forma individual por qSOFA1 y llega a ser muy \nsimiliar al de qSOFA \u22652. Aunque, futuros estudios multic\u00e9ntricos \nde validaci\u00f3n externa del modelo son necesarios. \nAGRADECIMIENTOS\n**Otros miembros del grupo INFURG-SEMES (Grupo \nde Infecciones de la Sociedad Espa\u00f1ola de Medicina de \nUrgencias y Emergencias) participantes en el estudio:  Jo-\nsep Mar\u00eda Guardiola Tey (Hospital de Sant Pau de Barcelona), \nMarta \u00c1lvarez Alonso (Hospital Universitario de Fuenlabrada), \nBego\u00f1a Mora Ordo\u00f1ez (Hospital Virgen de la Victoria de M\u00e1 -\nlaga), Oscar \u00c1lvarez L\u00f3pez (Hospital Universitario de M\u00f3stoles), \nFerr\u00e1n Llopis-Roca (Hospital Universitario de Bellvitge), Mar \nOrtega Romero (Hospital Cl\u00ednic de Barcelona), Esperanza Puga \nMontalvo (Hospital Campus de la Salud de Granada), Ram\u00f3n \nPerales Pardo (Complejo Hospitalario Universitario de Albace -\nte), Mikel Mart\u00ednez-Ortiz de Zarate (Hospital Universitario de \nBasurto), Mar\u00eda Jos\u00e9 Marchena Gonz\u00e1lez (Hospital Juan Ram\u00f3n \nJim\u00e9nez de Huelva), Mar\u00eda del Mar Sousa Reviriego (Hospital \nNuestra Se\u00f1ora del Prado de Talavera), Jos\u00e9 Mar\u00eda Ferreras \nAmez (Hospital Cl\u00ednico Universitario Lozano Blesa de Zarago -\nza), Henrique Villena Garc\u00eda del Real (Complejo Hospitalario \nUniversitario de Santiago de Compostela), Bel\u00e9n Arribas En -\ntrala (Hospital Universitario Miguel Servet de Zaragoza), Marta \nHonrado Fern\u00e1ndez de Valderrama (Hospital Santiago Ap\u00f3stol \nde Miranda de Ebro), Eva Quero Motto (Hospital Virgen de la \nArrixaca de Murcia), Agust\u00edn Ar\u00e9valo Velasco (Complejo Asis -\ntencial Universitario de Salamanca), Manel R. Chanovas-Borr\u00e0s \n(Hospital Verge de la Cinta de Tortosa), Mar\u00eda B\u00f3veda Garc\u00eda \n(Hospital La Fe de Valencia), Pascual Pi\u00f1era Salmer\u00f3n (Hospi -\ntal Universitario Re\u00edna Sof\u00eda de Murcia), \u00c1ngel Estella Garc\u00eda \n(Hospital Universitario de Jerez), Octavio Jos\u00e9 Salmer\u00f3n B\u00e9liz \n(Hospital Universitario Fundaci\u00f3n de Alcorc\u00f3n), Guillermo Bu -\nrillo Putze (Hospital Universitario de Canarias), Ester Moncl\u00fas \nCols (Hospital Sant Jaume de Calella de Barcelona), Marta Bala -\nguer Catal\u00e1n (Hospital Universitario Doctor Peset de Valencia), \nManuel Gil Mosquera (Hospital Universitario 12 de octubre de \nMadrid), F\u00e9lix Gonz\u00e1lez Mart\u00ednez (Hospital Virgen de la Luz de \nCuenca), Ainhoa Urraca Gamaury (Complejo Asistencial de Za -\nmora), Jes\u00fas \u00c1lvarez-Manzanares (Hospital Universitario R\u00edo \nHortega de Valladolid), Luis Quero Reboul  (Hospital Virgen de \nla Merced de Osuna), Agurtzane Auzmendi Aguirre (Hospital \nde Mendaro de Gipuzkoa), Federico Melgosa Latorre (Hospital \nde Alto Deba de Arrasate), Francisco Jos\u00e9 Ezponda Inchauspe \n(Hospital de Zum\u00e1rraga), Pilar Jim\u00e9nez (Hospital de Antequera),  \nJosefina Monedero La Orden  (Hospital de Almansa), Ariel Ruben \nLindo Noriega (Hospital de Villarrobledo), Marta Iglesias Vela \n(Complejo Asistencial Universitario de Le\u00f3n), Inmaculada Ad\u00e1n \nValero (Hospital de Valdepe\u00f1as), Julio Javier Gamazo-Del Rio \n(Hospital Universitario de Galdakao-Usansolo), Bel\u00e9n Rodr\u00edguez \n(Hospital Universitario Rey Juan Carlos), Francisco J Arambu -Capacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n \nen urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al.\nRev Esp Quimioter 2023;36(4): 408-415414ru (Complejo Hospitalario Universitario de Ourense), B\u00e1rbara \nD\u00edaz Garc\u00eda (Hospital de Barbanza), Virginia \u00c1lvarez Rodr\u00edguez \n(Hospital Universitario de Getafe), \u00c1ngel Jos\u00e9  Mac\u00edas L\u00f3pez \n(Complejo Asistencial de \u00c1vila), Mar\u00eda Deb\u00e1n Fern\u00e1ndez (Hos -\npital Central de Asturias), Fernando Rodr\u00edguez P\u00e9rez-Reverte \n(Hospital Universitario Santa Luc\u00eda de Cartagena en Murcia), \nNeus Robert (Hospital de Can Ruti), Silvia Flores Quesada (Hos -\npital San Pau i Santa Tecla de Tarragona), Rosa Garc\u00eda Garc\u00eda \n(Hospital Virgen de las Nieves de Granada), Raquel Rodr\u00edguez \nCalveiro (Hospital \u00c1lvaro Cunqueiro de Vigo), Manuel Garc\u00eda \nNovio (Hospital Universitario Lucus Augusti de Lugo), Laura \nGonz\u00e1lez Gonz\u00e1lez (Hospital del Salnes de Vilagarc\u00eda de Arou -\nsa), Elena Carrasco Fern\u00e1ndez (Hospital Virgen de Altagracia de \nManzanares), Mar\u00eda Pilar Lozano Garc\u00eda (Hospital Universitario \nde Guadalajara), Rigoberto Del Rio Navarro (Hospital de Torre -\nvieja), Elizabeth Ortiz Garc\u00eda (Hospital Santa B\u00e1rbara de Soria), \nLeopoldo S\u00e1nchez Santos (Hospital Universitario de Burgos), \nRosario Peinado (Hospital Infanta Cristina de Badajoz), Beatriz \nValle Borrego (Hospital Severo Ochoa de Legan\u00e9s), Pablo Javier \nMarchena Yglesias  (Parc Sanitari Sant Joan de D\u00e9u de Sant Boi \nde Llobregat), Cristina Herranz Mart\u00ednez (Hospital de Viladecans \nde Barcelona), N\u00faria Pomares (Fundaci\u00f3 Hospital de Mollet).\nFINANCIACI\u00d3N\nLos autores declaran que no han recibido financiaci\u00f3n para \nla realizaci\u00f3n de este estudio.  \nCONFLICTO DE INTERESES \nLos autores declaran no tener conflicto de intereses \nBIBLIOGRAF\u00cdA\n1. Juli\u00e1n-Jim\u00e9nez A, Supino M, L\u00f3pez Tapia JD, Ulloa Gonz\u00e1lez C, \nVargas T\u00e9llez LE, Gonz\u00e1lez del Castillo J, et al. Puntos clave y con -\ntroversias sobre la sepsis en los servicios de urgencias: propues -\ntas de mejora para Latinoam\u00e9rica. Emergencias 2019;31:123-135. \nPMID: 30963741\n2. Juli\u00e1n-Jim\u00e9nez A, Garc\u00eda DE, Gonz\u00e1lez del Castillo J, Guimara\u0303es HP, \nGarc\u00eda-Lamberechts EJ, Men\u00e9ndez E, et al, en nombre del Grupo de \nTrabajo Latinoamericano para la mejora de la atenci\u00f3n del pacien -\nte con Infecci\u00f3n en Urgencias (GT-LATINFURG). Puntos clave sobre \nla COVID-19 en los servicios de urgencias: propuestas de mejora \npara su atenci\u00f3n en Latinoam\u00e9rica. Emergencias. 2021;33:42-58. \nPMID: 33496399\n3. Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. \nMortality in sepsis and septic shock in Europe, North America and \nAustralia between 2009 and 2019 \u2013results from a systematic re -\nview and meta-analysis. Crit Care. 2020;24:239. doi: 10.1186/\ns13054-020-02950-2.\n4. Candel FJ, Borges Sa M, Belda S, Bou G, Del Pozo JL, Estrada O, et al. \nCurrent aspects in sepsis approach. Turning things around. Rev Esp \nQuimioter. 2018;31:298-315. PMID: 299389725. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, \nFrench C, et al. Surviving sepsis campaign: international guidelines \nfor management of sepsis and septic shock 2021. Crit Care Med. \n2021;49:e1063-e1143. doi: 10.1097/CCM.0000000000005337. \n6. Ar\u00e9valo P, Morales I, Olivares E, Guler I, Rodr\u00edguez MA, L\u00f3pez PJ. \nCapacidad predictiva de las escalas de alerta temprana en los ser -\nvicios de urgencias hospitalarios: revisi\u00f3n sistem\u00e1tica y metan\u00e1lisis. \nEmergencias. 2021;33:374-81. PMID: 34581531\n7. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane \nD, Bauer M, et al. The Third International Consensus Definitions for \nSepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-10. doi: \n10.1001/jama.2016.0287. \n8. Serafim R, Gomes JA, Salluh J, P\u00f3voa P. A comparison of the quick-\nSOFA and systemic inflammatory response s\u00edndrome criteria for the \ndiagnosis of sepsis and prediction of mortality: A systematic re -\nview and me- ta-analysis. Chest. 2018;153:646-55. doi: 10.1016/j.\nchest.2017.12.015.\n9. Rubio-D\u00edaz R, Juli\u00e1n-Jim\u00e9nez A, Gonz\u00e1lez Del Castillo J, Garc\u00eda-\nLamberechts EJ, Huarte Sanz I, Navarro Bustos C, et al. Capacidad \ndel lactato, procalcitonina y de los criterios definitorios de sepsis \npara predecir mortalidad a 30 d\u00edas, bacteriemia o infecci\u00f3n con -\nfirmada microbiol\u00f3gicamente en los pacientes atendidos por sos -\npecha de infecci\u00f3n en urgencias. Emergencias. 2022;34:181-9. \nPMID: 35736522\n10. Llopis-Roca F, L\u00f3pez Izquierdo R, Miro O, Garc\u00eda-Lamberechts JE, \nJuli\u00e1n Jim\u00e9nez A, Gonz\u00e1lez Del Castillo J. Mapa de la situaci\u00f3n \nactual de la atenci\u00f3n a la sepsis en los servicios de urgencias es -\npa\u00f1oles. Rev Esp Quimioter. 2022;35:192-203. doi: 10.37201/\nreq/150.2021. \n11. Juli\u00e1n-Jim\u00e9nez A, Ya\u00f1ez MC, Gonz\u00e1lez del Castillo J, Salido-Mota \nM, Mora-Ord\u00f3\u00f1ez B, Arranz-Nieto MJ, et al. Poder pron\u00f3stico de \nmortalidad a corto plazo de los biomarcadores en los ancianos \natendidos en Urgencias por infecci\u00f3n. Enferm Infecc Microbiol Clin. \n2019;37:11-8. doi: 10.1016/j.eimc.2017.11.017.\n12. Ya\u00f1ez MC, Salido Mota M, Fuentes Ferrer M, Juli\u00e1n-Jim\u00e9nez A, \nPi\u00f1era P, Llopis F, et al. Comparaci\u00f3n de distintas estrategias para la \npredicci\u00f3n de muerte a corto plazo en el paciente anciano infecta -\ndo. Rev Esp Quimioter. 2019;32:156-64. PMID: 30808154\n13. Juli\u00e1n-Jim\u00e9nez A, Candel-Gonz\u00e1lez FJ, Gonz\u00e1lez del Castillo J. Uti -\nlidad de los biomarcadores de inflamaci\u00f3n e infecci\u00f3n en los ser -\nvicios de urgencias. Enferm Infecc Microbiol Clin. 2014;32:177-90. \ndoi: 10.1016/j.eimc.2013.01.005\n14. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag \nA, et al. Assessment of Clinical Criteria for sepsis: Fort The Third \nInternational Consensus Definitions for sepsis and Septic Shock \n(sepsis-3). JAMA. 2016;315:762-74. doi: 10.1001/jama.2016.0288.\n15. Churpek MM, Snyder A, Han X, Sokol S, Pettit N, Howell MD, et al. \nQuick Sepsis-related Organ Failure Assessment, Systemic Inflam -\nmatory Response Syndrome, and Early Warning Scores for detec -\nting clinical deterioration in infected patients outside the Intensive \nCare Unit. Am J Resp Crit Care Med. 2017;7:906-11. doi: 10.1164/\nrccm.201604-0854OC\n16. Juli\u00e1n-Jim\u00e9nez A, Garc\u00eda DE, Gonz\u00e1lez Del Castillo J, L\u00f3pez Tapia Capacidad del qSOFA1-lactato para predecir mortalidad a 30 d\u00edas en los pacientes atendidos por infecci\u00f3n \nen urgenciasA. Juli\u00e1n-Jim\u00e9nez, et al.\nRev Esp Quimioter 2023;36(4): 408-415415JD. De la gu\u00edas internacionales \u201cCampa\u00f1a para sobrevivir a la sepsis \n2021\u201d a las gu\u00edas para \u201cDetectar, prevenir la progresi\u00f3n y atender \na los pacientes con infecci\u00f3n grave en urgencias\u201d elaboradas por \nurgenci\u00f3logos. Emergencias. 2022;34:471-73. PMID: 36625699\n17. De Santos Castro PA, Alonso Avil\u00e9s R, Arranz D\u00edez B, Mayo Garc\u00eda \nV, Gonz\u00e1lez Hurtado E, Mat\u00edas Rodr\u00edguez S. \u00bfPodemos rescatar el \nq-SOFA?. Rev Esp Urg Emeg. 2022;1:69-74\n18. De Santos Castro PA, Alonso Avil\u00e9s R. Sobre la capacidad de lac -\ntato, procalcitonina y los criterios definitorios de sepsis para pre -\ndecir mortalidad a 30 d\u00edas, bacteriemia o infecci\u00f3n confirmada \nmicrobiol\u00f3gicamente en los pacientes atendidos por sospecha de \ninfecci\u00f3n en urgencias. Emergencias 2022;34:406 PMDI:36217940\n19. Juli\u00e1n-Jim\u00e9nez A, Gonz\u00e1lez Del Castillo J, Garc\u00eda-Lamberechts EJ, \nHuarte Sanz I, Navarro Bustos C, Rubio D\u00edaz R, et al. A bacteraemia \nrisk prediction model: development and validation in an emergen -\ncy medicine population. Infection. 2022;50:203-21.  doi: 10.1007/\ns15010-021-01686-7.\n20. Fernando SM, Tran A, Taljaard M, Cheng W, Rochwerg B, Seely \nAJE, et al. Prognostic accuracy of the quick sequential organ fai -\nlure assessment for mortality in patients with suspected infection: \nA systematic review and meta-analysis. Ann Intern Med. 2018; \n168:266-75. doi: 10.7326/M17-2820.ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/014.2023\nRev Esp Quimioter 2023;36(4): 416-420416High macrolides and fluoroquinolones \nresistance rate in Mycoplasma genitalium  in \nsouthern Tenerife\nABSTRACT\nIntroduction. Mycoplasma genitalium (MG) is a recog -\nnized sexually transmitted pathogen. Increasing resistance to \nmain lines of treatment (macrolides and quinolones) justifies a \ngenetic study of mutations to improve cure rates.\nMaterial and methods. A total of 8,508 samples from \nApril 2018 to July 2022 were processed using Allplex TM STI Es -\nsential Assay. In MG positive cases 23S rRNA V domain , gyrA  \nand parC  genes were studied. Mutations detected were checked \nto assess their clinical significance and medical records were \nreviewed to obtain demographic and treatment information.\nResults. Resistance study was performed on 92 samples \n(65 men and 27 women). In relation to the genotypic study, \n28 patients presented mutations to macrolides (30.43%).Most \ncommon was A2059G (18.48%). For quinolones, 5 patients \n(5.43%) had clinically relevant mutations in parC gene.Of note \nwas a patient with G295 mutation in gyrA associated with \nG248T in parC. Thirty subjects underwent a test of cure (TOC). \nAzithromycin was the most common empirical regimen and \nmoxifloxacin the main alternative.\nConclusions. High rate of resistance in our environment \nevidences the need for targeted therapy by genotypic study of \nmacrolide resistance, supported by the detection of mutations \nin parC and gyrA to predict quinolones susceptibility and the \nuse of TOC to evaluate treatment response.\nKeywords: Mycoplasma genitalium , macrolides, fluoroquinolones.Elevada tasa de resistencia a macr\u00f3lidos y \nfluoroquinolonas en Mycoplasma genitalium  en el \n\u00e1rea sur de Tenerife\nServicio de Microbiolog\u00eda y Parasitolog\u00eda Hospital Universitario Nuestra Se\u00f1ora de Candelaria, Tenerife, SpainCristian Mateo Le\u00f3n\nDiego Garc\u00eda Mart\u00ednez de Artola\nBerta Pino-CalmOriginal breve\nArticle history\nReceived: 29 January 2023; Revision Requested: 14 February 2023; Revision Received: 6 March 2023;  \nAccepted: 23 March 2023; Published: 8 May 2023 \nRESUMEN\nIntroducci\u00f3n. Mycoplasma genitalium (MG) es un re -\nconocido pat\u00f3geno de transmisi\u00f3n sexual. El aumento de las \nresistencias asociadas a las principales l\u00edneas de tratamiento \n(macr\u00f3lidos y quinolonas) justifican un estudio gen\u00e9tico de \nmutaciones para mejorar las tasas de curaci\u00f3n.\nMaterial y m\u00e9todos. Un total de 8.508 muestras fueron \nanalizadas entre abril de 2018 y julio de 2022 para la detec -\nci\u00f3n de MG mediante la t\u00e9cnica de PCR multiplex Allplex TM \nSTI Essential Assay.En los casos positivos para MG se estudi\u00f3 \nel dominio V del gen 23S rRNA  y los genes  gyrA  y parC . Se \nevalu\u00f3 la importancia cl\u00ednica de las mutaciones y se revisaron \nlas historias cl\u00ednicas para obtener informaci\u00f3n demogr\u00e1fica y \nde tratamiento.\nResultados. Se realiz\u00f3 estudio de resistencias a 92 muestras \n(65 hombres y 27 mujeres). En lo relativo al estudio genot\u00edpico, \n28 pacientes presentaban mutaciones a macr\u00f3lidos (30,43%). La \nm\u00e1s habitual fue A2059G (18.48%). Para las quinolonas, 5 pa -\ncientes (5,43%) presentaron mutaciones cl\u00ednicamente relevantes \nen el gen parC. Destaca un paciente con la mutaci\u00f3n G295 en  \ngyrA asociada a G248T en parC.  Treinta individuos se sometieron \nal test de cura (TOC). La azitromicina fue el r\u00e9gimen emp\u00edrico m\u00e1s \ncom\u00fan y el moxifloxacino la principal alternativa.\nConclusiones. La elevada tasa de resistencias en nuestro \nentorno evidencia la necesidad de realizar una terapia dirigida \npor el estudio genot\u00edpico de resistencias a macr\u00f3lidos, apoy\u00e1n -\ndonos en la detecci\u00f3n de mutaciones en parC y gyrA para pre -\ndecir la susceptibilidad a quinolonas y en el uso del TOC para \nevaluar la respuesta al tratamiento.\nPalabras clave: Mycoplasma genitalium , macr\u00f3lidos, fluoroquinolonas.\nCorrespondence: \nCristian Mateo Le\u00f3n.\nServicio de Microbiolog\u00eda y Parasitolog\u00eda Hospital Universitario Nuestra Se\u00f1ora de Candelaria, \nTenerife, Spain.\nE-mail: cristianmateoleon@gmail.com.Elevada tasa de resistencia a macr\u00f3lidos y fluoroquinolonas en Mycoplasma genitalium  en el \u00e1rea sur de \nTenerifeC. Mateo Le\u00f3n, et al.\nRev Esp Quimioter 2023;36(4): 416-420417durante 7 d\u00edas.\nEn este contexto, el tratamiento dirigido basado en la de -\ntecci\u00f3n por reacci\u00f3n en cadena de la polimerasa (PCR) de las \nprincipales mutaciones que confieren resistencias a macr\u00f3lidos, \npermite comenzar de forma precoz con el tratamiento de se -\ngunda l\u00ednea, mejorando el porcentaje de curaci\u00f3n inicial de un \n60 a un 90 % aproximadamente  [5].\nPara evaluar la eficacia del tratamiento, la IUSTI recomien -\nda la realizaci\u00f3n de un test de cura (TOC) a partir de la tercera \nsemana de la finalizaci\u00f3n del tratamiento  [6].\nEl objetivo de este estudio se centra en conocer la epide -\nmiolog\u00eda y las resistencias asociadas a MG  en el \u00e1rea sur de Te -\nnerife, haciendo hincapi\u00e9 en el impacto que estas mutaciones \ntienen en el tratamiento.\nMATERIAL Y M\u00c9TODOS\nUn total de 8.508 muestras fueron analizadas en el per\u00edodo \nde abril de 2018 a julio de 2022 para la detecci\u00f3n de MG me -\ndiante la t\u00e9cnica de PCR multiplex en tiempo real AllplexTM STI \nEssential Assay (Seegene).\nSe excluyeron las muestras positivas de pacientes a los que \nse le realiz\u00f3 estudio de resistencias dentro de los 3 meses an -\nteriores. Adem\u00e1s, una carga bacteriana baja (Ct>30) supuso un \nimportante h\u00e1ndicap para la amplificaci\u00f3n y posterior detec -\nci\u00f3n de resistencias.INTRODUCCI\u00d3N\nMycoplasma genitalium  (MG) es un microorganismo de \ntransmisi\u00f3n sexual reconocido como un grave problema de sa -\nlud a nivel global debido a su alta tasa de resistencia a antimi -\ncrobianos. Se asocia a cervicitis, enfermedad p\u00e9lvica inflamato -\nria e infertilidad en mujeres, aunque destaca como causante de \nuretritis no gonoc\u00f3cica en varones, en porcentajes que oscilan \nentre el 10-30% [1].\nHist\u00f3ricamente, la presencia de requerimientos especiales \nen el cultivo y su lento crecimiento dificultan su identificaci\u00f3n \ny la realizaci\u00f3n del antibiograma. En la actualidad, las t\u00e9cnicas \nde amplificaci\u00f3n de \u00e1cidos nucleicos han supuesto una revolu -\nci\u00f3n en el diagn\u00f3stico de este pat\u00f3geno [2].\nEn relaci\u00f3n al tratamiento, la ausencia de pared celular li -\nmita las opciones terap\u00e9uticas. Las \u00faltimas recomendaciones \nde The International Union against Sexually Transmitted Infec -\ntions (IUSTI) proponen como tratamiento de elecci\u00f3n azitromi -\ncina 500 mg/d\u00eda 1 d\u00eda, seguido de 250 mg/ d\u00eda durante 4 d\u00edas. \nNo obstante, en los \u00faltimos a\u00f1os, diferentes metaan\u00e1lisis han \nnotificado un importante incremento de las resistencias aso -\nciadas a macr\u00f3lidos; del 10 % en estudios anteriores a 2010, a \nalrededor del 50 % en estudios publicados en 2016 y 2017 [3].\nLa principal alternativa terap\u00e9utica son las fluoroquinolo -\nnas, con un porcentaje de resistencias mucho menor (7-10%) \n[4], siendo la pauta m\u00e1s aceptada moxifloxacino 400 mg/d\u00eda \nFigura 1 Diagrama de flujo del procesamiento de las muestras.8508 muestras\n225 positivos 133 pacientes excluidos\u2022 121 pacientes con Ct>30\n\u2022 2 pacientes positivos en los 3 meses anteriores\n\u2022 1O pacientes con problemas relacionados con la muestra y/o \nsecuenciaci\u00f3n\n55 pacientes sin mutaciones\u2022 28 pacientes mutaciones en 23 S\n\u2022 15 pacientes mutaciones en gyrA/parC15 pacientes TOC92 muestras con estudio de resistencias\n65 hombres\n27 mujeresElevada tasa de resistencia a macr\u00f3lidos y fluoroquinolonas en Mycoplasma genitalium  en el \u00e1rea sur de \nTenerifeC. Mateo Le\u00f3n, et al.\nRev Esp Quimioter 2023;36(4): 416-420418el estudio de resistencias a 92 muestras (40.88%), de las cu\u00e1les \n65 (70.65%) correspond\u00edan a hombres y 27 (29,34%) a mujeres \n(Figura 1).\nEn las mujeres la muestra de elecci\u00f3n fue el exudado en -\ndocervical (92.6%), mientras que en los hombres fue el exuda -\ndo uretral (83,07%) y el rectal (9,23%). Tambi\u00e9n se detectaron \n4 casos en orina y 5 en otras localizaciones.\nEn lo relativo al estudio genot\u00edpico, 28 pacientes pre -\nsentaban mutaciones que confieren resistencias a macr\u00f3lidos \n(30,43%). Las m\u00e1s habituales fueron A2058T (1.09%), A2058G \n(10.87%) y A2059G (18.48%).\nPara las quinolonas, en el gen parC fueron detectadas mu -\ntaciones en 15 pacientes. Sin embargo, s\u00f3lo 5 de ellos (5,43%), \npresentaban resistencias con demostrada relevancia cl\u00ednica. As\u00ed, \nencontramos 1 mutaci\u00f3n G248T(S83I) (1.09%),1 G248A (S83N) \n(1.09%) y 3 G259T (D87Y) (3.26%). En relaci\u00f3n a las mutaciones \nen gyrA, cabe destacar a un paciente que presentaba la muta -\nci\u00f3n G295A (D99N) asociada a G248T(S83I) en parC.\nEl resto de polimorfismos \u00fanicos de nucle\u00f3tido (SNP) no \ndescritos en la bibliograf\u00eda o sin demostrado significado cl\u00ednico \naparecen recogidos en la Tabla 1.\nCon respecto a la antibioterapia, se realiz\u00f3 TOC a 30 pa -\ncientes (32.6%), de los cuales 11 presentan resistencias \u00fanica -\nmente a macr\u00f3lidos y 4 a macr\u00f3lidos y quinolonas.El estudio de resistencias se bas\u00f3 en analizar el dominio \nV del gen 23S rRNA  (283pb)  [7] para determinar la resistencia \nfrente a macr\u00f3lidos y la regi\u00f3n determinante de resistencia a \nquinolonas (QRDR) de los genes gyrA y parC, causantes de re -\nsistencia a fluoroquinolonas [8].\nLos amplicones fueron secuenciados mediante tecnolog\u00eda \nSanger BigDye Terminator v3.1 Cycle Sequence Kit (Applied \nBiosystems, Foster City, CA) en un secuenciador ABI 3500 \n(Applied Biosystems).\nLas mutaciones detectadas frente a la cepa de referencia \nMycoplasma genitalium G37  (NC_000908.2) fueron registradas \npara estudiar si supon\u00edan un cambio aminoac\u00eddico relacionado \ncon las resistencias descritas en las diferentes bases de datos.\nLas historias cl\u00ednicas de los pacientes fueron revisadas re -\ncopilando datos demogr\u00e1ficos, tratamiento antibi\u00f3tico utiliza -\ndo, realizaci\u00f3n de test de cura, nueva consulta en el centro o \npersistencia de los s\u00edntomas.\nRESULTADOS\nDurante el periodo estudiado, 225 muestras fueron posi -\ntivas para MG (2,64%), con una prevalencia mayor en hombres \n(3,59%) que en mujeres (1,68%). La mediana de edad fue 38,5 \na\u00f1os (rango 14-68).\nDespu\u00e9s de aplicar los criterios de exclusi\u00f3n se les realiz\u00f3 Macr\u00f3lidos: dominio V 23S rRNA N\u00ba muestrasaHombres Mujeres Relevancia cl\u00ednica\nA2058T 1 (1,09%) 1(1,54%) s\u00ed\nA2058G 10 (10,87%) 10 (15,38%) s\u00ed\nA2059G 17 (18,48) 16 (24,61%) 1 (3.7) s\u00ed\nQuinolonas\nparC\nC184T(P62S) 9 (9,78%) 7 (10,17%) 2 (7.40%) no\nG248T(S83I) 1 (1,09%) 1 (1,54%) s\u00ed\nG248A (S83N) 1 (1,09%) 1 (1,54%) s\u00edb\nG259T (D87Y) 3 (3,26%) 3 (4,61%) s\u00ed\nA281T (G94L) 1 (1,09%) 1 (1,54%) no descrita\ngyrA\nG286A(A96T) 1 (1,09%) 1 (1,54%) no descrita\nG295A (D99N)d1 (1,09%) 1 (1,54%) s\u00edcTabla 1  Mutaciones detectadas en macr\u00f3lidos (dominio V 23s) y quinolonas ( gyrA y parC).\naDatos sobre poblaci\u00f3n total a la que se le han realizado resistencias.\nbCaracter\u00edsticas similares a C284T (S83I).\ncAsociado a mutaciones en parC.\ndAsociada a la mutaci\u00f3n G248T(S83I) en parC.Elevada tasa de resistencia a macr\u00f3lidos y fluoroquinolonas en Mycoplasma genitalium  en el \u00e1rea sur de \nTenerifeC. Mateo Le\u00f3n, et al.\nRev Esp Quimioter 2023;36(4): 416-420419[9,10]. En las muestras que presentaron mutaciones, en cuatro \npacientes se observ\u00f3 tratamiento previo con 1,5 gramos de azi -\ntromicina; esta pauta se ha relacionado con un aumento de las \nresistencias a macr\u00f3lidos [3].\nPara las fluoroquinolonas, la ausencia de la mutaci\u00f3n S83I \nen parC  es altamente predictiva de curaci\u00f3n con moxifloxaci -\nno [11,12]. Otros SNP con relevancia cl\u00ednica son S83N, D87N \ny D87Y, aunque su papel est\u00e1 menos establecido y es nece -\nsario profundizar en su importancia en el futuro. El papel del \ngen parC ha sido escasamente descrito en estudios nacionales, \ncomo el de De Salazar et al [13].\nSolamente 5 de nuestros pacientes presentaban mutacio -\nnes relevantes cl\u00ednicamente. La mutaci\u00f3n D87Y se encontr\u00f3 en \n3 pacientes. En dos de ellos no se realiz\u00f3 test de cura, por lo que \nno podemos asegurar que se solventara el cuadro, y en el otro \nindividuo el cuadro se resolvi\u00f3 con moxifloxacino. Un paciente \npresentaba la mutaci\u00f3n S83N, del cual no se pudo obtener da -\ntos en relaci\u00f3n a la antibioterapia ni a la resoluci\u00f3n del caso y \nel \u00faltimo presentaba la mutaci\u00f3n G248T(S83I) en parC asociada \na G295A (D99N) en gyrA. Este paciente presentaba persistencia \nen los s\u00edntomas y finalmente fue tratado con minociclina. Aun -En la tabla 2 se describen los tratamientos emp\u00edricos y el \ntratamiento dirigido post test de cura de los pacientes con al -\nguna mutaci\u00f3n.\nPor otro lado, 13 pacientes a los que se les detect\u00f3 resis -\ntencias (13/28) no acudieron a consulta o no realizaron test \nde cura. Se obtuvo informaci\u00f3n acerca del tratamiento en 5 \nde ellos; dos pacientes resolvieron el cuadro cl\u00ednico con tra -\ntamiento emp\u00edrico con doxiciclina y al resto se les modific\u00f3 \nel tratamiento emp\u00edrico por persistencia de s\u00edntomas (en una \nocasi\u00f3n se cambi\u00f3 a eritromicina y en los otros 2 se utiliz\u00f3 \nmoxifloxacino).\nDISCUSI\u00d3N\nLos resultados de nuestro estudio evidencian una preva -\nlencia y una tasa de resistencias a los principales antibi\u00f3ticos \nimplicados en el tratamiento de MG  semejantes a lo descrito en \nla bibliograf\u00eda  [3].\nCon respecto a las mutaciones asociadas a la resistencia \na macr\u00f3lidos, los resultados son similares a los publicados en \notras regiones del pa\u00eds, siendo la mayoritaria la A2059G (17/28).  Paciente Tratamiento previo Mutaci\u00f3n 23 s Mutaci\u00f3n parC/gyrA Test de cura Tratamiento dirigido Resoluci\u00f3n del cuadro\n1* Azitromicina + Doxiciclina A2059G - - s\u00ed\n2* Azitromicina A2059G + Levofloxacino s\u00ed\n3* Peniciclina G + azitromicina A2058T - - s\u00ed\n4 Azitromicina A2059G C184T + Moxifloxacino s\u00ed\n5 Azitromicina A2059G + Doxiciclina s\u00ed\n6 Azitromicina A2058G + ND ND\n7 Azitromicina A2058GG248T/\nG295A+ ND No (minociclina)\n8*Penicilina G+ ceftriaxona + \nazitromicinaA2059G + Moxifloxacino s\u00ed\n9 ND A2059G G248A + ND ND\n10* Penicilina G A2059G - - s\u00ed\n11 ND A2058G + ND ND\n12 Azitromicina A2059G - - s\u00ed\n13 Azitromicina A2059G + Moxifloxacino s\u00ed\n14 Azitromicina A2059G + Moxifloxacino s\u00ed\n15 Azitromicina A2058G G259T + Moxifloxacino s\u00edTabla 2  Tratamiento emp\u00edrico, tratamiento de segunda l\u00ednea y evoluci\u00f3n de los pacientes con \nmutaciones detectadas que realizaron test de cura.\n-: Negativo; +: Positivo; ND: no disponible.\n*Paciente 1: coinfecci\u00f3n con Neisseria gonorrhoeae . Paciente 2: cobertura emp\u00edrica. Paciente 3 y 10: coinfecci\u00f3n con Treponema  pallidum .  \nPaciente 8: coinfecci\u00f3n con Neisseria  gonorrhoeae , Chlamydia  trachomatis  y Treponema  pallidum .Elevada tasa de resistencia a macr\u00f3lidos y fluoroquinolonas en Mycoplasma genitalium  en el \u00e1rea sur de \nTenerifeC. Mateo Le\u00f3n, et al.\nRev Esp Quimioter 2023;36(4): 416-420420que en nuestro estudio es un caso aislado, algunas mutaciones \nen gyrA se relacionan con fracaso terap\u00e9utico, tal y como su -\ngieren las \u00faltimas revisiones al respecto [11,14].\nEn la poblaci\u00f3n estudiada la mayor\u00eda de los casos son \nhombres (65/92) y adem\u00e1s suponen pr\u00e1cticamente la totalidad \nde los positivos con mutaciones (27/28 para macr\u00f3lidos y 5/5 \nen las mutaciones cl\u00ednicamente relevantes para fluoroquino -\nlonas). Entre ellos destacan los episodios de uretritis, siendo el \nexudado uretral la muestra m\u00e1s frecuente (83% de los casos).\nEntre las limitaciones de este estudio se encuentran la dif\u00edcil \namplificaci\u00f3n de los genes propuestos cuando la carga bacteria -\nna obtenida en la PCR era insuficiente (Ct >30) y la imposibilidad \nde obtener un antibiograma para correlacionar los resultados fe -\nnot\u00edpicos con las mutaciones detectadas. Tambi\u00e9n creemos que \nser\u00eda necesario acortar el tiempo de respuesta incorporando una \nPCR dirigida a SNP concretos, ya que las resistencias a macr\u00f3li -\ndos est\u00e1n bien descritas y podr\u00edamos obtener informaci\u00f3n r\u00e1pida.\nAdem\u00e1s, aunque el tratamiento de segunda l\u00ednea con fluo -\nroquinolonas en los pacientes con resistencia a macr\u00f3lidos supu -\nso la resoluci\u00f3n del cuadro en la mayor\u00eda de nuestros pacientes, \nla falta de informaci\u00f3n desde atenci\u00f3n primaria en relaci\u00f3n al \ntratamiento y la no realizaci\u00f3n del test de cura (30/92 secuencia -\ndos) impiden tener unos datos concluyentes sobre la efectividad \nde los tratamientos.\nA pesar de estas limitaciones, los resultados de este estudio \nson de un valor importante, debido a la gran cantidad de casos \nsecuenciados, el acceso a la informaci\u00f3n de la mayor\u00eda de los \ntratamientos junto a la evoluci\u00f3n cl\u00ednica de los pacientes, y la \nadici\u00f3n del estudio del gen gyrA.\nEn conclusi\u00f3n, la elevada tasa de resistencias en nuestro \nentorno evidencia la necesidad de realizar una terapia dirigida \npor el estudio genot\u00edpico de resistencias a macr\u00f3lidos, apoy\u00e1n -\ndonos en la detecci\u00f3n de mutaciones en parC (especialmente \nS83I) y gyrA para predecir la susceptibilidad a quinolonas y en \nel uso del test de cura para evaluar la respuesta al tratamiento.\nFINANCIACI\u00d3N\nLos autores declaran no haber recibido financiaci\u00f3n para la \nrealizaci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores no presentan ning\u00fan conflicto de intereses.\nBIBLIOGRAF\u00cdA\n1. Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline \non Mycoplasma genitalium  infections. J Eur Acad Dermatol Vene -\nreol. 2016 Aug 9;30(10):1650\u20136. DOI: 10.1111/jdv.13849 .\n2. Getman D, Cohen S, Jiang A. Distribution of Macrolide Resistant \nMycoplasma genitalium  in Urogenital Tract Specimens from Wo -\nmen Enrolled in a US Clinical Study Cohort. Clin Infect Dis. 2022 Jul \n23. DOI: 10.1093/cid/ciac602 .3. Read TRH, Fairley CK, Tabrizi SN, Bissessor M, Vodstrcil L, Chow EPF, \net al. Azithromycin 1.5g Over 5 Days Compared to 1g Single Dose \nin Urethral Mycoplasma genitalium  : Impact on Treatment Outco -\nme and Resistance. Clin Infect Dis. 2016 Oct 24;64(3):250\u20136. DOI: \n10.1093/cid/ciw719 .\n4. Machalek DA, Tao Y, Shilling H, Jensen JS, Unemo M, Murray G, et al. \nPrevalence of mutations associated with resistance to macrolides \nand fluoroquinolones in Mycoplasma genitalium : a systematic re -\nview and meta-analysis. Lancet Infect Dis. 2020 Nov;20(11):1302\u2013\n14. DOI: 10.1016/S1473-3099(20)30154-7 .\n5. Mycoplasma genitalium  - STI Guidelines Australia [Internet]. STI Guideli -\nnes Australia. 2021 [cited 2022 Apr 14]. Available from: https://sti.guide -\nlines.org.au/sexually-transmissible-infections/mycoplasma-genitalium .\n6. Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M. \n2021 European guideline on the management of Mycoplasma \ngenitalium  infections. J Eur Acad Dermatol Venereol. 2022 Feb \n19;36(5):641\u201350. DOI: 10.1111/jdv.17972 .\n7. Nijhuis RHT, Severs TT, Van der Vegt DSJM, Van Zwet AA, Kusters \nJG. High levels of macrolide resistance-associated mutations in \nMycoplasma genitalium  warrant antibiotic susceptibility-guided \ntreatment. J Antimicrob Chemother. 2015 May 20;70(9):2515\u20138. \nDOI: 10.1093/jac/dkv136 .\n8. Shimada Y, Deguchi T, Nakane K, Masue T, Yasuda M, Yokoi S, et al. \nEmergence of clinical strains of Mycoplasma genitalium  harbou -\nring alterations in ParC associated with fluoroquinolone resistance. \nInt J Antimicrob Agents. 2010;36(3):255\u20138. DOI: 10.1016/j,ijantimic\nag.2010.05.01 .\n9. Fern\u00e1ndez-Huerta M, Vall M, Fern\u00e1ndez-Naval C, Barber\u00e1 M-J, \nArando M, L\u00f3pez L, et al. Mycoplasma genitalium  macrolide resis -\ntance update: Rate among a 2016-2017 cohort of patients in Bar -\ncelona, Spain. Enferm Infecc Microbiol Clin. 2020 Mar 1];38(3):99\u2013\n104. DOI: 10.1016/j.eimc.2019.06.008 .\n10. Mu\u00f1oz Santa A, Aramburu Arnuelos J, Bernet S\u00e1nchez A, Bell\u00e9s Be -\nll\u00e9s A. Mycoplasma genitalium : Analysis of mutations associated \nwith macrolide resistance in Lleida, Spain. Enferm Infecc Microbiol \nClin.2022 Apr;40(4):209\u201310. DOI: 10.1016/j.eimce.2021.02.010 .\n11. Murray GL, Bodiyabadu K, Vodstrcil LA, Machalek DA, Danielewski J, \nPlummer EL, et al. parC Variants in Mycoplasma genitalium : Trends \nover Time and Association with Moxifloxacin Failure. Antimicrob \nAgents Chemoter. 2022 May 17;66(5). DOI: 10.1128/aac.00278-22\n12. Leng X, Zou H, Zhang K, Chen Y, Ke W. Can ParC Ser83Ile status \npredict fluoroquinolone efficacy in Mycoplasma genitalium  in-\nfection? Lancet Infect Dis. 2022 Sep;22(9):1273\u20134. DOI: 10.1016/\nS1473-3099(22)00450-9 .\n13. de Salazar A, Barrientos-Dur\u00e1n A, Espadafor B, Fuentes-L\u00f3pez A, \nChueca N, Garcia F. Macrolide and fluoroquinolone resistance of \nMycoplasma genitalium  in southern Spain, 2018\u20132019. Sex Transm \nInfect. 2020 Jul 13. DOI: 10.1136/sextrans-2019-054386.\n14. Chua T-P, Bodiyabadu K, Machalek DA, Garland SM, Bradshaw CS, \nPlummer EL, et al. Prevalence of Mycoplasma genitalium  fluoro -\nquinolone-resistance markers, and dual-class-resistance markers, \nin asymptomatic men who have sex with men.J Med Microbiol. \n2021 Sep 30;70(9).DOI: 10.1099/jmm.0.001429 .ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/132.2022\nRev Esp Quimioter 2023;36(4): 421-424421hyperinflammation and cytokine storm syndrome in COVID-19 \npatients. In fact, a recent meta-analysis confirmed that sys -\ntemic corticosteroids were associated with lower 28-day \nall-cause mortality compared with usual care or placebo in \nCOVID-19 patients who received oxygen or invasive mechani -\ncal ventilation [4].\nOther conditions that have been associated with nocar -\ndiosis include diabetes mellitus, alcoholism, chronic granulo -\nmatous disease, alveolar proteinosis, structural lung disease, \ntumor necrosis factor-alpha inhibitor (e.g., infliximab) therapy, \ninflammatory bowel disease, chronic obstructive pulmonary \ndisease, and tuberculosis.\nIn one review of 1050 cases [5] main clinical presentations \nof nocardiosis were systemic (32 %); pulmonary (only) 39 %; \nCNS (only) 9 %, cutaneous or lymphocutaneous (8 %) and sin -\ngle site extrapulmonary (egg, eyes, bone) 12 %. The onset of \npulmonary nocardiosis may be acute, subacute, or chronic and \nis not distinguished by any specific signs or symptoms. Fever, \nnight sweats, fatigue, anorexia, weight loss, dyspnea, cough, \nhemoptysis, and pleuritic chest pain have all been described. \nHere-in we report a case of a patient initially admitted \nand treated for COVID-19 pneumonia who was subsequently \nreadmitted due to persistent worsening dyspnea. Pulmonary \nnocardiosis after further evaluation was diagnosed. An English \nliterature review showed only other five reports of these asso -\nciations. Data regarding these cases are shown [6-10].\nAn 86-year-old man infected with SARS-CoV-2 was ad -\nmitted to the hospital for productive cough and dyspnea on \nminimal exertion. He was already suffering from multiple \nhealth conditions, including type 2 diabetes mellitus, hyper -\ntension, and atrial fibrillation treated with dabigatran. He was \nreceiving corticosteroid therapy and daily oral cyclophospha -\nmide because IgG lambda multiple myeloma. Among other \nmedical conditions, a chronic kidney disease IIIB2A stage di -\nabetic nephropathy and non-exacerbator COPD were remark -\nable features. The patient received acute inpatient care in a Pulmonary nocardiosis after covid-19 infection: \ncase report and literature review\n1Infectious Diseases Unit. Hospital Cl\u00ednico San Juan de Alicante. Spain.\n2University Miguel Hern\u00e1ndez of Alicante. Spain. Infectious Diseases Unit. Hospital Cl\u00ednico San Juan de Alicante. \nSpain.\n3Microbiology Department. Hospital Cl\u00ednico San Juan de Alicante. Spain.Jos\u00e9 Ortiz1\nFrancisco Jover2\nVictoria Ortiz de la Tabla3\nElisabet Delgado1Letter to the Editor\nArticle history\nReceived: 14 November 2022; Revision Requested: 11 January 2023; Revision Received: 29 January 2023;  \nAccepted: 6 February 2023; Published: 27 April 2023\nSir,\nAn increasing number of opportunistic infections in \nCOVID-19 patients are being described especially for patients \nwith underlying diseases and those who received immunosup -\npressive therapy. Among these opportunistic infections, fungal \ninfections account for most case reports in COVID-19 patients \n(mainly Aspergillus ). Other associated pathogens are viral, pro -\ntozoa, helminth, and bacterial infections. Regarding these last \nprospective cohort study in England, Scotland, and Wales an -\nalyzed data from COVID-19 inpatients showing that the most \ncommon pathogens causing early respiratory coinfections are \nStaphylococcus aureus  and Haemophilus influenzae . Indeed S. \naureus  and Enterobacteriaceae are also the most common sec -\nondary respiratory infections [1]. \nNocardia  is a gram-positive, ubiquitous, soilborne bac -\nterium that belongs to the family of aerobic actinomycetes \nthat seem like branching, filamentous rods on microscopy. \nThis genus Nocardia  includes more than eighty species, thir -\nty of which could affect humans. In retrospective studies, N. \nasteroides  and N. farcinica  have often been identified as the \npredominant species over the years [2].\nMost patients with nocardial infection are immunocom -\npromised with cell-mediated abnormalities. Their most com -\nmon causes are malignancy, organ and hematopoietic stem \ncell transplantation, and HIV infection. Glucocorticoid ther -\napy has traditionally been linked to nocardiosis. Recently a \nmatched retrospective study conducted at a tertiary hospital \nin central Israel of sixty hospitalized consecutive adult patients \nwith nocardiosis showed that systemic corticosteroid therapy \nwas strongly associated with pulmonary nocardiosis (matched \nOR 4.69, 95% CI 2.45\u20138.99, p < 0.001) [3].\nImmunosuppressive therapy has been used to alleviate \nCorrespondence:\nFrancisco Jover\nUniversity Miguel Hern\u00e1ndez of Alicante. Spain. Infectious Diseases Unit. Hospital Cl\u00ednico San \nJuan de Alicante. Spain. \nE-mail: fjoverdiaz@gmail.comPulmonary nocardiosis after covid-19 infection: case report and literature review F. Jover, et al.\nRev Esp Quimioter 2023;36(4): 421-424422Figure 1  Multifocal and bilateral caviated \ncondensations. Ground glass pattern \nareas and distal bronchial thickening.\nAuthor (year) [reference] Sex & Age Risk factorsDays after COVID-19 \ndiagnosisClinical picture CT scan features\nColaneri (2021) [6]Woman,  \n45 yearsUntreated HIV/HCV \nIDU5 daysFever, coughing, dyspnea, \nfatigability (10 days). Oxygen \nsaturation at room air: 94%Multiple necrotic core lesions \nin both lungs, kidneys and soft \ntissues with peripheral contrast \nenhancement\nLaplace (2021) [7]Male,  \n86 yearsType 2 DM, COPD,\nCrohn\u00b4s disease13 daysAcute dyspnea, fever, productive \ncoughDense consolidation with air \nbronchograms in lower lung lobes\nAtemnkeng (2021) [8]Male,  \n63 yearsMorbid obesity, Type \n2 DM32 daysWorsening shortness of breath. \nOxygen saturation at room air: 77%Near-complete opacification of \nthe left hemithorax with minimal \nsparing of the apical region\nMRI: multiple bilateral ring-\nenhancing lesions in the brain\nArif (2021) [9]Woman,  \n61 yearsType 2 DM, \nhypertension, HF10 days DyspneaRight upper lobe 3.3 x 3.2 cm mass \nand a left upper lobe 1.9 x 1.5 cm \nnodule\nDriscoll (2022) [10]Male,  \n16 yearsBronchiectasis \nPseudomonas \naeruginosa infection6 days Fever, dyspnea, cough, and lethargyLeft lower lobe opacification but no \nnecrosis or pulmonary embolus\nOrtiz (2023) [Present case]Male,  \n86 yearsType 2 DM, \nhypertension, \nmyeloma, COPD, atrial \nflutter, CKD11 daysIncreased productive cough, dyspnea \nOxygen saturation at room air: 82%Multifocal and bilateral cavitated \ncondensations. Ground glass pattern \nareas and distal bronchial thickeningTable 1  Risk factors and clinical characteristics of Nocardia  COVID-19 coinfected patients.\nType 2 DM: type 2 diabetes mellitus. COPD: Chronic obstructive pulmonary disease. CKD: Chronic kidney disease. HF: heart failure. HIV/HCV: chronic hepatitis C virus & \nHIV coinfected. IDU: Injecting drug user. SLE: Systemic lupus erythematosus.Pulmonary nocardiosis after covid-19 infection: case report and literature review F. Jover, et al.\nRev Esp Quimioter 2023;36(4): 421-424423While corticosteroids have been shown to have varying \neffects on T lymphocytes, high doses can cause a rapid de -\npletion of circulating T cells by redistribution of circulating \ncells to other body compartments. In addition, they cause \ninhibition of interleukin (IL)-2, a cytokine that is essential \nfor the function, differentiation, and proliferation of T-cells. \nThey can also induce apoptosis of T-lymphocytes, which fur -\nther depletes the total pool of mature functioning T-cells. All \nthese mechanisms result in a profound immunosuppressive \nstate that promotes the development of opportunistic infec -\ntions.\nIt has been previously demonstrated that due to the \ndownregulation of various proteins associated with immune \nfunction, the immune system is suppressed early during \nCOVID-19 [11]. There is now a growing body of evidence that \nsupports that COVID infection can lead to significant dysreg -\nulation of the immune system. Severe COVID infections have \nbeen characterized by lymphocytopenia, which is currently \nused as a prognostic indicator of clinical deterioration and \npoor outcomes.\nWe identified only five published case reports (6 overall \nincluding our case) of adult patients with a mean age of 59 \nyears (16-86). Main risk factors and clinical characteristics of \nNocardia COVID-19 coinfected patients are shown in table 1. \nFour patients were male (66%). Well-known risk factors were \npresent in all six patients (type 2 diabetes as the main factor). \nNocardia infection was diagnosed at a median of 13 days af -\nter diagnosis of Covid 19 (5-32 days). Main clinical features \nwere acute o worsening dyspnea, acute respiratory failure, \nand productive cough. Radiological imaging tests showed \nmainly lobar or multilobar consolidation and lung cavitating \nlesions. \nTable 2 summarizes microbiological and treatment fea -\ntures and outcomes of Nocardia COVID-19 coinfected pa -\ntients. As described in the literature Nocardia cryiacigeorgica , \nNocardia asteroides  and Nocardia farcinica  were predomi -\nnating species. Patients received appropriate combined No -\ncardia treatment including trimethoprim/sulfamethoxazole, \nmeropenem, linezolid or ceftriaxone. In hospital mortality \nwas 33%. \nEmpiric antimicrobial treatment included intravenous \nadministration of at least two agents that represent the first-\nline therapy (either amikacin, imipenem, or a third-genera -\ntion cephalosporin) and should trimethoprim sulfamethoxaz -\nole [12]. After a minimum of 3 weeks of intravenous therapy, \npatients can be switched to oral treatment.\nIn summary, severe COVID-19 lung infection, SARS-\nCoV-2 induced dysregulation of the immune system and \nwidespread use of steroids in COVID 19 can favor Nocardia \nas an opportunistic infection. We believe that these cases \nshould serve as an example of potential threats of high ste -\nroid exposure in this patient population. We would like also \nto point out the relevance of early attention to opportunistic \ninfections in patients with recent COVID infections.hospital for ten days including high-flow oxygen, oral dexa -\nmethasone, and ceftriaxone. Oral cyclophosphamide was tem -\nporarily stopped. \nThe patient had been in his usual state of health until \n5 days before this new admission (11 days after he was dis -\ncharged), when fever developed. He noted shortness of breath \nat rest and dyspnea on exertion. He was brought to the emer -\ngency department of our hospital for further evaluation.\nOn examination, the temperature was 36.7\u00b0C, the blood \npressure 107/62 mm Hg, the pulse 111 beats per minute, respi -\nratory rate twenty-eight breaths per minute, and oxygen satu -\nration 82% while the patient was breathing ambient air. Respi -\nratory rate decreased to twenty-two breaths per minute and the \noxygen saturation improved to 95% with the administration of \nsupplemental oxygen through a nasal cannula at a rate of four \nliters per minute. Inspiratory crackles could be heard at the lung \nbases. The heart sounds were regular, with tachycardia but no \nmurmur. There was no tenderness on palpation of the abdomen \nand no pitting edema were present in the legs.\nLaboratory test results at admission were: leukocytes 8.9 \n10e9/l (3.5-12.0), lymphocytes 0.08 10e9/l (1.30-4.00); mono -\ncytes 1.70 10e9/l (0.20-1.00); hemoglobin 9.9 g/dl (13.5-17.5); \nhematocrit 29.5% (41- 53); platelets 119 10e9/l (140-450); \nneutrophils/lymphocytes ratio 89.00 (<3.13 covid-19 more \nfavorable prognosis >3.13 COVID-19 less favorable progno -\nsis); prothrombin time 17 sec (9.40-12.50); Quick index 57% \n(70.00-100.00); INR 1.4 ratio (0.5-1.5); D-dimer 2,171 ng/ml \n(0.00-500.00); urea 85 mg/dl (18-44); creatinine 1.67 mg/dl \n(0.53-1.18); albumin 2.89 g/dl (3.50-4.60); C-reactive protein \n17.39 mg/dl (0.00-0.50); procalcitonin 0.91 ng/ml (0.00-0.50). \nHis arterial blood gas analysis (ABG) revealed: arterial pH 7.495 \npH (7.34 - 7.44); arterial pO2 50.1 mmHg (75.0-100.0); arterial \nHCO3- 26.7 mmol/l (22.0-26.0); arterial O2 saturation 86.3% \n(95.0 -98.0).\nChest x-ray revealed dense consolidations with air bron -\nchograms in the lower lung lobes. Both SARS CoV-2 antigen \nand rT-PCR in nasopharyngeal sweep were positive (Ct = or \n< 30 expressing high viral load). The patient was started on \nempirical meropenem, oxygen supplementation through nasal \nprongs, and intravenous remdesivir. \nA thoracic CT scan (Figure 1) revealed multifocal and bi -\nlateral cavitated condensations. Ground glass pattern areas \nand distal bronchial thickening. The sputum culture from day \nfive showed abundant leukocytes and no acid-alcohol resistant \nGram-positive branching rods in gram stain compatible with \nNocardia  species. \nHe was initially treated with broad-spectrum antibiotics \n(meropenem and vancomycin) and thereafter treatment was \nchanged to intravenous imipenem for 4 weeks. We ruled out \nthe use of cotrimoxazole or linezolid due to the foreseeable \ntoxicity at the kidney and bone marrow level in this specific \npatient.\nThe patient was discharged home on oral minocycline 100 \nmg every 12 hours for 6 months.Pulmonary nocardiosis after covid-19 infection: case report and literature review F. Jover, et al.\nRev Esp Quimioter 2023;36(4): 421-424424FUNDING\nNone to declare.\nCONFLICT OF INTEREST\nAuthors declare no have conflict of interest.\nREFERENCES\n1. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton \nDG et al. Co-infections, secondary infections, and antimicrobial use \nin patients hospitalized with COVID-19 during the first pandemic \nwave from the ISARIC WHO CCP-UK study: a multicenter, prospec -\ntive cohort study. Lancet Microbe. 2021 Aug;2(8): e354-e365. doi: \n10.1016/S2666-5247(21)00090-2.\n2. Mazzaferri F, Cordioli M, Segato E, Adami I, Maccacaro L, Sette P et \nal. Nocardia infection over 5 years (2011-2015) in an Italian tertiary \ncare hospital. New Microbiol. 2018 Apr;41(2):136-140\n3. Margalit I, Goldberg E, Ben Ari Y, Ben-Zvi H, Shostak Y, Krause I et al. \nClinical correlates of nocardiosis. Sci Rep. 2020 Aug 31;10(1):14272. \ndoi: 10.1038/s41598-020-71214-4.\n4. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) \nWorking Group. Association Between Administration of Systemic \nCorticosteroids and Mortality Among Critically Ill Patients With \nCOVID-19: A Meta-analysis. JAMA. 2020;324(13):1330\u20131341. doi: \n10.1001/jama.2020.17023.\n5. Beaman BL, Beaman L. Nocardia species: host-parasite relation -\nships. Clin Microbiol Rev. 1994 Apr;7(2):213-64.\n6. Colaneri M, Lupi M, Sachs M, Ludovisi S, Di Matteo A, Pagnucco \nL et al. A challenging case of SARS-CoV-2- AIDS and Nocardiosis \ncoinfection from the SMatteo COvid19 REgistry (SMACORE). New \nMicrobiol. 2021 Apr;44(2):129-134. 7. Laplace M, Flamand T, Ion C, Gravier S, Zadeh MM, Debriel D et al. \nPulmonary Nocardiosis as an Opportunistic Infection in COVID-19. \nEur J Case Rep Intern Med. 2022 Aug 22;9(8):003477. doi: \n10.12890/2022_003477.\n8. Atemnkeng F, Ducey J, Khalil A, Elemam A, Diaz K. Diagnosing Dis -\nseminated Nocardiosis in a Patient With COVID-19 Pneumonia. J \nMed Cases. 2021 Aug;12(8):319-324. doi: 10.14740/jmc3716.\n9. Arif M, Talon A, Sarma H, Munoz J, Charley E. Nocardia after \ncovid-19 infection. Chest. 2021 oct;160(4):a429. doi.org/10.1016/j.\nchest.2021.07.424\n10. Driscoll S, Carroll WD, Nichani S, Fishwick R, Bakewell K, Gilchrist FJ. \nCOVID-19 infection and nocardiosis causing the death of an ado -\nlescent with cystic fibrosis. Pediatr Pulmonol. 2022 Jul;57(7):1823-\n1825. doi: 10.1002/ppul.25954.\n11. Tian W, Zhang N, Jin R, Feng Y, Wang S, Gao S, et al. Immuno -\nsuppression in the early stage of COVID-19 disease. Nat Commun. \n(2020) 11:5859. doi: 10.1038/s41467-020-19706-9.\n12. Lu SH, Qian ZW, Mou PP, Xie L. Clinical Nocardia species: identi -\nfication, clinical characteristics, and antimicrobial susceptibility \nin Shandong, China. Bosn J Basis Med Sci. (2020) 20:531\u20138. doi: \n10.17305/bjbms.2020.4764.Author (year) [reference] Nocardia  species Sample COVID treatment Nocardia  treatment Outcome\nColaneri (2021) [6] Nocardia cyriacigeorgica Blood culture PIP/TAZ TMP/SMXLinezolid, TMP/SMX and \nCeftriaxone (one year)Cure\nLaplace (2021) [7] Nocardia cyriacigeorgica Sputum DXM 6 mg/24h, enoxaparin, cefotaxime Imipenem and TMP/SMX In hospital death\nAtemnkeng (2021) [8] Nocardia asteroides BALAzithromycin, ceftriaxone, REM, DXM y \nenoxaparinMeropenem/linezolid TMP/SMX \n(one year)Cure\nArif (2021) [9] Nocardia farcinica Lung biopsy DXM 4mg oralTMP/SMX\nMeropenem/linezolidDischarged\nDriscoll (2022) [10] Nocardia farcinicaBronchial \nsecretionTobramycin, ceftazidime DXM Linezolid In hospital death\nOrtiz (2023) [Present case] Nocardia spp Sputum REM (10 d\u00edas), ceftriaxone DXM Imipenem Ceftriaxone DischargedTable 2  Microbiological and treatment features and outcome of Nocardia  COVID-19 coinfected patients.\nCOVID-19: Coronavirus disease 2019. PIP/TAZ: Piperacillin/tazobactam. TMP/SMX: Trimethoprim/sulfamethoxazole. DXM: dexamethasone. BAL:  bronchoalveolar lavage. \nCSF: Cerebrospinal fluid. REM: remdesivir.ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/133.2022\nRev Esp Quimioter 2023;36(4): 425-426425Antifungal susceptibility testing was performed by mi -\ncrodilution (Sensititre YeastOne, Thermo Fisher). The min -\nimum inhibitory concentrations (MIC) of amphotericin B \n(0.50 mg/L), itraconazole (0.12 mg/L), voriconazole (0.03 \nmg/L), and posaconazole (0.03 mg/L) against the patho -\ngenic strain were found to be low. However, MIC of flu -\nconazole (8 mg/L), micafungin (>8 mg/L), caspofungin (>8 \nmg/L) and anidulafungin (>8 mg/L) were high. Based on \nthese results, voriconazole eye drops for two months and \noral voriconazole during three weeks were administered \nwith good clinical evolution.\nReviewing the literature, we have only found a few \ncases of eye infection by E. dermatitidis [1,3-6]. However, \nthis yeast is involved in diverse pathologies such as central \nline infection [7], pneumonia [8], meningoencephalitis [9] \nor skin and soft-tissue infections [10] among others. \nRegarding susceptibility, there are no defined break -\npoints for any species in the genus. Our strain had high \nMIC to fluconazole and echinocandins. These data are in \nline with other reported cases [1, 4]. It is necessary to \nstudy large number of cases in order to obtain represent -\native data of the antifungal susceptibility of this species.\nThe case presented here confirm the ability of E. der -\nmatitidis  as an opportunistic pathogen especially in pa -\ntients with ocular trauma, pre-existing ocular disease or \nimmunocompromised states.\nFUNDING \nNone to declare. \nCONFLICT OF INTEREST \nAuthors declare no have conflict of interest. Fungal corneal abscess caused by Exophiala \ndermatitidis\nUnidad de Microbiolog\u00eda. Hospital Universitari Arnau de Vilanova Lleida.  Institut de Recerca Biom\u00e8dica (IRB) Lleida. \nUniversitat de Lleida (UdL). SpainSaray Mormeneo Bayo \nAlba Bell\u00e9s Bell\u00e9s \nIv\u00e1n Prats S\u00e1nchez \nEric L\u00f3pez Gonz\u00e1lez\nJes\u00fas Aramburu Arnuelos\nAlbert Bernet S\u00e1nchez\nMerc\u00e8 Garc\u00eda Gonz\u00e1lezLetter to the Editor\nArticle history\nReceived: 17 November 2022; Revision Requested: 27 January 2023; Revision Received: 3 February 2023;  \nAccepted: 6 February 2023; Published: 20 April 2023\nSir\nExophiala dermatitidis  is a saprophytic black yeast. \nIt is widely distributed in the natural environment and it \nhas the capacity to grow in extreme conditions. Although \nhuman infections caused by E. dermatitidis  are rare, this \nfungus can occasionally cause subcutaneous and systemic \ninfections. Factors that contribute to pathogenicity are its \nability to produce biofilm and melanin, which forms part \nof the cell wall of black yeasts [1,2]. Here, we present a \ncase of corneal infection by E. dermatitidis .\nA 68-year-old woman was admitted to the Emergency \nDepartment for pain and red eye of one week of evolution. \nShe had undergone a protected penetrating keratoplasty a \nyear ago. Biomicroscopy revealed conjunctival hyperemia, \ntransparent corneal button, brownish corneal foreign body \nwith rubbery paracentral aspect with perilesional corneal \nthinning. Corneal foreign body was removed and a sample \nwas sent to our laboratory. The patient was initially treated \nwith moxifloxacin eye drops and oral doxycycline and later \nthe treatment was changed to vancomycin and ceztazi -\ndime eye drops and oral doxycycline.\nThe sample obtained was incubated in blood, choco -\nlate and Saboureaud agar and thioglycolate broth. There \nwas growth of dark colonies after 48 hours of incubation \nat 37\u00b0C in the three media and in the reseed of thiogly -\ncolate (Figure 1A). The Gram staining of these  colonies is \nshown in Figure 1B.\nThe identification of the microorganism isolated was \nrealized by matrix-assisted laser desorption/ionization-\ntime-of-flight-mass spectrometry (MALDI-TOF MS) (Mal -\ndi Biotyper\u00aeBruker Dal-tonics) resulting in E. dermatitidis  \nwith a score value of 2.4. \nCorrespondence: \nSaray Mormeneo Bayo.\nUnidad de Microbiolog\u00eda. Hospital Universitari Arnau de Vilanova Lleida. Spain\nE-mail: smormeneo.lleida.ics@gencat.catFungal corneal abscess caused by Exophiala dermatitidis S. Mormeneo Bayo, et al.\nRev Esp Quimioter 2023;36(4): 425-4264268.  Sekiguchi R, Urabe N, Sakamoto S, Sasaki M, Homma S, Kishi K. \nExophiala dermatitidis  pneumonia with bronchiectasis required \nprolonged voriconazole treatment. Respirol Case Rep. 2021 May \n25;9(6):e00783. doi:10.1002/rcr2.783.\n9.  Yu HY, Qu TT, Yang Q, Hu JH, Sheng JF. A fatal case of Exophiala \ndermatitidis meningoencephalitis in an immunocompetent host: \nA case report and literature review. J Infect Chemother. 2021 \nOct;27(10):1520-1524. doi:10.1016/j.jiac.2021.06.014.\n10.  Lang R, Minion J, Skinner S, Wong A. Disseminated Exophiala der -\nmatitidis causing septic arthritis and osteomyelitis. BMC Infect Dis. \n2018 Jun 4;18(1):255. doi:10.1186/s12879-018-3171-0.REFERENCES\n1. Iwahashi C, Eguchi H, Hotta F, Uezumi M, Sawa M, Kimura M, et al. \nAbscess caused by Exophiala dermatitidis following posterior sub -\ntenon injection of triamcinolone acetonide: a case report and a \nreview of literature related to Exophiala eye infections. BMC Infect \nDis. 2020 Aug 3;20(1):566. doi:10.1186/s12879-020-05294-y\n2.  suda D, Higashikawa T, Hotchi Y, Usami K, Shimozawa S, Tokun -\naga S, et al. Exophiala dermatitidis. World J Clin Cases. 2021 Sep \n26;9(27):7963-7972. doi:10.12998/wjcc.v9.i27.7963.\n3.  Homa M, Manikandan P, Saravanan V, Revathi R, Anita R, Naren -\ndran V, et al. Exophiala dermatitidis Endophthalmitis: Case Report \nand Literature Review. Mycopathologia. 2018 Jun;183(3):603-609. \ndoi:10.1007/s11046-017-0235-4.\n4.  Clamp MF, Jumper JM, Ku CW, McDonald HR, Johnson RN, Fu \nAD, et al. Chronic exogenous exophiala dermatitidis endophthal -\nmitis. Retin Cases Brief Rep. 2014 Fall;8(4):265-8. doi:10.1097/\nICB.0000000000000097\n5.  Patel SR, Hammersmith KM, Rapuano CJ, Cohen EJ. Exophiala der -\nmatitidis keratitis after laser in situ keratomileusis. J Cataract Re -\nfract Surg. 2006 Apr;32(4):681-4. doi:10.1016/j.jcrs.2006.01.040.\n6.  Gerard C, Duchesne B, Hayette MP, Lavalleye B, Marechal-Courtois \nC. Cas d\u2019un ulc\u00e8re \u00e0 Exophiala dermatitidis [A case of Exophiala \ndermatitidis ulceration]. Bull Soc Belge Ophtalmol. 1998;268:103-\n8. \n7.  Maraki S, Katzilakis N, Neonakis I, Stafylaki D, Meletiadis J, Hami -\nlos G,et al. Exophiala dermatitidis Central Line-Associated Blood -\nstream Infection in a Child with Ewing\u2019s Sarcoma: Case Report \nand Literature Review on Paediatric Infections. Mycopathologia. \n2022;187(5-6):595-602. doi:10.1007/s11046-022-00658-1.Figure 1  A) Image of brownish colonies of E. dermatitidis  in Sabouraud agar. B) Gram staining of E. dermatitidis  \ncolonies\nA BISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/136.2022\nRev Esp Quimioter 2023;36(4): 427-4284272022); 20 positivas para SARS CoV-2, 20 positivas para gripe \ny 20 positivas para virus respiratorio sincitial. No hay ning\u00fan \ncaso de infecci\u00f3n mixta por estos virus. Tambi\u00e9n hemos proce -\nsado las primeras 20 muestras negativas para los tres virus. En \neste periodo, la variante circulante m\u00e1s prevalente en nuestro \nmedio es Omicron (Linaje BA.5) y todos los casos de gripe son \ncausados por influenza A [3]. \nAmbas t\u00e9cnicas tienen formato individual y la prueba eva -\nluada es f\u00e1cil y r\u00e1pida de realizar (mezclar 10\u00b5l de Magnetic \nBeads y 200\u00b5l de muestra al cartucho de PCR que viene in -\ncluido en el kit y cargar en el aparato) por lo que el tiempo \nt\u00e9cnico de ambas t\u00e9cnicas es similar (menor de 5 minutos por \nmuestra). Como desventaja frente a la t\u00e9cnica de referencia, \nno permite diferenciar entre influenza A y B, el tiempo de pro -\ncesamiento de la t\u00e9cnica es m\u00e1s largo (84 versus 36 minutos) y \nse trata de una t\u00e9cnica cualitativa.\nEl an\u00e1lisis de concordancia muestra un elevado \u00edndice \nkappa (98% para SARS CoV-2 y 95% para gripe y virus respi -\nratorio sincitial) ya que la \u00fanica discrepancia detectada es la \nexistencia de 1 falso negativo para el primer virus y 2 falsos \nnegativos para los otros dos virus estudiados. Considerando \ncomo patr\u00f3n de referencia los datos aportados por el Genex -\npert /Cepheid) la sensibilidad de la prueba es: SARS CoV-2 \n95%, Gripe 90% y VRS 90% con una especificidad del 100% \nen todas ellas. Todas estas muestras discrepantes ten\u00edan baja \ncarga viral (Ct superiores a 35) por el sistema de referencia y \npor tanto, con baja capacidad de transmisi\u00f3n del proceso; es -\nta disminuci\u00f3n de la sensibilidad tambi\u00e9n se produce en otras \nt\u00e9cnicas como las basadas en RT-LAMP (reverse-transcription \nloop-mediated isothermal amplification) [4].\nLa disponibilidad de varios m\u00e9todos diagn\u00f3sticos que \nofrezcan resultados en menos de 90 min basados en la de -\ntecci\u00f3n del genoma de los tres virus de forma simult\u00e1nea, \naporta importantes ventajas para el manejo de estos pacien -\ntes en relaci\u00f3n con la detecci\u00f3n de ant\u00edgenos virales, t\u00e9cnicas \nque muestran una menor sensibilidad especialmente frente a Concordancia entre el GeneXpert y el Life Real \nDetection Kit en el diagn\u00f3stico de las infecciones \nrespiratorias agudas\n1Departamento Microbiolog\u00eda, Hospital General Universitario Doctor Balmis, Instituto de Investigaci\u00f3n Sanitaria y \nBiom\u00e9dica de Alicante (ISABIAL), Alicante, Espa\u00f1a\n2Departamento de Enfermedades Infecciosas, Hospital General Universitario Doctor Balmis, Instituto de Investiga -\nci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL), Alicante, Espa\u00f1aCelia Garc\u00eda-Rivera1\nIsabel Escribano1\nEsperanza Merino2\nJuan Carlos Rodriguez1Carta al Director\nArticle history\nReceived: 1 December 2022; Revision Requested: 4 January 2023; Revision Received: 18 January 2023;  \nAccepted: 14 February 2023; Published: 3 May 2023\nEstimado Editor:\nLos nuevos protocolos de manejo cl\u00ednico de los pacien -\ntes con infecci\u00f3n respiratoria aguda necesitan el diagn\u00f3stico \nr\u00e1pido de las infecciones por SARS CoV-2, gripe y virus respi -\nratorio sincitial por lo que los Laboratorios de Microbiolog\u00eda \ndeben disponer de los medios adecuados para dar respuesta \na esta demanda durante las 24 horas de los 7 d\u00edas de la se -\nmana. \nDesde el punto de vista cl\u00ednico, la detecci\u00f3n r\u00e1pida de las \ninfecciones respiratorias agudas producidas por SARS CoV-\n2 y gripe ayuda a seleccionar el tratamiento antiviral en los \npacientes vulnerables o con indicaci\u00f3n del mismo y dado que \ndicho tratamiento es m\u00e1s efectivo en funci\u00f3n de la precocidad \nde la administraci\u00f3n, la rapidez del diagn\u00f3stico contribuir\u00e1 a \nun tratamiento m\u00e1s eficaz, en la elecci\u00f3n del antiviral correc -\nto y su administraci\u00f3n precoz. En cuanto al VRS, en poblaci\u00f3n \nmuy seleccionada, contribuir\u00e1 a la indicaci\u00f3n del tratamiento, \ny en poblaci\u00f3n no susceptible de tratamiento, a evitar trata -\nmientos antibi\u00f3ticos en cuadros de infecci\u00f3n respiratoria de \nv\u00edas altas. Adem\u00e1s, de la importancia del diagn\u00f3stico r\u00e1pido en \nel manejo de los pacientes, es importante a la hora de aplicar \nmedidas de prevenci\u00f3n y control de infecciones de forma r\u00e1pi -\nda, como la r\u00e1pida gesti\u00f3n de aislamientos y camas en funci\u00f3n \ndel virus identificado [1,2].\nEn este marco, hemos evaluado la concordancia de uno de \nlos sistemas de diagn\u00f3stico r\u00e1pido m\u00e1s utilizados en la pr\u00e1c -\ntica cl\u00ednica asistencial (Genexpert\u00ae Xpert Xpress CoV-2/Flu/\nRSV plus, Cepheid) con un nuevo sistema que acaba de llegar \nal mercado (Life Real (2019-nCoV/Influenza/RSV Nucleic Acid \n(RNA) Detection Kit, HangZhou Lifereal Biotechnology).\nHemos analizado en paralelo las primeras 80 muestras re -\ncibidas durante el periodo estudiado (octubre y noviembre de \nCorrespondencia:\nCelia Garc\u00eda-Rivera\nDepartamento Microbiolog\u00eda, Hospital General Universitario Doctor Balmis, Instituto de Inves -\ntigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL), Alicante, Espa\u00f1a\nE-mail: garcia_celriv@gva.esConcordancia entre el GeneXpert y el Life Real Detection Kit en el diagn\u00f3stico de las infecciones \nrespiratorias agudasC. Garc\u00eda-Rivera, et al.\nRev Esp Quimioter 2023;36(4): 427-4284289. Erbak Y\u0131lmaz H, Iscan E, Oz O, Batur T, Erdo \u011fan A, K\u0131l\u0131\u00e7 S, et al. \nConsiderations for the selection of tests for SARS-CoV-2 mole -\ncular diagnostics. Mol Biol Rep. 2022 Oct;49(10):9725-9735. doi: \n10.1007/s11033-022-07455-5.algunas variantes virales (hasta el 50%) y que habitualmen -\nte ofrecen informaci\u00f3n exclusivamente sobre la presencia de \nSARS CoV-2, lo que limita su utilidad en la pr\u00e1ctica cl\u00ednica asis -\ntencial en los pr\u00f3ximos meses de convivencia de los tres virus \nen nuestro entorno [5-8].\nAunque hemos realizado una evaluaci\u00f3n preliminar, nues -\ntros datos muestran que la t\u00e9cnica evaluada puede ser una \nalternativa v\u00e1lida como complemento de las herramientas ya \ndisponibles en el mercado teniendo en cuenta que es reco -\nmendable disponer de varios m\u00e9todos diagn\u00f3sticos de estos \nprocesos que puedan paliar posibles roturas de stocks, proble -\nmas t\u00e9cnicos de los equipos, etc [9].\nFINANCIACI\u00d3N \nEste estudio no ha recibido financiaci\u00f3n pero la casa co -\nmercial suministr\u00f3 los materiales necesarios para llevar a cabo \nel trabajo. \nCONFLICTO DE INTERESES\nLos autores declaran no tener conflicto de intereses\nBIBLIOGRAF\u00cdA\n1. Christensen BB, Azar MM, Turbett SE. Laboratory Diagno -\nsis for SARS-CoV-2 Infection. Infect Dis Clin North Am. 2022 \nJun;36(2):327-347. doi:10.1016/j.idc.2022.02.002.\n2. Drain PK. Rapid Diagnostic Testing for SARS-CoV-2. N Engl J Med. \n2022 Jan 20;386(3):264-272. doi: 10.1056/NEJMcp2117115.\n3. Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, Moustafa \nAbo El-Ella D et al. Emerging COVID-19 variants and their impact \non SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. \n2022 Dec;54(1):524-540. doi: 10.1080/07853890.2022.2031274.\n4. Pu R, Liu S, Ren X, Shi D, Ba Y, Huo Y, et al. The screening value \nof RT-LAMP and RT-PCR in the diagnosis of COVID-19: systematic \nreview and meta-analysis. J Virol Methods. 2022 Feb;300:114392. \ndoi: 10.1016/j.jviromet.2021.114392.\n5. Dinnes J, Sharma P, Berhane S, van Wyk SS, Nyaaba N, Domen J, et \nal. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 \ninfection. Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. \ndoi: 10.1002/14651858.CD013705.pub2.\n6. Havasi A, Visan S, Cainap C, Cainap SS, Mihaila AA, Pop LA. Influen -\nza A, Influenza B, and SARS-CoV-2 Similarities and Differences - A \nFocus on Diagnosis. Front Microbiol. 2022 Jun 20;13:908525. doi: \n10.3389/fmicb.2022.908525.\n7. Kim J, Sung H, Lee H, Kim JS, Shin S, Jeong S, et al. Clinical Perfor -\nmance of Rapid and Point-of-Care Antigen Tests for SARS-CoV-2 \nVariants of Concern: A Living Systematic Review and Meta-Analy -\nsis. Viruses. 2022 Jul 6;14(7):1479. doi: 10.3390/v14071479.\n8. Sukhdeo S, Lee N. Influenza: clinical aspects, diagnosis, and \ntreatment. Curr Opin Pulm Med. 2022 May 1;28(3):199-204. doi: \n10.1097/MCP.0000000000000860.ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/140.2022\nRev Esp Quimioter 2023;36(4): 429-431429are more prevalent among Asians and rare or absent in Cau -\ncasians [7]. \nKFD diagnosis is based on histopathological analysis. The \ndisease may resolve spontaneously without treatment. NSAIDs \nor paracetamol are first line of treatment for symptomatic \ncontrol. Despite the overall prognosis is satisfactory, symptoms \ncan last up to weeks or months [8,9]. In chronic, recurrent or \ncomplicated cases; corticosteroids, intravenous immunoglobu -\nlins and hydroxychloroquine can represent an alternative [10].\nThe human papillomavirus (HPV) is a known etiological \nagent of cervical cancer and other types of cancer, reason \nwhy vaccination campaign is established for certain popula -\ntion groups. There are three different marketed vaccines that \ndiffer in the number of serotypes they contain; the bivalent \nvaccine (HPV2), which protects against HPV types 16 and 18; \nthe tetravalent vaccine (HPV4), which protects against types \n16, 18, 6, and 11; the 9-valent vaccine (HPV9), which protects \nagainst types 6, 11, 16, 18, 31, 33, 45, 52, and 58.\nIt is already widely proven that vaccines are effective, \ncost-effective and safe [11]. However, there have been reports \nof subacute course or complicated lymphadenopaties associat -\ned with HPV vaccination [12,13]. KFD associated to HPV vacci -\nnation has only been reported in the literature once [14].\nRecently, there have been reports of KFD related to vacci -\nnation, mainly to COVID-19 vaccines [15]. Due to this growing \nincrease, the immunomodulatory mechanism of vaccination \nand the underdiagnosis of KFD, a literature and adverse events \ndatabases search has been conducted to assess the possible re -\nlation between HPV vaccines and KFD.\nA search in the Spanish adverse events database (FEDRA) \nand the European adverse events database (Eudravigilance) \nwas carried out. To be aware of KFD cases, search criteria were \n\u201cHPV Vaccines; Gardasil\u00ae and Cervarix \u00ae\u201c and  the diagnosis \n\u201cHistiocytic necrotising lymphadenitis\u201d , as well as a search of \n\u201cHistiocytic necrotising lymphadenitis\u201d  for any drug. To know \nthe cases with any other lymphadenopathy a new search with Kikuchi-Fujimoto Disease: a rare type of \nlymphadenopathy and its plausible relationship \nwith human papillomavirus vaccines\n1Pharmacovigilance Division, Department of Pharmacy, Directorate General of Health Policy and Planning, \nRegional Ministry of Health of the Principality of Asturias, Spain\n2Department of Pharmacy, Hospital Universitario Central de Asturias, SpainAdri\u00e1n Rodr\u00edguez-Ferreras1\nIvan Maray2\nCovadonga Coya-Fern\u00e1ndez1\nManuela Mar\u00eda Octavio-Bocigas1\nManuel Felic\u00edsimo Fern\u00e1ndez-del R\u00edo1\nSusana Casares-L\u00f3pez1 \nJes\u00fas Ruiz-Salazar1Letter to the Editor\nArticle history\nReceived: 6 December 2022; Revision Requested: 14 February 2023; Revision Received: 14 February 2023;  \nAccepted: 24 February 2023; Published: 3 May 2023 \nSir,\nKikuchi-Fujimoto Disease (KFD) or histiocytic necrotizing \nlymphadenitys is a rare, benign self-limited disorder character -\nized by subacute necrotizing regional lymphadenopathy. It was \nthought that it commonly affected young Asian adults, mainly \nfemales. However, further research has shown that males and \nfemales are equally affected, and different cases have been re -\nported all over the world [1,2].\nKFD is usually presented as painful cervical nodes and is \nfrequently associated with fever, headache, night sweats, nau -\nsea, vomiting and sore throat. Cervical lymphadenopathy is \nevidenced in 60-90% of cases, with concomitant involvement \nof axillary and/or supraclavicular lymph nodes [1,2]. Extranod -\nal locations are uncommon [3]. Systemic symptoms like sple -\nnomegaly and hepatomegaly occur in less than 5% of cases \n[1]. Most patients have normal laboratory findings. Analytical \nabnormalities in some patients include elevated serum lactate \ndehydrogenase and aminotransferases. Leukopenia has been \ndetected in 50% of KFD patients [4,5].\nEtiology of KFD is still unknown. Two main theories have \nbeen postulated: infections and autoimmune origin. Numer -\nous viruses and other infectious agents have been proposed \nas etiologic agents of KFD: Epstein-Barr virus; herpes simplex \nvirus; varicella zoster virus; human herpesviruses 6, 7, and 8; \nparvovirus B19; paramyxovirus; parainfluenza virus; rubella; \ncytomegalovirus; hepatitis B virus; human immunodeficiency \nvirus; Brucella  spp., Bartonella henselae, Yersinia enterocol -\nitica, Toxoplasma gondii, Entamoeba histolytica,  and Myco -\nbacterium  spp. [6]. KFD seems to be related to an overactive \nT-cell-mediated immune response [2, 3]. Patients diagnosed \nwith KFD frequently have human leukocyte antigen (HLA) \nclass II alleles, specifically HLA-DPA1 and HLA-DPB1, which \nCorrespondence:\nAdri\u00e1n Rodr\u00edguez Ferreras\nPharmacovigilance Division, Department of Pharmacy, Directorate General of Health Policy \nand Planning, Regional Ministry of Health of the Principality of Asturias, Spain.\nE-mail: adrianrf7@gmail.comKikuchi-Fujimoto Disease: a rare type of lymphadenopathy and its plausible relationship with human \npapillomavirus vaccinesA. Rodr\u00edguez-Ferreras, et al.\nRev Esp Quimioter 2023;36(4): 429-431430of lymphadenopathy as well. Eight of them were serious and \nseven required hospitalization.\nKFD is a rare entity, which real incidence is unknown. Due \nto its self-limited course and its common symptoms, it is often \nmistaken with other lymphadenopathies, and is probably un -\nderdiagnosed [6]. \nThe current incidence of lymphadenopathy with HPV vac -\ncines is not clearly established. Data Sheets of bi and tetra-va -\nlent vaccines describe the frequency of lymphadenopathy as \n\u201cnot known\u201d, whilst in the 9-valent vaccine it is described as \n\u201crare\u201d. Underreporting and the fact that the data reported in \npharmacovigilance databases may be incomplete, are a clear \nlimitation to assess a relationship.\nIn the Spanish national adverse events database, 25 \nevents categorized under the MedDRA term \u201cLymphatic sys -\ntem disorders\u201d  have been reported for bi, tetra and 9-valent \nvaccines. This means that some of these cases could have been \nKFD and might have not been properly diagnosed.\nAccording to table 1, 3 of 5 cases correspond to female \nof Asian origin, which fits the data available. The literature re -\nview shows that KFD frequently presents concomitantly with \nother lymphadenopathies [1], and in the five cases described, \nany lymphadenopathy was also reported apart from KFD. The \nT-lymphocyte-mediated immune response at the lymph node \nlevel post-vaccination could also contribute to the develop -\nment of KFD [1]. In three of five cases, negative microbiological \ntest were available. Taking into account the infectious origin of \nKFD and the immunomodulated mechanisms, plausible causal \nrelationship may be reinforced, although more research is re -\nquired.\nSymptoms of KFD may be confused with lymphomas, \nmaking proper diagnosis mandatory to avoid unnecessary clin -\nical tests. Four cases required hospitalization. Knowledge of \nKFD could have avoided prolonged hospitalization as well as \nreduced health care costs. \nKFD is an entity of probably multifactorial origin and re -the criteria \u201c lymphadenopathy and linphadenitis \u201d for the same \nvaccines was conducted. According tothe Medical Diction -\nary for Medical Activities version 25.0 (MedDRA). All adverse \nevents registered as September 18 th 2022 were included. \nThe study was conducted in accordance with the ethical \nstandards established in the Declaration of Helsinki. Since FE -\nDRA and Eudravigilance are anonymized, no informed consent \nwas required.\nFEDRA encompassed only three KFD adverse reports, one \nrelated to methotrexate, other to elasomeran (Spikevax\u00ae) and \nthe other to tozinameran (Comirnaty\u00ae). No case of KFD asso -\nciated to HPV vaccines was found. On the other hand, Eudra -\nvigilance included a total of 62 KFD cases, of which 5 were \nassociated to HPV vaccines (table I) and 19 to other vaccines. \nRegarding HPV vaccines associated reports, 3 cases oc -\ncurred after Cervarix\u00ae vaccination [one case also had the Jap -\nanese encephalitis vaccine as suspected drug, Encevac\u00ae, and \ntwo after Gardasil\u00ae. Median age was 13 (range 12-26). Out of \nthe 5 cases, four required hospitalization and in all five cases \nother lymphadenopathy was also notified.\nIn case 2, screening for influenza A and B viruses was \nnegative. In case 3, the following serologies were negative: \nadenovirus, CMV, enterovirus, VEB, VHA, VHB, toxoplasma and \nmycoplasma. In both cases 2 and 3, Quantiferon test was al -\nso negative. In case 4, serologies for VEB, VIH, VHB, VHC and \nparvovirus B19 were negative. \nConcerning \u201c lymphadenopathy and linphadenitis \u201d, 7 cas -\nes for Cervarix\u00ae and 16 for Gardasil\u00ae were found in FEDRA. \nWhereas 108 and 547 cases were found for Cervarix\u00ae and Gar -\ndasil\u00ae, respectively, in Eudravigilance.\nIn relation to other vaccines, 15 cases of KFD related to \nCOVID-19 vaccines were found. Moreover two reports of KFD \ndisease connected to tetanus, diphtheria, pertussis, and polio \ndisease vaccine, one case of KFD related the flu vaccine was \nreported, and other one with bacilli Calmette-Guerin. Median \nage was 30 (range 10-52). Six of these cases had another type Case Sex Country Vaccine Other immune disorders* Outcome** Seriousness\n1 F Germany Gardasil (16,18)\u00ae Lymphadenopathy Recovered No\n2 F Japan Cervarix\u00ae Lymphadenopathy Not recovered Hospitalization\n3 F Japan Cervarix\u00aeLymphadenopathy\nSplenomegaly\nElevated aminotrasnferasesRecovered Hospitalization\n4 F JapanCervarix\u00ae\nEncevac\u00aePainful lymphadenopathy Recovered Hospitalization\n5 F Portugal Gardasil (6,11,16,18)\u00ae Lymphadenopathy Recovering HospitalizationTable 1  HPV vaccines associated KFD cases in Eudravigilance\n* Other reported AE apart from KFD. **At time of notificationKikuchi-Fujimoto Disease: a rare type of lymphadenopathy and its plausible relationship with human \npapillomavirus vaccinesA. Rodr\u00edguez-Ferreras, et al.\nRev Esp Quimioter 2023;36(4): 429-431431do PC, Gon\u00e7alves AK. Safety of Human Papillomavirus 9-Valent \nVaccine: A Meta-Analysis of Randomized Trials. J Immunol Res. \n2017;2017:3736201. doi:10.1155/2017/3736201\n12. Studdiford J, Lamb K, Horvath K, Altshuler M, Stonehouse A. Devel -\nopment of unilateral cervical and supraclavicular lymphadenop -\nathy after human papilloma virus vaccination. Pharmacotherapy. \n2008;28(9):1194-1197. doi:10.1592/phco.28.9.1194\n13. Pereira MP, Flores P, Neto AS. Neck and supraclavicular lymphad -\nenopathy secondary to 9-valent human papillomavirus vaccina -\ntion. BMJ Case Rep. 2019;12(11):e231582. doi:10.1136/bcr-2019-\n231582\n14. Watanabe T, Hashidate H, Hirayama Y, Iinuma Y. Kikuchi-Fujimoto \ndisease following vaccination against human papilloma virus in -\nfection and Japanese encephalitis. Eur J Pediatr. 2012;171(9):1409-\n1411. doi:10.1007/s00431-012-1729-1\n15. Tan HM, Hue SS, Wee A, See KC. Kikuchi-Fujimoto Disease Post \nCOVID-19 Vaccination: Case Report and Review of Literature. Vac -\ncines (Basel). 2021;9(11):1251. doi:10.3390/vaccines9111251search is needed to understand the origin of the disease. Re -\nporting of suspected adverse events is essential to assess the \nreal incidence and to optimize patient management present -\ning with lymphadenopathy of subacute course or with some \ncomplication. \nFUNDING \nNone to declare. \nCONFLICT OF INTEREST \nAuthors declare no have conflict of interest. \nREFERENCES\n1. Perry AM, Choi SM. Kikuchi-Fujimoto Disease: A Review. Arch \nPathol Lab Med. 2018;142(11):1341-1346. doi:10.5858/arpa.2018-\n0219-RA\n2. Ahmed Z, Quadir H, Hakobyan K, Gaddam M, Kannan A, Ojinnaka U \net al. Kikuchi-Fujimoto Disease: A Rare Cause of Cervical Lymphad -\nenopathy. Cureus. 2021;13(8):e17021. doi:10.7759/cureus.17021\n3. Spies J, Foucar K, Thompson CT, LeBoit PE. The histopathology of \ncutaneous lesions of Kikuchi\u2019s disease (necrotizing lymphadenitis): \na report of five cases. Am J Surg Pathol. 1999;23(9):1040-1047. \ndoi:10.1097/00000478-199909000-00006\n4. Pepe F, Disma S, Teodoro C, Pepe P, Magro G. Kikuchi-Fujimoto \ndisease: a clinicopathologic update. Pathologica. 2016;108(3):120-\n129. PMID:28195263\n5. Cheng CY, Sheng WH, Lo YC, Chung CS, Chen YC, Chang SC. Clini -\ncal presentations, laboratory results and outcomes of patients with \nKikuchi\u2019s disease: emphasis on the association between recurrent \nKikuchi\u2019s disease and autoimmune diseases. J Microbiol Immunol \nInfect. 2010;43(5):366-371. doi:10.1016/S1684-1182(10)60058-8\n6. Chong Y, Kang CS. Causative agents of Kikuchi-Fujimoto disease \n(histiocytic necrotizing lymphadenitis): a meta-analysis. Int J \nPediatrOtorhinolaryngol. 2014;78(11):1890-1897. doi:10.1016/j.\nijporl.2014.08.019\n7. Tanaka T, Ohmori M, Yasunaga S, Ohshima K, Kikuchi M, Sasazuki T. \nDNA typing of HLA class II genes (HLA-DR, -DQ and -DP) in Japa -\nnese patients with histiocytic necrotizing lymphadenitis (Kikuchi\u2019s \ndisease). Tissue Antigens. 1999;54(3):246-253. doi:10.1034/j.1399-\n0039.1999.540305.x\n8. Joean O, Thiele T, Raap M, Schmidt RE, Stoll M. Take a second look: \nit\u2019s Kikuchi\u2019s disease! A case report and review of literature. Clin \nPract. 2018;8(4):1095. doi:10.4081/cp.2018.1095\n9. Bosch X, Guilabert A. Kikuchi-Fujimoto disease. Orphanet J Rare \nDis. 2006;1:18. Published 2006 May 23. doi:10.1186/1750-1172-\n1-18\n10. Rezai K, Kuchipudi S, Chundi V, Ariga R, Loew J, Sha BE. Kikuchi-Fu -\njimoto disease: hydroxychloroquine as a treatment. Clin InfectDis. \n2004;39(12):e124-e126. doi:10.1086/426144\n11. Costa APF, Cobucci RNO, da Silva JM, da Costa Lima PH, Giral -ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/141.2022\nRev Esp Quimioter 2023;36(4): 432-433432subcultivos en agar sangre y Schaedler, incub\u00e1ndose el prime -\nro en atm\u00f3sfera enriquecida con CO 2 y el segundo en anae -\nrobiosis. A las 72 horas se observaron unas colonias gris\u00e1ceas \nde peque\u00f1o tama\u00f1o (aproximadamente 0,5mm de di\u00e1metro) \n\u00fanicamente en las placas incubadas en anaerobiosis. La espec -\ntrometr\u00eda de masas (MALDI-TOF MS [Bruker, Billerica, USA]) \nrealizada a partir de las colonias identific\u00f3 el microorganismo \ncomo S. moorei (score 2,33). \nLa concentraci\u00f3n m\u00ednima inhibitoria (CMI) obtenida me -\ndiante tiras de gradiente (Liofilchem, Roseto degli Abruzzi, Ita -\nlia) de penicilina, amoxicilina-clavul\u00e1nico y metronidazol fue \nde 0,19, 0,094 y 0,094 mg/L respectivamente. El aislado era \nsensible a todos ellos seg\u00fan los puntos de corte de CLSI (M100 \nED32:2022) y EUCAST (v11.0). Bacteriemia por Solobacterium moorei  en \npaciente con sinusitis\n1Servicio de Microbiolog\u00eda, Hospital de Galdakao, Spain\n2Servicio de Otorrinolaringolog\u00eda, Hospital de Galdakao, SpainIzaskun Alejo-Cancho1\nAna Gual-de-Torrella1\nRaquel Vielba Postigo2\nI\u00f1igo Perez Abraguin2\nLaura Redondo Farias2\nMar\u00eda Jos\u00e9 Lopez de Goikoetxea1Carta al Director\nArticle history\nReceived: 14 December 2022; Revision Requested: 27 January 2023; Revision Received: 19 March 2023;  \nAccepted: 22 March 2023; Published: 17 May 2023\nEstimado editor: Solobacterium moorei  es un bacilo \nGram-positivo anaerobio estricto que forma parte de la micro -\nbiota oral y fecal y juega un papel en la halitosis [1]. Sin em -\nbargo, tambi\u00e9n puede ser un pat\u00f3geno oportunista, causando \nbacteriemia, infecciones de herida u otros cuadros [2]. Presen -\ntamos un caso de bacteriemia por S. moorei , con foco probable \nen una sinusitis. \nUna mujer de 19 a\u00f1os acudi\u00f3 al Servicio de Urgencias \npor dolor en zona maxilar izquierda de 24 horas de evoluci\u00f3n, \nacompa\u00f1ado de fiebre, edema y eritema palpebral en hemicara \nizquierda. A su llegada la paciente estaba febril (39,6\u00baC), ta -\nquic\u00e1rdica (144 lpm) e hipotensa (97/55 mmHg). Se realiz\u00f3 TC, \ndonde se observaron hallazgos compatibles con sinusitis agu -\nda con ocupaci\u00f3n de la totalidad del seno maxilar y celdillas \netmoidales izquierdas. Se extrajeron hemocultivos e ingres\u00f3 a \ncargo del Servicio de Otorrinolaringolog\u00eda con pauta de amoxi -\ncilina-clavul\u00e1nico (1g/8h iv), metronidazol (500mg/100ml/12h \niv) y corticoide (20mg/8h iv). \nUn TC realizado el cuarto d\u00eda de ingreso (Figura 1) mos -\ntraba una sinusitis izquierda con patr\u00f3n de obstrucci\u00f3n de \nunidad osteomeatal complicada con absceso subperi\u00f3stico que \nimprontaba a la grasa extraconal orbitaria. Debido a la ma -\nla evoluci\u00f3n, se realiz\u00f3 abordaje quir\u00fargico mediante cirug\u00eda \nendosc\u00f3pica nasosinusal, logrando drenar el seno maxilar, las \nceldillas, etmoidales y el absceso subperi\u00f3stico adyacente. Se \ntomaron muestras del material purulento para cultivo.\nLos hemocultivos recogidos en el Servicio de Urgencias \nse remitieron al Servicio de Microbiolog\u00eda en frascos aerobios \ny anaerobios y fueron incubados en el equipo BD Bactec Fx \n(Becton Dickinson, Franklin Lakes, USA). Tras 64 horas de in -\ncubaci\u00f3n se detect\u00f3 crecimiento en un frasco anaerobio, cuya \ntinci\u00f3n de Gram mostr\u00f3 bacilos Gram-positivos. Se realizaron \nCorrespondencia:\nIzaskun Alejo-Cancho\nServicio de Microbiolog\u00eda, Hospital de Galdakao, Barrio Labeaga, 46 A, 48960, Galdakao \n(Spain)\nE-mail: i.alejo.cancho@gmail.comFigura 1  TC en el que se aprecia ocupaci\u00f3n de los \nsenos izquierdos. \nBacteriemia por Solobacterium moorei  en paciente con sinusitis I. Alejo-Cancho, et al.\nRev Esp Quimioter 2023;36(4): 432-433433tions. Heliyon 2020;6:e05371. doi: 10.1016/j.heliyon.2020.e05371\n2.  Alauzet C, Aujoulat F, Lozniewski A, Brahim S Ben, Domenjod C, En -\nault C, et al. A new look at the genus solobacterium: A retrospecti -\nve analysis of twenty-seven cases of infection involving S. moorei \nand a review of sequence databases and the literature. Microorga -\nnisms 2021 1;9. doi: 10.3390/microorganisms9061229\n3.  Pedersen RM, Holt HM, Justesen US.  Solobacterium moorei bac-\nteremia: Identification, antimicrobial susceptibility, and clinical \ncharacteristics. J Clin Microbiol 2011;49:2766\u20138. doi: 10.1128/\nJCM.02525-10\n4.  Zheng G, Summanen PH, Talan D, Bennion R, Rowlinson MC, Fine -\ngold SM. Phenotypic and molecular characterization of Solobac -\nterium moorei  isolates from patients with wound infection. J Clin \nMicrobiol 2010;48:873\u20136. doi: 10.1128/JCM.01381-09\n5.  S\u00e1rv\u00e1ri KP, S\u00e1ntha D, Kov\u00e1cs R, K\u00f6rm\u00f6ndi S, Pet \u0151 Z, Vereb T, et al. \nSix cases of Solobacterium moorei isolated alone or in mixed cul -\nture in Hungary and comparison with previously published cases. \nAnaerobe 2020 1;65. doi: 10.1016/j.anaerobe.2020.102241\n6.  Lee J, Lee S, Park DH, Kim MN, Jung J. First case report of Solobac -\nterium moorei bacteremia due to acute cholangitis in South Korea. \nAnaerobe 2020 1;66. doi: 10.1016/j.anaerobe.2020.102278\n7.  Ovia\u00f1o M, Rodr\u00edguez-S\u00e1nchez B. MALDI-TOF mass spectrometry \nin the 21st century clinical microbiology laboratory. Enferm In -\nfecc Microbiol Clin (Engl Ed) 2021 1;39:192\u2013200. doi: 10.1016/J.\nEIMC.2020.02.027\n8.  Genderini FG, Martiny D, Ponthieux F, Argud\u00edn MA, Gomez Gal -\ndon M, Zaarour A, et al. First case of Campylobacter rectus  and \nSolobacterium moorei  mixed bacteraemia successfully identi -\nfied by MALDI TOF-MS. New Microbes New Infect 2019 1;31. doi: \n10.1016/j.nmni.2019.100587\n9.  Veloo ACM, Jean-Pierre H, Justesen US, Morris T, Urban E, Wybo I, \net al. Validation of MALDI-TOF MS Biotyper database optimized for \nanaerobic bacteria: The ENRIA project. Anaerobe 2018 1;54:224\u2013\n30. doi: 10.1016/J.ANAEROBE.2018.03.007En las muestras de pus creci\u00f3 abundante microbiota mixta \naerobia y anaerobia, entre la cual se hallaba S. moorei . \nEl cuadro cl\u00ednico mejor\u00f3 tras el drenaje quir\u00fargico y la pa -\nciente fue dada de alta tras 11 d\u00edas de ingreso, manteniendo \nel tratamiento con amoxicilina-clavul\u00e1nico 875/125mg/8h du -\nrante 7 d\u00edas m\u00e1s.\nS. moorei  forma parte de la microbiota oral y fecal, pero la \nmuestra cl\u00ednica en la que m\u00e1s frecuentemente ha sido aislado \nes la sangre [2,3]. Esto podr\u00eda deberse, entre otras causas, a \nun mayor esfuerzo por parte de los microbi\u00f3logos para alcan -\nzar la identificaci\u00f3n a nivel de especie en este tipo de muestra. \nAdem\u00e1s, es frecuente que S. moorei  forme parte de infecciones \npolimicrobianas [2,4,5], lo cual dificulta establecer cual es real -\nmente su papel pat\u00f3geno en esas ocasiones.\nEl caso que describimos se present\u00f3 como un cuadro s\u00e9p -\ntico derivado de una sinusitis, en el que se pudo identificar S. \nmoorei  como \u00fanico microorganismo presente en la sangre de \nla paciente, aisl\u00e1ndose tambi\u00e9n junto a abundante flora mixta \nen las muestras del pus drenadas de la sinusitis, lo que sugiere \nque pudiera ser el origen de la bacteriemia. Es el primer caso de \nbacteriemia por S. moorei  publicado cuyo foco probable fue una \nsinusitis. Otros estudios mencionan como posible foco infeccio -\nnes bucales, colangitis o translocaci\u00f3n de flora intestinal [2,6]. \nHasta el momento, los casos descritos de bacteriemia por \nS.moorei  se hab\u00edan descrito en pacientes con patolog\u00eda de base, \nenfermedad hematol\u00f3gica u oncol\u00f3gica [2,3,5], siendo este el pri -\nmero publicado en una paciente joven sin enfermedades de base. \nS. moorei  es un pat\u00f3geno oportunista poco frecuente, de \ncrecimiento lento y de dif\u00edcil identificaci\u00f3n. La identificaci\u00f3n \nmediante secuenciaci\u00f3n del gen 16S rRNA es lenta, costosa y \nno est\u00e1 disponible en todos los laboratorios. En nuestro caso, la \nidentificaci\u00f3n se realiz\u00f3 gracias a la espectrometr\u00eda de masas, \nuna herramienta ampliamente empleada hoy en d\u00eda en los la -\nboratorios de Microbiolog\u00eda que permite identificar pat\u00f3genos \nde manera r\u00e1pida y fiable [2,5,7,8]. Las mejoras en las bases \nde datos han aumentado el n\u00famero de microorganismos que \npueden ser identificados, como es el caso de los anaerobios [9]. \nEl empleo de estas t\u00e9cnicas podr\u00eda explicar el mayor n\u00famero \nde infecciones por S. moorei observadas en los \u00faltimos a\u00f1os, \ncuyo papel como pat\u00f3geno a\u00fan est\u00e1 por determinar. \nFINANCIACI\u00d3N\nLos autores no han recibido financiaci\u00f3n para la realiza -\nci\u00f3n de este estudio.\nCONFLICTO DE INTERESES\nLos autores declaran no tener conflicto de inter\u00e9s. \nBIBLIOGRAF\u00cdA\n1.  Barrak I, St\u00e1jer A, Gajd\u00e1cs M, Urb\u00e1n E. Small, but smelly: the impor -\ntance of Solobacterium moorei  in halitosis and other human infec -ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/143.2022\nRev Esp Quimioter 2023;36(4): 434-435434Case 2\nA 77-year-old man was admitted due to traumatic brain \ninjury with a subdural hematoma. A craniotomy was per -\nformed. 2 months later cranioplasty with autologous bone \nwas made, and 1 week afterwards patient developed a subdur -\nal empyema in surgical site. Re-intervention was performed, \ncollection was removed, and culture showed polymicrobi -\nal growth of EBSL-producing Escherichia Coli, Enterococcus \nfaecalis , methicillin-resistant and linezolid-resistant (MIC  \n> 4 mg/L) Staphylococcus epidermidis  and Corynebacterium \namycolatum . Treatment was initiated with meropenem and \nvancomycin. Nevertheless, CT scan performed 2 weeks later \nrevealed worsening of the epidural collection with data sug -\ngestive of cerebritis. Surgical debridement was made again and \nautologous bone plasty was removed. Antibiotic therapy was \nchanged to meropenem + ceftaroline (600mg every 8 hours) \nand maintained for 4 weeks. CT scan then showed resolution \nof the collection. \nThese two cases show the usefulness of ceftaroline for \ncomplicated CNS infections in which resistant-gram positive \nmicroorganisms\u2019 participation is suspected. The first case is an \ninfection of ventriculoperitoneal shunt by MSSA with second -\nary bacteriemia. While waiting for susceptibility test, daptomy -\ncin was considered inappropriate as first-line therapy because \nof its low penetration in CSF, as it was linezolid for its bacte -\nriostatic effect in bacteriemia. The second case is a complex \npatient with post-surgical epidural empyema with multi-re -\nsistant isolations. Here, ceftaroline was used against methicil -\nlin-resistant S. epidermidis  after clinical failure with vancomy -\ncin, being linezolid ruled out because of resistance. \nAvailable literature in this scenario is scarce. A large ret -\nrospective study conducted by Britt et al. evaluated ceftaroline \nin 764 patients, 2% of which had meningitis. Mortality was \nlow (6%), but microbiological etiology or causes of death were \nnot provided [2]. Martin-Cerezuela et al performed a retro -\nspective study involving patients with Streptococcus pneumo -Use of ceftaroline in complex central nervous \nsystem infections\nComplejo Hospitalario Universitario A Coru\u00f1a, SpainAlicia Alonso \u00c1lvarez\nEfr\u00e9n S\u00e1nchez Vidal\nLuc\u00eda Ramos Merino\nDolores Sousa Regueiro\nJoaqu\u00edn Serrano Areba\nEnrique M\u00edguez Rey\nPedro Llinares Mod\u00e9jarLetter to the Editor\nArticle history\nReceived: 18 December 2022; Revision Requested: 11 January 2023; Revision Received: 15 January 2023;  \nAccepted: 23 January 2023; Published: 31 May 2023 \nSir,\nCeftaroline fosamil is a fifth-generation cephalosporin \napproved for skin and soft tissue infections and pneumonia, \nbut its use in out-off-label indications is increasing, as we have \npreviously reported in this journal [1]. It is particularly valuable \nin serious infections with participation of resistant gram-pos -\nitive microorganisms, in which other options as vancomycin, \nlinezolid or daptomycin may be restricted because of adverse \neffects or low efficacy. Few data are available about its use in \ncentral nervous system (CNS) infections.\nIn the last 5 years, we have recorded 5 CNS infections \ntreated with ceftaroline [1]. We here present two of them \nwhich were evaluable.\nCase 1\nA 67-year-old woman was admitted due to fever and \ngait instability. She was carrying a ventriculoperitoneal shunt \ndevice placed 10 years ago. Blood cultures were obtained, \nand methicillin-susceptible Staphylococcus aureus  (MSSA) \ngrew 23 hours later in 2 of 2 sets. MIC to vancomycin was \n2 mg/L using microdilution and 1.5 mg/L by E-test. A sample \nof cerebrospinal fluid (CSF) was obtained from the ventricu -\nloperitoneal shunt reservoir. Gram stain revealed Gram-pos -\nitive cocci in grape-like clusters and MSSA grew in aerobic \nculture. Infection of the ventriculoperitoneal shunt was then \nconfirmed and the device was removed. While waiting for \ndefinite antibiotic susceptibility testing and confirming mi -\ncrobiological clearance in repeated blood cultures, ceftaro -\nline (600mg every 8 hours) was employed for the first 7 days \nand then switched to cloxacillin plus linezolid. After 2 weeks \nof antibiotic treatment, CSF culture was negative, ventricu -\nloperitoneal shunt was replaced, and patient was discharged \none week afterwards.\nCorrespondence:\nAlicia Alonso Alvarez \nComplexo Hospitalario Universitario A Coru\u00f1a, Spain \nE-mail: aliciaaloalv@gmail.comUse of ceftaroline in complex central nervous system infections A. Alonso \u00c1lvarez, et al.\nRev Esp Quimioter 2023;36(4): 434-4354353. Mart\u00edn-Cerezuela M, Padr\u00f3s Olmedo M\u0178, Piqueres SP, de Pedro \nMB, Art\u00e9s JF, Galleymore PR. Ceftaroline versus standard ther -\napy for pneumococcal meningitis in critically ill patients. Med \nIntensiva (Engl Ed). 2022 Jun;46(6):348-350. doi: 10.1016/j.medi -\nne.2021.05.007. \n4. Bucheit J, Collins R, Joshi P. Methicillin-resistant S taphylococcus \naureus epidural abscess treated with ceftaroline fosamil salvage \ntherapy. Am J Health Syst Pharm. 2014 Jan 15;71(2):110-3. doi: \n10.2146/ajhp130246.\n5. Balouch MA, Bajwa RJ, Hassoun A. Successful use of ceftaroline for \nthe treatment of MRSA meningitis secondary to an infectious com -\nplication of lumbar spine surgery. J Antimicrob Chemother. 2015 \nFeb;70(2):624-5. doi: 10.1093/jac/dku392. \n6. Ebot J, Freeman WD, Wharen R, Diaz MA, Libertin C. MRSA Spinal \nEpidural Abscess as a Neurosurgical and Infectious Disease Emer -\ngency with Unresolved Antimicrobial Solution. Case Rep Infect Dis. \n2019 Jan 30;2019:7413089. doi: 10.1155/2019/7413089.\n7. Sakoulas G, Nonejuie P, Kullar R, Pogliano J, Rybak MJ, Nizet V. \nExamining the use of ceftaroline in the treatment of  Streptococcus \npneumoniae meningitis with reference to human cathelicidin LL-\n37. Antimicrob Agents Chemother. 2015 Apr;59(4):2428-31. doi: \n10.1128/AAC.04965-14. \n8. Chauzy A, Nadji A, Combes JC, Defrance N, Bouhemad B, Couet W, \nChavanet P. Cerebrospinal fluid pharmacokinetics of ceftaroline in \nneurosurgical patients with an external ventricular drain. J Anti -\nmicrob Chemother. 2019 Mar 1;74(3):675-681. doi: 10.1093/jac/\ndky489.\n9. Helfer VE, Zavascki AP, Zeitlinger M, de Ara\u00fajo BV, Dalla Costa T. \nPopulation Pharmacokinetic Modeling and Probability of Target \nAttainment of Ceftaroline in Brain and Soft Tissues. Antimicrob \nAgents Chemother. 2022 Sep 20;66(9):e0074122. doi: 10.1128/\naac.00741-22. \n10. Mermer S, Turhan T, Bolat E, Aydemir S, Yamazhan T, Pullukcu H, \nArda B, Sipahi H, Ulusoy S, Sipahi OR. Ceftaroline versus vancomy -\ncin in the treatment of methicillin-resistant Staphylococcus aureus  \n(MRSA) in an experimental MRSA meningitis model. J Glob Antimi -\ncrob Resist. 2020 Sep;22:147-151. doi: 10.1016/j.jgar.2020.02.001. \n11. Cottagnoud P, Cottagnoud M, Acosta F, Stucki A. Efficacy of cef -\ntaroline fosamil against penicillin-susceptible and -resistant  Strep -\ntococcus pneumoniae  in an experimental rabbit meningitis mod -\nel. Antimicrob Agents Chemother. 2013 Oct;57(10):4653-5. doi: \n10.1128/AAC.00286-13. niae penicillin-susceptible meningitis, comparing ceftaroline \n(n=5) and standard therapy (n=20). There was a non-statis -\ntically significant lower mortality in ceftaroline group (0% vs \n40%, P=0,016) despite of being more severe cases [3]. Most \nexperience comes from case series, including some regarding \nceftaroline use in epidural abscess, mainly due to MRSA, with \npromising results [4-6]. Skoulas et al described 5 patients with \ngram positive bacterial meningitis (4 due to S. pneumoniae, of \nwhich one was penicillin-resistant, and 1 MSSA). Four of them \ntreated with 600mg of ceftaroline fosamil every 8 hours were \nsuccessful whilst the other one with 600mg very 12 hours \nfailed [7]. Both cases reported here were treated with 600mg \nevery 8 hours.\nLittle is known about CSF penetration of ceftaroline. \nChauzy et al reported a mean of 9% in a series of 11 patients \nwith external ventricular drain, but without meningeal inflam -\nmation [8]. However, this penetration can be enhanced with \nmeningeal inflammation, as showed by Helfer et alt [9]. In fact, \nanimal models of meningitis show variable rates from 15 to \n51%. Ceftaroline was no-inferior to vancomycin in an animal \nstudy of meningitis by SARM and was superior to ceftriaxone \nin meningitis by penicillin-susceptible S. pneumoniae  and to \ncombination of ceftriaxone plus vancomycin in penicillin-re -\nsistant pneumococcal meningitis [10-11].\nIn summary, ceftaroline fosamil administrated 600mg \niv every 8 hours is an attractive option in CNS infections. Al -\nthough there is little experience in meningitis by penicillin-re -\nsistant S. pneumoniae  or MRSA, its penetration in CSF is like \nother third-generation cephalosporins and better to vancomy -\ncin, which together with its higher in vitro activity makes it an \ninteresting option in this scenario. In neurosurgical infections \nby linezolid-resistant S. epidermidis  \u2013 an emerging problem \nwith taxes of 17% in our center- ceftaroline could be the best \nchoice, as it was in our second case.\nFUNDING\nNone to declare\nCONFLICTS OF INTEREST \nAuthors declare no conflict of interest\nREFERENCES\n1. Alonso \u00c1lvarez A, Ramos Merino L, Castelo Corral LM, Pad\u00edn Trigo \nA, Sousa Regueiro D, M\u00edguez Rey E, S\u00e1nchez Vidal E. Ceftaroline \nfosamil: clinical experience after 23-month prescription in a ter -\ntiary hospital. Rev Esp Quimioter. 2021 Apr;34(2):115-119. doi: \n10.37201/req/119.2020. \n2. Britt RS, Evoy KE, Lee GC, Reveles KR, Sorensen KM, Jones X, \nBollinger M, Frei CR. Early Use of Ceftaroline Fosamil in the United \nStates Veterans Health Care System. Drugs. 2017 Aug;77(12):1345-\n1351. doi: 10.1007/s40265-017-0785-2. ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/147.2022\nRev Esp Quimioter 2023;36(4): 436-438436persistencia de Cp indetectable en el d\u00eda +40 se suspendi\u00f3 la \nrifampicina y se asoci\u00f3 fosfomicina (4.000 mg c/8h). A partir de \neste momento, se realizaron controles peri\u00f3dicos de linezolid \nen los que la Cp continu\u00f3 indetectable pese a los incrementos \nde dosis y la interrupci\u00f3n de la rifampicina (Figura 1). En el d\u00eda \n+49 con una dosis de 1.800 mg c/24h en PC se detect\u00f3 por \nprimera vez presencia del f\u00e1rmaco (1,77 mg/L). Posteriormente, \nel d\u00eda +57 se alcanz\u00f3 valores terap\u00e9uticos (3,56 mg/L) junto \ncon la disminuci\u00f3n de un 90,9% de la prote\u00edna C reactiva (PCR) \nrespecto del valor inicial al comenzar la TDM (Figura 2). Du -\nrante el seguimiento, no se observaron reacciones adversas al \nlinezolid y tanto la creatinina s\u00e9rica como la bilirrubina, ambos \nfactores predictivos de eliminaci\u00f3n para linezolid [3], se man -\ntuvieron constantes (Figura 2). Finalmente, en el d\u00eda +64 fue \ndada de alta. \nLa Cp indetectable se puede atribuir a una interacci\u00f3n en -\ntre linezolid y rifampicina ya que no se identific\u00f3 otra posible \ninteracci\u00f3n con el tratamiento instaurado. La disminuci\u00f3n de la \nCp de linezolid por la rifampicina es conocida [4], pero los me -\ncanismos subyacentes no est\u00e1n del todo definidos. El linezolid \nse metaboliza mediante reacciones de oxidaci\u00f3n del anillo de \nmorfolina. Las enzimas implicadas eran desconocidas, por este \nmotivo se denomin\u00f3 como \u201cmetabolismo oxidativo no enzim\u00e1 -\ntico\u201d. Sin embargo, un estudio reciente demuestra la partici -\npaci\u00f3n del sistema microsomal (CYP450) mediante las enzimas \nCYP2J2, CYP4F2 y CYP1B1 [5]. El metabolismo se iniciar\u00eda con \nla formaci\u00f3n de 2-hidroxilinezolid y finalizar\u00eda con desetilenli -\nnezolid, aunque se forman tambi\u00e9n otros metabolitos. De estos \ncitocromos, el CYP2J2 es el que mayor importancia tiene en el \nmetabolismo, tanto en la reacci\u00f3n inicial como en las sucesi -\nvas. Est\u00e1 presente en el h\u00edgado, pero predomina en el miocar -\ndio, donde representa la mayor parte de los CYP450 de este \ntejido [6]. Adem\u00e1s, el miocardio dispone de una v\u00eda de s\u00edntesis \nde \u00e1cidos epoxieicosatrienoicos (AEET) [6] con actividad antiin -\nflamatoria en la que el CYP2J2 es una enzima implicada en la \ns\u00edntesis de dichos mediadores. En presencia de estr\u00e9s oxidativo, \nel CYP2J2 est\u00e1 sobreexpresado en el tejido mioc\u00e1rdico [6], por Ajuste posol\u00f3gico de linezolid por interacci\u00f3n con \nrifampicina en endocarditis infecciosa\n1Farmacia Hospitalaria, Hospital General Universitario de Castell\u00f3n, Castell\u00f3n de la Plana, Espa\u00f1a\n2Medicina Interna, Hospital General Universitario de Castell\u00f3n, Castell\u00f3n de la Plana, Espa\u00f1aAaron Pupl\u00e0 Bartoll1 \nM\u00aa Dolores Bell\u00e9s Medall1  \nIgnacio P\u00e9rez Catal\u00e1n2 \nCelia Roig Mart\u00ed2  \nJulia Bodega Azuara1  \nMayte Gil Candel1 \nVicent Esteve L\u00f3pez1 \nRa\u00fal Ferrando Piqueres1Carta al Director\nArticle history\nReceived: 28 December 2022; Revision Requested: 27 January 2023; Revision Received: 8 February 2023;\nAccepted: 22 February 2023; Published: 28 April 2023\nEstimado Editor:\nPresentamos el caso de una mujer de 60 a\u00f1os con ante -\ncedentes de hipertensi\u00f3n arterial, espondilitis anquilosante, \nmeningiomatosis m\u00faltiple y s\u00edndrome de seno cavernoso. Acu -\ndi\u00f3 a urgencias por imposibilidad para movilizar los miembros \ninferiores y desorientaci\u00f3n. Ingres\u00f3 en UCI por shock s\u00e9ptico, \nd\u00f3nde se inici\u00f3 tratamiento emp\u00edrico con meropenem (2g \nc/8h) en perfusi\u00f3n extendida tras extracci\u00f3n de hemocultivos. \nSe aisl\u00f3 Staphylococcus aureus  sensible a meticilina (SASM) y \nse realiz\u00f3 ecocardiograf\u00eda que confirm\u00f3 endocarditis infecciosa \nsobre v\u00e1lvula nativa (EIVN) tric\u00faspidea, por lo que se modifi -\nc\u00f3 el tratamiento a daptomicina (750 mg c/24h) y cloxacilina \n(2000 mg c/4h) [1]. \nEn el d\u00eda +7 de ingreso, es trasladada a medicina inter -\nna manteniendo episodio febril por lo que se asoci\u00f3 linezolid \n(600 mg c/12h) para ampliar la cobertura debido a la aparici\u00f3n \nde \u00e9mbolos s\u00e9pticos pulmonares, as\u00ed como por persistencia de \nSAMS en hemocultivos seriados. En el d\u00eda +10 estaba afebril y \nnegativiz\u00f3 los hemocultivos. Transcurridos siete d\u00edas se retir\u00f3 \nla daptomicina y se mantuvo la asociaci\u00f3n de linezolid/cloxa -\ncilina. \nPese a que la asociaci\u00f3n de rifampicina s\u00f3lo est\u00e1 reco -\nmendada en endocarditis infecciosa sobre v\u00e1lvula prot\u00e9sica \n[2], debido a la progresi\u00f3n de las lesiones card\u00edacas observadas \nmediante PET-TAC el d\u00eda +30 y a la presencia de clips quir\u00fargi -\ncos por una reciente meningioblastectom\u00eda, se decidi\u00f3 asociar \nrifampicina (600 mg c/24h). \nEn el d\u00eda +36 se realiz\u00f3 monitorizaci\u00f3n farmacocin\u00e9tica \n(TDM) del linezolid debido a la potencial interacci\u00f3n con ri -\nfampicina, obteni\u00e9ndose una concentraci\u00f3n plasm\u00e1tica (Cp) \nindetectable, por lo que se decidi\u00f3 administrar el linezolid en \nperfusi\u00f3n cont\u00ednua (PC) con dosis de 1200 mg c/24h. Ante \nCorrespondencia: \nAaron Pupl\u00e0 Bartoll\nFarmacia Hospitalaria, Hospital General Universitario de Castell\u00f3n, Castell\u00f3n de la Plana, \nEspa\u00f1a\nE-mail: pupla_aar@gva.esAjuste posol\u00f3gico de linezolid por interacci\u00f3n con rifampicina en endocarditis infecciosa A. Pupl\u00e0 Bartoll, et al.\nRev Esp Quimioter 2023;36(4): 436-438437longarse hasta dos semanas tras la suspensi\u00f3n del tratamiento \n[7]. Este efecto explicar\u00eda la ausencia de linezolid pese a Cp de \nrifampicina indetectables en el d\u00eda +48 (Figura 1D).\nLa interacci\u00f3n entre linezolid y rifampicina es relevante y \nrequiere de TDM.  Adem\u00e1s, debido a la importancia del CYP2J2 \nen el metabolismo y la poca evidencia disponible actualmente, \nparece l\u00f3gico pensar que en cualquier endocarditis tratada con \nlinezolid deber\u00eda realizarse TDM independientemente del trata -\nmiento concomitante con rifampicina, ya que su metabolismo \npodr\u00eda estar aumentado por la sobreactivaci\u00f3n de la v\u00eda de los \nAEET. lo que es razonable pensar que tambi\u00e9n podr\u00eda estarlo en el \ncaso de endocarditis. \nPor otro lado, la rifampicina posee una gran capacidad \ninductora del metabolismo oxidativo, aunque parece que no \nafecta significativamente al CYP2J2 [6]. El 80% de la rifam -\npicina se elimina en forma desacetilada en la bilis por lo que \nla persistencia de la interacci\u00f3n pese a la suspensi\u00f3n de la ri -\nfampicina se puede explicar por una eliminaci\u00f3n disminuida de \n\u00e9sta (Figura 1C) ya que la paciente present\u00f3 un patr\u00f3n colest\u00e1 -\nsico objetivado por valores de GGT elevados (Figura 2). Hay que \nconsiderar que el efecto inductor del metabolismo puede pro -Figura 1  Concentraci\u00f3n plasm\u00e1tica de linezolid (mg/L) medida a lo largo del seguimiento. \nLas dosis de linezolid se muestran adjuntas sobre cada monitorizaci\u00f3n (l\u00ednea azul). El gradiente morado intenta representar de forma te\u00f3rica el \nefecto inductor de la rifampicina, donde se consideran cuatro escenarios: (A) efecto inductor total; (B)  semivida de la rifampicina (3-4h); (C)  \nposible tiempo de acumulaci\u00f3n por colestasis; (D) posible tiempo de inducci\u00f3n diferida una vez eliminada la rifampicina. La l\u00ednea roja en 2 mg/L \nrepresenta el l\u00edmite inferior del intervalo terap\u00e9utico para linezolid. En amarillo se indican los d\u00edas tras el ingreso.\nAjuste posol\u00f3gico de linezolid por interacci\u00f3n con rifampicina en endocarditis infecciosa A. Pupl\u00e0 Bartoll, et al.\nRev Esp Quimioter 2023;36(4): 436-438438Figura 2  Representaci\u00f3n de la evoluci\u00f3n de diferentes valores bioqu\u00edmicos durante el \nseguimiento. Para facilitar la interpretaci\u00f3n, se ha anotado sobre cada determinaci\u00f3n \nel valor obtenido, ya que son de magnitudes diferentes.\nFINANCIACI\u00d3N\nLos autores declaran que no han recibido financiaci\u00f3n pa -\nra la realizaci\u00f3n de este estudio. \nCONFLICTO DE INTERESES\nLos autores declaran no tener conflicto de intereses. \nBIBLIOGRAF \u00cdA\n1. Garc\u00eda de la M\u00e0ria C, Garc\u00eda-Gonz\u00e1lez J, Villamonte M, Almela M, \nAmbrosioni J, Quintana E, et al. Eficacia de daptomicina y cloxa -\ncilina en el tratamiento de la endocarditis experimental por Sta-\nphylococcus aureus  sensible a la meticilina. Cirug\u00eda Cardiovascular. \n2019; 26 (2): 132-133. doi: 10.1016/j.circv.2019.01.051. \n2. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, del \nZotti F, et al. Gu\u00eda ESC 2015 sobre el tratamiento de la endocarditis \ninfecciosa. Rev Esp Cardiol. 2016; 69(1):69.e1-e49. doi: 10.1016/j.\nrecesp.2015.11.015. \n3. Metaxas EI; Falagas ME. Update on the safety of linezo -\nlid. Expert Opinion on Drug Safety. 2009;8(4):485-91. doi: \n10.1517/14740330903049706. \n4. Okazaki F, Tsuji Y, Seto Y, Ogami C, Yamamoto Y, To H. Effects of a \nrifampicin pre-treatment on linezolid pharmacokinetics. PLoS One . \n2019;14(9):e0214037. doi: 10.1371/journal.pone.0214037. 5. Obach RS. Linezolid Metabolism is Catalyzed by CYP2J2, CYP4F2 \nand CYP1B1. Drug Metabolism and Disposition. 2022;50(4):413-\n421. doi: 10.1124/dmd.121.000776. \n6. Evangelista EA, Lemaitre RN, Sotoodehnia N, Gharib SA, Totah RA. \nCYP2J2 Expression in Adult Ventricular Myocytes Protects Aga -\ninst Reactive Oxygen Species Toxicity. Drug Metab Dispos. 2018 \nApr;46(4):380-386. doi: 10.1124/dmd.117.078840. \n7. Ficha t\u00e9cnica Rimactan\u00ae 300 mg c\u00e1psulas duras. Centro de infor -\nmaci\u00f3n online de medicamentos de la AEMPS - CIMA [internet]. \nConsultado el 15/05/2022ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/001.2023\nRev Esp Quimioter 2023;36(4): 439-441439Prevotella oris  was identified by 16S rRNA gene sequencing of \nbronchial brushing and bronchoalveolar lavage samples with \nan homology percentage of 99.50% and 99.82%, respectively. \nThe second sequence was registered in GenBank with acces -\nsion number OP601405. After switching to IV 1 g/8 h cefotax -\nime and 260 mg/6 h vancomycin, the patient improved until \nresolution of the infection 18 days after admission (Figure 1C).\nCase 2\nA 13-year-old patient with a history of Glanzmann\u2019s \nthrombasthenia and allergic asthma came to the emergency \ndepartment for left flank pain radiating to the shoulder and \nrespiratory distress. Examination showed hypoventilation in \nthe left lung base and blood tests showed a C-reactive protein \nof 180 mg/L, 25,340 leukocytes/\u00b5L with 22,280 neutrophils/\u00b5L. \nChest X-ray (Figure 2A) showed condensation in the left lung \nbase, being admitted with IV antibiotic treatment with 2 g/6 \nh of ampicillin. The patient had daily febrile fever for 5 days \nuntil reaching a fever of 39\u00baC, at which time lung ultrasound \nwas performed (Figure 2B) and the presence of bilateral pleural \neffusion was confirmed. The pleural effusion was drained by \nevacuating thoracentesis and sent to the laboratory for micro -\nbiological studies and cultures. The treatment was changed to \nIV 2 g/8 h of cefotaxime, 1 g/8 h of vancomycin and 500 mg/8 \nh of clindamycin. \nThe fluid was compatible with empyema presenting \n396,000 leukocytes/\u00b5L with 74% neutrophils, LDH of 5,447 U/L \nand glucose of 0 mg/dL. In microbiological cultures there was \nno growth after 5 days, being performed sequencing of the \n16S rRNA gene with P. oris  with a homology percentage of \n98.94%. The sequence was registered in GenBank with acces -\nsion number OP601436. After 5 more days of treatment the \npatient was discharged with good evolution (Figure 2C).\nThe occurrence of oral commensals as a cause of pul -\nmonary infections is invariably related to aspiration of food \nor other secretions, which together with dental procedures \nconstitute the most likely cause of these infections. In addi -Two cases of Prevotella oris  causing serious \npleuropulmonary infections\n1Clinical microbiology service. Basurto University Hospital. Bilbao (Biscay). Spain.\n2Biocruces Bizkaia Health Research Institute. Biscay. Spain.\n3Radiodiagnosis service of Cruces University Hospital. Bilbao (Biscay). Spain.Domingo Fern\u00e1ndez Vecilla1,2\nMary Paz Roche Matheus1,2 \nGotzon Iglesias Hidalgo3\nEst\u00edbaliz Ugalde Z\u00e1rraga1,2\nMiren Josebe Unzaga Bara\u00f1ano1,2\nJos\u00e9 Luis D\u00edaz de Tuesta del Arco1,2Letter to the Editor\nArticle history\nReceived: 2 January 2023; Revision Requested: 22 February 2023; Revision Received: 22 February 2023;  \nAccepted: 17 March 2023; Published: 16 May 2023\nSir,\nThe genus Prevotella  is a group of obligate anaerobic \nGram-negative bacteria that includes more than 50 species, \nmany of them associated with the human microbiota, where \nthey are commensals of the upper respiratory tract and the \ngenitourinary system. Prevotella oris  was isolated for the first \ntime in 1982 in a patient with periodontitis being named Bac-\nteroides oris  and reclassified years later as P. oris  [1]. In this \nmanuscript, we describe two cases of serious pleuropulmonary \ninfections, a necrotizing pneumonia and a pneumonia associ -\nated with pleural empyema.\nCase 1\nA 4-year-old patient with a history of sickle cell anemia \npresented with fever up to 39\u00baC associated with cough and pu -\nrulent expectoration of 19 days of evolution. At the beginning \nof the clinical picture, the patient was diagnosed as a respira -\ntory viriasis due to Influenza A virus by PCR. On examination, \nno alarm signs were observed and the blood analysis showed \n20,680 leukocytes with 81% neutrophils and a C-reactive pro -\ntein of 210 mg/L. A Pulmonary ultrasound showed condensa -\ntion in the right upper lobe (Figure 1A) and the patient was \nadmitted for study and IV antibiotic treatment with 1 g/6 h of \nampicillin, obtaining bronchoaspirate, bronchoalveolar lavage \nand bronchial brushing samples, ruling out Mycobacterium tu -\nberculosis  by PCR with the GeneXpert MTB/RIF panel (Cepheid, \nCalifornia, USA). \nAfter two days of hospitalization, a computed tomogra -\nphy scan was conducted with data consistent with necrotizing \npneumonia (Figure 1B). In the aerobic culture of the broncho -\naspirate sample, Lautropia mirabillis  (oral cavity commensal \npreviously isolated from children with HIV) was isolated, while \nCorrespondence:\nDomingo Fern\u00e1ndez Vecilla, \nClinical microbiology Service, Basurto University Hospital. \nMontevideo Avenue, 18, Gurtubay pavilion, 3rd floor. Postal code: 48013, Bilbao (Basque \ncountry). Spain. \nE-mail: domingofvec@gmail.comTwo cases of Prevotella oris  causing serious pleuropulmonary infections D. Fern\u00e1ndez Vecilla, et al.\nRev Esp Quimioter 2023;36(4): 439-441440discrepancies. This idea is stated in both the articles by Wy -\nbo I et al. and G\u00fcrsoy M et al., in which they collect statistics \nconcerning the percentage of strains identified by MALDI-TOF \nMS at the genus and species level of Prevotella spp. [9, 10]. In \nthe first article, out of 102 isolates, the genus was identified \nin 73.5% and the species in 62.7%, while in the second one, \nout of 123 isolates, the genus was identified in 100% and the \nspecies in 88%. Although MALDI-TOF MS is of great help, the \nidentification should be confirmed by another more accurate \ntechnique such as 16S rRNA gene sequencing and expand the \nMALDI-TOF database to increase the accuracy of identification \nas stated in the articles of Wybo I et al and G\u00fcrsoy M et al. \nFurthermore, in our experience, we believe that confirmation is \nnecessary in order to avoid misidentifications of some species \nof Prevotella. In fact, in one case, our Bruker \u00ae MALDI-TOF MS \nidentified the isolate as Prevotella bivia  with a value greater \nthan 2, while 16S rRNA gene sequencing identified it as P. oris  tion, poor oral hygiene or periodontitis increases the growth \nof mouth commensals such as P. oris , favoring severe oppor -\ntunistic infections to occur [2]. Previously, P. oris  has been as -\nsociated with clinical pictures such as abscesses or bacteremia, \namong others [3,4]. Although rare, it has also been described \ncausing pleuropulmonary infections in the form of pneumonia \nand pleural empyema in both adult and pediatric populations \n[2,5-8]. Both the article by Viswanath LS et al. and Cobo F et \nal. describe cases in which P. oris  are an unequivocal cause of \npleural pathology. These cases and the ones presented here \nshow that P. oris  should be taken into account in the etiolo -\ngy of pleuropulmonary infections after bronchoaspiration or \nwhen there is a history of previous birth procedures with con -\nsequent antibiotic coverage. \nIn terms of diagnosis, the MALDI-TOF mass spectrometer \nis a rapid tool of great help for the identification of numerous \nspecies, however, in the case of Prevotella spp. there may be Figure 2  Chest X-ray (A) showing a condensation in the left pulmonary base (arrow). Ultrasound (B) showed \npresence of empyema (asterisk), which was drained with a trocar (arrow). The control radiograph (C) \nshows the placement of the drainage catheter (arrow) achieving complete resolution of the picture.\nFigure 1  Chest X-ray (A) showing condensation in the right upper lobe (arrow). Contrast-enhanced CT (B) shows \nthe condensation (arrow) with the presence of an air level suggestive of cavitary pneumonia (asterisk). \nThe control radiograph (C) shows complete resolution of the picture.\nTwo cases of Prevotella oris  causing serious pleuropulmonary infections D. Fern\u00e1ndez Vecilla, et al.\nRev Esp Quimioter 2023;36(4): 439-441441with a homology percentage greater than 99% (with a refer -\nence strain studied through complete genomic sequence).\nIn terms of treatment, control of the focus by draining the \ncollections associated with antibiotics would be of choice [5-\n8]. In recent years, antimicrobial resistance is increasing among \nanaerobic anaerobic bacteria worldwide. Prevotella spp.  have \ntraditionally been considered susceptible to penicillin, but an \nincreasing rate of resistance to this drug has been lately doc -\numented [11-13]. Prevotella spp.  are generally susceptible to \nbeta-lactams associated with beta-lactamase inhibitor, met -\nronidazole, tigecycline or cefoxitin. Some strains could be re -\nsistant to clindamycin, tetracyclines or moxifloxacin as can be \nseen, for example, in the multicenter study by Ulger Toprak N \net al [13]. On the other hand, metronidazole has been reported \nas resistant in a case of bacteremia caused by Prevotella spp.  \nalthough this is exceptional, retaining good activity against \nmost strains [14]. Therefore, empirical treatment with penicil -\nlin should not be recommended in infections caused by species \nof the genus Prevotella, whereas beta-lactams associated with \nbeta-lactamase inhibitors, carbapenems or anaerobicides such \nas clindamycin or metronidazole could be used. In our cases, \nit was not possible to study the susceptibility of the strains as \nthey were identified only by sequencing of the 16S rRNA gene. \nThis may be due to the fact that the patients had received in -\ntravenous antibiotics in the days prior to sampling.\nFUNDING \nNone to declare. \nCONFLICT OF INTEREST \nAuthors declare no have conflict of interest. \nREFERENCES\n1. Holdeman LV, Moore WEC, Churn PJ, Johnson JL. Bacteroides oris \nand Bacteroides buccae New Species from Human Periodontitis \nand Other Human Infections. Int J Syst Evol Microbiol . 1982; 32, \n125-131. doi: 10.1099/00207713-32-1-125 .\n2. Brook I. Anaerobic pulmonary infections in children. Pediatr Emerg \nCare. 2004;20:636-40. doi: 10.1097/01.pec.0000139751.63624.0b.\n3. Frat, J. P.; Godet, C.; Grollier, G.; Blanc, J. L.; Robert, R. Cervical spinal \nepidural abscess and meningitis due to Prevotella oris  and Peptos -\ntreptococcus micros  after retropharyngeal surgery. Intensive Care \nMed 2004, 30, 1695. doi: 10.1007/s00134-004-2265-x.\n4. Cobo F, P\u00e9rez-Carrasco V, P\u00e9rez-Rosillo M\u00c1, Garc\u00eda-Salcedo JA, \nNavarro-Mar\u00ed JM. Bacteremia due to Prevotella oris  of probable \nhepatic origin. Anaerobe. 2022;76:102586. doi: 10.1016/j.anaer -\nobe.2022.102586.\n5. Civen R, Jousimies-Somer H, Marina M, Borenstein L, Shah H, Fi -\nnegold SM. A retrospective review of cases of anaerobic empye -\nma and update of bacteriology. Clin Infect Dis. 1995 Jun;20 Suppl \n2:S224-9. doi: 10.1093/clinids/20.supplement_2.s224. 6. Bartlett JG. Anaerobic bacterial infections of the lung and pleural \nspace. Clin Infect Dis. 1993;16 Suppl 4:S248-55. doi: 10.1093/clin -\nids/16.supplement_4.s248. \n7. Viswanath LS, Gunalan A, Jamir I, S B, S A, K A, Biswas R. Prevotella \noris: A lesser known etiological agent of pleural effusion. Anaerobe. \n2022;78:102644. doi: 10.1016/j.anaerobe.2022.102644.\n8. Cobo F, Lara-Oya A, Correa I, Rodr\u00edguez-Guerrero E, P\u00e9rez-Carras -\nco V, Garc\u00eda-Salcedo JA, Navarro-Mar\u00ed JM. Two rare cases of pleu -\nral infection due to Prevotella species. Rev Esp Quimioter  2022; \n35(5):503-505 doi: 10.37201/req/046.2022.\n9. Wybo I, Soetens O, De Bel A, Echahidi F, Vancutsem E, Vandoors -\nlaer K, Pi\u00e9rard D. Species identification of clinical Prevotella iso -\nlates by matrix-assisted laser desorption ionization-time of flight \nmass spectrometry. J Clin Microbiol. 2012;50:1415-8. doi: 10.1128/\nJCM.06326-11.\n10. G\u00fcrsoy M, Harju I, Matom\u00e4ki J, Bryk A, K\u00f6n\u00f6nen E. Performance of \nMALDI-TOF MS for identification of oral Prevotella species. Anaer -\nobe. 2017;47:89-93. doi: 10.1016/j.anaerobe.2017.04.008.\n11. Jeverica, S.; Kolenc, U.; Mueller-Premru, M.; Papst, L. Evaluation \nof the routine antimicrobial susceptibility testing results of clin -\nically significant anaerobic bacteria in a Slovenian tertiary-care \nhospital in 2015. Anaerobe  2017, 47, 64-69. DOI: 10.1016/j.anaer -\nobe.2017.04.007.\n12. Boyanova L, Kolarov R, Gergova G, Dimitrova L, Mitov I. Trends \nin antibiotic resistance in Prevotella species from patients of the \nUniversity Hospital of Maxillofacial Surgery, Sofia, Bulgaria, in \n2003-2009. Anaerobe. 2010;16:489-92. doi: 10.1016/j.anaer -\nobe.2010.07.004.\n13. Ulger Toprak, N.; Veloo, A. C. M.; Urb\u00e1n, E.; Wybo, I.; Justesen, U. S.; \nJean-Pierre, H. l. n.; Morris, T.; Akgul, O.; Kulekci, G.; Soyletir, G.; et \nal. A multicenter survey of antimicrobial susceptibility of Prevotella \nspecies as determined by E-test methodology. Anaerobe. 2018; 52, \n9-15. doi: 10.1016/j.anaerobe.2018.05.005.\n14. Mory, F.; Carlier, J. P.; Alauzet, C.; Thouvenin, M.; Schuhmacher, \nH.; Lozniewski, A. Bacteremia caused by a metronidazole-resistant \nPrevotella spp.  strain. J Clin Microbiol.  2005; 43, 5380-5383. doi: \n10.1128/JCM.43.10.5380-5383.2005.ISSN: 0214-3429 / \u00a9The Author 2023. Published by Sociedad Espa\u00f1ola de Quimioterapia. This article is distributed under the terms of the Creative Commons \nAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).\nRevista Espa\u00f1ola de Quimioterapia  \ndoi:10.37201/req/003.2023\nRev Esp Quimioter 2023;36(4): 442-443442VM, correspondiendo 10 a HSV-1 (62,5%) y 6 a HSV-2 (37,5%). \nLos tres casos de enterovirus correspond\u00edan a ni\u00f1os con diag -\nn\u00f3stico del s\u00edndrome mano-pie-boca, que tambi\u00e9n presenta \nlesiones plantares. El resto de virus y su \u00e1mbito de detecci\u00f3n se \npresentan en la Tabla 1.\nA pesar de las caracter\u00edsticas dermatol\u00f3gicas espec\u00edfica, \naunque no siempre, existen otros virus causantes de manifes -\ntaciones cut\u00e1neas y lesiones muy parecidas a alguna de las fa -\nses evolutivas presentes en la VM [3,4]. La principal es el virus \nvaricela-z\u00f3ster, que en su forma de varicela del adulto puede \nconfundirse como sospecha de la VM. De este modo, hemos \nconfirmado como de las alternativas virol\u00f3gicas a la VM, el vi -\nrus varicela-z\u00f3ster ha sido el responsable del 50% de los casos, \nseguidos del herpes simple tipo 1 (26,3%), herpes simple tipo 2 \n(15,7%) y los enterovirus (7,8%). \nLas infecciones por el VVZ en el adulto son mas severas \nque en la infancia y asociadas en ocasiones a complicaciones \nneurol\u00f3gicas. Un estudio realizado en la Rep\u00fablica Democr\u00e1ti -\nca del Congo [5] mostr\u00f3 que en 730 pacientes diagnosticados \ncl\u00ednicamente de varicela-z\u00f3ster, el virus de la VM era el respon -\nsable del 3,3% de estas lesiones (confirmaci\u00f3n de laboratorio) \ny otro 7,3% se diagnosticaron de z\u00f3ster at\u00edpico (sin confirma -\nci\u00f3n etiol\u00f3gica); por ello se recomienda la toma muestras y \nsu estudio etiol\u00f3gico viral tanto en \u00c1frica como fuera de es -\nte continente. La epidemia de 2022 represent\u00f3 un nuevo reto \ndiagn\u00f3stico, aunque sin la endemicidad africana, la sospecha \nde VM se estableci\u00f3 de una forma prioritaria, mientras que las \notras etiolog\u00edas virales se realizaron de forma secundaria.\nEn el estudio de Hughes et al.[3] realizado en la Rep\u00fa -\nblica Democr\u00e1tica del Congo en 2021, observan que de 991 \nmuestras cut\u00e1neas analizadas en adultos 400 (40,4%) estaban \ncausadas por el VM, 457 (46,1%) por el virus varicela-z\u00f3ster y \n134 (13,5%) eran infecciones mixtas entre ambos virus. Se en -\ncontraron diferencias en la gravedad y los s\u00edntomas en aque -\nllos con coinfecciones en comparaci\u00f3n con aquellos con VM \no varicela-z\u00f3ster solos. Los casos de coinfecci\u00f3n presentaban Diagn\u00f3stico v\u00edrico alternativo en las sospechas de \nviruela del mono \nUnidad de Virolog\u00eda, Servicio de Microbiolog\u00eda, Hospital Universitario Son Espases. Facultad de Medicina de la Uni -\nversitat Illes Balears. Palma de Mallorca.Jordi Reina \nElisa Gonz\u00e1lez de HerreroCarta al Director\nArticle history\nReceived: 10 January 2023; Accepted: 22 February 2023; Published: 4 May 2023\nEstimado Editor:\nLas caracter\u00edsticas dermatol\u00f3gicas de las lesiones cut\u00e1neas \nasociadas a la infecci\u00f3n por la viruela del mono (VM) son bas -\ntante espec\u00edficas, aunque var\u00edan en su proceso evolutivo [1]. Su \nlocalizaci\u00f3n en las palmas y plantas es muy sugerente, pero en \nla epidemia de 2022 un porcentaje elevado de las lesiones se \npresentaban adem\u00e1s en las zonas genitales. Las lesiones cut\u00e1 -\nneas junto al comportamiento sexual de las personas afectadas \ny el contexto epidemiol\u00f3gico, se constituyeron como el princi -\npal indicio de sospecha de VM [2]. \nDurante el per\u00edodo epid\u00e9mico situado entre el 1 de junio \ny el 30 de noviembre de 2022 se analizaron 367 muestras cu -\nt\u00e1neas con sospecha cl\u00ednica de VM. La detecci\u00f3n del virus de la \nVM se realiz\u00f3 mediante una RT-PCR comercial en tiempo real \nbasada en la prote\u00edna de fusi\u00f3n 14-kDA del g\u00e9nero Orthopox -\nvirus (LightMix Modular Orthopox virus; Roche). Las muestras \nnegativas al VM se analizaron mediante una RT-PCR comercial \n(Meningitis V1/V2 Assay; Seegen) que detecta todos los her -\npesvirus y enterovirus.\nDe las 367 muestras analizadas muestras analizadas 293 \n(79,8%) correspond\u00edan al \u00e1mbito hospitalario y 74 (20,2%) a \natenci\u00f3n primaria. De las 141 muestras consideradas como \npositivas a VM (78,7%), 133 (94,3%) lo fueron en el \u00e1mbito \nhospitalario y 8 (5,7%) de primaria. El virus de la VM se detect\u00f3 \nen 133 muestras/159 positivas (83,6%) hospitalarias y en 8/20 \npositivas (40%) de primaria. De los 38 (21,2%) diagn\u00f3sticos \netiol\u00f3gicos alternativos, el virus varicela-z\u00f3ster represent\u00f3 el \n50% (19 casos). El diagn\u00f3stico alternativo v\u00edrico m\u00e1s frecuente \nfue el de VZV, detect\u00e1ndose 12 casos (7,5%) en hospitales y \n7 (35%) en primaria. Los virus no-VM representaron el 16,5% \nen hospitales frente al 60% en primaria. De las lesiones ge -\nnitales 16 (8,9%) fueron diagnosticadas como alternativa a la \nCorrespondencia:\nJordi Reina \nUnidad de Virolog\u00eda, Servicio de Microbiolog\u00eda, Hospital Universitario Son Espases. Facultad de \nMedicina de la Universitat Illes Balears. Carretera Valldemossa 79. 07120 Palma de Mallorca.\nE-mail: jorge.reina@ssib.esDiagn\u00f3stico v\u00edrico alternativo en las sospechas de viruela del mono J. Reina , et al.\nRev Esp Quimioter 2023;36(4): 442-4434432. Ponencia de alertas y planes de preparaci\u00f3n y respuesta. Protocolo \npara la detecci\u00f3n precoz y manejo de casos ante la alerta de vi -\nruela de los monos (monkeypox) en Espa\u00f1a. Ministerio de Sanidad. \n5 de agosto de 2022. Disponible en: https://www.sanidad.gob.es/\nprofesionales/saludPublica/ccayes/alertasActual/alertaMonkeypox/\nhome.htm .\n3. Tumewu J, Wardiana M, Ervianty E, Rahmadewi S, Astindari R, \nAnggraeni S et al. An adult patient with suspected of monkeypox \ninfection differential diagnosed to chickenpox. Infect Dis Report \n2020; 12:8724. doi:10.4081/idr.2020.8724 .\n4. Hughes CM, Liu L, Davidson WB, Radford KW, Wilkins K, Monroe \nB et al. A tale of two viruses: coinfections of monkeypox and var -\nicela-zoster virus in the Democratic Republic of Congo. Am J Trop \nMed Hyg 2021; 104:604-11. doi:10.4269/ajtmh.20-0589 .\n5. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M, Grab B. Human \nmonkeypox: confusi\u00f3n with chikenpox. Acta Trop 1988; 45:297-\n307. PMID: 2907258.\n6. Lewis A, Josiowicz A, Maris S, Riade H, Tous M, Palacios G et al. \nIntroduction and differential diagnosis of monkeypox in Ar -\ngentina, 2022. Emerg Infect Dis 2022; 28:2123-5. doi:10.3201/\neid2810.221075 .m\u00e1s s\u00edntomas asociados con la VM y ten\u00edan mayor n\u00famero de \nlesiones que los casos con varicela-z\u00f3ster solo. Es posible que \nla coinfecci\u00f3n entre estos dos virus pueda modular no s\u00f3lo la \nexpresi\u00f3n dermatol\u00f3gica de las lesiones sino incluso la grave -\ndad o complicaciones de la misma [3,4]. En nuestro estudio las \nmuestras positivas a la VM no fueron sometidas a la detecci\u00f3n \nde otros virus cut\u00e1neos, con lo que no tenemos datos de las \nposibles coinfecciones entre ambos virus.\nEs destacable el mayor porcentaje de detecci\u00f3n de casos \nde VM en las urgencias hospitalarias frente a atenci\u00f3n prima -\nria. Probablemente la existencia de dermat\u00f3logos en el hos -\npital haya facilitado esta sospecha. Adem\u00e1s es posible que en \natenci\u00f3n primaria no tengan muchas oportunidades de obser -\nvar casos de varicela del adulto, que ha sido la primera causa \nalternativa (35% frente al 7,5% hospitalaria). \nLos tres casos de enterovirus correspond\u00edan a ni\u00f1os con \ndiagn\u00f3stico del s\u00edndrome mano-pie-boca, que tambi\u00e9n pre -\nsenta lesiones plantares. En un estudio realizado en Argentina \nsobre 9 casos de sospecha de VM, s\u00f3lo 3 (33,3%) fueron VM y 4 \n(44,4%) correspond\u00edan a enterovirus [6].\nLa r\u00e1pida incorporaci\u00f3n de la detecci\u00f3n molecular espec\u00ed -\nfica frente a la VM ha permitido no s\u00f3lo establecer un diagn\u00f3s -\ntico r\u00e1pido y espec\u00edfico de la infecci\u00f3n, sino que ha permitido \nla adopci\u00f3n de medidas preventivas para contener la epidemia.\nFINANCIACI\u00d3N\nNo se ha recibido ninguna financiaci\u00f3n para la realizaci\u00f3n \nde este trabajo.\nCONFLICTO DE INTERESES\nLos autores declaran no tener ning\u00fan conflicto de inte -\nreses.\nBIBLIOGRAF\u00cdA\n1. McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014; \n58:260-7. doi:10.1093/cid/cit703 .N\u00famero de muestras Hospitales Atenci\u00f3n primaria Total\n(293) (74) (367)\nViruela del mono 133 8 141\nVaricela-Z\u00f3ster 12 7 19\nHSV-1 7 3 10\nHSV-2 5 1 6\nEnterovirus 2 1 3\nTotal 159 20 179Tabla 1  Principales virus detectados en los casos \nde sospecha de viruela del mono.", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}